# data[].attributes.headline
Metabolism Assays Market worth $2.1 billion by 2028 

# data[].attributes.subject
Metabolism Assays Market worth $2.1 billion by 2028 

# data[].attributes.body
OPPORTUNITY: Integration with wearable devices

The overall health monitoring and management experience for individuals can be enhanced by integrating metabolism assay data with digital health platforms, apps, and wearable devices. For instance, Sweat-based wearable technologies have great potential to collect important data on biomarkers which are related to metabolic syndrome and its associated diseases. These wearable devices can measure glucose, CRP, cortisol, and sodium levels, making them invaluable for patients at risk of developing diabetes and cardiovascular diseases.

# data[].attributes.attachment_link.provider_name
MarketsandMarkets Blog - Market Research Insights

# data[].attributes.attachment_link.readable_text
The Metabolism Assays Market is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 7.8% during the forecast period. The growth in this market is attributed to the growing prevalence of diabetes, the global increase in the number of hospitals, and the high rate of obese population. However, alternative methods or techniques restrain the growth of this market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=135163479 Market Dynamics Drivers

Increasing funding and investments in metabolic research

Drug discovery and development

Rise in prevalence of chronic diseases

Increased use of metabolism assays in fitness and sports

Growing demand for personalized medicines

Restraints

High cost of metabolism assay analyzers

Presence of alternative methods and techniques

Opportunities

Integration with wearable devices

Growing life science research in emerging economies

Challenges

Complexity of assay development
Key Market Players
Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), Agilent Technologies Inc. (US), Kaneka Eurogentec S.A. (Belgium), Sartorius AG (Germany), Promega Corporation (US), Elabscience Biotechnology Inc. (US), RayBiotech Life Inc. (US), BMG LABTECH (Germany), BIOTREND ChemiKalien GmbH (Germany), 3H Biomedical AB (Sweden), BioAssay Systems (US), EMELCA Bioscience (Netherlands), Creative Bioarray (US), Tempo Bioscience, Inc (US), Ncardia (Netherlands), NOVOCIB (France), Eton Bioscience Inc. (US), Cayman Chemical Company (US), Enzo Lifesciences, Inc. (US), and Abnova Corporation (Taiwan)
Thermo Fisher Scientific, Inc. (US)
Thermo Fisher is the leading player in the metabolism assays market. The company has a strong presence in North America, Europe, Asia Pacific, and Latin America, as well as numerous subsidiaries and distribution channels. Thermo Fisher's strategic acquisition of PPD in December 2021 demonstrate the company's commitment to expanding its portfolio and market presence. These acquisitions contribute to Thermo Fisher's financial success and position the company as a leading player in the life science sector.
Merck KGaA (Germany)
Merck is the second leading player in the metabolism assays market. The company is globally present including Europe, North America, Asia Pacific, Latin America, the Middle East & Africa. Majorly, Merck focuses on external partnerships in its R&D operations, in-house research and maximizing research efficiency while reducing financial outlays. A solid foundation for the continued development of safe and cost-effective products has been provided by the Merck's strong heritage of technology, leadership, and innovation.
Abcam Plc.
Abcam is a leading player in the global metabolism assays market. The company offers robust products. It has a wide geographic presence in North America, Europe, Asia Pacific, and the Middle East & Africa. Across the globe, Abcam has direct and indirect distribution network, which will protect the company's business from building fluctuations in demand in various geographies.
North America dominates the global metabolism assay market.
Based on the region, the metabolism assay market is segmented into North America, Europe, Asia Pacific, and Rest of the World. North American market is driven by well-established pharmaceutical and biotechnology industry, investments around drug discovery and toxicity testing. The Asia Pacific segment is projected to register the highest CAGR during the forecast period. The presence of a large population base coupled with large patient population and increasing rate of obesity are some of the major factors driving the growth of this regional market.
Recent Developments:

In 2022, Thermo Fisher Scientific, Inc. (US) collaborated with Symphogen (Denmark) and Servier (France) for biopharmaceutical discovery and development laboratories.

In 2021, Abcam Plc. (UK) acquired BioVision (UK). This acquisition of BioVision represents a compelling strategic fit for Abcam. This will bring greater control over the innovation and distribution of BioVision's product portfolio and create value through portfolio expansion and leveraging Abcam's global channels to market.

In 2021, Agilent Technologies Inc. (US) launched Agilent Seahorse XF HS Miniplate which is the latest addition to Agilent's range of Seahorse XF platforms, which analyze mitochondrial respiration, glycolysis, and ATP production in live cells, in real-time.

Request 10% Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=135163479

# data[].attributes.attachment_link.title
Metabolism Assays Market Report: Current Status and Future Prospects - MarketsandMarkets Blog

# data[].attributes.attachment_link.description
The Metabolism Assays Market is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 7.8% during the forecast period.

# data[].attributes.headline
Innovations in Allergy Diagnostics: Latest Developments and Breakthroughs 

# data[].attributes.subject
Innovations in Allergy Diagnostics: Latest Developments and Breakthroughs 

# data[].attributes.body
The Global Allergy Diagnostics Market boasts a total value of $4.8 billion in 2021 and is projected to register a growth rate of 11.1% to reach a value of $8.2 billion by 2026. Factors such as, rising environmental pollution levels, high incidence of allergic diseases, increasing funds by organizations in allergy diagnostics are anticipated to drive growth of the global market.

# data[].attributes.attachment_link.readable_text
The Global Allergy Diagnostics Market boasts a total value of $4.8 billion in 2021 and is projected to register a growth rate of 11.1% to reach a value of $8.2 billion by 2026. Factors such as, rising environmental pollution levels, high incidence of allergic diseases, increasing funds by organizations in allergy diagnostics are anticipated to drive growth of the global market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=232871701 Market Dynamics DRIVER: Rising environmental pollution levels
Exposure to indoor and outdoor air pollutants, allergens, and occupational exposure are the major risk factors causing chronic respiratory diseases. The prevalence of allergic disorders among the urban population is higher than those living in rural areas due to the higher exposure to environmental pollutants in cities (as a result of vehicular pollution and industrial activities).

As per the WHO, more than 80% of people living in urban areas are exposed to air quality levels that exceed the WHO safety limits; though this is a global trend, its effects are more severe in the urban areas of low-income countries. This is a major indicator for the growth of the allergy diagnostics market, as air pollution from motor vehicles has been indicated as one of the major risk factors responsible for allergic diseases.
OPPORTUNITY: Use of mHealth in allergy diagnosis
The use of mHealth for the diagnosis of rhinitis is currently limited, with a small number of mHealth tools for allergic rhinitis (AR) diagnosis published in peer-reviewed journals. Recent developments in integrated biosensors, wireless communication, and power harvesting techniques generate a new breed of point-of-care devices. However, AR is a very common disease. Any diagnostic device connected to a smartphone (e.g., peak nasal inspiratory flow meters or intranasal biosensors) would need to be inexpensive to be affordable.
Restraints: Premium costs associated with allergy diagnostic instruments
Several allergy diagnostics instruments, such as luminometers, blot analyzers, scanners, ELISA analyzers, and immunoassay analyzers, are periodically updated by market players. As these instruments are equipped with advanced features and functionalities, they are priced at a premium (the price of each instrument varies based on its accuracy, flexibility, and TAT). For instance, immunoassay analyzers cost between USD 10,000 and USD 20,000, while luminometers cost between USD 3,000 and USD 14,000. Semi-automated ELISA readers cost between USD 2,000 and USD 5,000, while fully automated analyzers cost around USD 14,000. Furthermore, maintenance and insurance, laboratory supervision, and overheads (including utilities, space, and administration) are additional expenses required to operate this equipment.
Trends: Reagent rental agreements
Reagent rental agreements are sales agreements between end users (such as hospitals and diagnostic laboratories) and allergy diagnostic product manufacturers. Under these agreements, the end user rents or purchases instruments at a subsidized rate by entering into a reagent-purchase contract with the manufacturer. This mutually beneficial agreement lowers the initial capital investment for the end user while assuring the manufacturer of purchases over a substantial time period. In some cases, analyzers are rented out to the end user at a cost-per-test rate.
Request 10% Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=232871701 Market Segmentation: By Product & Service By Allergen

Inhaled Allergens

Food Allergens

Drug Allergens

Other Allergens

By Test Type By End User

Diagnostic Laboratories

Hospital-based Laboratories

Academic Research Institutes

Other End Users

"North America commanded the largest share of the allergy diagnostics industry in 2021."
Based on region, the global market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America commanded the largest share of this market. The large share of North America can be attributed to the rising incidence of allergies, favorable reimbursement scenarios for allergy diagnosis, and the availability of supportive initiatives by associations.
Key Market Players:
Thermo Fisher Scientific Inc., (US), Siemens Healthineers (Germany), Danaher (US), Omega Diagnostics Group PLC (UK), bioMérieux SA (France), Romer Labs Division Holding (Austria), EUROIMMUN Medizinische Labordiagnostika AG (Germany), HollisterStier Allergy (US), NEOGEN Corporation (US), Eurofins Scientific (Luxembourg), Minaris Medical America, Inc. (US), Stallergenes Greer (UK), HOB Biotech Group Corp., Ltd. (China), HYCOR Biomedical (US), R-Biopharm AG (Germany), AESKU.GROUP GmbH (Germany), ACON Laboratories, Inc. (US), Lincoln Diagnostics, Inc. (US), Astra Biotech GmbH (Germany), and Erba Group (UK).
Report Objectives

To define, describe, and forecast the allergy diagnostics market based on product & service, allergen, test type, end user, and region.

To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, trends, opportunities, and challenges, and COVID-19 Impact Analysis)

To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall allergy diagnostics market

To analyse market opportunities for stakeholders and provide details of the competitive landscape for key players.

To forecast the size of the market segments in four geographical regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.

To profile the key players and comprehensively analyse their product portfolios, market positions, and core competencies.

To track and analyse competitive developments such as product launches, deals and expansions in the allergy diagnostics market.

# data[].attributes.attachment_link.title
Innovations in Allergy Diagnostics: Latest Developments and Breakthroughs - MarketsandMarkets Blog

# data[].attributes.attachment_link.description
The Global Allergy Diagnostics Market boasts a total value of $4.8 billion in 2021 and is projected to register a growth rate of 11.1% to reach a value of $8.2 billion by 2026. Factors such as, rising environmental pollution levels, high incidence of allergic diseases, ...

# data[].attributes.headline
Breath Analyzer Market is Expected to Reach $1,167 million by 2025

# data[].attributes.subject
Breath Analyzer Market is Expected to Reach $1,167 million by 2025

# data[].attributes.body
The breath analyzer industry is poised for significant growth in the near future as advancements in technology and increased awareness of its applications continue to drive demand. With a growing emphasis on public safety and health, breath analyzers are expected to find expanding use not only in law enforcement for detecting alcohol intoxication but also in various sectors like healthcare, workplace safety, and personal wellness. Miniaturization and enhanced accuracy in sensor technology will enable the development of portable and affordable breath analyzers, making them more accessible to a wider range of users. Additionally, the integration of AI and data analytics will enhance the capabilities of these devices, making them valuable tools in monitoring and managing health conditions such as diabetes and asthma. As regulatory frameworks evolve to accommodate these innovations, the breath analyzer industry is on the brink of transformative growth, promising a safer, healthier future for individuals and society at large.

# data[].attributes.attachment_link.title
Breath Analyzer Market is Expected to Reach $1,167 million | MarketsandMarkets.

# data[].attributes.attachment_link.description
Chicago, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The breath analyzer industry is poised for significant growth in the near future as advancements in…

# data[].attributes.headline
Global Intraoral/IOL Scanners Market worth $1.0 billion by 2028

# data[].attributes.subject
Global Intraoral/IOL Scanners Market worth $1.0 billion by 2028

# data[].attributes.body
The Global Intraoral Scanner Market in terms of revenue was estimated to be worth $0.6 billion in 2023 and is poised to reach $1.0 billion by 2028, growing at a CAGR of 11.0% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The incidence of dental problems such as dental caries, increase in awareness of oral health and hygiene, increase in the demand for clear aligners, increase in demand for same-day dentistry, technological advancements in intraoral scanners, and the growing market for dental tourism in developing countries are major key drivers for the market. However, the high cost of intraoral scanner systems and the high cost of dental procedures are the factors that impede market growth.

# data[].attributes.attachment_link.readable_text
Chicago, Aug. 04, 2023 (GLOBE NEWSWIRE) -- In the near future, the intraoral scanner industry is poised to experience remarkable growth and advancements. With rapid developments in technology and increasing demand for efficient and patient-friendly dental procedures, intraoral scanners will emerge as an indispensable tool for dental professionals worldwide. These scanners will witness significant improvements in accuracy, speed, and ease of use, empowering dentists to capture precise digital impressions swiftly and enhancing the overall dental experience for patients. Furthermore, advancements in artificial intelligence and machine learning will enable intraoral scanners to automate diagnosis, aid in treatment planning, and optimize chairside workflows. Integration with cloud-based platforms and seamless compatibility with various dental CAD/CAM systems will facilitate streamlined collaboration and enhance communication between dental teams. As the industry continues to innovate, costs are expected to decrease, making these devices more accessible to a broader spectrum of dental practices and fueling the widespread adoption of intraoral scanners, ultimately revolutionizing modern dentistry.

Intraoral Scanner market in terms of revenue was estimated to be worth $0.6 Billion in 2023 and is poised to reach $1.0 Billion by 2028, growing at a CAGR of 11.0% from 2023 to 2028 according to a latest report published by MarketsandMarkets™. With the increase in adoption of newer advanced technologies such as intraoral scanners, with the advent of intraoral scanners, images captured can be viewed on digital displays. The intraoral scanners are easy to operate and provide precise and high-quality images, thus eliminating the time spent and cost. This also helps reduce the time of diagnosis and treatment, as the images are immediately available and can be shared with a practitioner or dental laboratories through the Internet to obtain faster consultations/results.

Market Revenue in 2023

$0.6 Billion

Estimated Value by 2028

$1.0 Billion

Growth Rate

Poised to grow at a CAGR of 11.0%

Market Size Available for

2023-2028

Forecast Period

2023-2028

Forecast Units

Value (USD Billion)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

Intraoral Scanner - End User, Application, Modality, and Region

Geographies Covered

Asia Pacific, North America, Europe, Latin America, the Middle East and Africa

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunities

Potential for growth in emerging countries

Key Market Drivers

Technological advancements in intraoral scanners

Intraoral Scanner market major players covered in the report, such as:

DENTSPLY SIRONA Inc. (US)

3 Shape (US)

Envista Holdings Corporation (US)

Medit (South Korea)

Align Technology Inc. (US)

Planmeca Oy (Finland)

Guangdong Launca medical device technology Co. Ltd (China)

Densys Ltd. (India)

Alliedstar (China)

Panda Scanner (China)

Neoss AG (Switzerland)

Condor Technologies NV (Belgium)

Intelliscan 3D (US)

Runyes Medical Instrument Co. Ltd (South Korea)

BLZ Dental (China)

imes-icore GmbH (Germany)

3M Oral Care (US)

Amann Girrbach AG (Austria)

Shining3D (China)

Ivoclar Vivadent (Liechtenstein)

Fussen Tech (China) and Jiangsu Weiyun Artificial Intelligence Co. Ltd (China)

and Among Others

The study categorizes the intraoral scanner market based on Modality, Application, End User, and Region. Modality Applications End User

Dental Hospitals and Clinics

Dental Academic and research institutes

Other End Users

Region The key stakeholders in the Intraoral Scanner market include:

Manufacturers and distributors of medical devices

Intraoral scanner manufacturers

Contract manufacturers of intraoral scanner

Distributors of intraoral scanner

Research and consulting firms

Raw material suppliers of intraoral scanner

Dental hospitals and clinics

Dental laboratories and associations

Dental practitioners

Dental laboratory technicians

Healthcare institutions

Diagnostic laboratories

Hospitals and clinics

Academic institutions

Research institutions

Government associations

Market research and consulting firms

Venture capitalists and investors

Recent Developments:

In September 2022, DENTSPLY SIRONA Inc. launched a new laptop version of the prime scan intraoral scanner. It provides easy scanning of the intraoral cavity.

In September 2022, one of the market leaders, 3Shape, introduced TRIOS 5 Wireless, a completely new, state-of-the-art intraoral scanner designed to make it easier than ever for dentists to go digital with their dentistry.

In July 2021, DENTSPLY SIRONA Inc.(US) partnered with 3 Shape (Denmark) To provide better access for TRIOS users to SureSmile Clear aligners.

Frequently Asked Questions (FAQs) of Intraoral Scanner Market:
Question 1: Which are the largest and fastest-growing segments of the intraoral scanner market by modality?

Answer: By modality, wired scanners occupy the largest share in 2022, and wireless scanners are expected to grow at the highest CAGR during the forecast period. This faster growth of wireless scanners can be attributed to the fact that they are convenient to use and do not require wires or cords. This makes them more patient-and dentist-friendly in terms of freedom of movement. Both wired and wireless scanners show enhanced images that can be used to provide better dental treatment.

Question 2: Which country occupies the largest share of the intraoral scanner market globally?

Answer: Out of all countries included under Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa, the US occupied the largest share of the market in 2022. This can be chalked down to factors like the presence of major market players in the country and the uptake of the latest technologies to a high number of dental surgeries to be performed.

Question 3: What is the impact of the recession on the intraoral scanner market?

Answer: The impending recession may curb consumer spending on devices and result in a decrease in nonemergency care, like the situation in 2020 amid the COVID-19 pandemic. Similarly, in dental care, elective procedures are expected to be impacted the most, whereas emergency procedures are less likely to show any impact. Since intraoral scanners have applications in both situations, the market for intraoral scanners is expected to show a moderate impact.

Question 4: Out of applications, which is the fastest-growing segment in the forecast period?

Answer: The market is segmented into Prosthodontics, Orthodontics, Implantology, and others based on application. Orthodontics has gained a lot of traction in recent years, and the demand for clear aligners has increased at a lot of pace. Owing to these factors, Orthodontics is expected to be the fastest-growing segment in the intraoral scanners market from 2023 to 2028

Question 5. What are various technologies used in intraoral scanners?

Answer: The technologies used in intraoral scanner includes confocal microscopy technology, triangulation, stereophotogrammetry, three-dimensional motion video technology, and caries detection technology. Caries detection technology is one of the newer advancements in this field. The technology involves diverse ways through which various tooth structures interact with such light is the basis for caries detection utilizing near-infrared light.
Report Objectives:

To define, describe, segment, and forecast the intraoral scanner market by modality, application, end user, and region/country

To provide detailed information about the factors influencing the market growth (drivers, restraints, opportunities, and challenges)

To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market

To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players

To forecast the size of the intraoral scanner market in Europe, North America, Asia Pacific, Latin America, and the Middle East and Africa.

To strategically profile key players in the intraoral scanner market and comprehensively analyze their core competencies2

To track and analyze competitive developments, such as acquisitions, product launches, partnerships, and collaborations

To analyze the impact of the recession on the intraoral scanner market

Related Reports: Dental 3D Printing Market 3D Printing Medical Devices Market Dental Equipment Market Dental Consumables Market Restorative Dentistry Market

# data[].attributes.attachment_link.title
Intraoral Scanner Market is Expected to Reach $1.0 Billion | MarketsandMarkets.

# data[].attributes.attachment_link.description
Chicago, Aug. 04, 2023 (GLOBE NEWSWIRE) -- In the near future, the intraoral scanner industry is poised to experience remarkable growth and advancements....

# data[].attributes.headline
Veterinary Equipment and Supplies Market worth $2.9 Billion by 2027

# data[].attributes.subject
Veterinary Equipment and Supplies Market worth $2.9 Billion by 2027

# data[].attributes.body
The global veterinary equipment market in terms of revenue was estimated to be worth $2.0 billion in 2022 and is poised to reach $2.9 billion by 2027, growing at a CAGR of 8.1% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Veterinary equipment and supplies are used in surgeries and the monitoring & treatment of diseases in animals. Growth in the companion animal population, growing demand for pet insurance and rising animal health expenditure, and the increasing prevalence of diseases in animals are the primary growth drivers for the global market during the forecast period.

# data[].attributes.attachment_link.readable_text
Chicago, July 07, 2022 (GLOBE NEWSWIRE) -- According to the new market research report " Veterinary Equipment and Supplies Market by Type (Consumables, Patient Monitors, Anesthesia, Infusion Pumps), Application (Surgical (Gynecology, Dental), Diagnosis), Animal (Companion, Bovines), End User (Hospitals, Clinics) - Global Forecast to 2027", published by MarketsandMarkets™, the global veterinary equipment market is projected to reach USD 2.9 Billion by 2027 from USD 2.0 Billion in 2022, at a CAGR of 8.1% during the forecast period. The Rising animal health expenditure, growing demand for pet insurance, an increasing number of veterinary practitioners in developed regions, and growth in the companion animals segment are the major growth factors for this market.

Browse in-depth TOC on " Veterinary Equipment and Supplies Market"
445 - Tables
61 - Figures
404 - Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=14169630

The Emerging markets, such as India and China, and growing companion animal ownership in the APAC region are also expected to offer significant growth opportunities for players in the veterinary supplies market. However, low animal health awareness and the high costs of veterinary equipment are factors expected to restrain the markets growth to a certain extent.

The impact of the COVID-19 pandemic and the lockdowns it triggered is visible in various markets, including the veterinary equipment and supplies market. In 2020 and early 2021, the overall growth of various sectors was heavily impacted, specifically in countries with a high incidence rate of COVID-19, such as India, Brazil, China, the US, and several European countries (including Russia, Italy, the UK, and Spain).
The COVID-19 pandemic is expected to negatively impact the veterinary equipment market or its growth during the forecast period. The outbreak of COVID-19 originated from a meat market in Wuhan (China), which has negatively affected the consumption of food products derived from animal sources. Unfavorable changes in regulations and guidelines are hampering the growth of this market. The closing down of manufacturing facilities due to lockdowns, disruptions in supply chains, and recruitment challenges for clinical trials have further impacted the overall market growth. Furthermore, trade barriers in various regions are also expected to restrain the markets growth.
The critical care consumables segment accounted for the largest share during the forecast period.
By type, the veterinary equipment and supplies market is categorized into critical care consumables, anesthesia equipment, fluid management equipment, temperature management equipment, rescue & resuscitation equipment, research equipment, and patient monitoring equipment.
The critical care consumables segment accounted for the largest share of the global veterinary supplies market. The large share of this segment can be attributed to the increasing use of consumables in the monitoring & treating of animals owing to the growing incidence of diseases.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=14169630

The dogs segment accounted for the largest share of small companion animals during the forecast period
The small companion animals segment includes dogs, cats, and other small companion animals. The veterinary equipment and supplies market for dogs accounted for the largest share in 2021. The increasing adoption of dogs and the rising prevalence of chronic diseases are the key factors driving the growth of the veterinary equipment market for dogs.
The surgical application segment accounted for the largest share in the veterinary equipment and supplies market
By application, the veterinary supplies market is categorized into surgical application and diagnosis, monitoring, and therapy. The surgical application segment accounted for the largest share of the global veterinary equipment market. Factors such as the increasing number of pet owners and growing animal healthcare expenditure are leading to improvements in veterinary healthcare infrastructure across the globe, thus encouraging the use of surgical equipment.
The veterinary clinics accounted for the largest share of the global veterinary equipment and supplies market
By end user, the veterinary supplies market is categorized into veterinary clinics, veterinary hospitals, and veterinary research institutes. The veterinary clinics accounted for the largest share of the global market. The large share of this segment can be attributed to the growing number of patient visits and the increasing number of private clinical practices.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=14169630

APAC is expected to grow at the highest growth rate in 2021
The Asia Pacific market is projected to grow at the highest CAGR during the forecast period. Factors such as the growing population of companion & livestock animals and rising per capita income in these countries are driving the growth of this regional segment. The APAC countries, especially India and China, represent the highest growth potential for veterinary equipment and supplies. Livestock farming is a major source of income in these countries. Furthermore, the demand for animal-based products, such as meat and milk, is increasing in the emerging APAC markets.
Key players in the Veterinary Equipment and Supplies Market:

B. Braun Vet Care GmbH (Germany),

Covetrus Inc. (US),

BD Animal Health (US),

Cardinal Health (US),

ICU Medical, Inc. (US),

Neogen Corporation (US),

Integra LifeSciences (US),

Midmark Corporation (US),

Jorgensen Laboratories (US),

Shenzhen Mindray Animal Medical Technology Co., Ltd. (China),

Nonin Medical (US),

Digicare Animal Health (US),

Hallowell Engineering And Manufacturing Corporation (US),

Grady Medical (US),

Mila International Inc. (US),

Burtons Medical Equipment Ltd (UK),

Bionet America, Inc (South Korea),

Masimo Corporation (US),

Vetronic Services Ltd (UK),

Advancis Veterinary (UK),

New Gen Medical Systems (India),

Dispomed (Canada),

Eickemeyer (Germany),

J & J Instruments (US), and

Avante Animal Health (US).

Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting
Browse Related Reports:
Veterinary Diagnostics Market by Product(Instruments, Consumables), Technology (Immunodiagnostics (Lateral Flow, ELISA), Clinical Biochemistry, PCR, Hematology, Urinalysis), Animal (Dog, Cat, Cattle, Pig, Poultry, Horse) (2022 - 2026)
https://www.marketsandmarkets.com/Market-Reports/veterinary-diagnostics-market-26017452.html

Veterinary Imaging Market by Product (Ultrasound (2D, 3D, Doppler), X-Ray (CR, DR), MRI, CT, Software, Reagent), Therapeutic Area (Orthopedics, Gynecology, Oncology, Dentistry), Animal (Small, Large), End User (Hospital, Clinic) - Global Forecast to 2026
https://www.marketsandmarkets.com/Market-Reports/veterinary-imaging-market-80889726.html

# data[].attributes.attachment_link.title
Veterinary Equipment and Supplies Market worth $2.9 Billion by 2027 - Exclusive Report by MarketsandMarkets™

# data[].attributes.attachment_link.description
Chicago, July 07, 2022 (GLOBE NEWSWIRE) -- According to the new market research report "Veterinary Equipment and Supplies Market by Type (Consumables,...

# data[].attributes.headline
Liquid Biopsy Market worth $10.0 billion by 2027

# data[].attributes.subject
Liquid Biopsy Market worth $10.0 billion by 2027

# data[].attributes.body
The Global Liquid Biopsy Market in terms of revenue was estimated to be worth $4.3 billion in 2022 and is poised to reach $10.0 billion by 2027, growing at a CAGR of 18.3% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market is driven by the rising incidence and prevalence of cancer and the increasing preference for non-invasive treatment procedures.

# data[].attributes.attachment_link.title
Liquid Biopsy Market worth $10.0 billion by 2027 - Exclusive Report by MarketsandMarkets™

# data[].attributes.attachment_link.description
/PRNewswire/ -- Liquid Biopsy Market is projected to reach USD 10.0 billion by 2027 from USD 4.3 billion in 2022, at a CAGR of 18.3% according to a new report…

# data[].attributes.headline
Pen Needles Market worth $2.5 billion by 2028

# data[].attributes.subject
Pen Needles Market worth $2.5 billion by 2028

# data[].attributes.body
Pen Needles Market in terms of revenue was estimated to be worth $1.6 Billion in 2023 and is poised to reach $2.5 Billion by 2028, growing at a CAGR of 9.1% from 2023 to 2028 according to a new report by MarketsandMarkets™.
The increasing healthcare expenditure on diabetes care, and mandates pertaining to safety pen needles are some factors that provide lucrative opportunities for key players in the market. However, reuse and misuse of pen injectors, and factors such as needles anxiety and preference of alternative modes of drug delivery, such as infusion pumps, are expected to restrain the market and pose significant challenges for market players.

# data[].attributes.attachment_link.readable_text
Chicago, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The pen needles industry is poised for significant growth in the near future. With the increasing prevalence of diabetes and the growing demand for convenient and efficient insulin delivery methods, pen needles are set to play a pivotal role in this space. Advancements in technology, such as ultra-thin and painless needles, coupled with user-friendly designs, will continue to drive innovation. Furthermore, the global focus on healthcare and the importance of self-administered therapies during the COVID-19 pandemic have highlighted the importance of pen needles, further boosting their adoption. As healthcare systems worldwide evolve, the pen needles industry is expected to flourish, providing patients with improved access to precise and hassle-free insulin delivery solutions.

Pen Needles market in terms of revenue was estimated to be worth $1.6 billion in 2023 and is poised to reach $2.5 billion by 2028, growing at a CAGR of 9.1% from 2023 to 2028 according to a latest report published by MarketsandMarkets™. Major factors such as growing adoption of self-administration and decreasing price of insulin formulations and related devices by major players are expected to drive the market during the forecast period. In this report, the pen needles market is segmented by type, length, application, mode of purchase, setting, and region.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=75948613

Market Revenue in 2023

$1.6 billion

Estimated Value by 2028

$2.5 billion

Growth Rate

Poised to grow at a CAGR of 9.1%

Market Size Available for

2021-2028

Forecast Period

2023-2028

Forecast Units

Value (USD Billion)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

Application, Type, Setting, Mode of Purchase, Region, and Length

Geographies Covered

Europe (Germany, the UK, France, Italy, Spain, and RoE), North America (US & Canada), LATAM (Brazil, Mexico, and RoLATAM), APAC (Japan, China, Australia, South Korea India, and the RoAPAC), and MEA

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunities

Emerging markets

Key Market Drivers

Growing adoption of self-administration

Pen Needles market major players covered in the report, such as:

Embecta Corp. (US)

Novo Nordisk (Denmark)

Ypsomed Holding AG (Switzerland)

B. Braun Melsungen AG (Germany)

Owen Mumford (UK)

Terumo Corporation (Japan)

Nipro Corporation (Japan)

Allison Medical (US)

AdvaCare Pharma (US)

Berpu Medical Technology (China)

ARKRAY (Japan)

GlucoRx (UK)

HTL-STREFA (Poland)

UltiMed, (US)

Hindustan Syringes and Medical Devices (India)

Artsana Group (Italy)

PromiseMed Diabetes Care (Canada)

Montmed (Canada)

Trividia Health (US)

VOGT Medical Vertrieb (Germany)

Van Heek Medical (Netherlands)

Simple Diagnostics (US)

Iyon (Turkey)

Links Medical Products (US)

MHC Medical Products (US)

and Among Others

Buy a Pen Needles Industry Report (250 Pages PDF with Insightful Charts, Tables, and Figures): This research report categorizes the pen needles market based on setting, length, region, type, mode of purchase, and application. By Type https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=75948613 By Length By Application

Standard Pen Needles

Safety Pen Needles

By Mode of Purchase

Insulin Therapy

GLP-1 Therapy

Growth Hormone Therapy

Osteoporosis

Other Applications

By Setting By Region Request for FREE Sample Pages: The key stakeholders in the Pen Needles market include: https://www.marketsandmarkets.com/requestsampleNew.asp?id=75948613 Recent Developments:

Prescription-based

Over the Counter

Online Purchase

Other Modes of Purchase

Frequently Asked Questions (FAQs) of Pen Needles Market: What are the drivers for the pen needles market?

Manufacturers of pen needles, insulin pens, injectable drug delivery devices, and diabetes supplies

Original equipment manufacturing companies

Suppliers and distributors of pen needles, insulin pens, injectable drug delivery devices, and diabetes supplies

Healthcare service providers

Teaching hospitals and academic medical centers

Health insurance players

Government bodies/municipal corporations

Regulatory bodies

Business research and consulting service providers

Authorities framing reimbursement policies for pen needles

Venture capitalists

Market research and consulting firms

By Type, which segment provides the most opportunity for growth?

In February 2023, Montmed, Inc. (Canada) announced issuance of a second US Patent for Sitesmart Pen Needles.

In April 2022, Embecta Corp. (US) completed the spin-off from Becton, Dickinson and Company (US) and started operating globally as a standalone pure-play diabetes care company.

In February 2021, UltiMed, Inc. (US) launched UltiCare safety pen needles in two sizes, 5mm 30G and 8mm 30 G.

In January 2021, NHS (UK) chose Owen Mumford (UK) as the sole supplier of safety pen needles. With this partnership, Owen's pen needles will be used in all NHS Wales hospitals.

Who are the leading vendors operating in this market?
A favorable reimbursement scenario in select countries and decreasing price of insulin formulations and related devices by major players are likely to propel the market growth, among other factors, during the forecast period. Additionally, the growing preference for biosimilar drugs, emerging markets, increasing healthcare expenditure on diabetes care, and mandates pertaining to safety pen needles provide a wide range of growth opportunities for key players in the market.
Which region is expected to witness significant demand for pen needles in the coming years?
By type, the safety pen needles segment is expected to grow at a faster rate, while the standard pen needles segment is set to occupy the larger market share, even during the forecast period. The fast growth of the safety pen needles segment can be attributed to the fact that many national and international organizations are recommending using safety syringes and needles to prevent needlestick injuries. Since pen needles are most often used at home without the presence of a healthcare professional, usage of pen needles gains even more importance.
What is the impact of recession on pen needles market in the coming years?
Embecta Corp. (US), Novo Nordisk (Denmark), Ypsomed Holding AG (Switzerland), and B. Braun Melsungen AG (Germany) are some of the leading players in the pen needles market.
Get 10% Free Customization on this Report: Report Objectives: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=75948613 Related Reports: Insulin Delivery Devices Market Topical Drug Delivery Market Pharmaceutical Drug Delivery Market
The Asia Pacific is the fastest-growing geographic segment in the pen needles market, during the forecast period. This is attributed to the rising population base with chronic diseases, especially diabetes, increase in the healthcare expenditure, growing utilization of pen injectors, and lower manufacturing costs in the region.
Content Source: https://www.marketsandmarkets.com/PressReleases/pen-needles.asp
Since diabetes is a chronic condition which requires daily injections, the existing demand for pen needles is expected to remain stable during the recession. However, other cheaper methods of administering insulin, including syringes, might become the better choice for new users.

To define, describe, and forecast the global pen needles market on the basis of length, application, type, setting, mode of purchase, and region.

To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)

To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market

To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for major market leaders

To forecast the size of the market segments with respect to five main regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, Southeast Asia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and Rest of Latin America), and the Middle East & Africa

To profile the key market players and comprehensively analyze their market shares and core competencies2

To track and analyze competitive developments such as partnerships, agreements, collaborations, and expansions in the global pen needles market

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/pen-needles-market.asp

# data[].attributes.attachment_link.title
Pen Needles Market is Expected to Reach $2.5 billion | MarketsandMarkets.

# data[].attributes.attachment_link.description
Chicago, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The pen needles industry is poised for significant growth in the near future. With the increasing prevalence...

# data[].attributes.headline
Metabolism Assays Market worth $2.1 billion by 2028 

# data[].attributes.subject
Metabolism Assays Market worth $2.1 billion by 2028 

# data[].attributes.body
Metabolism Assays market in terms of revenue was estimated to be worth $1.4 billion in 2023 and is poised to reach $2.1 billion by 2028, growing at a CAGR of 7.8% from 2023 to 2028 according to a latest report published by MarketsandMarkets™. The rising investments by pharmaceutical and biotechnology companies for drug metabolism studies and disease research and the use of metabolism assays for fitness and sports are the factors driving the growth of this market. However, the high cost of metabolism assay analyzers and the presence of alternative methods and techniques will restrain the market during the forecast period.

# data[].attributes.attachment_link.readable_text
Chicago, Oct. 04, 2023 (GLOBE NEWSWIRE) -- The metabolism assays industry is poised for remarkable growth in the near future, driven by advancements in biotechnology, personalized medicine, and drug development. With the increasing emphasis on understanding the metabolic processes within cells, tissues, and organisms, there is a growing demand for innovative assays that can provide detailed insights into metabolism. These assays are expected to play a pivotal role in drug discovery, toxicity screening, and the development of precision medicine approaches. As technology continues to evolve, we can anticipate the emergence of more sophisticated and high-throughput metabolism assays, enabling researchers and pharmaceutical companies to unlock new therapeutic targets and enhance our understanding of metabolic disorders, ultimately leading to improved healthcare outcomes.

Metabolism Assays market in terms of revenue was estimated to be worth $1.4 billion in 2023 and is poised to reach $2.1 billion by 2028, growing at a CAGR of 7.8% from 2023 to 2028 according to a latest report published by MarketsandMarkets™. The rising investments by pharmaceutical and biotechnology companies for drug metabolism studies and disease research and the use of metabolism assays for fitness and sports are the factors driving the growth of this market. However, the high cost of metabolism assay analyzers and the presence of alternative methods and techniques will restrain the market during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=135163479

Market Revenue in 2023

$1.4 billion

Estimated Value by 2028

$2.1 billion

Growth Rate

Poised to grow at a CAGR of 7.8%

Market Size Available for

2021-2028

Forecast Period

2023-2028

Forecast Units

Value (USD Billion)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

Product, Technology, Application, and End User

Geographies Covered

North America, Europe, Asia Pacific, Rest of the World

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunities

Integration with wearable devices

Key Market Drivers

Increasing funding and investments in metabolic research

Metabolism Assays market major players covered in the report, such as:

Merck KGaA (Germany)

Thermo Fisher (US)

Abcam Plc. (UK)

Agilent Technologies Inc. (US)

Kaneka Eurogentec S.A. (Belgium)

Sartorius AG (Germany)

Promega Corporation (US)

Elabscience Biotechnology Inc. (US)

RayBiotech Life Inc. (US)

BMG LABTECH (Germany)

BIOTREND ChemiKalien GmbH (Germany)

3H Biomedical AB (Sweden)

BioAssay Systems (US)

EMELCA Bioscience (Netherlands)

Creative Bioarray (US)

Tempo Bioscience, Inc (US)

Ncardia (Netherlands)

NOVOCIB (France)

Eton Bioscience Inc. (US)

Cayman Chemical Company (US)

Enzo Lifesciences, Inc. (US)

Abnova Corporation (Taiwan)

and Among Others

Buy a Metabolism Assays Industry Report (192 Pages PDF with Insightful Charts, Tables, and Figures): This research report categorizes the Metabolism assays market into the following segments and subsegments: Regional Split Product Split https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=135163479 Application Split End User Split

Instruments & Analyzers

Assay Kits & Reagents

Technology Split

Colorimetry

Fluorimetry

Spectrometry

Request for FREE Sample Pages: The key stakeholders in the Metabolism Assays market include: https://www.marketsandmarkets.com/requestsampleNew.asp?id=135163479 Recent Developments:

Hospitals

Diagnostics Laboratories

Pharmaceutical & Biotechnology Companies and CROs & Academic Research Institutes

Frequently Asked Questions (FAQs) of Metabolism Assays Market:

Senior Management

Finance/Procurement Department

Pathologist/Researchers/Technician

In 2022, Thermo Fisher Scientific, Inc. (US) collaborated with Symphogen (Denmark) and Servier (France) for biopharmaceutical discovery and development laboratories.

In 2021, Abcam Plc. (UK) acquired BioVision (UK). This acquisition of BioVision represents a compelling strategic fit for Abcam. This will bring greater control over the innovation and distribution of BioVision's product portfolio and create value through portfolio expansion and leveraging Abcam's global channels to market.

In 2021, Agilent Technologies Inc. (US) launched Agilent Seahorse XF HS Miniplate which is the latest addition to Agilent's range of Seahorse XF platforms, which analyze mitochondrial respiration, glycolysis, and ATP production in live cells, in real-time.

Question 1: What is the projected market value of the global Metabolism assays market?
Answer: The global market of Metabolism assays is projected to reach USD 2.1 Billion by 2028

Question 2: What is the estimated growth rate (CAGR) of the global Metabolism assays market for the next five years?
Answer: The global Metabolism assays market is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.8% from 2023 to 2028.
Question 3: Which product segment of the Metabolism assays market witness the highest market share?
Answer: The assay kits & reagents segment is projected to observe the highest market share due to its growing use in diagnostics.
Get 10% Free Customization on this Report: Report Objectives: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=135163479 Related Reports: High Throughput Screening Market Cell-based Assays Market Point of Care Molecular Diagnostics Market Research Insight: Content Source: https://www.marketsandmarkets.com/PressReleases/metabolism-assays.asp https://www.marketsandmarkets.com/ResearchInsight/metabolism-assays-market.asp
Question 4: What are the major revenue pockets in the Metabolism assays market currently?
Answer: Asia Pacific is expected to grow at the highest pace during the forecast period, primarily due to large patient pool in China, Japan, and India. Currently, China is considered a huge market due to the emerging local players.

Question 5: Who are the key players operating in the metabolism assays market, and what are the key growth strategies applied?
Answer: In 2022, the global Metabolism assays market was dominated by Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), and Agilent Technologies Inc. (US). The players adopted key strategies, such as collaborations, partnerships, acquisitions, expansions, and product launches, to increase their market penetration.

To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)

To define, describe, segment, and forecast the metabolism assays market by product, technology, application, end-user, and region

To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players

To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall metabolism assay market

To forecast the size of the metabolism assays market in five main regions along with their respective key countries, namely, North America, Europe, the Asia Pacific, Rest of the world.

To profile key players in the metabolism assays market and comprehensively analyze their core competencies and market shares

To track and analyze competitive developments, such as acquisitions; product launches; expansions; collaborations, agreements, & partnerships; and R&D activities of the leading players in the metabolism assays market.

To benchmark players within the metabolism assays market using the Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product strategy

# data[].attributes.attachment_link.title
Metabolism Assays Market is Expected to Reach $2.1 billion | MarketsandMarkets.

# data[].attributes.attachment_link.description
Chicago, Oct. 04, 2023 (GLOBE NEWSWIRE) -- The metabolism assays industry is poised for remarkable growth in the near future, driven by advancements in...

# data[].attributes.headline
Global Single-Use Assemblies Market worth $5.2 billion by 2028

# data[].attributes.subject
Global Single-Use Assemblies Market worth $5.2 billion by 2028

# data[].attributes.body
Single Use Assemblies Market in terms of revenue was estimated to be worth $2.5 billion in 2023 and is poised to reach $5.2 billion by 2028, growing at a CAGR of 15.6% from 2023 to 2028

# data[].attributes.attachment_link.title
Single Use Assemblies Market worth $5.2 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
PRNewswire/ -- The single-use assemblies industry is poised for significant growth in the near future, driven by the increasing demand for flexible and...

# data[].attributes.headline
Pen Needles Market worth $2.5 billion by 2028

# data[].attributes.subject
Pen Needles Market worth $2.5 billion by 2028

# data[].attributes.body
The global pen needles market in terms of revenue was estimated to be worth $1.6 billion in 2023 and is poised to reach $2.5 billion by 2028, growing at a CAGR of 9.1% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

# data[].attributes.attachment_link.readable_text
, /PRNewswire/ -- The pen needles industry is poised for substantial growth in the near future as advancements in diabetes management and injectable therapies continue to drive innovation. With a rising global prevalence of diabetes and an increasing emphasis on patient convenience and safety, pen needles are expected to evolve with more user-friendly designs, enhanced precision, and compatibility with a wider range of drug formulations. The integration of smart technology, such as Bluetooth connectivity and dose tracking, will likely become more common, allowing patients and healthcare providers to monitor and optimize treatment regimens. Moreover, the industry is anticipated to witness increased competition and investment, resulting in cost-effective and sustainable solutions for individuals with diabetes, ultimately improving their quality of life and treatment outcomes.

Pen Needles Market in terms of revenue was estimated to be worth $1.6 Billion in 2023 and is poised to reach $2.5 Billion by 2028, growing at a CAGR of 9.1% from 2023 to 2028 according to a new report by MarketsandMarkets™.

The increasing healthcare expenditure on diabetes care, and mandates pertaining to safety pen needles are some factors that provide lucrative opportunities for key players in the market. However, reuse and misuse of pen injectors, and factors such as needles anxiety and preference of alternative modes of drug delivery, such as infusion pumps, are expected to restrain the market and pose significant challenges for market players.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=75948613 Browse in-depth TOC on "Pen Needles Market" Pen Needles Market"Discounts offered on the online purchases of pen needles to drive the growth of this segment" Scope:
Online purchase is the fastest growing segment of the pen needles market, by mode of purchase. The convenience of online purchases, and time-efficient drive the growth of this segment. Additionally, patients who need pen needles on a regular basis can even get subscriptions for a monthly supply, which further makes it more convenient.
"Asia Pacific likely to emerge as the fastest-growing pen needles market, globally"
The over-the counter purchase segment accounted for the largest share of the pen needles market by mode of purchase, in 2022. This is due to the large number of patients buying pen needles from local pharmacies without the need of a prescription. Additionally, distributors and suppliers provide discounts to hospitals and clinics on bulk purchases, which further contributes to the large share of this segment.
Request Sample Pages: Pen Needles Market Drivers: Dynamics: Restraints: https://www.marketsandmarkets.com/requestsampleNew.asp?id=75948613 Opportunities: Challenge: Key Market Players of Pen Needles Industry Recent Developments: : Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=75948613 Pen Needles Market Advantages:
The pen needles market is segmented into five major regions, namely, North America, Europe, Asia Pacific (APAC), Latin America, and the Middle East and Africa. Asia Pacific attributes to the highest growth rate amongst the other regions. The emerging Asian countries, such as China, India, and Japan, are offering significant growth opportunities for market players. The expansion of healthcare infrastructure and increase in disposable incomes, increase incidences of diabetes are factors which are likely to support the growth of pen needles market in the region.
Related Reports:

Growing adoption of self-administration

Preference for alternative modes of drug delivery

The key players in the pen needles market B. Braun Melsungen AG (Germany), Embecta Corp. (US), and Novo Nordik A/S (Germany). These companies adopted strategies such as collaborations, partnerships, and investments to strengthen their presence in the market.

In February 2023, Montmed, Inc. (Canada) announced issuance of a second US Patent for Sitesmart Pen Needles.

In April 2022, Embecta Corp. (US) completed the spin-off from Becton, Dickinson and Company (US) and started operating globally as a standalone pure-play diabetes care company.

In February 2021, UltiMed, Inc. (US) launched UltiCare safety pen needles in two sizes, 5mm 30G and 8mm 30 G.

In January 2021, NHS (UK) chose Owen Mumford (UK) as the sole supplier of safety pen needles. With this partnership, Owen's pen needles will be used in all NHS Wales hospitals.

Convenience: Pen needles are user-friendly and require minimal setup, making them a convenient option for self-administration of medications, particularly for individuals with diabetes.

Precision: These needles offer precise and consistent dosing, reducing the risk of medication errors and ensuring accurate delivery of treatment.

Pain Reduction: Many pen needles are designed with features like ultra-thin gauges and advanced injection mechanisms to minimize pain and discomfort during injections.

Portability: Pen needles are compact and easily portable, allowing individuals to carry them discreetly and administer injections anywhere, contributing to a more flexible lifestyle.

Reduced Fear: Their compact design and less intimidating appearance can help alleviate the fear associated with injections, especially in pediatric and needle-phobic patients.

Compatibility: Pen needles are compatible with a wide range of medications, making them versatile for various therapeutic needs beyond diabetes.

Smart Technology Integration: Many modern pen needles are equipped with smart features like dose memory, Bluetooth connectivity, and mobile apps for tracking and monitoring injections, enabling patients and healthcare providers to manage treatment more effectively.

Reduced Cross-Contamination Risk: Disposable pen needles reduce the risk of cross-contamination as they are designed for single use, promoting safety and hygiene.

Cost-Effective: The competitive market has driven prices down, making pen needles an affordable option for a broad patient demographic.

Improved Quality of Life: The advantages of pen needles, such as pain reduction, precision, and convenience, collectively contribute to an improved quality of life for individuals requiring injectable therapies, ultimately enhancing treatment adherence and overall well-being.

About MarketsandMarkets™:
Needles Market - Global Forecasts To 2027

Topical Drug Delivery Market - Global Forecasts to 2027

Pharmaceutical Drug Delivery Market - Global Forecasts to 2026

Injection Pen Market - Global Forecasts to 2026

Wearable Injectors Market - Global Forecasts to 2026

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/pen-needles-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/pen-needles.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Pen Needles Market Worth $2.5 Billion | MarketsandMarkets

# data[].attributes.attachment_link.description
PRNewswire/ -- The pen needles industry is poised for substantial growth in the near future as advancements in diabetes management and injectable therapies...

# data[].attributes.headline
Cell Dissociation Market is Expected to Reach $1.4 Billion by 2028

# data[].attributes.subject
Cell Dissociation Market is Expected to Reach $1.4 Billion by 2028

# data[].attributes.body
The global cell dissociation market in terms of revenue was estimated to be worth $0.6 billion in 2023 and is poised to reach $1.4 billion by 2028, growing at a CAGR of 17.8% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

# data[].attributes.attachment_link.readable_text
Chicago, Aug. 09, 2023 (GLOBE NEWSWIRE) -- In the near future, the cell dissociation industry is poised for transformative growth, driven by advancements in biotechnology and tissue engineering. Innovative techniques utilizing enzymatic and mechanical dissociation methods will revolutionize cell isolation, enabling more efficient and gentle extraction of cells from complex tissues. This will have profound implications across various sectors, from regenerative medicine and drug development to personalized therapies. The industry's evolution will be characterized by automated and high-throughput dissociation platforms, offering researchers and clinicians unprecedented access to diverse cell populations, accelerating scientific discovery and paving the way for tailored treatments that harness the full potential of cellular therapies.

Cell Dissociation market in terms of revenue was estimated to be worth $0.6 Billion in 2023 and is poised to reach $1.4 Billion by 2028, growing at a CAGR of 17.8% from 2023 to 2028 according to a latest report published by MarketsandMarkets™. Growing focus on personalized medicine is set to drive the market growth. Novel cell dissociation technologies are being developed to address the research needs of developing personalized medicine. Advent of new cell dissociation technologies is expected resolve the limitations of personalized cancer treatment.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=97548003 Cell Dissociation market major players covered in the report, such as:

Market Revenue in 2023

$0.6 Billion

Estimated Value by 2028

$1.4 Billion

Growth Rate

Poised to grow at a CAGR of 17.8%

Market Size Available for

2021-2028

Forecast Period

2023-2028

Forecast Units

Value (USD Billion)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

Product, Tissue Type, Application, End User, and Region

Geographies Covered

North America, Europe, Asia Pacific, Latin America and MEA

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunities

Advancements in non-enzymatic tissue dissociation

Key Market Drivers

Increase in recombinant therapeutics sourced from mammalian cells

Buy Cell Dissociation Industry Report (204 Pages PDF with Insightful Charts, Tables, and Figures): This research report categorizes the cell dissociation market into the following segments and subsegments: https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=97548003

Merck KGaA (Germany)

Danaher Corporation (US)

Thermo Fisher Scientific Inc. (US)

Corning Incorporated (US)

Becton, Dickinson and Company (US)

STEMCELL Technologies (Canada)

PromoCell GmbH (Germany)

Miltenyi Biotec (Germany)

ATCC (US)

HiMedia Laboratories (India)

PAN-Biotech (Germany)

CellSystems GmbH (Germany)

AMSBIO (England)

Neuromics (US)

VitaCyte LLC. (US)

ALSTEM (US)

Biological Industries (Israel)

Gemini Bio (US)

Innovative Cell Technologies Inc. (US)

Central Drug House (P) Ltd. (India)

Worthington Biochemical Corporation (US)

Capricorn Scientific (Germany)

Abeomics (US)

Genlantis Inc. (US)

and Among Others

Tissue Type
Product
Application

Enzymatic Dissociation Agents

Collagenase

Trypsin

Papain

Elastase

DNase

Hyaluronidase

Other Enzymes

Non-Enzymatic Dissociation Agents

Instruments & Accessories

End User

Connective Tissues

Epithelial Tissues

Other Tissues

Region Request for FREE Sample Pages: The key stakeholders in the Cell Dissociation market include: https://www.marketsandmarkets.com/requestsampleNew.asp?id=97548003

Tissue dissociation

Cell detachment

Recent Developments:

Pharmaceutical and Biotechnology companies

Research and Academic Institutes

Other End Users

Frequently Asked Questions (FAQs) of Cell Dissociation Market:

Research Institutions and Laboratories: These entities use cell dissociation techniques to isolate and study specific cell types for various research purposes, contributing to advancements in science and medicine.

Biotechnology and Pharmaceutical Companies: These companies leverage cell dissociation methods to develop new drugs, conduct preclinical testing, and explore therapeutic applications, driving innovation in the pharmaceutical and biotech sectors.

Reagent and Equipment Suppliers: Suppliers of enzymes, chemicals, instruments, and other necessary tools for cell dissociation play a pivotal role in enabling efficient and effective cell isolation processes.

Regulatory Agencies and Ethics Committees: These stakeholders ensure that cell dissociation methods are used safely, ethically, and in compliance with established guidelines, maintaining the integrity of research and applications.

Healthcare Providers and Clinicians: Dissociated cells are used in diagnostics, personalized medicine, and regenerative therapies, making healthcare providers and clinicians crucial in translating dissociation techniques into practical medical applications.

Investors and Funding Organizations: Investors provide financial support that drives research, development, and innovation in cell dissociation technologies, influencing the direction and pace of advancements in the field.

Patients and Patient Advocacy Groups: As potential beneficiaries of advancements in cell dissociation, patients and their advocates have a vested interest in the responsible and effective use of these techniques for improved treatments and outcomes.

Academic and Industry Researchers: Scientists and researchers across academia and industry utilize cell dissociation methods to explore cellular functions, disease mechanisms, and potential therapeutic interventions, contributing to the expansion of knowledge.

Educational Institutions: These institutions train future scientists, technicians, and healthcare professionals in the principles and techniques of cell dissociation, ensuring a skilled workforce to sustain the field's growth.

Government Agencies: Government bodies influence the funding, regulation, and oversight of cell dissociation research and applications, contributing to the overall development and responsible use of these technologies.

Non-Profit Organizations: Organizations focused on specific diseases or scientific advancement may support research and advocacy related to cell dissociation, furthering the understanding and application of these methods.

These stakeholders collectively shape the Cell Dissociation market's trajectory, from scientific discovery and innovation to practical applications in medicine and industry.

In 2020, Miltenyi Biotec launched automated and closed adherent cell culture solutions on CliniMACS Prodigy.

In 2020, Merck the company expanded its Life Sciences production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire (US).

In 2020, STEMCELL Technologies partnered with CollPlant to secure CollPlant rhCollagen for STEMCELL's use in cell culture applications.

In 2021, Danaher (Cytiva) partnered with Diamyd Medical, wherein Diamyd selected Cytiva's FlexFactory platform for making precision medicine type-1 diabetes vaccines.

In 2021, Danaher (Cytiva) collaborated with the Government of Telangana (India) to strengthen the biopharma industry in India with new labs.

Question 1: What is the projected market value of the global cell dissociation market?
Answer: The global market of cell dissociation is projected to reach USD 1.4 Billion by 2028.

Question 2: What is the estimated growth rate (CAGR) of the global cell dissociation market for the next five years?
Answer: The global cell dissociation market is projected to grow at a compound annual growth rate (CAGR) of 17.8% from 2023 to 2028.
Get 10% Free Customization on this Report: Report Objectives: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=97548003 Related Reports: Regenerative Medicine Market Research Insight: Content Source: https://www.marketsandmarkets.com/PressReleases/cell-dissociation.asp https://www.marketsandmarkets.com/ResearchInsight/cell-dissociation-market.asp
Question 3: Who are the major players offering cell dissociation in the market?
Answer: Merck KGaA (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Corning Incorporated (US), and Becton, Dickinson and Company (US)

Question 4: Which type of segment of the global cell dissociation market is expected to witness the highest growth?
Answer: The tissue dissociation segment is projected to grow at the highest CAGR during the forecast period.

Question 5: Which end user segment is expected to grow at the highest CAGR during the forecast period?
Answer: The pharmaceutical and biotechnology industries to register the highest growth during the forecast period.

To define, describe, and forecast the global cell dissociation market based on product, tissue type, application, end user, and region

To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)

To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market

To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders

To forecast the size of market segments with respect to four main regions-North America, Europe, Asia Pacific, Latin America and the Middle East and Africa

To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies

To track and analyze competitive developments such as acquisitions, new product launches, expansions, regulatory approvals, and agreements in the cell dissociation market

# data[].attributes.attachment_link.title
Cell Dissociation Market is Expected to Reach $1.4 Billion | MarketsandMarkets.

# data[].attributes.attachment_link.description
Chicago, Aug. 09, 2023 (GLOBE NEWSWIRE) -- In the near future, the cell dissociation industry is poised for transformative growth, driven by advancements...

# data[].attributes.headline
Cancer Diagnostics Market worth $26.6 billion by 2026

# data[].attributes.subject
Cancer Diagnostics Market worth $26.6 billion by 2026

# data[].attributes.body
The Global Cancer Diagnostics Market in terms of revenue was estimated to be worth $17.2 billion in 2021 and is poised to grow at a CAGR of 11.5% from 2021 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth of the market is driven mainly by increasing incidence of cancer and growth in the number of private diagnostic laboratories.

# data[].attributes.attachment_link.readable_text
Published October 6, 2023

Cancer Diagnostics market in terms of revenue was estimated to be worth $17.2 billion in 2021 and is poised to reach $26.6 billion by 2026, growing at a CAGR of 11.5% from 2021 to 2026 according to a latest report published by MarketsandMarkets™
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186559121 Cancer Diagnostics Industry Dynamics Drivers: Growth in the number of private diagnostic centers
The Global Cancer Diagnostics Market in terms of revenue was estimated to be worth $17.2 billion in 2021 and is poised to grow at a CAGR of 11.5% from 2021 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth of the market is driven mainly by increasing incidence of cancer and growth in the number of private diagnostic laboratories.

The number of private diagnostic centers is increasing across the globe as there is a rising demand for diagnostic imaging procedures and a growing burden on public hospitals due to the limited number of imaging modalities at their disposal. In January 2021, FUJIFILM Corporation opened NURA, a medical screening center focusing on cancer screening in Bangalore, India. This medical screening center is operated by FUJIFILM DKH LLP (FUJIFILM DKH) and Dr. Kutty's Healthcare (DKH). FUJIFILM DKH LLP (FUJIFILM DKH) is a joint venture of FUJIFILM and Dr. Kutty's Healthcare (DKH), which runs hospitals and screening centers in India and the Middle East.

Opportunities: Recommendations for breast cancer screening
Challenges: Increasing adoption of refurbished diagnostic imaging systems
In an attempt to detect cancer in the early stages and bring down the mortality rate, governments in developed countries and primary care doctors are recommending cancer screening tests for patients. The US Preventive Services Task Force (USPSTF) recommends screening for colorectal cancer starting at 50 years of age to 75 years of age in the US as a means of preventing disease incidence and ensuring early-stage treatment. Canada has also implemented guidelines for biennial colorectal cancer screening for people aged 50 to 74 years.

Many hospitals in developing countries cannot invest in diagnostic imaging equipment due to their higher cost, poor reimbursement rates, and budgetary constraints. However, due to the high demand for diagnostic imaging procedures in these nations, hospitals that cannot afford to invest in new imaging systems prefer to opt for refurbished ones. Refurbished systems are priced lower than new systems and are approximately in the range of 40% to 60% of the original price of the equipment.
Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=186559121 The consumables segment of cancer diagnostics market, is expected to grow at the highest CAGR during the forecast period
Owing to this, many market leaders are now promoting refurbished devices through various programs. For instance, Siemens' Medical Proven Excellence Program, GE Healthcare's Gold Seal Program, and Philips' Diamond Select Program are some noteworthy global refurbishing programs that promote the utilization of refurbished diagnostic imaging systems.
By technology, the Biopsy testing segment accounted for the largest industry share in 2020
Based on the product, the market is segmented into consumables and instruments. The consumables segment is projected to witness the highest growth during the forecast period. The repeated purchase and high consumption, and the high prevalence of diseases the major factors supporting the growth of this segment.
Hospitals are the largest end-users of the cancer diagnostics industry
Based on the technology, the cancer diagnostics market is segmented into IVD testing, imaging based technique and biopsy technique. The IVD testing segment accounted for the largest market share in 2020. The increasing incidence of cancer and technological advancement are major driving factors for this market.
North America dominates the global lung cancer diagnostics industry
Based on end-users, the cancer diagnostics market is segmented into hospitals and diagnostic laboratories. The hospitals segment accounted for the largest market share in 2020 due to the rising number of in-house diagnostic procedures performed in hospitals, growing awareness regarding early diagnosis, and the availability of reimbursements.
Recent Developments:
The cancer diagnostics market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World. In 2020, North America accounted for the largest share of the cancer diagnostics market. The large share of North America can be attributed to factors such as the increasing incidences of cancer, growing awareness early diagnosis and technological advancement.
Report Objectives

In 2020, GE Healthcate entered into partnership with GenesisCare to improve patient outcomes for the two biggest health burdens globally, cancer and heart disease. GE Healthcare will provide CT, MRI, PET/CT, SPECT, digital mammography, and ultrasound equipment to GenesisCare's 440+ cancer and cardiovascular disease treatment centers across Australia, the US, the UK, and Spain

In 2020, Roche Diagnostics entered into partnership with Illumina to provide broad access to clinical oncology next-generation sequencing

Key Players:

To define, describe, and forecast the global cancer diagnostics market based on product, technology, application, end user, and region

To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)

To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market

To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders

To forecast the size of market segments with respect to four main regions-North America, Europe, Asia Pacific and the Rest of the World (RoW)2

To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3

To track and analyze competitive developments such as acquisitions, new product launches, expansions, regulatory approvals, and agreements in the cancer diagnostics market

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=186559121
Danaher Corporation (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US.), F. Hoffman-La Roche AG (Switzerland), QIAGEN N.V. (Netherlands), Fujifilm Corporation (Japan), Aglient Technologies (US) and Thermo Fisher Scientific Inc. (US) etc.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/cancer-diagnostics-market-186559121.html

# data[].attributes.attachment_link.title
Cancer Diagnostics Market is expected to reach USD 26.6 billion by 2026 with CAGR of 11.5%

# data[].attributes.attachment_link.description
Published October 6, 2023 Cancer Diagnostics market in terms of revenue was estimated to be worth $17.2 billion in 2021 and is poised to reach $26.6 billion by 2026, growing at a CAGR of 11.5% from 2021 to 2026 according to a latest report published by MarketsandMarkets™ Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186559121 Cancer Diagnostics Industry Dynamics Drivers: Growth in the number of private diagnostic centers The Global Cancer Diagnostics Market in terms of revenue was estimated to be worth $17.2 billion in 2021 and is poised to grow at a CAGR of 11.5% from 2021 to 2026.

# data[].attributes.headline
Global Precision Medicine Market worth $50.2 billion by 2028

# data[].attributes.subject
Global Precision Medicine Market worth $50.2 billion by 2028

# data[].attributes.body
The global precision medicine market in terms of revenue was estimated to be worth $29.1 billion in 2023 and is poised to reach $50.2 billion by 2028, growing at a CAGR of 11.5% from 2023 to 2028.

# data[].attributes.attachment_link.readable_text
Precision Medicine Market in terms of revenue was estimated to be worth $29.1 billion in 2023 and is poised to reach $50.2 billion by 2028, growing at a CAGR of 11.5 % from 2023 to 2028 according to a new report by MarketsandMarkets™. The rising number of product approvals followed by growing focus on genetic testing, a prerequisite for precision medicine therapeutics, are the factors supporting market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=215185595&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Hospitals and Clinics subsegment accounted is the fastest growing of the precision medicine market by product & service

Among the end user, the market is segmented hospitals and clinics and home care setting. In 2022, the hospitals and clinics segment accounted for the highest growth rate of the precision medicine market by end user. Growth in this market segment can be attributed to factors such as availability of better facilities and assistance in hospitals and clinics, accessibility to advanced diagnostic tests along with precise therapeutic regime among others.

Oncology is the fastest-growing segment of the precision medicine market by applications

Among the applications, the precision medicine market is segmented into drug discovery, clinical diagnostics, soil microbiome applications, industrial applications, ecological & environmental applications, veterinary applications, and other applications. In 2023, the drug discovery segment accounted for the fastest-growing share of the usage segment of precision medicine market. Growth in this market segment can be attributed to one of the major factors which is the growing number of research activities for development of new drugs.

Europe: The second-largest region in the precision medicine market.

The European market is the second-largest precision medicine market globally, mainly due to factors such as presence of key market players in the region. Europe is considered a major hub for precision medicine players and organizations. Moreover, greater awareness among people about newly emerging area of precision medicine, especially compared to developing regions.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=215185595&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Precision Medicine Market Dynamics:

Drivers:

Growth in genetic testing and companion diagnostics

Restraints:

High costs of therapeutics

Opportunities:

Growing demand for cell and gene therapies

Challenges:

Challenges associated with adoption of precision medicine

Key Market Players:

The market for precision medicine is competitive, with key players strategizing to capture the market. Prominent players in the precision medicine market are F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Bristol Myers Squibb (US), Gilead Sciences, Inc. (US), AstraZeneca (UK), Pfizer Inc. (US), AbbVie Inc. (US), Eli Lilly and Company (US), , GlaxoSmithKline plc (UK), Sanofi (France), Johnson & Johnson (US), Merck KGaA (Germany), Amgen, Inc. (US), Takeda Pharmaceutical Company Limited (Japan) among others.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=215185595&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
This release was published on openPR.

# data[].attributes.attachment_link.title
Precision Medicine Market worth $50.2 billion | F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Bristol Myers Squibb (US), Gilead Sciences, Inc. (US), AstraZeneca (UK)

# data[].attributes.attachment_link.description
Precision Medicine Market in terms of revenue was estimated to be worth 29 1 billion in 2023 and is poised to reach 50 2 billion by 2028 growing at a CAGR of 11 5 from 2023 to 2028 according to ...

# data[].attributes.headline
Blood Screening Market worth $3.4 billion by 2028

# data[].attributes.subject
Blood Screening Market worth $3.4 billion by 2028

# data[].attributes.body
The Global Blood Screening Market in terms of revenue was estimated to be worth $2.4 billion in 2023 and is poised to reach $3.4 billion by 2028, growing at a CAGR of 7.2% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The need for blood is ever-increasing, forcing the number of blood donations to rise as well throughout the world. Combining this factor along with the growing infectious diseases is the major contributor for the growing blood screening market.

# data[].attributes.attachment_link.readable_text
, /PRNewswire/ -- The blood screening industry is poised for a transformative future as technological advancements continue to drive innovation. In the near future, we can expect a paradigm shift in the way blood screening is conducted, with the integration of cutting-edge automation, artificial intelligence, and molecular biology techniques. This convergence will lead to faster and more accurate diagnostics, enabling early detection of a wide range of diseases, from cancers to infectious agents. Moreover, personalized medicine will gain momentum as genetic and proteomic profiling become more accessible, allowing for tailored treatment plans. The industry's future holds the promise of improved patient outcomes, reduced healthcare costs, and a more proactive approach to healthcare management on a global scale.

Blood Screening Market in terms of revenue was estimated to be worth $2.4 billion in 2023 and is poised to reach $3.4 billion by 2028, growing at a CAGR of 7.2% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growth in this market is mainly driven by the growing requirement for donated blood, the rising number of blood donations around the world, and the ever-increasing infectious diseases. However, operational barriers and the high cost of Blood screening instruments is likely to hamper the growth of blood screening market.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267747042 Browse in-depth TOC on "Blood Screening Market" Blood Screening Market The Reagents & Kits segment is expected to account for the largest share in 2022. Scope: Nucleic Acid Test segment aimed the highest share during the forecast period
Based on product, the blood screening market is segmented into reagents & kits, instruments, and software & services. Increase in demand and continuous use of the reagents and kits during blood transfusion processes, post blood donations is responsible for the large segment of this segment.
North America has the upper hand in the global Blood screening market
The blood screening market is segmented into nucleic acid tests (NAT), serology/immunoassay, rapid tests, western blot assays, and next-generation sequencing (NGS). In 2022, the nucleic acid test (NAT) segment accounted for the largest share of the blood screening market. From all the other technologies, NAT provides high precision, sensitivity and accuracy for blood screening and therefore, holds the largest share.
Request Sample Pages: Blood Screening Market Drivers: Dynamics: Restraints: https://www.marketsandmarkets.com/requestsampleNew.asp?id=267747042 Opportunities: Challenge:
By regional segmentation, the blood screening market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East Africa. North America has the largest share and is continuing to dominate the blood screening market. The factors responsible for the large share of North America in this market are the increasing prevalence of infectious diseases, rising awareness in blood donations, and the growing healthcare system that is highly developed in the US and Canada.
Key Market Players:

Increasing number of blood donations worldwide
Recent Developments:

Alternative technologies
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=267747042 Blood Screening Market Advantages:

High cost of blood screening technologies

The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Grifols (Spain), Abbott Laboratories, Inc. (US), Bio-Rad Laboratories, Inc. (US), Danaher (Beckman Coulter, Inc.) (US), bioMérieux (France), Hologic (US), Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company (US), DiaSorin (Italy), Siemens Healthineers (Germany), QuidelOrtho Corporation (US), Merck KGaA (Germany), Revvity (Earlier known as PerkinElmer Inc.) (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc. (US), J. Mitra & Co. Pvt. Ltd. (India) and Tulip Diagnostics (India).
Related Reports:

In February 2023, Thermo Fisher Scientific Inc. (US) acquired TIB Molbiol (Germany), to expand its PCR test portfolio with a wide range of assays for infectious diseases.

In December 2021, Hologic, Inc. (US) launched Panther Trax for high-volume molecular testing.

In May 2021, Beckmann Coulter (US) launched SARS-CoV-2 IgG.

In September 2021, Roche Diagnostics (Switzerland) acquired TIB Molbiol Group (Germany). This acquisition will enhance Roche's broad portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.

Early Disease Detection: Blood screening allows for the early detection of various diseases, including infections, cancers, and chronic conditions. Early diagnosis often leads to more effective treatment and improved patient outcomes.

Preventative Medicine: It enables preventative measures by identifying risk factors and potential health issues before they become serious. This proactive approach can lead to better health management and reduced healthcare costs.

Transfusion Safety: Blood screening is vital in ensuring the safety of blood transfusions. It screens for infectious agents like HIV, hepatitis, and syphilis, minimizing the risk of transmitting diseases through donated blood.

Population Health Management: Blood screening data can be analyzed on a population level, helping healthcare systems identify trends, allocate resources more effectively, and develop targeted public health interventions.

Personalized Medicine: Advances in blood screening techniques, such as genetic testing, allow for personalized treatment plans tailored to an individual's genetic makeup, improving the effectiveness of therapies and reducing adverse reactions.

Research and Drug Development: Blood screening plays a pivotal role in clinical trials and drug development, providing insights into treatment efficacy, patient response, and biomarker identification.

Point-of-Care Testing: Point-of-care blood screening devices enable rapid diagnostics in diverse settings, from clinics to remote areas, facilitating timely medical interventions and reducing the burden on healthcare facilities.

Healthcare Efficiency: Automating blood screening processes increases efficiency, reduces human error, and speeds up results, allowing healthcare providers to make quicker and more informed decisions.

Global Health: Blood screening contributes to global health efforts by identifying and controlling infectious diseases, making it an essential tool in disease surveillance and outbreak management.

Improved Quality of Life: Ultimately, the blood screening market's advantages contribute to an overall improvement in the quality of life for individuals and communities, promoting better health and well-being.

In summary, the blood screening market's advantages encompass early detection, preventative care, safety, personalized medicine, research, and healthcare efficiency, all of which have a profound impact on healthcare outcomes and public health.

Molecular Diagnostics Market - Global Forecasts to 2028

Immunoassay Market - Global Forecasts to 2027
About MarketsandMarkets™:
In Vitro Diagnostics Market - Global Forecasts to 2027

Western Blotting Market - Global Forecasts to 2026

Mycoplasma Testing Market - Global Forecasts to 2025

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/blood-screening-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/blood-screening.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Blood Screening Market worth $3.4 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
PRNewswire/ -- The blood screening industry is poised for a transformative future as technological advancements continue to drive innovation. In the near...

# data[].attributes.headline
Metabolism Assays Market worth $2.1 billion by 2028 

# data[].attributes.subject
Metabolism Assays Market worth $2.1 billion by 2028 

# data[].attributes.body
The Metabolism Assays Market is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 7.8% during the forecast period. The growth in this market is attributed to the growing prevalence of diabetes, the global increase in the number of hospitals, and the high rate of obese population. However, alternative methods or techniques restrain the growth of this market.

# data[].attributes.attachment_link.readable_text
, Sept. 28, 2023 /PRNewswire/ -- In the near future, the metabolism assays industry is poised for remarkable growth and innovation, driven by advancements in biotechnology, automation, and personalized medicine. With a growing emphasis on understanding the intricate metabolic processes within cells, this industry is set to revolutionize drug discovery, toxicity testing, and disease management. The integration of cutting-edge technologies like CRISPR-Cas9 and high-throughput screening systems will enable researchers to delve deeper into cellular metabolism, paving the way for the development of more effective therapies and precision medicine approaches. Furthermore, the adoption of AI-driven data analysis will streamline research processes, leading to faster and more cost-effective drug development. As metabolic profiling becomes increasingly tailored to individual patient needs, the metabolism assays industry will play a pivotal role in shaping the future of healthcare and pharmaceuticals.

Metabolism Assays Market in terms of revenue was estimated to be worth $1.4 billion in 2023 and is poised to reach $2.1 billion by 2028, growing at a CAGR of 7.8% from 2023 to 2028 according to a new report by MarketsandMarkets™. The growth of this market is majorly driven by rising initiatives by government to promote metabolic & disease research, innovation in metabolism assays technology by integrating with wearable devices, increase in prevalence of metabolic disorders such as diabetes and obesity, and adoption of metabolism assays by fitness and sports industries.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=135163479 Metabolism Assays Market Assay Kits and reagents segment is expected to account for the larger share in 2022. Scope: The diagnostic segment held the largest market share in the metabolism assay market.
The metabolism assay market, by product, has been segmented into instruments & analyzers and assay kits & reagents. In 2022, the assay kits & reagents dominated the products market and are also estimated to grow at the highest CAGR during the forecast period. The large share is due to the recurrence of assay kits & reagents and easy availability.
North America dominates the global metabolism assay market.
By application, the global metabolism assay market is broadly segmented into diagnostics and research. The diagnostics segment accounted for the larger share of the market in 2022. The diagnostics segment is also estimated to grow at the highest CAGR during the forecast period. The large share of this segment can be attributed to various factors, such as the growing number of obese population and the growing number of hospitals which are important end users for metabolism assays.
Request Sample Pages: Metabolism Assays Market Drivers: Dynamics: Restraints: https://www.marketsandmarkets.com/requestsampleNew.asp?id=135163479 Opportunities:
Based on the region, the metabolism assay market is segmented into North America, Europe, Asia Pacific, and Rest of the World. North American market is driven by well-established pharmaceutical and biotechnology industry, investments around drug discovery and toxicity testing. The Asia Pacific segment is projected to register the highest CAGR during the forecast period. The presence of a large population base coupled with large patient population and increasing rate of obesity are some of the major factors driving the growth of this regional market.
Challenge:
1. Increasing funding and investments in metabolic research
Key Market Players:
1. High cost of metabolism assay analyzers
Recent Developments:
1. Integration with wearable devices
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=135163479 Metabolism Assays Market Advantages:
1. Complexity of assay development

Major players in metabolism assays market include Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), Agilent Technologies Inc. (US), and Kaneka Eurogentec S.A. (Belgium).
Related Reports:

In 2022, Thermo Fisher Scientific, Inc. (US) collaborated with Symphogen (Denmark) and Servier (France) for biopharmaceutical discovery and development laboratories.

In 2021, Abcam Plc. (UK) acquired BioVision (UK). This acquisition of BioVision represents a compelling strategic fit for Abcam. This will bring greater control over the innovation and distribution of BioVision's product portfolio and create value through portfolio expansion and leveraging Abcam's global channels to market.

In 2021, Agilent Technologies Inc. (US) launched Agilent Seahorse XF HS Miniplate which is the latest addition to Agilent's range of Seahorse XF platforms, which analyze mitochondrial respiration, glycolysis, and ATP production in live cells, in real-time.

Early Drug Discovery: Metabolism assays enable the identification of potential drug candidates by assessing how compounds interact with cellular metabolic pathways. This accelerates the drug discovery process by quickly identifying promising leads and eliminating ineffective compounds.

Toxicity Screening: These assays are essential for evaluating the safety of drugs and chemicals. They help identify potential toxic effects on cellular metabolism, aiding in the development of safer pharmaceuticals and consumer products.

Personalized Medicine: Metabolism assays can be used to tailor treatments to individual patients by assessing their unique metabolic profiles. This approach allows for more precise and effective therapeutic interventions.

Disease Mechanism Understanding: Researchers can gain insights into the metabolic dysregulations underlying various diseases, including cancer, diabetes, and metabolic disorders. This knowledge is crucial for developing targeted therapies.

High-Throughput Capabilities: Automation and high-throughput screening technologies enable the rapid analysis of a large number of compounds or samples, significantly increasing research efficiency and productivity.

Data-Driven Decision-Making: Advances in data analysis and machine learning enable the extraction of valuable insights from metabolism assay data, facilitating informed decision-making in drug development and disease research.

Reduction in Animal Testing: Metabolism assays offer alternatives to traditional animal testing, contributing to ethical and regulatory considerations in drug development and toxicity assessment.

Cost Savings: By streamlining drug discovery processes and reducing the likelihood of late-stage drug failures, metabolism assays can lead to substantial cost savings in pharmaceutical research and development.

Biotechnology Advancements: The metabolism assays market drives innovation in biotechnology, leading to the development of novel assay techniques, reagents, and instrumentation that benefit various areas of life sciences research.

Interdisciplinary Research: Metabolism assays promote collaboration between researchers in different fields, including biology, chemistry, pharmacology, and informatics, fostering a holistic approach to understanding metabolism and its implications for health and disease.

In summary, the metabolism assays market plays a pivotal role in advancing biomedical research and pharmaceutical development by offering a range of benefits, from accelerating drug discovery to enabling personalized medicine and improving the safety and efficacy of therapeutic interventions.

CT/NG Testing Market - Global Forecasts to 2028

High Throughput Screening Market - Global Forecasts to 2028
About MarketsandMarkets™:
ATP Assays Market - Global Forecasts to 2028

Cell-based Assays Market - Global Forecasts to 2028

Point of Care Molecular Diagnostics Market - Global Forecasts to 2028

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/metabolism-assays-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/metabolism-assays.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Metabolism Assays Market worth $2.1 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
PRNewswire/ -- In the near future, the metabolism assays industry is poised for remarkable growth and innovation, driven by advancements in biotechnology,...

# data[].attributes.headline
Global Bone Cement & Glue Market worth $2,248 million by 2028

# data[].attributes.subject
Global Bone Cement & Glue Market worth $2,248 million by 2028

# data[].attributes.body
The Global Bone Cement & Glue Market is projected to reach USD 2,248 million by 2028 from USD 1,644 million in 2023, at a CAGR of 6.5% during the forecast period. The growth of this market is majorly driven by the Rising Demand for Minimally Invasive Surgeries with robotic assistance and Growing healthcare sector and Increasing Incidence of Orthopedic Conditions. However, Challenges associated with Variability of pathogen resistance may threat the growth of this market.

# data[].attributes.attachment_link.readable_text
, /PRNewswire/ -- In the near future, the bone cement and glue industry is poised for significant advancements and growth, driven by emerging technologies and a rising global demand for innovative medical solutions. Manufacturers in this sector are expected to develop more efficient and bio-compatible formulations, enhancing the efficacy of bone adhesives in orthopedic surgeries and dental applications. The adoption of 3D printing technology is likely to revolutionize the production process, enabling personalized and patient-specific implants and prosthetics. Additionally, research in bioactive additives and nanotechnology will pave the way for enhanced bone regeneration properties and reduced complications. With an aging population and increasing cases of musculoskeletal disorders, the bone cement and glue industry is anticipated to play a pivotal role in improving patient outcomes and quality of life through cutting-edge materials and techniques.

Bone Cement & Glue Market in terms of revenue was estimated to be worth $1,644 million in 2023 and is poised to reach $2,248 million by 2028, growing at a CAGR of 6.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. The growth of this market is majorly driven by Growing number of road traffic accidents and rising number of surgical procedures. However, High costs and Product-related complications may challenge the growth of this market.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131540876 Bone Cement & Glue Market France in European Bone cement & glue market to witness the highest shares during the forecast period. Scope: Hospitals, & Ambulatory Surgical Centers in End user' Bone cement & glue market to witness the highest growth rate during the forecast period.
The Europe Bone cement & glue market is segmented into Germany, France, the UK, and the Rest of Europe. France is projected to occupy the highest share during the forecast period. The major factors contributing to the growth of this market are the high prevalence of Orthopedic Conditions, the growing geriatric population, In addition, France has a well-developed healthcare system with access to advanced medical technologies and treatments. This infrastructure supports the adoption of bone cement and glue products in various orthopedic and dental procedures. Likewsie, France has a skilled workforce of healthcare professionals, including orthopedic surgeons, who are adept at using bone cement and glue products in surgical procedures.
China dominates the Asia Pacific Bone cement & glue market.
Based on the end user, the Bone cement & glue market is segmented into Hospitals, & Ambulatory Surgical Centers, and Clinics/Physician offices. The Hospitals, & Ambulatory Surgical Centers registered the highest CAGR, increasing orthopedic Surgical Procedures, Hospitals and ASCs are key providers of joint replacement surgeries, such as total hip arthroplasty (THA) and total knee arthroplasty (TKA), moreover Hospitals and ASCs cater to patients of all ages, but the aging population is more likely to require orthopedic surgeries that involve bone cement and glue. As the global population ages, the demand for joint replacement surgeries and other orthopedic procedures is increasing, benefiting the bone cement and glue market.
Request Sample Pages: Bone Cement & Glue Market Drivers:

Growing incidences of sports injuries

Restraints:

High costs and extensive clinical data requirements for launching new bone cements

Opportunities:

Rising awareness and demand for minimally invasive procedures

Challenges: Key Market Players: Dynamics: Recent Developments:

In 2021, The company Smith & Nephew (UK) acquired the Extremity Orthopedics business of Integra LifeSciences to expand its shoulder, upper, and lower extremities product portfolio.

In 2021, Zimmer Biomet (US) Completed the spinoff of spine and dental businesses into a new public company, ZimVie Inc. ("ZimVie"). The transaction was intended to benefit its stockholders by enhancing the focus of both Zimmer Biomet and ZimVie to meet the needs of patients and customers.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=131540876 Bone Cement & Glue Market Advantages:

Enhanced Surgical Outcomes: Bone cement and glue products provide strong and stable fixation in orthopedic surgeries, improving the chances of successful joint replacements and fracture repairs. These materials help in bonding implants to bone surfaces securely, reducing the risk of implant loosening or failure.

Minimally Invasive Procedures: The use of bone cement and glue allows for less invasive surgical techniques, as they eliminate the need for extensive hardware and screws. This leads to smaller incisions, reduced tissue damage, and faster patient recovery times.

Bone Support and Stability: These materials not only serve as adhesives but also provide structural support to weakened or damaged bones. They can help fill voids and gaps in bone structures, aiding in fracture stabilization and enhancing bone healing.

Bio-compatibility and Biodegradability: Advanced bone cements and glues are designed to be bio-compatible with the body's tissues, reducing the risk of adverse reactions or rejection. Additionally, some products are biodegradable, gradually breaking down over time as the natural bone regenerates and integrates with the material.

Versatility in Applications: Bone cement and glue products find applications in various medical specialties, including orthopedics, traumatology, neurosurgery, and dentistry. Their versatility allows healthcare professionals to address a wide range of bone-related issues effectively.

Customization and 3D Printing: Advancements in technology enable the customization of bone cement and glue products, providing tailored solutions for individual patients. 3D printing allows for patient-specific implants and prosthetics, enhancing surgical precision and patient satisfaction.

Cost-Effectiveness: Bone cement and glue can lead to cost savings in healthcare systems by reducing the need for more extensive and expensive surgical procedures, hospital stays, and long-term rehabilitation.

Faster Operating Room Procedures: The ease of use and quick setting times of bone cement and glue enable faster surgeries, leading to reduced operating room time and increased efficiency for healthcare providers.

Addressing Osteoporotic Fractures: With an aging population, osteoporosis-related fractures are becoming more prevalent. Bone cement and glue offer effective solutions for stabilizing and reinforcing weakened bones, improving the quality of life for elderly patients.

https://www.marketsandmarkets.com/requestsampleNew.asp?id=131540876 Related Reports:
The APAC amniotic products market is segmented into Japan, China, India, and Rest of Apac. In 2022, China accounted for the largest share of the Asian Bone cement & glue market. The large share of China can be attributed to the economic growth in the country, rising incidence of orthopedic cases, significantly high cases of road accidents, increasing disposable income of the middle-class population, growth in the geriatric population, and favourable government support.

The significant players in the Bone cement & glue market are Stryker (US), Zimmer Biomet (US), DePuy Synthes (a subsidiary of Johnson & Johnson - US), Enovis (US), Heraeus Holding (Germany), Medtronic (Ireland)

Overall, the advantages of bone cement and glue in the medical field highlight their essential role in promoting better patient outcomes, enabling advanced surgical techniques, and addressing various bone-related conditions with enhanced precision and effectiveness.

Cold Pain Therapy Market - Global Forecasts to 2027

Orthopedic Braces and Supports Market - Global Forecasts to 2027
About MarketsandMarkets™:
Physiotherapy Equipment Market - Global Forecasts to 2027

Foot and Ankle Devices Market - Global Forecasts to 2025

Biomaterials Market - Global Forecasts to 2025

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/bone-cement-glue-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/bone-cement-glue.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

View original content: https://www.prnewswire.com/news-releases/bone-cement--glue-market-worth-2-248-million--marketsandmarkets-301890102.html

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Bone Cement & Glue Market worth $2,248 million | MarketsandMarkets

# data[].attributes.attachment_link.description
In the near future, the bone cement and glue industry is poised for significant advancements and growth, driven by emerging technologies and a rising global demand for innovative medical solutions. Manufacturers in this sector are expected to develop more efficient and bio-compatible formulations, enhancing the efficacy of bone adhesives in orthopedic surgeries and dental applications.

# data[].attributes.headline
Global Biobanking Market Size, Share, Trends and Forecast 2028

# data[].attributes.subject
Global Biobanking Market Size, Share, Trends and Forecast 2028

# data[].attributes.body
Biobanking Market in terms of revenue was estimated to be worth $2.9 billion in 2023 and is poised to reach $5.0 billion by 2028, growing at a CAGR of 11.4% from 2023 to 2028 according to a new report by MarketsandMarkets™. The global biobanking market is expected to grow at a CAGR of 11.4% during the forecast period. The growth of this market is driven by increasing number of private cord blood banks has led to a rise in competition among biobanks, which has driven innovation and improvements in the quality of biobanking services. This, in turn, has fueled growth in the biobanking market as more companies seek to enter this expanding field and meet the growing demand for cord blood stem cell preservation.

# data[].attributes.attachment_link.title
Biobanking Market worth $5.0 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
/PRNewswire/ -- The biobanking industry is expected to witness significant growth and transformation in the near future. Biobanks play a crucial role in…

# data[].attributes.headline
Orthodontic Supplies Market worth $10.1 billion by 2027

# data[].attributes.subject
Orthodontic Supplies Market worth $10.1 billion by 2027

# data[].attributes.body
The Global Orthodontic Supplies Market boasts a total value of $6.9 billion in 2022 and is projected to register a growth rate of 7.9% to reach a value of $10.1 billion by 2027.
The growth of the orthodontic supplies market can be attributed to the orthodontic supplies market is mainly driven by factors such as the growing number of patients with malocclusions, jaw diseases, tooth decay/tooth loss, and jaw pain; increasing disposable incomes and the expanding middle-class population in developing countries; increasing awareness about advanced orthodontic treatments; and ongoing research and technological advancements in orthodontic products. Also, initiatives undertaken by governments to increase awareness about orthodontic treatments are expected to drive the demand for orthodontic supplies.

# data[].attributes.attachment_link.readable_text
, /PRNewswire/ -- Orthodontic Supplies Market size is projected to reach USD 10.1 billion by 2027 from USD 6.9 billion in 2022, at a CAGR of 7.9% during the forecast period according to a new report by MarketsandMarkets™. Increasing number of malocclusion cases among teenagers and adults, growing awareness about the presence of orthodontic treatment, technological advancements and growth strategies adopted by the players in the orthodontic supplies such as product launches, agreements, partnerships, and acquisitions are expected to propel the growth of the market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=236529189 Browse in-depth TOC on "Orthodontic Supplies Market" Orthodontic Supplies Market Scope: Aesthetic benefits to boost the demand for removable braces among the target population
The orthodontic supplies market includes major Tier I and II suppliers of orthodontic products are Align Technology (US), 3M (US), Envista Holdings Corporation (US), Institut Straumann AG (Switzerland), and Dentsply Sirona (US). Other prominent players in this market include Henry Schein (US), American Orthodontics (US), Rocky Mountain Orthodontics (US), G&H Orthodontics (US), Dentaurum (Germany), TP Orthodontics (US), Great Lakes Dental Technologies (US), DB Orthodontics (UK), Morelli Ortodontia (Brazil), Institut Straumann AG (Switzerland), Ultradent Products (US), Aditek Orthodontics (Brazil), MATT Orthodontics (US), JJ Orthodontics (India), Sino Ortho Limited (China), and JISCOP Co., Ltd. (South Korea).
Orthodontic supplies market is anticipated to grow at the fastest pace in Asia Pacific
Removable braces or clear aligners offers enhanced comfort and are easy to remove in comparison to traditional orthodontic braces. They also reduced the risk of periodontal diseases & tooth decay. The invisible nature and aesthetic advantage offered by removable braces are driving teens & adult populations to opt for orthodontic treatment with removable braces. Moreover, a growing number of manufacturers offering removable braces is further expected to support the growth of the removable braces segment in the coming years.
Request Sample Pages: Orthodontic Supplies Market Dynamics: Drivers: https://www.marketsandmarkets.com/requestsampleNew.asp?id=236529189 Restraints:
The Asia Pacific orthodontic supplies market is projected to grow at the highest CAGR of 9.7% from 2022 to 2027. Increasing personal disposable income, increased patient population with malocclusion and tooth decay, expansion of healthcare infrastructure, rising number of dental clinics are some of the factors likely to support the growth of the orthodontic supplies market in the region. Moreover, the emergence of new manufacturers in the orthodontic supplies market and rising awareness about dental hygiene are likely to drive the growth of the APAC orthodontic supplies market.
Opportunities:

1. Growing number of patients with malocclusions, jaw diseases, tooth decay/tooth loss, and jaw pain

2. Increasing disposable incomes and expanding middle-class population in developing countries

3. Increasing awareness about advanced orthodontic treatments

4. Ongoing research and technological advancements in orthodontic products

Challenges:

1. Risks and complications associated with orthodontic treatments

2. High cost of advanced orthodontic treatments in some nations

Key Market Players:

1. Growth opportunities offered by emerging markets

2. Integration with digital technologies such as CAD/CAM and software

3. Increasing use of social media by patients and dental professionals

4. Direct-to-consumer orthodontics

Recent Developments:

Dearth of trained dental practitioners
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=236529189 Related Reports:
Prominent players in this market are 3M (US), Envista Holdings Corporation (US), Dentsply Sirona (US), Align Technology (US), Rocky Mountain Orthodontics (US), G&H Orthodontics (US), Dentaurum (Germany), TP Orthodontics (US), Great Lakes Dental Technologies (US), DB Orthodontics (UK), among others

In May 2022, Align Technology entered into strategic partnership with Asana, Inc. Through this strategic partnership, Align Technology will provide its Invisalign clear aligners to trained doctors in the US through the Asana Smile customizable workflow solution.

In May 2022, Straumann acquired PlusDental to expand its footprint in the doctor-led consumer orthodontics segment across the Netherlands, Sweden, and the UK.

In January 2021, Dentsply Sirona acquired Byte, an at-home aligner company, in with an aim to strengthen its clear aligner product portfolio.

Browse Adjacent Market: Medical Devices Market Research Reports & Consulting

Dental Implants and Dental Prosthetics Market - Global Forecasts to 2027

Dental Consumables Market - Global Forecasts to 2027
About MarketsandMarkets™:
Oral Care Market - Global Forecasts to 2026

Dental Impression Systems Market - Global Forecasts to 2025

Cosmetic Dentistry Market - Global Forecasts to 2025

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/orthodontic-supplies-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/orthodontic-supplies.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Orthodontic Supplies Market worth $10.1 billion by 2027 - Exclusive Report by MarketsandMarkets™

# data[].attributes.attachment_link.description
PRNewswire/ -- Orthodontic Supplies Market size is projected to reach USD 10.1 billion by 2027 from USD 6.9 billion in 2022, at a CAGR of 7.9% during the...

# data[].attributes.headline
The Growing Demand for Cell Dissociation Market: Trends and Forecast

# data[].attributes.subject
The Growing Demand for Cell Dissociation Market: Trends and Forecast

# data[].attributes.body
Cell Dissociation Market in terms of revenue was estimated to be worth $0.6 billion in 2023 and is poised to reach $1.4 billion by 2028, growing at a CAGR of 17.8% from 2023 to 2028 according to a new report by MarketsandMarkets™. Key drivers of the cell dissociation market include, growing use of tissue dissociation products in mammalian cell culture and expanding cell therapy production facilities. The mammalian-based capacity for recombinant proteins grew yearly at 10.8%, whereas recombinant microbial-based capacity grew at 3.0% yearly. As cell culture is an integral part of developing mammalian-based recombinant therapeutics, the uptake of cell dissociation products is expected to increase with it.

# data[].attributes.attachment_link.readable_text
Industrial and Manufacturing

The cell dissociation industry is expected to experience significant growth over the next few years, driven by advances in cell culture technology, the increasing use of stem cells in research and drug discovery, and the development of novel cell-based therapies.

Cell Dissociation Market in terms of revenue was estimated to be worth $0.6 billion in 2023 and is poised to reach $1.4 billion by 2028, growing at a CAGR of 17.8% from 2023 to 2028 according to a new report by MarketsandMarkets™. Key drivers of the cell dissociation market include, growing use of tissue dissociation products in mammalian cell culture and expanding cell therapy production facilities.

The mammalian-based capacity for recombinant proteins grew yearly at 10.8%, whereas recombinant microbial-based capacity grew at 3.0% yearly. As cell culture is an integral part of developing mammalian-based recombinant therapeutics, the uptake of cell dissociation products is expected to increase with it.
Download PDF Brochure: www.marketsandmarkets.com/pdfdown...d=97548003
Browse in-depth TOC on " Collagenase Cell Dissociation Industry"

206 - Tables

37 - Figures

204 - Pages
Enzymatic dissociation products accounted for the larger share of the cell dissociation industry in 2022
Based on the product, the cell dissociation market is segmented enzymatic dissociation products, instruments & accessories, and non-enzymatic dissociation products. In 2022, the enzymatic cell dissociation products segment accounted for the highest revenue.

Uptake of cell dissociation enzymes is expected to increase attributed to increasing cell-based research activities.
By tissue type, the connective tissue segment accounted for the largest market share in 2022
Based on the tissue type, the cell dissociation market is segmented into epethilial tissues, connective tissues, and other tissues such as muscles tissues and nervous tissues. The connective tissues is the dominant segment of the cell dissociation market in 2022 and is also expected to grow at the fastest pace through 2023-2028.

In the past few years, extensive research has been performed to achieve a granular understanding of connective tissue structures.
Pharmaceutical and biotechnology companies are the largest end-users of the elastase market
Based on end-users, the cell dissociation market is segmented into research & academic isntitutes, pharmaceutical & biotechnology companies, and other end users. The pharmaceutical and biotechnology companies are the key end users of the cell dissociation market, with highest revenue share in 2022.

Increasing insvestments by pharmaceutical companies to develop stem cell-based therapies is expected to strengthen the adoption of cell dissociation products.
North America dominates the global trypsin cell dissociation industry
The cell dissociation market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2022, North America accounted for the largest share in the cell dissociation market, which is attributed to increasing investments in the development of novel cell-based therapies.
Request Free Sample Pages: www.marketsandmarkets.com/request...d=97548003 Cell Dissociation Industry Dynamics: Drivers:

Increase in recombinant therapeutics sourced from mammalian cells

Growing focus on personalized medicine

cGMP approvals for new cell therapy production facilities

Restraints:

High cost of cell-based research
Opportunities:

Advancements in non-enzymatic tissue dissociation
Challenges:

Limitations associated with dissociated cell culture
Key Market Players:
The cell dissociation market is moderately consolidated in nature with prominent market players such as Merck KGaA (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Corning Incorporated (US), Becton, Dickinson and Company (US), STEMCELL Technologies (Canada), PromoCell GmbH (Germany), Miltenyi Biotec (Germany), ATCC (US), HiMedia Laboratories (India), PAN-Biotech (Germany), CellSystems GmbH (Germany), AMSBIO (England), Neuromics (US), VitaCyte, LLC.

(US), ALSTEM (US), Biological Industries (Israel), Gemini Bio (US), Innovative Cell Technologies, Inc. (US), Central Drug House (P) Ltd.

(India), Worthington Biochemical Corporation (US), Capricorn Scientific (Germany), Abeomics (US), and Genlantis, Inc. (US).
Recent Developments

In 2020, Miltenyi Biotec launched automated and closed adherent cell culture solutions on CliniMACS Prodigy.

In 2020, Merck The company expanded its Life Sciences production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire (US).

In 2020, STEMCELL Technologies partnered with CollPlant to secure CollPlant rhCollagen for STEMCELL's use in cell culture applications.

In 2021, Danaher (Cytiva) partnered with Diamyd Medical, wherein Diamyd selected Cytiva's FlexFactory platform for making precision medicine type-1 diabetes vaccines.

In 2021, Danaher (Cytiva) collaborated with the Government of Telangana (India) to strengthen the biopharma industry in India with new labs.

Get 10% Free Customization on this Report: www.marketsandmarkets.com/request...d=97548003 Cell Dissociation Market Advantages:

Increased Efficiency: Cell dissociation reagents provide a more efficient and reliable method for dissociating cell samples, which can significantly reduce processing time and improve the quality of the results.

Higher Yields: Cell dissociation reagents are designed to maximize cell yield, allowing for more effective downstream applications such as flow cytometry and immunological assays.

Improved Quality: Cell dissociation reagents help to ensure that cells are undamaged during the isolation process, thereby resulting in higher quality samples.

Cost Effective: Cell dissociation reagents provide a cost-effective solution, as they are typically less expensive than traditional methods.

Greater Flexibility: Cell dissociation reagents offer greater flexibility in terms of the types of cells that can be isolated, allowing for a wider range of downstream applications.

News From

MarketsandMarkets™
Category: Market Research Publishers and Retailers Profile: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, w ...

# data[].attributes.attachment_link.title
Cell Dissociation Market size, share, trends and revenue forecast 2028

# data[].attributes.attachment_link.description
Cell Dissociation Market Product (Trypsin, Papain, DNase, Hyaluronidase, Instruments), Tissue Type (Connective Tissue, Epithelial Tissue), End User (Pharma, Biopharma, Research Institutes), Region- Global Forecast to 2028

# data[].attributes.headline
Global Therapeutic Drug Monitoring Market worth $2.9 billion by 2027

# data[].attributes.subject
Global Therapeutic Drug Monitoring Market worth $2.9 billion by 2027

# data[].attributes.body
The global therapeutic drug monitoring market in terms of revenue was estimated to be worth $1.8 billion in 2022 and is poised to reach $2.9 billion by 2027, growing at a CAGR of 9.6% from 2022 to 2027. The growth of this market is primarily driven by an amplifying focus on research experimentation associated with therapeutic drug monitoring and an increase in severe diseases. However, the requirement for massive capital investments and the hesitancy of compact hospitals to offer therapeutic drug monitoring services may restrain the growth of this market.

# data[].attributes.attachment_link.readable_text
Medical and Health Markets

Therapeutic drug monitoring is used before administering immunosuppressants as it minimises the pharmacokinetic component of variability. Improper drug concentrations in immunosuppressants can lead to adverse effects in transplant patients.

Therapeutic Drug Monitoring Market in terms of revenue was estimated to be worth $1.8 billion in 2022 and is poised to reach $2.9 billion by 2027, growing at a CAGR of 9.6% from 2022 to 2027 according to a new report by MarketsandMarkets™. The growth of this market is majorly driven by the Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis.

However, Alternatives to conventional TDM may challenge the growth of this market.
Download PDF Brochure: www.marketsandmarkets.com/pdfdown...=155350443 Browse in-depth TOC on "Antiepileptic Drug Monitoring Industry" 178 - Tables 50 - Figures 221 - Pages Germany in European Antibiotic Therapeutic drug monitoring market to witness the highest shares during the forecast period.
The Europe Therapeutic Drug Monitoring Market is segmented into Germany, Italy, France, Spain, the UK, and the Rest of Europe. Germany is projected to occupy the highest share during the forecast period.

The major factors contributing to the growth of this market are the rising geriatric population, increasing incidence of chronic and infectious diseases, rising healthcare expenditure, and increasing R&D investments.
Japan dominates the Asia Pacific Immunosuppressant Drug Monitoring industry
The APAC Therapeutic Drug Monitoring market is segmented into Japan, China, and India. In 2021, Japan accounted for the largest share of the Asian Therapeutic Drug Monitoring market.

The large share of Japan can be attributed to the large geriatric population in the country, the rising prevalence of chronic medical conditions such as cancer, growing budgetary allocations for healthcare, and the presence of a well-developed healthcare system.
chemiluminescence immunoassays (CLIAs) in the product's immunoassay therapeutic drug monitoring segment to witness the highest growth as well as the largest share in the therapeutic drug monitoring market during the forecast period.
The market is divided into chemiluminescence immunoassays, colorimetric immunoassays, fluorescence immunoassays, radioimmunoassays, and other immunoassays based on the immunoassay. The chemiluminescence immunoassays segment is projected to grow at the highest CAGR during the forecast period because these assays are commonly used in TDM in either enzyme-amplified or direct chemiluminescence measurements.
Request 10% Customization: www.marketsandmarkets.com/request...=155350443 Antiarrhythmic Drug Monitoring Industry Dynamics: Drivers:

Importance of TDM in organ transplant procedures

Use of TDM across various therapeutic fields

Increasing preference for precision medicine

Growing focus on R&D related to TDM

Technological advancements

Restraints:

Requirement of high capital investments

Reluctance of small hospitals to offer TDM services

Opportunities:

Increasing adoption in the treatment of autoimmune diseases
Challenges:

Alternatives to conventional TDM

Operational barriers faced in conducting TDM

Key Market Players:
The significant players in the Therapeutic Drug Monitoring industry are Abbott (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories (US), bioMérieux SA (France), Theradiag SA (France), Grifols S.A.

(Spain), Exagen Inc. (US), R-Biopharm AG (Germany), ARK Diagnostics, Inc. (US), apDia Group (Belgium), Immundiagnostik AG (Germany), and Sekisui Medical Co.

Ltd. (Japan).
Recent Developments:

In May 22, Theradiag (France) Announced the launch of ez-Track1, a Point-of-Care Testing solution for TDM.

In Jan 2021, Theradiag (France) Announced CE marking for four new i-Tracker test kits for biotherapy monitoring.

Report Objectives

To define, describe, and forecast the global Therapeutic Drug Monitoring market based on product, and region

To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)

To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the total market

To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders

To forecast the size of market segments with respect to four main regions-North America, Europe, Asia Pacific, and the Rest of the World (RoW)2

To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3

To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the Therapeutic Drug Monitoring market

Report Link: ( Therapeutic Drug Monitoring Market )

News From

MarketsandMarkets™
Category: Market Research Publishers and Retailers Profile: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, w ...

# data[].attributes.attachment_link.title
Global Therapeutic Drug Monitoring Market worth $2.9 billion by 2027

# data[].attributes.attachment_link.description
Therapeutic drug monitoring is used before administering immunosuppressants as it minimises the pharmacokinetic component of variability. Improper…

# data[].attributes.headline
Global Lateral Flow Assays Market to grow at a CAGR of 2.0% during the forecast 2027

# data[].attributes.subject
Global Lateral Flow Assays Market to grow at a CAGR of 2.0% during the forecast 2027

# data[].attributes.body
The Global Lateral Flow Assays Market in terms of revenue was estimated to be worth $20.5 billion in 2022 and is poised to reach $22.6 billion by 2027, growing at a CAGR of 2.0% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Increasing adoption of kits & reagents and lateral flow assay readers for infectious diseases testing, veterinary diagnostics, and drug of abuse testing, cardiac marker testing. Whereas most of lateral flow assays are having limitation of qualitative detection, lot to lot variation like factors may hinder the growth of global market during the forecast period.

# data[].attributes.attachment_link.readable_text
Industrial and Manufacturing

The Lateral Flow Assays industry is expected to grow significantly in the near future due to the increasing demand for rapid, portable, and easy-to-use diagnostic tests. Lateral flow assays have already proven to be valuable in a variety of applications, including medical diagnostics, food safety testing, environmental monitoring, and drug testing, among others.

The Global Lateral Flow Assays Market in terms of revenue was estimated to be worth $20.5 billion in 2022 and is poised to reach $22.6 billion by 2027, growing at a CAGR of 2.0% from 2022 to 2027. The new research study consists of an industry trend analysis of the market.

The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Increasing adoption of kits & reagents and lateral flow assay readers for infectious diseases testing, veterinary diagnostics, and drug of abuse testing, cardiac marker testing.

Whereas most of lateral flow assays are having limitation of qualitative detection, lot to lot variation like factors may hinder the growth of global market during the forecast period.
Download PDF Brochure: www.marketsandmarkets.com/pdfdown...=167205133 Key Market Players:
The prominent players in the global lateral flow assays market include Abbott Laboratories (US), Quidel Corporation (US), F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), Siemens AG (Germany), BD (US), bioMérieux SA (France), Thermo Fisher Scientific, Inc.

(US), PerkinElmer Inc. (US), Hologic Inc. (US), QIAGEN N.V. (Netherlands), and Merck KGaA (Germany).
Kits & reagents segment accounted for the largest share in the lateral flow assay market.
The global market is segmented into kits & reagents and lateral flow readers. Kits & reagents accounted for the larger share of the global market.

The large share of kits & reagents is due to the increasing the adoption of kits & reagents for infectious disease testing.
Food Safety & Environmental Testing segment is expected to witness the fastest growth, in global lateral flow assays market, during the forecast period.
The global market is segmented into clinical testing, veterinary diagnostics, food safety & environmental testing, and drug development & quality testing based on the application. The food safety & environmental testing segment is expected to witness the fastest growth during the forecast period.

The fastest of this segment can be attributed to the available LFA tests for identifying toxins and other contaminants in the food industry can potentially compete with other immunoassay methods, such as immuno-chips and immuno-sensors and other analytical methods. The food & beverage industry is shifting from lab-based conventional microbiology techniques to rapid LFA tests for faster result generation
Competitive assays technique accounted for the second largest share of lateral flow assays industry
The global market is segmented into competitive assays, sandwich assays, and multiplex detection assays. In competitive assay technique, the absence of color at the test line indicates the presence of analytes, while the appearance of color at both the test and control lines indicates a negative result.
Others samples accounted for the largest share of lateral flow assays market
The global market is segmented into blood, urine, saliva, and others samples. Others samples accounted for the largest market share.

The global market for others samples is likely to be driven by increased R&D and the need for more specific and accurate disease testing. Nasal swabs, throat swabs, and vaginal fluid have been considered as other samples in the study.
The Diagnostics laboratories segment accounted for the third largest share of lateral flow assays market
Based on end users, the market is segmented into hospitals & clinics, diagnostic laboratories, home care settings, pharmaceutical & biotechnology companies, and other end users. The diagnostics laboratories segment accounted for the third largest market share The COVID-19 pandemic has resulted in an increased demand for rapid lateral flow-based diagnostic testing in laboratories.

These tests may be conducted to gather data regarding the viral spread nationwide by government organizations and individuals for confirmation of symptomatic or asymptomatic cases with contact exposure.
North America accounted for the largest share of the lateral flow assays market
The market is sub-segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. North America accounted for the largest share of the lateral flow assay market, followed by Asia-Pacific, Europe, Latin America, and the Middle East & Africa.

However, the APAC is expected to grow at the highest CAGR during the forecast period.
Request 10% Customization: www.marketsandmarkets.com/request...=167205133 Lateral Flow Assays Industry Dynamics: Drivers:

High prevalence of infectious diseases across the globe

Rapidly increasing geriatric population

Growing usage of home-based lateral flow assay devices

Growing demand for point-of-care testing

Need for rapid diagnostic testing for COVID-19

Restraints:

Inconsistent results of lateral flow assay tests
Opportunities:

Evolving applications of lateral flow assays
Rising demand for lateral flow assays in the food & beverage industry

1. Omicron - The new variant of concern is an opportunity for the lateral flow assays market

2. Government initiatives for omicron

3. Initiatives of Medical diagnostic companies for omicron

Challenges:

Limited reimbursements for lateral flow assay products

Difficulties in procuring quality raw materials for the development of lateral flow assay tests

Recent Developments:

In October 2022, F. Hoffmann-La Roche Ltd. (Switzerland) a next-generation portfolio of SARS-CoV-2 rapid antigen test 2.01, SARS-CoV-2 Rapid Antigen Test 2.0 Nasal2, and SARS-CoV-2 Rapid Antigen Test 2.0 Nasal3

In June 2021, Abbott Laboratories (US) received the CE approval for PanBio Rapid Antigen Self-test, opening access throughout Europe to fast, reliable COVID-19 testing

Report Link: ( Lateral Flow Assay Market )

News From

MarketsandMarkets™
Category: Market Research Publishers and Retailers Profile: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, w ...

# data[].attributes.attachment_link.title
Global Lateral Flow Assays Market to grow at a CAGR of 2.0% during the forecast 2027

# data[].attributes.attachment_link.description
Lateral Flow Assays Market by Product (Kits, Readers), Application (Clinical Testing, Veterinary Diagnostics, Food Safety & Environmental Testing), Technique (Sandwich, Multiplex Detection Assay), End User (Hospitals, Home care) - Global Forecast to 2027

# data[].attributes.headline
Unveiling the Latest Innovations in Single-Use Assemblies for Biomanufacturing

# data[].attributes.subject
Unveiling the Latest Innovations in Single-Use Assemblies for Biomanufacturing

# data[].attributes.body
The global Single Use Assemblies Market in terms of revenue was estimated to be worth $2.7 billion in 2022 and is poised to reach $6.5 billion by 2027, growing at a CAGR of 18.8% from 2022 to 2027. The growth of the single use assemblies market is largely driven by the advantages of single-use assemblies over traditional stainless steel equipment, such as quick implementation from small to large-scale production and a cost-effective solution. Additionally, growing adoption of single-use assemblies in research activities, coupled with increased investments in biopharmaceutical R&D activities, is spurring market growth across the globe.

# data[].attributes.attachment_link.readable_text
Updated on : February 09, 2023

The global Single Use Assemblies Market in terms of revenue was estimated to be worth $2.7 billion in 2022 and is poised to reach $6.5 billion by 2027, growing at a CAGR of 18.8% from 2022 to 2027. The growth of the single use assemblies market is largely driven by the advantages of single-use assemblies over traditional stainless steel equipment, such as quick implementation from small to large-scale production and a cost-effective solution. Additionally, growing adoption of single-use assemblies in research activities, coupled with increased investments in biopharmaceutical R&D activities, is spurring market growth across the globe.

To know about the assumptions considered for the study, Request for Free Sample Report

Single Use Assemblies Market Dynamics

Drivers: Increasing Biopharmaceutical R&D is projecting the market growth

Key players operating in the global single use assemblies market are increasingly focused on developing and commercializing technologically advanced single-use assemblies products that offer streamlined workflows, ease of operability, and rapid implementation. As single-use assemblies contribute largely to small and large scale biopharmaceutical manufacturing, increasing investments in biopharmaceutical R&D for product development are attributed to the high market growth of single-use assemblies. Single-use assembly market growth is being driven by benefits such as reduced product cross-contamination and the elimination of additional sterilisation processes. For example, in 2021, the 15 largest pharmaceutical companies will invest a record USD 133 billion in R&D.

Restraints: Issues related to extractables and leachables

Most end users, such as large research facilities and pharmaceutical companies, require many single-use assemblies to simultaneously carry out multiple research studies and production processes. These studies and processes take place at high temperatures and in harsh environments. Single-use assemblies made of polymers and plastics contain various preservatives that are likely to degrade in the form of extractables and leachables in small amounts. This poses the risk of cross-contamination of the material. Thus, extractables and leachables are major concerns limiting the market growth of single-use assemblies.

Opportunities: Emerging Countries

Due to their advantages, the adoption of single-use assemblies has increased significantly during the last decade. In addition to the supportive regulatory environment and cost advantages in emerging countries like China, India, and South Korea, many pharmaceutical and biopharmaceutical companies are expected to expand their single-use manufacturing plants to make this country a hub for bioprocess outsourcing. This is also supported by the increasing number of investments from key players in the market into developing countries. For instance, Cytiva, in collaboration with Wego Pharmaceutical, expanded its manufacturing capacity in China to strengthen its supply chain in the APAC region.

Biopharmaceuticals & Pharmaceutical companies held a dominant share in end user segment in Single use assemblies market

Based on end user, the single-use assemblies market is segmented into biopharmaceuticals and pharmaceutical companies, contract research organizations and contract manufacturing organizations, and academic and research institutes. The biopharmaceuticals and pharmaceutical companies segment accounted for the largest market share in 2021. Higher adoption of standard solutions is mainly due to the flexibility of their use with pre-qualified components of different assemblies, increased cost-efficiency, and rapid implementation of a production plan from small scale to large scale. These are the factors attributed to the increasing demand for single-use assembly products in this end user segment. Additionally, growing investments by pharmaceutical companies in research activities further support market growth.

North America accounted for largest share in single use assemblies market in 2021

Geographically, the single use assemblies market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America held the dominant share, followed by Europe. North America held a dominant share owing to various factors such as increased biologic and biosimilar production in the region, followed by the huge number of key market players with well-established infrastructure for large-scale manufacturing. However, the APAC market is expected to grow at a higher CAGR during the forecast period. Factors such as the presence of a favourable business environment and increased capital investments in biopharmaceutical R&D and life sciences research are accountable for the growth of the single-use assemblies market in the region.

To know about the assumptions considered for the study, download the pdf brochure

Key players in the global single use assemblies market Thermo Fisher Scientific, Inc. (US), Sartorius Stedim Biotech (France), Danaher Corporation (US), Merck KGaA (Germany), Avantor Inc. (US) and among others.

Single Use Assemblies Market Report Scope

This report categorizes the global single use assemblies market into the following segments:

By Products

Bag Assemblies

Filtration Assemblies

Bottle Assemblies

Mixing System Assemblies

Other Products

By Solutions

Standard Solutions

Customized Solutions

By Applications

By End Users

Biopharmaceutical & Pharmaceutical Companies

Contract Research Organizations & Contract Manufacturing Organizations

Academic & Research Institutes

By Regions

Recent Developments

In April 2022, Merck KGaA (Germany), planed to invest around USD 110 million for expanding the existing Wuxi production site (China) to substantially expand biopharma single-use assemblies and custom design capabilities. With this expansion, Merck will broaden its geographic footprint and strengthen its supply chain in China and the Asia-Pacific region.

September 2021, Cytiva planned to triple single-use component production in China through Wego Pharmaceutical Co.'s Weihai, China. 11 manufacturing lines are planned to be launched by end of Q3 2022.

Frequently Asked Questions (FAQ):

What is the size of Single use Assemblies Market ?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

# data[].attributes.attachment_link.title
Single Use Assemblies Market Growth Drivers & Opportunities | MarketsandMarkets

# data[].attributes.attachment_link.description
The global Single Use Assemblies Market in terms of revenue was estimated to be worth $2.7 billion in 2022 and is poised to reach $6.5 billion by 2027, growing at a CAGR of 18.8% from 2022 to 2027.

# data[].attributes.headline
A Comprehensive Guide to the Precision Medicine Market and its Outlook

# data[].attributes.subject
A Comprehensive Guide to the Precision Medicine Market and its Outlook

# data[].attributes.body
The global precision medicine market in terms of revenue was estimated to be worth $29.1 billion in 2023 and is poised to reach $50.2 billion by 2028, growing at a CAGR of 11.5% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth in the precision medicine industry is Currently the focus on genomic research is growing continuously. Is mainly due to the realisation of the potential that genetic targeted therapies hold. This is facilitating increasing adoption of precision medicine. Additionally, genetic testing add companion diagnostics are also witnessing growth. These factors along with the increasing approvals for personalised medicines from prominent regulatory bodies are supporting the growth of this market.

# data[].attributes.attachment_link.readable_text
Chicago, Sept. 12, 2023 (GLOBE NEWSWIRE) -- The healthcare education industry is poised for a transformative shift in the near future, driven by rapid advancements in technology, changing healthcare delivery models, and evolving educational methodologies. With the increasing demand for healthcare professionals, particularly in response to global health crises, institutions will leverage virtual reality, augmented reality, and artificial intelligence to enhance immersive and interactive learning experiences. Moreover, the industry will witness a greater emphasis on interdisciplinary education, fostering collaboration among medical, nursing, and allied health programs. The integration of telemedicine and telehealth education will become increasingly prevalent, ensuring that healthcare professionals are well-prepared to navigate the digital healthcare landscape. As the healthcare ecosystem continues to evolve, the healthcare education sector will play a pivotal role in producing highly skilled and adaptable professionals who can address the complex healthcare challenges of the future.

Precision Medicine market in terms of revenue was estimated to be worth $29.1 billion in 2023 and is poised to reach $50.2 billion by 2028, growing at a CAGR of 11.5% from 2023 to 2028 according to a latest report published by MarketsandMarkets™. Growth in the precision medicine market is mainly driven by factors such as growing focus on genomic research, growth in genetic testing and companion diagnostics, increasing regulatory approvals for personalized therapeutics.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=215185595

Market Revenue in 2023

$29.1 billion

Estimated Value by 2028

$50.2 billion

Growth Rate

Poised to grow at a CAGR of 11.5%

Market Size Available for

2023-2028

Forecast Period

2023-2028

Forecast Units

Value (USD Billion)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

Type, Indication, End User

Geographies Covered

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunities

Growing demand for cell and gene therapies

Key Market Drivers

Growth in genetic testing and companion diagnostics

Precision Medicine market major players covered in the report, such as:

F. Hoffmann-La Roche Ltd. (Switzerland)

Novartis AG (Switzerland)

Bristol Myers Squibb (US)

Gilead Sciences, Inc. (US)

AstraZeneca (UK)

Pfizer Inc. (US)

AbbVie Inc. (US)

Eli Lilly and Company (US)

GlaxoSmithKline plc (UK)

Sanofi (France)

Johnson & Johnson (US)

Merck KGaA (Germany)

Amgen, Inc. (US)

Takeda Pharmaceutical Company Limited (Japan)

Regeneron Pharmaceuticals,Inc. (US)

Sarepta Therapeutics, Inc. (US)

bluebird bio, Inc. (US)

Immunocore Ltd. (UK)

Blueprint Medicines Corporation (US)

Vertex Pharmaceuticals Incorporated (US)

Horizon Therapeutics Plc (Ireland)

Alnylam Pharmaceuticals, Inc. (US)

Rigel Pharmaceuticals, Inc. (US)

Taiho Pharmaceutical Co., Ltd. (Japan)

Seagen Inc. (US)

Alnylam Pharmaceuticals, Inc. (US)

BridgeBio Pharma, Inc. (US)

Incyte Corporation (US)

argenx SE (Netherlands)

Mirati Therapeutics, Inc. (US)

Trevena, Inc. (US)

Agios Pharmaceutical, Inc. (US)

Rhythm Pharmaceuticals, Inc. (US)

MacroGenics, Inc. (US)

and Among Others

Buy a Precision Medicine Industry Report (240 Pages PDF with Insightful Charts, Tables, and Figures): All the market segments have been divided for Precision medicine market in the report. This report categorizes the Precision Medicine Market into the following segments: Precision Medicine Market, by Type https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=215185595 Precision Medicine Market by Indication

Inhibitor drugs

Monoclonal Antibodies

Cell & Gene Therapy

Antiviral & Anti-retroviral drugs

Other Therapeutic Products

Precision Medicine Market, by End User

Oncology

Rare Diseases

Infectious diseases

Hematological disorders

Other indications

Precision Medicine Market, by region Request for FREE Sample Pages: The key stakeholders in the Precision Medicine market include: https://www.marketsandmarkets.com/requestsampleNew.asp?id=215185595 Recent Developments:

Hospitals and Clinics

Home care settings

Frequently Asked Questions (FAQs) of Precision Medicine Market:

Pharmaceutical Companies

Biotechnology Companies

Research Institutions and Academic Centers

Regulatory Agencies

Health Insurers and Payers

Private & government-funding organizations

In February 2023, Roche received EC approval for expansion of the Hemlibra (emicizumab) European Union (EU) marketing authorization.

In January 2022, AstraZeneca (UK) collaborated with Scorpion Therapeutics to develop and commercialize precision medicines against hard-to-target cancer proteins, with an aim to transform oncology treatment. The size of this deal accounted for USD 75 billion.

Question 1. Who are the key players in the overall precision medicine market?
Answer: Key players in the precision medicine market include F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (US), Bristol Myers Squibb (US), AstraZeneca (UK), Gilead Sciences, Inc. (US), AbbVie Inc. (US), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Sanofi (France), Johnson & Johnson (US), Merck KGaA (Germany), Amgen, Inc. (US) among others.

Question 2: Which type of segment dominates in the precision medicine market?
Answer: The type of segment is segmented as inhibitor drugs, monoclonal, cell & gene therapy, antiviral & antiretroviral drugs, and other therapeutic products. The large share of this segment can be attributed to factors such as the growing number of approved inhibitor drugs as personalized medicines, coverage of major indications such as oncology, rare diseases among others.

Question 3: Which indication segment of the precision medicine market is expected to witness lucrative growth?
Answer: Based on indication, the precision medicine market is segmented into oncology, rare diseases, infectious diseases, hematological disorders and other indications The oncology indication accounted for the largest share of this market owing to factors such as presence of a significant number of approved personalized or precision therapeutics for this indication, availability of genetic testing, diagnostics, among others.
Get 10% Free Customization on this Report: Report Objectives: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=215185595 Related Reports: Viral Vector Manufacturing Market Cell & Gene Therapy Manufacturing Services Market Biologics Safety Testing Market Research Insight: Content Source: https://www.marketsandmarkets.com/PressReleases/precision-medicine.asp https://www.marketsandmarkets.com/ResearchInsight/precision-medicine-market.asp
Question 4: What is the market size for precision medicine market?
Answer: The global precision medicine market is projected to reach USD 50.2 billion in 2028 from USD 29.1 billion in 2023, growing at a CAGR of 11.5%.

Question 5: What are the drivers and opportunites for global precision medicine market?
Answer: The major factors driving the growth of the global precision medicine market are the continuously growing advancements in genomic research, increasing focus on genomic testing and diagnostics among others. Moreover, growing cell and gene therapy research and commercialization is expected to offer opportunities in this market.

To define, describe, and forecast the global precision medicine market by type, indication, end user and region.

To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall precision medicine market

To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.

To provide detailed information regarding the major factors influencing the market growth, such as drivers, restraint, opportunity, and challenge

To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa

To strategically analyze the market structure and profile the key players of the global precision medicine market and comprehensively analyze their core competencies2

To track and analyze competitive developments such as expansions, acquisitions, partnerships, collaborations, agreements, and product approvals in the precision medicine market.

# data[].attributes.attachment_link.title
Precision Medicine Market is Expected to Reach $50.2 billion | MarketsandMarkets.

# data[].attributes.attachment_link.description
Chicago, Sept. 12, 2023 (GLOBE NEWSWIRE) -- The healthcare education industry is poised for a transformative shift in the near future, driven by rapid...

# data[].attributes.headline
Global Dental Practice Management Software Market worth $2.3 billion by 2028 

# data[].attributes.subject
Global Dental Practice Management Software Market worth $2.3 billion by 2028 

# data[].attributes.body
The Global Dental Practice Management Software Market in terms of revenue was estimated to be worth $1.5 billion in 2023 and is poised to reach $2.3 billion in 2028, growing at a CAGR of 8.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The rising awareness of oral hygiene and dental treatment, the increasing demand for advanced dental procedures, and the growing market for dental tourism in developing countries are major key drivers for the market. However, data privacy and security issues are the factors which may slow down market growth.

# data[].attributes.attachment_link.readable_text
Medical and Health Markets

Dental Practice Management Software Market by Deployment Mode (Cloud-based, Web-based), Application (Patient Communication, Insurance Management, Billing/Invoice), End User (Dental Clinics, Hospitals, DSO, Academic Institutes) - Global Forecast to 2028

The dental practice management software industry is poised for significant growth and transformation in the near future. With advancements in technology and increasing digitalization, dental practices are adopting software solutions to streamline their operations, improve patient care, and enhance overall efficiency. Dental practice management software offers a wide range of features, including appointment scheduling, patient records management, billing and invoicing, treatment planning, and communication tools. These software solutions help dental practices automate manual tasks, reduce paperwork, and improve accuracy in managing patient information. In addition, the integration of electronic health records (EHR) and digital imaging capabilities further enhances the capabilities of dental practice management software.

The Global Dental Practice Management Software Market in terms of revenue was estimated to be worth $1.5 billion in 2023 and is poised to reach $2.3 billion in 2028, growing at a CAGR of 8.6% from 2023 to 2028.
Download PDF Brochure: www.marketsandmarkets.com/pdfdown...=153532396 Browse in-depth TOC on "Dental Practice Management Software Market"
Major Players: 186 - Pages Dental Practice Management Software Market Drivers Dynamics: Restraints
Dental practice management software market include Patterson Companies, Inc. (US), Henry Schein, Inc. (US), Carestream Dental LLC (US), and Open Dental Software Inc.(US)
Opportunities

Increasing prevalence of oral health disorders

Technological advancements in dentistry

High return on investment from dental practice management software adoption

Rising demand for advanced cosmetic dental procedures

Challenges

Data privacy and security issues
"In 2022, Asia Pacific is expected to be the fastest growing segment in the Dental PMS industry during the forecast period"

Consolidation of dental practices

Potential for growth in emerging countries

Shortage of healthcare IT professionals

Resistance to switch to dental PMS

Recent Developments of the Dental Practice Management Software Industry
Based on region, the dental PMS market is segmented into five major regions, namely, North America, Europe, Asia Pacific (APAC), Latin America, and the Middle East and Africa.
Report: www.marketsandmarkets.com/request...=153532396
Asia Pacific is expected to be the region with the highest CAGR from 2023 to 2028. This can be attributed to the rising dental tourism, rising disposable incomes, increasing awareness about new technologies, increasing prevalence of dental disorders, and rising need for quality dental care in the developing countries of the region.

In January 2023 A Henry Schein, Inc. (US) subsidiary, eAssist Dental Solutions (US), acquired a majority interest in Unitas PPO Solutions (US) to improve fee analysis services offered by Henry Schein, and enhance the collection processes of the eAssist platform.

In April 2023, Henry Schein, Inc. (US) acquired a majority ownership position in Biotech Dental SAS (France), aiming to create a digital workflow that provides a seamless journey for customers to increase case acceptance and improve clinical outcomes for practitioners.

In November 2022, The Curve Dental LLC (US) and Pearl Inc. (US) organizations announced plans to integrate Pearl's Second Opinion disease detection capabilities within Curve Dental's all-in-one SuperHero practice management system.

In February 2022, Straumann Group acquired a minority share (29.6%) in CareStack, which gradually increased to 36.3%. This enabled CareStack to expand its service offering and presence in the US.

News From

MarketsandMarkets™
Category: Market Research Publishers and Retailers Profile: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, w ...

# data[].attributes.attachment_link.keywords[]
dental practice management software industry

# data[].attributes.attachment_link.title
Global Dental Practice Management Software Market worth $2.3 billion by 2028 according to a new research report as

# data[].attributes.attachment_link.description
The global dental practice management software market boasts a total revenue value of $2.3 billion in 2028.

# data[].attributes.headline
X-Ray Detectors Market worth $4.0 billion by 2027 

# data[].attributes.subject
X-Ray Detectors Market worth $4.0 billion by 2027 

# data[].attributes.body
The Global X-Ray Detectors Market in terms of revenue was estimated to be worth $3.1 billion in 2022 and is poised to reach $4.0 billion by 2027, growing at a CAGR of 5.2% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Due to increasing cardiac arrest in the US and all over the globe, the mortality rate has increased. The help of imaging systems and advancements in imaging products it is helping in cardiac imaging and the early detection of diseases. The developments are enhancing the diagnostic and prognostic skills of medical professionals, which are allowing them to better assist patients with tumors, orthopedic pains, veterinary doctors, and other healthcare providers.

# data[].attributes.attachment_link.readable_text
, /PRNewswire/ -- X-Ray Detectors Market size is projected to reach USD 4.0 billion by 2027 from USD 3.1 billion in 2022, at a CAGR of 5.2% according to a new report by MarketsandMarkets™. Increasing investments in advancing healthcare facilities & digital imaging technologies, growing demand for early diagnosis, and widening scope of clinical applications of X-ray detectors, rising chronic disorders which need quick examinations and increasing sedentary lifestyles are some of the key factors driving market growth.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=7004984 Browse in-depth TOC on "X-Ray Detectors Market" X-Ray Detectors Market Body Contouring segment to register significant growth rate over the forecast period of 2022-2027 Scope: Medical applications segment accounted for the largest share of the X-Ray detectors market by Applications in 2021
Based on the product type, the global X-Ray detector market is segmented into Flat Panel Detectors, Computed Radiography detectors, Line-Scan detectors, and Charged Coupled detectors. The flat-Panel detector segment is expected to register the highest growth rate over the forecast period. The computed Radiography segment accounts for the second share in the X-Ray detectors market.
The Asia Pacific market to register the highest growth in the market during the forecast period
The medical application segmented accounted for almost 70.1% of the total applications for X ray detectors. The vast share of this segment can be attributed to the factors like increasing disorders where screening is necessary before the diagnosis and increasing technological advancements in medical industry is also one of the reasons for the vast share.
Request Sample Pages: X-Ray Detectors Market Dynamics: Drivers: https://www.marketsandmarkets.com/requestsampleNew.asp?id=7004984
The Asia Pacific X-Ray detectors market is projected to register the highest growth during the forecast period of 2022 to 2027. Asia Pacific is registered to grow at the highest CAGR of 6.4%. Moreover, market players also focus on expanding their presence in the APAC healthcare imaging industry and are trying to establish new subsidiaries in the Asia Pacific region to attract huge market which will help them to increase their revenue.

1. Increasing demand for early diagnosis and widening scope of clinical applications of X-ray detectors

2. Investments to advance healthcare facilities and digital imaging technologies

3. Rising target patient population

4. Rising prevalence of animal diseases and growing number of veterinary practitioners

5. Growing demand for cosmetic dentistry
Restraints:
6. Increasing demand for X-ray-based security enhancement solutions at airports

7. Reimbursement cuts for analog X-rays
Opportunities:
1. High cost of X-ray detectors

2. Health hazards of full-body scanning
Challenges:
1. Rising healthcare expenditure across developing countries

2. Technological advancements

1. Lack of animal healthcare awareness in emerging countries
Key Market Players:
2. Increasing adoption of refurbished X-ray units
Recent Developments:
3. Hospital budget cuts
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=7004984 Related Reports:
The X-Ray detector market is moderately competitive, with both established companies and upcoming competitors for the same market share. As of 2021, the key player operating in the global X-Ray detector market are Varex Imaging Corporation (US), Canon Inc. (Japan), Agfa-Gevaert NV (Belgium), FUJIFILM Holdings Corporation (Japan)., Thales Group(France), Teledyne Technologies Incorporated (US), Carestream Health, Inc. (US), Konica Minolta, Inc. (Japan), Rayence (US), Vieworks Co., Ltd (South Korea), Hamamatsu Photonics KK (Japan), iRay Technology (China), CareRay Medical Systems Co. (China) and Analogic Corporation (US).

In November 2022, Varex Imaging Corporation launched the AZURE flat Panel detector in RSNA 2022. The product has faster integration with high speed and low noise for real-time image applications.

In March 2021, Thales Group launched Pixium 3040F, which has high image quality, optimized spatial resolution, higher contrast, and superior sensitivity at low doses when used in radiotherapy.

In March 2021, Canon Inc launched XCDI-RF wireless B1, wireless FPD in Japan for radiography and for fluoroscopy purposes.

Browse Adjacent Market: Medical Devices Market Research Reports & Consulting

Sterilization Services Market - Global Forecasts to 2027

Diagnostic Imaging Services Market - Global Forecasts to 2027
About MarketsandMarkets™:
Medical Power Supply Market - Global Forecasts to 2027

Teleradiology Market - Global Forecasts to 2026

Veterinary Imaging Market - Global Forecasts to 2026

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Contact:
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/x-ray-detectors-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/x-ray-detectors.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
X-Ray Detectors Market worth $4.0 billion by 2027 - Exclusive Report by MarketsandMarkets™

# data[].attributes.attachment_link.description
PRNewswire/ -- X-Ray Detectors Market size is projected to reach USD 4.0 billion by 2027 from USD 3.1 billion in 2022, at a CAGR of 5.2% according to a new...

# data[].attributes.headline
Biobanking Market is Expected to Reach $5.0 Billion by 2028

# data[].attributes.subject
Biobanking Market is Expected to Reach $5.0 Billion by 2028

# data[].attributes.body
The Global Biobanking Market in terms of revenue was estimated to be worth $2.9 billion in 2023 and is poised to reach $5.0 billion by 2028, growing at a CAGR of 11.4% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of this market is majorly driven by the growing investments and funding for biobanks, focus on genetic testing and precision medicine, increasing trend in the preservation of cord blood stem cells from newborns, and favorable funding scenario for research related to regenerative medicine. On the other hand, the high cost of automated equipment and issues related to biospecimen sample management are restraining the growth of this market.

# data[].attributes.headline
The Growing Demand for Leukapheresis: Market Overview and Outlook

# data[].attributes.subject
The Growing Demand for Leukapheresis: Market Overview and Outlook

# data[].attributes.body
The Global Leukapheresis Products Market was estimated to be worth USD 70 million in 2023 and is poised to reach USD 100 million by 2028, growing at a CAGR of 8.3%. The global leukopaks market was estimated to be worth USD 200 million in 2023 and is poised to reach USD 1020 million by 2028, growing at a CAGR of 38.1%.
One of the key trends in the leukopaks market is the increasing use of leukopaks in CAR T-cell therapy. CAR T-cell therapy is a type of immunotherapy that uses the patient's own immune cells to fight cancer. It is a promising new treatment for leukemia and other blood cancers. Leukopaks are used to collect the patient's immune cells, which are then modified to fight cancer. Other trends in the leukopaks market include the increasing demand for leukopaks in personalized medicine and the development of new leukopak collection and storage methods.

# data[].attributes.attachment_link.readable_text
, /PRNewswire/ -- In the near future, the leukapheresis industry is poised for remarkable growth and transformation, driven by advancements in medical technology and increasing demand for targeted and personalized therapies. With a focus on precision medicine, the industry is expected to witness the development of more efficient and innovative leukapheresis techniques, enabling the isolation and collection of specific white blood cell populations for diverse therapeutic applications, including immunotherapy, cancer treatment, and autoimmune disorder management. Moreover, streamlined automation, integration of artificial intelligence, and enhanced data analytics are likely to optimize the leukapheresis process, minimizing patient discomfort and maximizing cell yield. This evolution in leukapheresis holds the potential to revolutionize how we approach complex diseases, providing patients with novel, tailored treatment options and paving the way for substantial advancements in the field of cellular therapies.

Leukapheresis Market in terms of revenue was estimated to be worth $70 million in 2023 and is poised to reach $100 million by 2028, growing at a CAGR of 8.3 % from 2023 to 2028 according to a new report by MarketsandMarkets™. The global leukopaks market is anticipated to reach USD 1020 million by 2028 from USD 200 million in 2023, at a CAGR of 38.1%. The leukopaks market is driven by the increasing demand for leukopaks in research applications, such as the development of new cancer treatments. The demand for leukopaks is growing due to the increasing number of research studies being conducted on cancer. The development of new cancer treatments is also driving the demand for leukopaks. Other factors that are contributing to the growth of the leukopaks market include the increasing incidence and prevalence of cancer, the growing popularity of personalized medicine, advances in medical technology, and growing awareness about leukopaks and their benefits in developing nations.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=20283148 Browse in-depth TOC on "Leukapheresis Market" Leukapheresis Market Scope: The disposables segment accounted for the larger share of the leukapheresis products market.
In this report, the overall leukapheresis market is divided into the leukapheresis products market and the Leukopaks Market. The leukapheresis products Market is classified into segments including type, application, end user, and region, and the leukopaks Market is classified into segments such as type, indication, end user, and region.
The mobilized leukopaks segment dominated the leukopaks market based on type.
By type, the leukapheresis products market can be segmented into devices and disposables. The disposables segment occupied a larger share of the leukapheresis products market in 2022. The disposables used in leukapheresis procedures are products used to access blood vessels and store blood components, replacement fluids, and anticoagulants to prevent blood from clotting in the process. Disposables are used for both automated blood collection and therapeutic leukapheresis. They include apheresis catheters, needle sets, centrifuge bowls, tubing sets/pipeline systems, collection bags, and various solutions such as saline, anticoagulants, media, columns, filters, and cell separation kits.
North American region dominated the Leukapheresis market with the largest market share.
By type, the leukopaks market is categorized into mobilized leukopaks, non-mobilized leukopaks, diseased leukopaks, and isolated PBMCs. The mobilized leukopaks segment dominated the leukopaks market in 2022. Mobilized leukopaks are mainly used in preclinical and clinical research in a variety of fields, including cancer immunotherapy, cell therapy, and regenerative medicine. Charles River Laboratories (US), Discovery Life Sciences (US), StemExpress (US), BioIVT (US), and Caltag Medsystems (UK) are some of the major players offering mobilized leukopaks for research and clinical applications.
Request Sample Pages: Leukapheresis Market Drivers: Dynamics: Restraints: https://www.marketsandmarkets.com/requestsampleNew.asp?id=20283148 Opportunities:
The Leukapheresis market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America reported the largest share of the Leukapheresis market in 2022. The incidence and prevalence of leukemia are increasing in North America, due to factors such as environmental pollution, exposure to radiation, and unhealthy lifestyle habits. This is driving the demand for leukapheresis products, which are used to treat leukemia.
Challenges:
1. Increased demand for leukopaks in clinical research
Key Market Players:
1. Complications associated with therapeutic leukapheresis
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=20283148 Leukapheresis Market Advantages:

Targeted Cell Collection: Leukapheresis enables precise isolation and collection of specific white blood cell populations, ensuring higher purity and potency of cells for various therapeutic applications.

Personalized Medicine: The technique contributes to personalized medicine by tailoring treatments to individual patients, leveraging their unique genetic profiles for more effective and customized therapies.

Efficiency and Automation: Ongoing innovation and automation within the leukapheresis industry streamline procedures, reducing treatment time, patient discomfort, and optimizing cell yield for improved outcomes.

Consistency and Reliability: Automation ensures consistent cell collection, enhancing reproducibility and reliability in research and clinical applications.

Therapeutic Breakthroughs: Leukapheresis has facilitated advancements in treating diseases like cancer and autoimmune disorders through the development of novel therapies like CAR-T cell therapy.

Research Advancements: The technique supports medical research by providing researchers with purified cell populations for studying disease mechanisms, drug development, and therapy optimization.

Reduced Side Effects: Targeted cell collection minimizes unwanted side effects by focusing only on the specific cell populations needed for treatment.

Minimized Patient Risk: Leukapheresis reduces the need for invasive procedures, lowering patient risk while obtaining essential cells for treatment.

Expanded Treatment Options: The technique expands the range of treatment options available to patients, especially for those with limited alternatives or complex medical conditions.

Clinical Versatility: Leukapheresis finds applications across various medical fields, from cancer and immunology to regenerative medicine, showcasing its versatility in addressing different health challenges.

Pioneering Cellular Therapies: The advancements in leukapheresis techniques have been instrumental in driving the development and success of cutting-edge cellular therapies.

Improved Patient Outcomes: By enhancing the quality and effectiveness of isolated cell populations, leukapheresis contributes to improved patient outcomes and quality of life.

Cost-Effectiveness: In the long term, leukapheresis can offer cost-effective solutions by providing more targeted treatments, potentially reducing the need for extensive and costly interventions.

1. Gaps in current leukapheresis technologies
Recent Developments:

In May 2022, Fresenius Kabi (Germany) acquired Ivenix, Inc. (US). This acquisition adds a next-generation infusion therapy platform for the significant US market to Fresenius Kabi's portfolio and provides the company with key capabilities in hospital connectivity.

In March 2022, Charles River Laboratories International Inc. (US) acquired Retrogenix Limited (UK) to enhance the company's scientific expertise with additional large molecule and cell therapy discovery capabilities.

In November 2021, Discovery Life Sciences (US) announced the launch of the Discovery BIOstore, which provides real-time access to Discovery's inventory of millions of human biospecimens to scientists.

Related Reports:
1. Blood transfusion safety in developing countries

Key players in the leukapheresis products market include Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany). Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US). These companies adopted strategies such as product launches, business expansions, agreements, partnerships, and acquisitions to strengthen their presence in the Leukapheresis market.

Medical Progress: The leukapheresis market represents a significant stride toward the future of medicine, fostering innovation and progress in healthcare through its specialized cell collection capabilities.

Plasma Fractionation Market - Global Forecasts to 2027

Continuous Renal Replacement Therapy Market - Global Forecasts to 2026
About MarketsandMarkets™:
Corporate Wellness Solutions Market - Global Forecasts to 2026

US Therapeutic Plasma Exchange Market - Global Forecasts to 2025

Apheresis Market - Global Forecasts to 2025

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/leukapheresis-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/leukapheresis.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

View original content: https://www.prnewswire.com/news-releases/leukapheresis-market-worth-100-million--marketsandmarkets-301914634.html

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Leukapheresis Market worth $100 million | MarketsandMarkets

# data[].attributes.attachment_link.description
In the near future, the leukapheresis industry is poised for remarkable growth and transformation, driven by advancements in medical technology and increasing demand for targeted and personalized therapies.

# data[].attributes.headline
Cold Pain Therapy Market is Expected to Reach $2.4 billion by 2027

# data[].attributes.subject
Cold Pain Therapy Market is Expected to Reach $2.4 billion by 2027

# data[].attributes.body
The report "Cold Pain Therapy Market by Product (OTC (Gels, Creams, Patches, Wraps, Pads), Prescription (Motorized, Non-motorized)), Application (Musculoskeletal, Post-Op, Sports Injuries), Distribution Channel (Hospital, Retail, E-Pharmacy) - Global Forecast to 2027", is projected to reach USD 2.4 billion by 2027 from USD 1.8 billion in 2022, at a CAGR of 5.1%.

# data[].attributes.attachment_link.readable_text
Chicago, March 13, 2023 (GLOBE NEWSWIRE) -- The global cold pain therapy market refers to the market for devices and products that provide relief from pain and inflammation through the application of cold temperatures. This market includes various products such as ice packs, cooling gels, sprays, and wraps, as well as more advanced technologies such as cryotherapy chambers and devices that use low-level laser therapy. The demand for cold pain therapy products is driven by various factors, including the increasing prevalence of musculoskeletal disorders, sports injuries, and arthritis, as well as a growing awareness of the benefits of non-invasive and drug-free pain management solutions. Additionally, the rise in the aging population, who are more susceptible to chronic pain, is also contributing to the growth of this market.

Cold Pain Therapy Market in terms of revenue was estimated to be worth $1.8 billion in 2022 and is poised to reach $2.4 billion by 2027, growing at a CAGR of 5.1% from 2022 to 2027 according to a latest report published by MarketsandMarkets™. Market growth is driven by the rising geriatric population coupled with increasing prevalence of musculoskeletal disorders, and easy availability of cold pain therapy products.
Download an Illustrative overview: Cold Pain Therapy Market Scope: Notable Cold Pain Therapy mergers and acquisitions for 2021 - 2022 include: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=55543905 Growth Drivers of Cold Pain Therapy Market from M Macro Level: acro to Micro: Micro Level:

Market Revenue in 2022

$1.8 billion

Estimated Value by 2027

$2.4 billion

Growth Rate

Poised to grow at a CAGR of 5.1%

Market Size Available for

2020-2027

Forecast Period

2022-2027

Forecast Units

Value (USD Billion)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

Product, Application, Distribution Channel and Region

Geographies Covered

North America, Europe, Asia Pacific, Latin America, and Middle East and Africa

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunity

Increasing adoption of analgesic patches

Key Market Drivers

Increasing number of hip and knee surgeries

Request for FREE Sample Pages: Hypothetic Challenges of Cold Pain Therapy Market in Near Future: https://www.marketsandmarkets.com/requestsampleNew.asp?id=55543905 Top 3 Use Cases of Cold Pain Therapy Market:

Medline Industries, Inc. acquired Strategent LLC in January 2021. Strategent is a healthcare solutions provider that specializes in product development and commercialization.

DJO Global, Inc. acquired Trilliant Surgical in February 2021. Trilliant Surgical is a manufacturer of orthopedic implants and instrumentation.

Sanofi acquired Kadmon Holdings, Inc. in September 2021. Kadmon is a biopharmaceutical company that develops therapies for immune and inflammatory diseases, including pain management.

Rohto Pharmaceutical Co., Ltd. acquired Mentholatum Company in October 2021. Mentholatum is a manufacturer of topical analgesic products, including pain relief creams and ointments.

Increasing prevalence of chronic pain: The growing incidence of musculoskeletal disorders, arthritis, and sports injuries is driving demand for non-invasive and drug-free pain management solutions such as cold pain therapy.

Growing awareness of the benefits of cold pain therapy: There is an increasing awareness among patients and healthcare professionals about the benefits of cold pain therapy in reducing inflammation and pain, without the risk of addiction or side effects associated with some pain medications.

Technological advancements in cold pain therapy devices: There have been significant advances in the development of cold pain therapy devices, such as cryotherapy chambers and low-level laser therapy devices, which offer more targeted and effective pain relief.

Increase in healthcare expenditure: As global healthcare expenditure continues to rise, the demand for pain management solutions is also increasing, driving growth in the cold pain therapy market.

Related Reports: Compression Therapy Market Neuromodulation Market Pain Management Devices Market Sports Medicine Market Patient Handling Equipment Market

Growing demand for over-the-counter (OTC) products: The growing trend towards self-medication and the availability of OTC cold pain therapy products is driving demand for these products among consumers.

Aging population: As the global population ages, there is an increasing incidence of chronic pain, which is driving demand for pain management solutions such as cold pain therapy.

Sports and fitness industry growth: The growing popularity of sports and fitness activities is driving demand for cold pain therapy products, particularly among athletes and fitness enthusiasts.

Online availability of cold pain therapy products: The increasing availability of cold pain therapy products through online channels is making these products more accessible to consumers, driving market growth.

Competition from alternative pain management solutions: While cold pain therapy has many benefits, there are many other pain management solutions available, such as heat therapy, acupuncture, and physical therapy. Increased competition from these alternatives could impact the demand for cold pain therapy products.

Stringent regulations: As cold pain therapy devices become more advanced, regulatory bodies may introduce more stringent regulations that could increase the time and cost of bringing new products to market.

Adverse effects of cold therapy: While cold pain therapy is generally considered safe, in rare cases, it can lead to adverse effects such as frostbite, nerve damage, or skin irritation. If there are reports of adverse effects, it could impact consumer confidence and demand for cold pain therapy products.

Availability of substitutes: As more alternative pain management solutions become available, some consumers may choose to use these substitutes rather than cold pain therapy products, leading to a decline in demand for these products.

Economic instability: In times of economic instability, consumers may cut back on discretionary spending, including spending on pain management products, which could impact market growth.

Sports medicine: Cold pain therapy is commonly used in sports medicine to treat acute injuries such as sprains, strains, and bruises. Athletes and sports professionals use cold therapy devices such as ice packs, cold compression therapy units, and cryotherapy chambers to reduce inflammation and pain, and to accelerate the healing process.

Arthritis and chronic pain management: Cold pain therapy is also widely used for chronic pain management, particularly for conditions such as osteoarthritis, rheumatoid arthritis, and fibromyalgia. Cold therapy devices such as cold therapy wraps, ice baths, and cold lasers are commonly used to alleviate pain and stiffness, and to improve joint mobility.

Post-operative recovery: Cold pain therapy is also used in post-operative recovery to reduce swelling, inflammation, and pain. Cold therapy devices such as cold therapy machines and ice packs are used to promote healing and improve patient comfort after surgeries such as joint replacements, orthopedic surgeries, and cosmetic surgeries.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=55543905

# data[].attributes.attachment_link.title
Cold Pain Therapy Market is Expected to Reach $2.4 billion | MarketsandMarkets.

# data[].attributes.attachment_link.description
Chicago, March 13, 2023 (GLOBE NEWSWIRE) -- The global cold pain therapy market refers to the market for devices and products that provide relief from...

# data[].attributes.headline
Global Viral Vector & Plasmid DNA Manufacturing Market worth $12.8 billion by 2028

# data[].attributes.subject
Global Viral Vector & Plasmid DNA Manufacturing Market worth $12.8 billion by 2028

# data[].attributes.body
The Global Viral Vector Manufacturing Market in terms of revenue was estimated to be worth $5.5 billion in 2023 and is poised to reach $12.8 billion by 2028, growing at a CAGR of 18.2% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of this market is majorly driven by g rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, and effectiveness of viral vectors in gene therapy delivery. On the other hand, high operational cost associated with cell & gene therapy manufacturing is restraining the growth of this market.

# data[].attributes.attachment_link.readable_text
We've detected unusual activity from your computer network

To continue, please click the box below to let us know you're not a robot.

Why did this happen?

Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. For more information you can review our Terms of Service and Cookie Policy.

Need Help?

For inquiries related to this message please contact our support team and provide the reference ID below.

# data[].attributes.headline
Global Precision Medicine Market worth $50.2 billion by 2028

# data[].attributes.subject
Global Precision Medicine Market worth $50.2 billion by 2028

# data[].attributes.body
Precision Medicine Market in terms of revenue was estimated to be worth $29.1 billion in 2023 and is poised to reach $50.2 billion by 2028, growing at a CAGR of 11.5 % from 2023 to 2028 according to a new report by MarketsandMarkets™. The rising number of product approvals followed by growing focus on genetic testing, a prerequisite for precision medicine therapeutics, are the factors supporting market growth.

# data[].attributes.attachment_link.readable_text
Chicago, Sept. 12, 2023 (GLOBE NEWSWIRE) -- The healthcare education industry is poised for a transformative shift in the near future, driven by rapid advancements in technology, changing healthcare delivery models, and evolving educational methodologies. With the increasing demand for healthcare professionals, particularly in response to global health crises, institutions will leverage virtual reality, augmented reality, and artificial intelligence to enhance immersive and interactive learning experiences. Moreover, the industry will witness a greater emphasis on interdisciplinary education, fostering collaboration among medical, nursing, and allied health programs. The integration of telemedicine and telehealth education will become increasingly prevalent, ensuring that healthcare professionals are well-prepared to navigate the digital healthcare landscape. As the healthcare ecosystem continues to evolve, the healthcare education sector will play a pivotal role in producing highly skilled and adaptable professionals who can address the complex healthcare challenges of the future.

Precision Medicine market in terms of revenue was estimated to be worth $29.1 billion in 2023 and is poised to reach $50.2 billion by 2028, growing at a CAGR of 11.5% from 2023 to 2028 according to a latest report published by MarketsandMarkets™. Growth in the precision medicine market is mainly driven by factors such as growing focus on genomic research, growth in genetic testing and companion diagnostics, increasing regulatory approvals for personalized therapeutics.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=215185595

Market Revenue in 2023

$29.1 billion

Estimated Value by 2028

$50.2 billion

Growth Rate

Poised to grow at a CAGR of 11.5%

Market Size Available for

2023-2028

Forecast Period

2023-2028

Forecast Units

Value (USD Billion)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

Type, Indication, End User

Geographies Covered

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunities

Growing demand for cell and gene therapies

Key Market Drivers

Growth in genetic testing and companion diagnostics

Precision Medicine market major players covered in the report, such as:

F. Hoffmann-La Roche Ltd. (Switzerland)

Novartis AG (Switzerland)

Bristol Myers Squibb (US)

Gilead Sciences, Inc. (US)

AstraZeneca (UK)

Pfizer Inc. (US)

AbbVie Inc. (US)

Eli Lilly and Company (US)

GlaxoSmithKline plc (UK)

Sanofi (France)

Johnson & Johnson (US)

Merck KGaA (Germany)

Amgen, Inc. (US)

Takeda Pharmaceutical Company Limited (Japan)

Regeneron Pharmaceuticals,Inc. (US)

Sarepta Therapeutics, Inc. (US)

bluebird bio, Inc. (US)

Immunocore Ltd. (UK)

Blueprint Medicines Corporation (US)

Vertex Pharmaceuticals Incorporated (US)

Horizon Therapeutics Plc (Ireland)

Alnylam Pharmaceuticals, Inc. (US)

Rigel Pharmaceuticals, Inc. (US)

Taiho Pharmaceutical Co., Ltd. (Japan)

Seagen Inc. (US)

Alnylam Pharmaceuticals, Inc. (US)

BridgeBio Pharma, Inc. (US)

Incyte Corporation (US)

argenx SE (Netherlands)

Mirati Therapeutics, Inc. (US)

Trevena, Inc. (US)

Agios Pharmaceutical, Inc. (US)

Rhythm Pharmaceuticals, Inc. (US)

MacroGenics, Inc. (US)

and Among Others

Buy a Precision Medicine Industry Report (240 Pages PDF with Insightful Charts, Tables, and Figures): All the market segments have been divided for Precision medicine market in the report. This report categorizes the Precision Medicine Market into the following segments: Precision Medicine Market, by Type https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=215185595 Precision Medicine Market by Indication

Inhibitor drugs

Monoclonal Antibodies

Cell & Gene Therapy

Antiviral & Anti-retroviral drugs

Other Therapeutic Products

Precision Medicine Market, by End User

Oncology

Rare Diseases

Infectious diseases

Hematological disorders

Other indications

Precision Medicine Market, by region Request for FREE Sample Pages: The key stakeholders in the Precision Medicine market include: https://www.marketsandmarkets.com/requestsampleNew.asp?id=215185595 Recent Developments:

Hospitals and Clinics

Home care settings

Frequently Asked Questions (FAQs) of Precision Medicine Market:

Pharmaceutical Companies

Biotechnology Companies

Research Institutions and Academic Centers

Regulatory Agencies

Health Insurers and Payers

Private & government-funding organizations

In February 2023, Roche received EC approval for expansion of the Hemlibra (emicizumab) European Union (EU) marketing authorization.

In January 2022, AstraZeneca (UK) collaborated with Scorpion Therapeutics to develop and commercialize precision medicines against hard-to-target cancer proteins, with an aim to transform oncology treatment. The size of this deal accounted for USD 75 billion.

Question 1. Who are the key players in the overall precision medicine market?
Answer: Key players in the precision medicine market include F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (US), Bristol Myers Squibb (US), AstraZeneca (UK), Gilead Sciences, Inc. (US), AbbVie Inc. (US), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Sanofi (France), Johnson & Johnson (US), Merck KGaA (Germany), Amgen, Inc. (US) among others.

Question 2: Which type of segment dominates in the precision medicine market?
Answer: The type of segment is segmented as inhibitor drugs, monoclonal, cell & gene therapy, antiviral & antiretroviral drugs, and other therapeutic products. The large share of this segment can be attributed to factors such as the growing number of approved inhibitor drugs as personalized medicines, coverage of major indications such as oncology, rare diseases among others.

Question 3: Which indication segment of the precision medicine market is expected to witness lucrative growth?
Answer: Based on indication, the precision medicine market is segmented into oncology, rare diseases, infectious diseases, hematological disorders and other indications The oncology indication accounted for the largest share of this market owing to factors such as presence of a significant number of approved personalized or precision therapeutics for this indication, availability of genetic testing, diagnostics, among others.
Get 10% Free Customization on this Report: Report Objectives: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=215185595 Related Reports: Viral Vector Manufacturing Market Cell & Gene Therapy Manufacturing Services Market Biologics Safety Testing Market Research Insight: Content Source: https://www.marketsandmarkets.com/PressReleases/precision-medicine.asp https://www.marketsandmarkets.com/ResearchInsight/precision-medicine-market.asp
Question 4: What is the market size for precision medicine market?
Answer: The global precision medicine market is projected to reach USD 50.2 billion in 2028 from USD 29.1 billion in 2023, growing at a CAGR of 11.5%.

Question 5: What are the drivers and opportunites for global precision medicine market?
Answer: The major factors driving the growth of the global precision medicine market are the continuously growing advancements in genomic research, increasing focus on genomic testing and diagnostics among others. Moreover, growing cell and gene therapy research and commercialization is expected to offer opportunities in this market.

To define, describe, and forecast the global precision medicine market by type, indication, end user and region.

To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall precision medicine market

To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.

To provide detailed information regarding the major factors influencing the market growth, such as drivers, restraint, opportunity, and challenge

To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa

To strategically analyze the market structure and profile the key players of the global precision medicine market and comprehensively analyze their core competencies2

To track and analyze competitive developments such as expansions, acquisitions, partnerships, collaborations, agreements, and product approvals in the precision medicine market.

# data[].attributes.attachment_link.title
Precision Medicine Market is Expected to Reach $50.2 billion | MarketsandMarkets.

# data[].attributes.attachment_link.description
Chicago, Sept. 12, 2023 (GLOBE NEWSWIRE) -- The healthcare education industry is poised for a transformative shift in the near future, driven by rapid...

# data[].attributes.headline
The Growing Global Market for Lateral Flow Assays: Trends and Forecasts

# data[].attributes.subject
The Growing Global Market for Lateral Flow Assays: Trends and Forecasts

# data[].attributes.body
The Global Lateral Flow Assays Market in terms of revenue was estimated to be worth $20.5 billion in 2022 and is poised to reach $22.6 billion by 2027, growing at a CAGR of 2.0% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Increasing adoption of kits & reagents and lateral flow assay readers for infectious diseases testing, veterinary diagnostics, and drug of abuse testing, cardiac marker testing. Whereas most of lateral flow assays are having limitation of qualitative detection, lot to lot variation like factors may hinder the growth of global market during the forecast period.

# data[].attributes.attachment_link.title
Lateral Flow Assays Market worth $22.6 billion | MarketsandMarkets | ABNewswire

# data[].attributes.headline
Understanding the Role of Animal Genetics in Livestock Production

# data[].attributes.subject
Understanding the Role of Animal Genetics in Livestock Production

# data[].attributes.body
Animal Genetics Market in terms of revenue was estimated to be worth $6.6 billion in 2023 and is poised to reach $9.5 billion by 2028, growing at a CAGR of 7.4% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as better accessibility to technologies and well-established distribution channels drive growth in the developed markets across Europe and North America. Moreover, the growing demand for livestock food products has driven the need for genetic materials and live animals, as breeders and the animal food products industry seek higher productivity standards.

# data[].attributes.attachment_link.readable_text
, /PRNewswire/ -- In the near future, the animal genetics industry is poised to undergo a transformative revolution, driven by rapid advancements in genomics, biotechnology, and data analytics. This industry will witness the emergence of cutting-edge techniques such as precision breeding, gene editing, and synthetic biology, enabling the tailored enhancement of livestock traits for improved productivity, disease resistance, and environmental sustainability. Ethical considerations and regulatory frameworks will play a pivotal role in shaping the direction of this industry, ensuring that breakthroughs are balanced with responsible practices. As genetic insights continue to unravel, the animal genetics sector will likely foster collaborations between biotech companies, research institutions, and agricultural stakeholders to create a more resilient and efficient global food supply chain.

Animal Genetics Market in terms of revenue was estimated to be worth $6.6 billion in 2023 and is poised to reach $9.5 billion by 2028, growing at a CAGR of 7.4% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as better accessibility to technologies and well-established distribution channels drive growth in the developed markets across Europe and North America. Moreover, the growing demand for livestock food products has driven the need for genetic materials and live animals, as breeders and the animal food products industry seek higher productivity standards.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12462093 Browse in-depth TOC on "Animal Genetics Market" Animal Genetics Market Live animals segment accounted for the largest share of the animal genetics market. Scope: The poultry segment accounted for the largest share of the animal genetics market.
The animal genetic products segment is categorized into live animals and genetic materials. In 2022, the live animals segment commanded the largest share of the animal genetics market. This is attributed to the high demand for live animals to breed generations with high-productivity traits, high maternity ability, high growth rates, and feed efficiencies. Also, growing demand for animal proteins, the rising awareness of the benefits of genetic improvement in livestock, and the technological advancements in animal breeding are further boosting the market growth. The key players in the live animal genetics market are Genus plc, EW Group, , Cobb-Vantress, Topigs Norsvin, and Hendrix Genetics.
Europe accounted for the largest share of the animal genetics market.
The live animal segment is segmented into canine, poultry, porcine, bovine, and other live animals. The poultry segment accounted for largest share of the live animal market in 2022. The high demand for poultry meat and eggs in developed countries and the increasing demand for the same in developing countries due to the growing population and rapid urbanization drive the growth of the poultry segment.
Request Sample Pages: Animal Genetics Market Drivers: Dynamics: Restraints: https://www.marketsandmarkets.com/requestsampleNew.asp?id=12462093 Opportunities:
The global animal genetics market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, Europe accounted for the largest share of the animal genetics market, followed by North America and Asia Pacific. Market growth is driven by the need to improve livestock productivity, growing demand for animal food products, and the high intake of animal-derived proteins.
Challenges:

Growing global population and rapid urbanization
Key Market Players:

The emergence of alternative such as lab-based meat
Recent Developments:

Innovations in phenotyping services
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=12462093 Animal Genetics Market Advantages:

Economic sustainability in local breeds

Some of the major market players in the animal genetics market include Neogen Corporation (US), Genus (Uk), Urus (US), EW Group Gmbh (Germany), Groupe Grimaud (France).
Related Reports:

In March 2023, URUS Group collaborated with Genetics Australia. The JV will be 60 percent owned by URUS and 40 percent owned by Genetics Australia (GA). It will have access to the full suite of GENEX products and access to the PEAK program.

In January 2023, Zoetis collaborated with VAS to give farmers better compatibility crossover between Vas's PULSE platform, a broad farm management cloud-based software, and DairyComp, a herd health system with Zoetis's CLARIFIDE genetic and fertility testing.

Improved Productivity: Animal genetics advancements enable the breeding of livestock with enhanced traits such as faster growth rates, increased milk or egg production, and efficient feed conversion, leading to higher overall agricultural productivity.

Disease Resistance: Selective breeding and genetic engineering allow for the development of animals with increased resistance to diseases, reducing the need for antibiotics and minimizing disease-related economic losses.

Quality Enhancement: Genetic improvements can lead to better meat quality, improved taste, tenderness, and nutritional content, meeting consumer demands for high-quality and nutritious products.

Environmental Sustainability: By breeding animals that require fewer resources, produce less waste, and emit fewer greenhouse gases, the industry contributes to more sustainable and eco-friendly farming practices.

Resource Efficiency: Animal genetics helps optimize resource utilization by minimizing inputs such as feed, water, and land while maximizing outputs, thus reducing the overall environmental impact of agriculture.

Biodiversity Preservation: Focused breeding programs can help conserve and protect endangered or rare animal breeds, maintaining biodiversity within livestock populations.

Reduced Food Insecurity: Enhanced genetics lead to increased food production, helping to address global food security challenges and ensuring a stable supply of animal-derived products.

Economic Benefits: Farmers can benefit from increased profitability due to improved yields, reduced mortality rates, and access to premium markets willing to pay for genetically superior products.

Human Health Research: Studying animal genetics can provide insights into human genetics and diseases, contributing to advancements in medicine and biotechnology.

Innovation and Technological Progress: The animal genetics market drives technological innovation, fostering collaborations between biotech firms, researchers, and agricultural stakeholders to develop cutting-edge solutions.

Customization: Advances in gene editing and synthetic biology enable the customization of animal genetics to meet specific market demands and consumer preferences.

Ethical Considerations: Ethical practices within the industry, such as ensuring animal welfare and addressing potential concerns, help create a more responsible and transparent approach to genetic enhancements.

In summary, the animal genetics market offers a range of advantages that encompass improved agricultural productivity, environmental sustainability, economic growth, and ethical considerations, ultimately contributing to the development of a more resilient and responsible global food system.

Veterinary Equipment Market - Global Forecasts to 2027

Veterinary Diagnostics Market - Global Forecasts to 2027
About MarketsandMarkets™:
Veterinary Reference Laboratory Market - Global Forecasts to 2027

Companion Animal Pharmaceuticals Market - Global Forecasts to 2027

Next Generation Sequencing Market - Global Forecasts to 2027

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/animal-genetic-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/animal-genetic.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Animal Genetics Market worth $9.5 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
PRNewswire/ -- In the near future, the animal genetics industry is poised to undergo a transformative revolution, driven by rapid advancements in genomics,...

# data[].attributes.headline
Exploring the Advancements in Leukapheresis Technology

# data[].attributes.subject
Exploring the Advancements in Leukapheresis Technology

# data[].attributes.body
The Global Leukapheresis Products Market was estimated to be worth USD 70 million in 2023 and is poised to reach USD 100 million by 2028, growing at a CAGR of 8.3%. The global leukopaks market was estimated to be worth USD 200 million in 2023 and is poised to reach USD 1020 million by 2028, growing at a CAGR of 38.1%.

# data[].attributes.attachment_link.readable_text
, /PRNewswire/ -- In the near future, the leukapheresis industry is poised for remarkable growth and transformation, driven by advancements in medical technology and increasing demand for targeted and personalized therapies. With a focus on precision medicine, the industry is expected to witness the development of more efficient and innovative leukapheresis techniques, enabling the isolation and collection of specific white blood cell populations for diverse therapeutic applications, including immunotherapy, cancer treatment, and autoimmune disorder management. Moreover, streamlined automation, integration of artificial intelligence, and enhanced data analytics are likely to optimize the leukapheresis process, minimizing patient discomfort and maximizing cell yield. This evolution in leukapheresis holds the potential to revolutionize how we approach complex diseases, providing patients with novel, tailored treatment options and paving the way for substantial advancements in the field of cellular therapies.

Leukapheresis Market in terms of revenue was estimated to be worth $70 million in 2023 and is poised to reach $100 million by 2028, growing at a CAGR of 8.3 % from 2023 to 2028 according to a new report by MarketsandMarkets™. The global leukopaks market is anticipated to reach USD 1020 million by 2028 from USD 200 million in 2023, at a CAGR of 38.1%. The leukopaks market is driven by the increasing demand for leukopaks in research applications, such as the development of new cancer treatments. The demand for leukopaks is growing due to the increasing number of research studies being conducted on cancer. The development of new cancer treatments is also driving the demand for leukopaks. Other factors that are contributing to the growth of the leukopaks market include the increasing incidence and prevalence of cancer, the growing popularity of personalized medicine, advances in medical technology, and growing awareness about leukopaks and their benefits in developing nations.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=20283148 Browse in-depth TOC on "Leukapheresis Market" Leukapheresis Market Scope: The disposables segment accounted for the larger share of the leukapheresis products market.
In this report, the overall leukapheresis market is divided into the leukapheresis products market and the Leukopaks Market. The leukapheresis products Market is classified into segments including type, application, end user, and region, and the leukopaks Market is classified into segments such as type, indication, end user, and region.
The mobilized leukopaks segment dominated the leukopaks market based on type.
By type, the leukapheresis products market can be segmented into devices and disposables. The disposables segment occupied a larger share of the leukapheresis products market in 2022. The disposables used in leukapheresis procedures are products used to access blood vessels and store blood components, replacement fluids, and anticoagulants to prevent blood from clotting in the process. Disposables are used for both automated blood collection and therapeutic leukapheresis. They include apheresis catheters, needle sets, centrifuge bowls, tubing sets/pipeline systems, collection bags, and various solutions such as saline, anticoagulants, media, columns, filters, and cell separation kits.
North American region dominated the Leukapheresis market with the largest market share.
By type, the leukopaks market is categorized into mobilized leukopaks, non-mobilized leukopaks, diseased leukopaks, and isolated PBMCs. The mobilized leukopaks segment dominated the leukopaks market in 2022. Mobilized leukopaks are mainly used in preclinical and clinical research in a variety of fields, including cancer immunotherapy, cell therapy, and regenerative medicine. Charles River Laboratories (US), Discovery Life Sciences (US), StemExpress (US), BioIVT (US), and Caltag Medsystems (UK) are some of the major players offering mobilized leukopaks for research and clinical applications.
Request Sample Pages: Leukapheresis Market Drivers: Dynamics: Restraints: https://www.marketsandmarkets.com/requestsampleNew.asp?id=20283148 Opportunities:
The Leukapheresis market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America reported the largest share of the Leukapheresis market in 2022. The incidence and prevalence of leukemia are increasing in North America, due to factors such as environmental pollution, exposure to radiation, and unhealthy lifestyle habits. This is driving the demand for leukapheresis products, which are used to treat leukemia.
Challenges:
1. Increased demand for leukopaks in clinical research
Key Market Players:
1. Complications associated with therapeutic leukapheresis
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=20283148 Leukapheresis Market Advantages:

Targeted Cell Collection: Leukapheresis enables precise isolation and collection of specific white blood cell populations, ensuring higher purity and potency of cells for various therapeutic applications.

Personalized Medicine: The technique contributes to personalized medicine by tailoring treatments to individual patients, leveraging their unique genetic profiles for more effective and customized therapies.

Efficiency and Automation: Ongoing innovation and automation within the leukapheresis industry streamline procedures, reducing treatment time, patient discomfort, and optimizing cell yield for improved outcomes.

Consistency and Reliability: Automation ensures consistent cell collection, enhancing reproducibility and reliability in research and clinical applications.

Therapeutic Breakthroughs: Leukapheresis has facilitated advancements in treating diseases like cancer and autoimmune disorders through the development of novel therapies like CAR-T cell therapy.

Research Advancements: The technique supports medical research by providing researchers with purified cell populations for studying disease mechanisms, drug development, and therapy optimization.

Reduced Side Effects: Targeted cell collection minimizes unwanted side effects by focusing only on the specific cell populations needed for treatment.

Minimized Patient Risk: Leukapheresis reduces the need for invasive procedures, lowering patient risk while obtaining essential cells for treatment.

Expanded Treatment Options: The technique expands the range of treatment options available to patients, especially for those with limited alternatives or complex medical conditions.

Clinical Versatility: Leukapheresis finds applications across various medical fields, from cancer and immunology to regenerative medicine, showcasing its versatility in addressing different health challenges.

Pioneering Cellular Therapies: The advancements in leukapheresis techniques have been instrumental in driving the development and success of cutting-edge cellular therapies.

Improved Patient Outcomes: By enhancing the quality and effectiveness of isolated cell populations, leukapheresis contributes to improved patient outcomes and quality of life.

Cost-Effectiveness: In the long term, leukapheresis can offer cost-effective solutions by providing more targeted treatments, potentially reducing the need for extensive and costly interventions.

1. Gaps in current leukapheresis technologies
Recent Developments:

In May 2022, Fresenius Kabi (Germany) acquired Ivenix, Inc. (US). This acquisition adds a next-generation infusion therapy platform for the significant US market to Fresenius Kabi's portfolio and provides the company with key capabilities in hospital connectivity.

In March 2022, Charles River Laboratories International Inc. (US) acquired Retrogenix Limited (UK) to enhance the company's scientific expertise with additional large molecule and cell therapy discovery capabilities.

In November 2021, Discovery Life Sciences (US) announced the launch of the Discovery BIOstore, which provides real-time access to Discovery's inventory of millions of human biospecimens to scientists.

Related Reports:
1. Blood transfusion safety in developing countries

Key players in the leukapheresis products market include Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany). Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US). These companies adopted strategies such as product launches, business expansions, agreements, partnerships, and acquisitions to strengthen their presence in the Leukapheresis market.

Medical Progress: The leukapheresis market represents a significant stride toward the future of medicine, fostering innovation and progress in healthcare through its specialized cell collection capabilities.

Plasma Fractionation Market - Global Forecasts to 2027

Continuous Renal Replacement Therapy Market - Global Forecasts to 2026
About MarketsandMarkets™:
Corporate Wellness Solutions Market - Global Forecasts to 2026

US Therapeutic Plasma Exchange Market - Global Forecasts to 2025

Apheresis Market - Global Forecasts to 2025

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/leukapheresis-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/leukapheresis.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

View original content: https://www.prnewswire.com/news-releases/leukapheresis-market-worth-100-million--marketsandmarkets-301914634.html

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Leukapheresis Market worth $100 million | MarketsandMarkets

# data[].attributes.attachment_link.description
In the near future, the leukapheresis industry is poised for remarkable growth and transformation, driven by advancements in medical technology and increasing demand for targeted and personalized therapies.

# data[].attributes.headline
Global Ultrasound Market worth $11.6 billion by 2028 

# data[].attributes.subject
Global Ultrasound Market worth $11.6 billion by 2028 

# data[].attributes.body
The Global Ultrasound Market in terms of revenue was estimated to be worth $8.5 billion in 2023 and is poised to reach $11.6 billion by 2028, growing at a CAGR of 6.3% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The increasing patient population, rising prevalence of chronic diseases, and rising focus on non-invasive procedures are expected to drive the market during the forecast period.

# data[].attributes.attachment_link.readable_text
, /PRNewswire/ -- In the near future, the ultrasound industry is poised for remarkable advancements, revolutionizing medical diagnostics and healthcare practices. Rapid technological innovations in ultrasound machines will enable higher resolution imaging, real-time 3D visualization, and enhanced portability, making them more accessible to remote and underserved areas. AI-driven algorithms will play a crucial role in automating image analysis, expediting diagnoses, and improving accuracy. Additionally, miniaturization and wearable ultrasound devices will empower patients to monitor their health in real-time, ushering in a new era of personalized medicine. As the cost of ultrasound technology decreases and its applications expand, we can expect a surge in adoption across various fields, from obstetrics and cardiology to musculoskeletal and point-of-care settings, ultimately enhancing patient outcomes and transforming the landscape of modern healthcare.

Ultrasound Market in terms of revenue was estimated to be worth $8.5 billion in 2023 and is poised to reach $11.6 billion by 2028, growing at a CAGR of 6.3% from 2023 to 2028 according to a new report by MarketsandMarkets™. The major factors driving the growth of this market include rising patient population, various chronic diseases, and technological advancements along with the increasing adoption of ultrasound for diagnostic imaging.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=467 Browse in-depth TOC on "Ultrasound Market" Ultrasound Market Technology segment to register significant growth rate over the forecast period of 2023-2028 Scope: Portability segment to register significant growth rate over the forecast period of 2023-2028
Based on technology, the global ultrasound imaging market is segmented into diagnostic and therapeutic ultrasound. The therapeutic ultrasound segment is anticipated to register the second highest growth rate over the forecast period. The diagnostic ultrasound segment accounted for the highest share of the ultrasound market in 2022.
Component segment accounted for the largest share of the ultrasound market, by application in 2022.
Based on the portability, the ultrasound market is segmented into trolly/cart-based ultrasound, compact/handheld ultrasound systems, and POC ultrasound systems. The trolly/cart-based ultrasound segment is anticipated to register the highest growth rate over the forecast period. The compact/handheld ultrasound systems segment accounted for the highest share of the ultrasound market in 2022.

Based on component, the global the ultrasound market is segmented into transducers/probes, workstations, other components. Transducer/probes segment accounted for the largest share of the market in 2022 and is expected to grow at the highest CAGR during the forecast period.
The hospital and clinics segment accounted for the largest share of the ultrasound market, by end user, in 2022
Factors such as the rising incidence of cancer cases, the growing geriatric population, and the launch of integrated modalities drive the growth of ultrasound products.
The Asia Pacific market to register a significant growth in the market during the forecast period
Based on end user, the ultrasound market is segmented into hospitals, surgical centres, diagnostic centres, maternity centres, ambulatory centres, research and academia and other end users. The hospitals, surgical centres, diagnostic centres segment accounts for the largest share of the market in 2022. Factors attributing to the share of this particular are increasing cancer incidences and increasing number of dermatological surgeries performed in hospitals and clinics are driving the growth of this segment.
Request Sample Pages: Ultrasound Market Drivers: Dynamics: Restraints: https://www.marketsandmarkets.com/requestsampleNew.asp?id=467 Opportunities:
The Asia Pacific ultrasound market is estimated to register a significant growth from 2023 to 2028. The increasing patient population, rising geriatric population, rapid economic growth and increasing disposable income are driving the market growth in APAC countries. This region is having a rise in healthcare investment and expenditure, offering significant growth opportunities for the key players.
Challenges:
1. Increasing prevalence of target diseases
Key Market Players:
1. Unfavorable healthcare reforms in the US
Recent Developments:

In February 2023, GE HealthCare has acquired Caption Health, thereby expanding the capabilities of ultrasound technology to assist new users through FDA-cleared, AI-powered image guidance. By leveraging Caption AI applications, ultrasound examinations can be streamlined, accelerating the process and empowering a wider range of healthcare professionals to perform fundamental echocardiogram exams.

In November 2022, Canon Inc. revealed its plans to form a new subsidiary called Canon Healthcare USA, Inc. With this strategic move, Canon intends to enhance its position within the influential American medical market and expedite the expansion of its medical business.

In April 2022, The enhanced partnership between GE HealthCare and Sinopharm focuses on the development and commercialization of medical equipment designed to meet the specific healthcare requirements of China.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=467 Ultrasound Market Advantages:

Non-Invasive: Ultrasound is a non-invasive imaging technique, meaning it does not require any incisions or exposure to ionizing radiation, making it safer for patients and reducing the risk of complications.

Real-Time Imaging: Ultrasound provides real-time imaging, allowing medical professionals to observe and assess dynamic processes within the body, such as blood flow, organ movements, and fetal development.

Portability: Advancements in technology have led to the development of portable and handheld ultrasound devices, enabling point-of-care imaging in remote or resource-limited settings and increasing accessibility to medical care.

Cost-Effective: Compared to other imaging modalities like MRI or CT scans, ultrasound is generally more cost-effective, making it a cost-efficient choice for both healthcare providers and patients.

No Ionizing Radiation: Ultrasound uses sound waves instead of ionizing radiation, making it a safer option for imaging pregnant women, children, and individuals who require frequent imaging studies.

Wide Range of Applications: Ultrasound has a diverse range of applications across various medical specialties, including obstetrics, gynecology, cardiology, radiology, gastroenterology, and more, making it a versatile tool for healthcare professionals.

Real-Time Guidance: Ultrasound can be used in real-time to guide medical procedures, such as needle biopsies, drain placements, and catheter insertions, increasing accuracy and reducing the risk of complications.

High Patient Tolerance: Patients generally find ultrasound examinations comfortable and painless, contributing to improved patient compliance and satisfaction.

Safe for Repetitive Use: Ultrasound can be used repeatedly without any harm to the patient, making it suitable for monitoring and follow-up examinations.

Accessibility: Ultrasound machines are widely available in medical facilities, from large hospitals to smaller clinics, allowing for prompt and convenient access to imaging services.

1. Expanding applications of therapeutic ultrasound
Related Reports:
1. Growing end-user preference for refurbished equipment

As of 2022, prominent players in the ultrasound market are GE healthcare (US), Koninklijke Philips N.V. (Netherlands), Canon Medical Systems Corporation (Japan), Siemens AG (Germany), Fujifilm Corporation (Japan), and Hologic, Inc. (US)

Overall, the advantages of ultrasound make it an indispensable tool in modern medicine, facilitating early and accurate diagnoses, improving patient care, and contributing to better health outcomes.

Veterinary Ultrasound Market - Global Forecasts to 2027

Diagnostic Imaging Services Market - Global Forecasts to 2027
About MarketsandMarkets™:
Digital X-Ray Market - Global Forecasts to 2026

Minimally Invasive Surgical Instruments Market - Global Forecasts to 2026

Medical Equipment Maintenance Market - Global Forecasts to 2026

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Contact:
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/ultrasound-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/ultrasound-devices.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

View original content: https://www.prnewswire.com/news-releases/ultrasound-market-worth-11-6-billion--marketsandmarkets-301893449.html

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Ultrasound Market worth $11.6 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
In the near future, the ultrasound industry is poised for remarkable advancements, revolutionizing medical diagnostics and healthcare practices. Rapid technological innovations in ultrasound machines will enable higher resolution imaging, real-time 3D visualization, and enhanced portability, making them more accessible to remote and underserved areas.

# data[].attributes.headline
Precision Medicine Market worth $50.2 billion by 2028

# data[].attributes.subject
Precision Medicine Market worth $50.2 billion by 2028

# data[].attributes.body
The global precision medicine market in terms of revenue was estimated to be worth $29.1 billion in 2023 and is poised to reach $50.2 billion by 2028, growing at a CAGR of 11.5% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth in the precision medicine industry is Currently the focus on genomic research is growing continuously. Is mainly due to the realisation of the potential that genetic targeted therapies hold. This is facilitating increasing adoption of precision medicine. Additionally, genetic testing add companion diagnostics are also witnessing growth. These factors along with the increasing approvals for personalised medicines from prominent regulatory bodies are supporting the growth of this market.

# data[].attributes.attachment_link.readable_text
, /PRNewswire/ -- In the near future, the precision medicine industry is poised to revolutionize healthcare by harnessing the power of genomic and personalized data. With advancements in technology, including high-throughput sequencing, AI-driven analytics, and targeted therapies, precision medicine will become increasingly accessible and tailored to individual patients. This transformative approach will not only lead to more accurate disease diagnosis and treatment selection but also enable proactive disease prevention strategies. As collaborations between pharmaceutical companies, research institutions, and healthcare providers continue to flourish, the precision medicine field will pave the way for more effective, personalized, and cost-efficient healthcare solutions, ultimately improving patient outcomes and reshaping the landscape of medicine as we know it.

Precision Medicine Market in terms of revenue was estimated to be worth $29.1 billion in 2023 and is poised to reach $50.2 billion by 2028, growing at a CAGR of 11.5 % from 2023 to 2028 according to a new report by MarketsandMarkets™. The rising number of product approvals followed by growing focus on genetic testing, a prerequisite for precision medicine therapeutics, are the factors supporting market growth.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=215185595 Browse in-depth TOC on "Precision Medicine Market" Precision Medicine Market Hospitals and Clinics subsegment accounted is the fastest growing of the precision medicine market by product & service Scope: Oncology is the fastest-growing segment of the precision medicine market by applications
Among the end user, the market is segmented hospitals and clinics and home care setting. In 2022, the hospitals and clinics segment accounted for the highest growth rate of the precision medicine market by end user. Growth in this market segment can be attributed to factors such as availability of better facilities and assistance in hospitals and clinics, accessibility to advanced diagnostic tests along with precise therapeutic regime among others.
Europe: The second-largest region in the precision medicine market.
Among the applications, the precision medicine market is segmented into drug discovery, clinical diagnostics, soil microbiome applications, industrial applications, ecological & environmental applications, veterinary applications, and other applications. In 2023, the drug discovery segment accounted for the fastest-growing share of the usage segment of precision medicine market. Growth in this market segment can be attributed to one of the major factors which is the growing number of research activities for development of new drugs.
Request Sample Pages: Precision Medicine Market Drivers: Dynamics: Restraints: https://www.marketsandmarkets.com/requestsampleNew.asp?id=215185595 Opportunities:
The European market is the second-largest precision medicine market globally, mainly due to factors such as presence of key market players in the region. Europe is considered a major hub for precision medicine players and organizations. Moreover, greater awareness among people about newly emerging area of precision medicine, especially compared to developing regions.
Challenges:

Growth in genetic testing and companion diagnostics
Key Market Players:

High costs of therapeutics
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=215185595 Precision Medicine Market Advantages:

Growing demand for cell and gene therapies

Challenges associated with adoption of precision medicine
Recent Developments:
The market for precision medicine is competitive, with key players strategizing to capture the market. Prominent players in the precision medicine market are F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Bristol Myers Squibb (US), Gilead Sciences, Inc. (US), AstraZeneca (UK), Pfizer Inc. (US), AbbVie Inc. (US), Eli Lilly and Company (US), , GlaxoSmithKline plc (UK), Sanofi (France), Johnson & Johnson (US), Merck KGaA (Germany), Amgen, Inc. (US), Takeda Pharmaceutical Company Limited (Japan) among others.
Related Reports:

Personalized Treatment: Precision medicine tailors medical treatment and interventions to individual patients based on their genetic makeup, lifestyle, and specific health characteristics. This approach ensures that treatments are more effective, with fewer adverse effects, as they are customized to the patient's unique needs.

Improved Diagnostic Accuracy: Precision medicine relies on advanced diagnostic tools and genomic sequencing to identify diseases and their underlying causes with unparalleled accuracy. This leads to earlier and more precise diagnoses, enabling timely and targeted interventions.

Enhanced Drug Development: Pharmaceutical companies benefit from precision medicine by developing drugs that target specific genetic mutations or biomarkers associated with diseases. This approach streamlines drug development, reduces the likelihood of trial failures, and accelerates the availability of innovative treatments.

Reduced Healthcare Costs: By avoiding trial-and-error approaches to treatment and focusing on therapies that are more likely to work for a given patient, precision medicine can potentially lower healthcare costs in the long run. Fewer unnecessary treatments, hospitalizations, and adverse reactions contribute to cost savings.

Preventative Medicine: Precision medicine also emphasizes preventive strategies by identifying individuals at higher risk for certain diseases based on their genetic predispositions and lifestyle factors. This proactive approach allows for early interventions and lifestyle modifications to reduce disease risk.

Data-Driven Insights: The collection and analysis of extensive patient data, including genomic and clinical information, enable researchers to uncover new insights into disease mechanisms and treatment responses. This data-driven approach accelerates medical research and innovation.

Patient Empowerment: Precision medicine empowers patients by involving them in their healthcare decisions. Patients gain a better understanding of their health risks, treatment options, and potential outcomes, leading to more informed choices and improved overall healthcare experiences.

Tailored Therapies for Rare Diseases: Precision medicine is particularly advantageous for rare and orphan diseases, where traditional treatment options may be limited. By identifying specific genetic abnormalities associated with these conditions, researchers can develop targeted therapies that offer hope to patients who previously had few treatment options.

Global Health Impact: Precision medicine has the potential to address global health challenges by providing tailored solutions to diseases that affect diverse populations worldwide. It can facilitate the development of region-specific treatments and healthcare strategies.

Long-Term Healthcare Sustainability: As precision medicine advances, it contributes to the sustainability of healthcare systems by focusing resources on treatments that are most likely to be effective, reducing unnecessary healthcare expenditures, and improving overall health outcomes.

In summary, the precision medicine market holds the promise of revolutionizing healthcare by providing individualized, data-driven, and effective treatment options, ultimately benefiting patients, healthcare providers, pharmaceutical companies, and society at large.

In February 2023, Roche received EC approval for expansion of the Hemlibra (emicizumab) European Union (EU) marketing authorization.

In January 2022, AstraZeneca (UK) collaborated with Scorpion Therapeutics to develop and commercialize precision medicines against hard-to-target cancer proteins, with an aim to transform oncology treatment. The size of this deal accounted for USD 75 billion.

Plasma Fractionation Market - Global Forecasts to 2028

Biosimilars Market - Global Forecasts to 2028
About MarketsandMarkets™:
Immunohistochemistry Market - Global Forecasts to 2028

Epigenetics Market - Global Forecasts to 2027

Research Antibodies & Reagents Market - Global Forecasts to 2027

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/precision-medicine-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/precision-medicine.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Precision Medicine Market worth $50.2 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
PRNewswire/ -- In the near future, the precision medicine industry is poised to revolutionize healthcare by harnessing the power of genomic and personalized...

# data[].attributes.headline
Healthcare Data Monetization Market worth $0.9 billion by 2028

# data[].attributes.subject
Healthcare Data Monetization Market worth $0.9 billion by 2028

# data[].attributes.body
The Global Healthcare Data Monetization Market in terms of revenue was estimated to be worth $0.4 billion in 2023 and is poised to reach $0.9 billion by 2028, growing at a CAGR of 18.5% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of EHR adoption primarily drives the market growth, the increase in use of external data sources, the need to curtail escalating healthcare costs, increasing partnerships and collaborations among players, and growing investments in advanced analytics. Additionally, factors such rising adoption of AI in precision medicine, and the explosion in bioinformatics data and large healthcare datasets are also contributing to the market growth.

# data[].attributes.attachment_link.readable_text
CHICAGO, June 13, 2023 /PRNewswire/ -- The healthcare data monetization industry is poised for significant growth in the near future. With the increasing digitalization of healthcare systems and the abundance of data being generated, healthcare organizations are recognizing the immense value of their data assets. In the coming years, we can expect to see a surge in initiatives focused on leveraging healthcare data for monetization purposes. This industry will witness the emergence of innovative data monetization platforms, advanced analytics tools, and secure data marketplaces. Healthcare organizations will actively explore opportunities to collaborate with research institutions, pharmaceutical companies, and technology firms to unlock the potential of their data for research, development, and commercial purposes. The healthcare data monetization industry will not only drive additional revenue streams for healthcare organizations but also foster data-driven decision-making, accelerate medical research, and ultimately contribute to improved patient outcomes. However, it will be crucial to address concerns related to data privacy, security, and regulatory compliance to build trust and ensure ethical data practices in this evolving landscape.

Healthcare Data Monetization Market in terms of revenue was estimated to be worth $0.4 billion in 2023 and is poised to reach $0.9 billion by 2028, growing at a CAGR of 18.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as exponentially increasing data volume and generation of large and complex healthcare datasets, the need to curtail escalating healthcare costs, expanding partnerships and collaborations among players, and growing investments in the adoption of EHR systems primarily drive the growth of this market. Furthermore, the rising adoption of AI in precision medicine and the growing demand for real-world evidence (RWE) would provide lucrative opportunities to solution providers.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=56622234 Browse in-depth TOC on "Healthcare Data Monetization Market"
Healthcare Data Monetization Market The cloud segment is expected to be the fastest-growing healthcare data monetization market, by deployment, during the forecast period. Scope: The pharmaceutical & biotechnology companies segment, by end-user, is expected to be the largest healthcare data monetization market in 2023 292 - Pages Asia Pacific is expected to be the fastest-growing in healthcare data monetization market during the forecast period.
Based on deployment, the market is segmented into on-premise and cloud. The cloud segment is expected to grow at a higher CAGR during the forecast period due to increased agility and scalability offered by cloud-based data monetization solutions. Cloud platforms provide secure and scalable storage solutions for vast amounts of healthcare data, including electronic health records, medical images, and patient-generated data. Furthermore, cloud-based analytics tools enable healthcare organizations to perform advanced data analysis, leveraging machine learning algorithms and artificial intelligence to gain valuable insights from complex datasets.
Request Sample Pages: Healthcare Data Monetization Market Drivers: Dynamics: Restraints: https://www.marketsandmarkets.com/requestsampleNew.asp?id=56622234 Opportunities:
Based on the end user, the market is broadly segmented into pharmaceutical & biotechnology companies; healthcare payers; healthcare providers; medical technology companies; and other end users. Pharmaceutical & biotechnology companies would account for the largest share of the global end-user market in 2023. Market growth can be attributed to the rising demand for solutions to cut the time and costs of drug development. Pharmaceutical and biotechnology companies can benefit significantly from healthcare data monetization, as it can help them develop new drugs, identify potential markets, and improve patient outcomes.
Challenges: Key Market Players:
The global market has been segmented based on region: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Asia Pacific market is projected to register the highest CAGR during the forecast period. Emerging countries in the Asia Pacific, such as India and China, offer lucrative growth opportunities for market players, primarily due to the increasing adoption of digital healthcare technologies, increasing public and private funding, improving IT infrastructure, the demand for affordable healthcare, favorable government norms, growing awareness about precision medicine, and the high incidence of cancer and chronic diseases are expected to boost the adoption of healthcare data monetization solutions in Asia Pacific.
Get 10% Free Customization on this Report: Recent Developments: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=56622234 Healthcare Data Monetization Market Advantages:

Increase in use of external data sources
Healthcare Data Monetization Market - Key Stakeholders:

Regulatory constraints to impact the growth of the market during the forecast period
Related Reports:

Rising Demand for Real-World Evidence

Major players operating in the healthcare data monetization market are Oracle Corporation (US), Microsoft Corporation (US), Google (US), Salesforce, Inc. (US), SAS Institute Inc. (US), SAP SE (Germany), TIBCO Software Inc. (US), Sisense Inc. (US), Snowflake Inc. (US), QlikTech International AB (US), HealthVerity, Inc. (US), Accenture (Ireland), Availity, LLC (US), Domo, Inc. (US), Komodo Health, Inc. (US), ThoughtSpot Inc. (US), Datavant (US), Verato (US), Infor, Inc. (US), Virtusa (US), Infosys (India), Particle Health, Inc. (US), Innovaccer, Inc. (US), H1 (US), and Medoble Inc. (US).

In October 2022, Oracle Corporation introduced a planning solution for the healthcare industry as part of its Fusion Cloud Enterprise Performance Management (EPM) offering. The solution aims to help healthcare organizations improve financial performance and patient care by enabling them to model scenarios, optimize resources, and make better finance, workforce, and patient care decisions.

In April 2023, Microsoft Corporation and Epic Systems expanded their collaboration to integrate generative AI into healthcare by combining Azure OpenAI Service with Epic's electronic health record (EHR) software. The collaboration aimed to enhance patient care, increase productivity, and improve financial integrity in health systems globally.

In February 2023, Redox and Google Cloud partnered to simplify the exchange of healthcare data, enabling better and faster decision-making for healthcare organizations. Redox's platform would be replicated on Google Cloud, offering customers access to Redox's products and services.

In April 2023, Salesforce announced new Customer 360 for Health capabilities aimed at enhancing personalized patient experiences and reducing operational costs for healthcare providers. These innovations leverage real-time data, AI, and automation to address the challenges faced by healthcare organizations in meeting customer expectations.

In May 2023, HTEC Group joined the SAS IoT Partner Ecosystem to partner on delivering innovative solutions in industries such as healthcare, life sciences, logistics, and more. The partnership aimed to develop joint offerings that enable global enterprise companies to apply cutting-edge data-driven, IoT, edge, and cloud-enabled solutions to their business challenges.

Revenue Generation: Healthcare organizations possess vast amounts of valuable data, including patient records, clinical data, claims data, and real-world evidence. By monetizing this data, healthcare organizations can generate additional revenue streams. They can sell anonymized and aggregated data to researchers, pharmaceutical companies, insurance providers, and other interested parties, creating a new source of income.

Data-Driven Decision Making: Monetizing healthcare data encourages organizations to invest in robust data analytics capabilities. By analyzing and deriving insights from the data, healthcare providers and stakeholders can make informed decisions to improve patient outcomes, optimize operations, and identify opportunities for innovation. Data monetization drives a data-driven culture within the healthcare industry.

Research and Development: Monetizing healthcare data can accelerate research and development activities. Pharmaceutical companies and medical researchers can access comprehensive datasets for drug discovery, clinical trials, epidemiological studies, and population health research. This fosters collaboration and innovation, ultimately leading to the development of new treatments, therapies, and medical advancements.

Improving Healthcare Delivery: By monetizing healthcare data, organizations can gain insights into patient populations, disease patterns, and treatment outcomes. This information can be leveraged to enhance care delivery, optimize care pathways, and implement personalized medicine approaches. Data monetization drives continuous improvement in healthcare delivery by facilitating evidence-based decision making and enhancing patient outcomes.

Cost Optimization: Healthcare data monetization can help organizations optimize costs and resource allocation. By analyzing data on healthcare utilization, supply chain management, and operational efficiencies, organizations can identify areas for cost reduction, waste elimination, and process improvement. This leads to more efficient healthcare operations and better financial sustainability.

Collaborative Opportunities: Monetizing healthcare data opens up opportunities for collaboration and partnerships. By sharing data with external stakeholders, such as research institutions or technology companies, healthcare organizations can foster innovation, develop new solutions, and drive advancements in healthcare. Collaborative data initiatives promote knowledge exchange, interdisciplinary research, and the overall growth of the healthcare ecosystem.

Improved Patient Outcomes: Leveraging healthcare data for monetization purposes contributes to the advancement of personalized medicine and precision healthcare. By analyzing patient data, providers can tailor treatment plans, predict disease risks, and implement preventive measures. This leads to improved patient outcomes, reduced healthcare costs, and enhanced patient satisfaction.

Enhanced Data Governance: Monetizing healthcare data necessitates robust data governance frameworks, ensuring compliance with privacy regulations, data security standards, and ethical considerations. Organizations that engage in data monetization are compelled to prioritize data governance practices, leading to better data management, improved data quality, and increased patient privacy protection.

Overall, healthcare data monetization offers numerous advantages, including revenue generation, data-driven decision making, research acceleration, improved healthcare delivery, cost optimization, collaborative opportunities, improved patient outcomes, and enhanced data governance. These benefits collectively contribute to the growth and advancement of the healthcare industry.

Healthcare Data Monetization Solution Providers

Platform Providers

Technology Providers

AI System Providers

Raw Data Providers

Data Buyers

Data Sellers

Healthcare Providers

Healthcare Payers

Pharmaceutical & Biotechnology Companies

Medical Technology Companies

Physician Groups and Organizations

Universities and Research Organizations

Forums, Alliances, and Associations

Academic Research Institutes

Healthcare Institutions

Distributors

Venture Capitalists

Government Organizations

Institutional Investors and Investment Banks

Investors/Shareholders

Consulting Companies in the Data Monetization Sector

Raw Materials and Component Manufacturers

About MarketsandMarkets™:
Population Health Management Market - Global Forecasts to 2027

Healthcare Payer Services Market - Global Forecasts to 2027

Healthcare IT Market - Global Forecasts to 2027

Medical Terminology Software Market - Global Forecasts to 2027

5G in Healthcare Market - Global Forecasts to 2026

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/healthcare-data-monetization-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/healthcare-data-monetization.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Healthcare Data Monetization Market worth $0.9 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
PRNewswire/ -- The healthcare data monetization industry is poised for significant growth in the near future. With the increasing digitalization of healthcare...

# data[].attributes.headline
The Rising Demand for Rotator Cuff Injury Treatment: Market Analysis

# data[].attributes.subject
The Rising Demand for Rotator Cuff Injury Treatment: Market Analysis

# data[].attributes.body
Rotator Cuff Injury Treatment Market in terms of revenue was estimated to be worth $989.3 million in 2021 and is poised to reach $1,244.2 million by 2026, growing at a CAGR of 4.7% from 2021 to 2026 according to a latest report published by MarketsandMarkets™. Various factors such as rising number of sports-related shoulder injuries, technological advancements in rotator cuff rupture arthroscopic surgical devices, greater product affordability and market availability, and growing public awareness related to the availability of different treatments for rotator cuff rupture. Moreover, the ongoing developments in regenerative biologics are likely to offer significant growth opportunities for players in the rotator cuff injury treatment market.

# data[].attributes.headline
Exploring the Booming Biobanking Market: Opportunities and Challenges

# data[].attributes.subject
Exploring the Booming Biobanking Market: Opportunities and Challenges

# data[].attributes.body
The global biobanking market in terms of revenue was estimated to be worth $2.9 billion in 2023 and is poised to reach $5.0 billion by 2028, growing at a CAGR of 11.4% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of this market is majorly driven by the growing investments and funding for biobanks, focus on genetic testing and precision medicine, increasing trend in the preservation of cord blood stem cells from newborns, and favorable funding scenario for research related to regenerative medicine. On the other hand, the high cost of automated equipment and issues related to biospecimen sample management are restraining the growth of this market.

# data[].attributes.attachment_link.provider_name
MarketsandMarkets Blog - Market Research Insights

# data[].attributes.attachment_link.readable_text
The biobanking industry is expected to witness significant growth and transformation in the near future. Biobanks play a crucial role in collecting, storing, and managing biological samples and associated data for research and healthcare purposes. With the advancements in precision medicine, personalized therapies, and genomic research, the demand for high-quality biological specimens for biomedical research, drug development, and diagnostic applications is increasing. Biobanks serve as valuable resources for researchers, providing them with access to well-characterized and diverse samples for studying diseases, understanding genetic variations, and identifying biomarkers.

Biobanking Market in terms of revenue was estimated to be worth $2.9 billion in 2023 and is poised to reach $5.0 billion by 2028, growing at a CAGR of 11.4% from 2023 to 2028 according to a new report by MarketsandMarkets™. The global biobanking market is expected to grow at a CAGR of 11.4% during the forecast period.

Browse in-depth TOC on " Biobanking Industry "
334 - Tables 48 - Figures 398 - Pages. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=594 Biobanking Market: Impact Analysis Drivers

Growing investments and funding for biobanks

Focus on genetic testing and precision medicine

Increasing trend in preservation of cord blood stem cells from newborns

Favorable funding scenario for research related to regenerative medicine

Restraints

High cost of automated equipment

Issues related to biospecimen sample management

OPPORTUNITIES

Challenges

High operational cost of biobanks

Storage of samples

Recent Developments

In February 2023, PHC Corporation of North America launched the PHCbi Brand VIP ECO SMART Ultra-low Temperature Freezer with industry-leading energy efficiency.

In September 2022, Cryoport entered into a strategic partnership with BioLife Plasma Services to offer supply chain solutions and service offerings, such as bioservices and cryo-processing, for BioLife Plasma Services.

Key players in the biobanking market include Thermo Fisher Scientific, Inc. (US), PHC Holdings Corporation (Japan), Becton, Dickinson and Company (US), QIAGEN N.V. (Germany), Merck KGaA (Germany), Avantor, Inc. (US), Cryoport, Inc. (US), Tecan Trading AG (Switzerland), Azenta, Inc. (US), Greiner Holding AG (Austria), Hamilton Company (US), Micronic (Netherlands), AMSBIO (UK), Bay Biosciences LLC (US), BioKryo (Germany), SPT Labtech (UK), ASKION GmbH (Germany), Cell&Co BioServices (France), Ziath Ltd. (UK), CTIBiotech (France), Cureline (US), Firalis Group (France), Sopachem (Netherlands), ProteoGenex (US), and US Biolab Corporation, Inc. (US).
Request 10% Customization https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=594 About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441 Email : sales@marketsandmarkets.com

# data[].attributes.attachment_link.title
Exploring the Booming Biobanking Market: Opportunities and Challenges - MarketsandMarkets Blog

# data[].attributes.attachment_link.description
The biobanking industry is expected to witness significant growth and transformation in the near future. Biobanks play a crucial role in collecting, storing, and managing biological samples and associated data for research and healthcare purposes.

# data[].attributes.headline
Metaverse in Healthcare Market worth $79.6 billion by 2028

# data[].attributes.subject
Metaverse in Healthcare Market worth $79.6 billion by 2028

# data[].attributes.body
Metaverse in Healthcare Market in terms of revenue was estimated to be worth $9.5 billion in 2023 and is poised to reach $79.6 billion by 2028, growing at a CAGR of 52.9% from 2023 to 2028 according to a new report by MarketsandMarkets™. The increasing adoption of mixed reality for performing minimally invasive surgeries, growing focus on telemedicine, increasing use of digital twins, and the growing importance of blockchain technology in healthcare are the key factors driving the growth of this market. However, increasing concerns over data privacy and security and the high implementation cost of technologies are expected to restrain the growth of this market.

# data[].attributes.attachment_link.readable_text
Browse 121 market data Tables and 39 Figures spread through 237 Pages and in-depth TOC on "Metaverse in Healthcare Market by Component (Hardware, Services, Software), Technology (AR/VR, MR, AI, Blockchain, IoT), Application(Telehealth, Diagnostics, Medical Training & Education), End User (Provider, Patients, Payers, Pharma) - Global Forecast to 2028

Metaverse in Healthcare Market in terms of revenue was estimated to be worth $9.5 billion in 2023 and is poised to reach $79.6 billion by 2028, growing at a CAGR of 52.9% from 2023 to 2028 according to a new report by MarketsandMarkets™. The increasing adoption of mixed reality for performing minimally invasive surgeries, growing focus on telemedicine, increasing use of digital twins, and the growing importance of blockchain technology in healthcare are the key factors driving the growth of this market. However, increasing concerns over data privacy and security and the high implementation cost of technologies are expected to restrain the growth of this market.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=225839181 The Software segment accounted for the largest share in the metaverse in healthcare market, by component.
The metaverse in healthcare market, by component, is segmented into hardware, software, and services. The software segment includes platforms and applications that enable the creation, customization, and deployment of virtual experiences. The hardware segment includes devices such as head-mounted displays and haptic feedback gloves that enable users to interact with the virtual environment, while the services segment includes consulting, development, and support services that enable healthcare providers to integrate the metaverse into their workflows.

In 2022, the software segment accounted for the largest market share in metaverse in healthcare market. The large share of this segment is attributed to the increased adaptation of AR/VR software in the healthcare industry and the significant rise in investments made in software development.
By Technology, the Augmented/Virtual reality segment registered the highest growth in the metaverse in healthcare market during the forecast period
Based on technology, the metaverse in healthcare market is segmented into augmented and virtual reality, mixed reality, artificial intelligence, blockchain, digital twin, Internet of Things, and medical wearables. The augmented and virtual reality segment accounted for the largest share of 28.2% of the metaverse in healthcare market in 2022. The large share of the augmented and virtual reality segment can be attributed to the growing adoption of VR and AR in the healthcare industry, improved patient outcomes, and the growing focus on enhancing medical training, reducing costs, increasing accessibility, improving patient engagement, and driving innovation.
By Application, the medical education and surgical training segment accounted for the largest share in the metaverse in healthcare market.
In 2022, Based on application, the medical education and surgical training segment accounted for the largest share of 26.6% of the metaverse in healthcare market. The large share of this segment can be attributed to factors such as the increasing budget of hospitals to improve the quality of care provided and reduce the cost of care.
By End User, the healthcare providers segment accounted for the largest share in the metaverse in healthcare market.
In 2022, The healthcare providers segment accounted for the largest share of the metaverse in healthcare market. The large share of this segment can be attributed to the rising need for an efficient healthcare system, growing patient volume, increasing number of hospitals and ambulatory care centers, growth in telehealth, and the rising adoption of metaverse technology in healthcare.
Asia Pacific is expected to exhibit the highest growth during the forecast period
The Asia Pacific market is estimated to register the highest CAGR during the forecast period. Favorable government initiatives for implementing metaverse technologies in the healthcare industry, the growing adoption of AR/VR in healthcare, the rising need for advanced healthcare technologies to track and monitor the large volume of patients, and the rising demand for quality healthcare at low costs are driving the growth of this regional market.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=225839181 Metaverse in Healthcare Market Dynamics: Drivers:

1. Increasing adoption of mixed reality for performing minimally invasive surgeries

2. Applications of metaverse in telemedicine

3. Increasing use of digital twins

4. Increasing importance of blockchain technology in healthcare

Restraints:

1. Data privacy and security concerns

2. High implementation cost

3. Health and mental issues from excessive use

Opportunities:

1. Increasing use of metaverse in medical education and training

2. Use of metaverse in surgical applications

Challenges:

1. HIPAA regulations for healthcare metaverse

2. Interoperability issues

3. Local government restrictions coupled with environmental impact

Key Market Players:
Microsoft (US), NVIDIA Corporation (US), XRHealth (US), CAE Inc. (Canada), Koninklijke Philips N.V. (Netherlands), ImmersiveTouch, Inc. (US), Wipro (India), Siemens Healthineers AG (Germany), Medtronic plc (Ireland), GE HealthCare (US), Intuitive Surgical (US), 8Chili, Inc. (US), MindMaze (Switzerland), AccuVein, Inc. (US), EON Reality (US), Brainlab AG (Germany), Novarad Corporation (US), Oodles Technologies (India), CMR Surgical (UK), Merative (US), BioflightVR (US), WorldViz, Inc. (US), Google (US), Oculus (Meta Platforms, Inc.) (US), and Augmedics (US) are the major players in this market. These companies are majorly focusing on the strategies such as acquisitions, product launches, agreements, collaborations, partnerships, and expansions in order to remain competitive and further increase their share in the market.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=225839181 Recent Developments:

In March 2023 NVIDIA Corporation (US) partnered with Microsoft (US) , This collaboration will help connect Microsoft 365 applications and NVIDIA Omniverse to digitalize their operations, engage in the industrial metaverse, and train advanced models for generative AI and other applications

In February 2023, Wipro (India) launched Decentralized Identity and Credential Exchange (DICE) ID, which enables the insurance and verification of tamper-proof, self-verifiable digital credentials for current or potential healthcare or financial service providers, as well as educational institutions.

In November 2022, GE Healthcare (US) collaborated with MediviewXR(US) . This collaboration was aimed at developing the OmnifyXR medical imaging system.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/metaverse-in-healthcare-market-225839181.html

Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Metaverse in Healthcare Market worth $79.6 billion by 2028

# data[].attributes.attachment_link.title
Metaverse in Healthcare Market worth $79.6 billion by 2028 - Ucommune International (NASDAQ:UK)

# data[].attributes.attachment_link.description
"Microsoft (US), NVIDIA Corporation (US), XRHealth (US), CAE Inc. (Canada), Koninklijke Philips N.V. (Netherlands), ImmersiveTouch, Inc. (US), Wipro (India), Siemens Healthineers AG (Germany), Medtronic plc (Ireland), GE

# data[].attributes.headline
Cryo-electron Microscopy Market worth $2.1 billion by 2028

# data[].attributes.subject
Cryo-electron Microscopy Market worth $2.1 billion by 2028

# data[].attributes.body
Cryo-electron Microscopy Market in terms of revenue was estimated to be worth $1.1 billion in 2022 and is poised to reach $2.1 billion by 2028, growing at a CAGR of 11.6% from 2022 to 2028 according to a new report by MarketsandMarkets™. The major factors driving the growth of this market includes increasing use of high-end instruments in life science, nanotechnology, material science, healthcare, and lucrative opportunities in emerging markets.

# data[].attributes.attachment_link.readable_text
Published September 1, 2023

Browse 130 market data Tables and 33 Figures spread through 187 Pages and in-depth TOC on "Cryo-electron Microscopy Market by Product & Service (Instruments, Software, Services), Technology (Electron Crystallography, Cryo-ET), Voltage (300 kV), Application (Cancer, Omics, Gene Therapy, Nanotechnology, Vaccine) - Global Forecast to 2028
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=217602093 Services segment to register significant growth rate over the forecast period of 2022-2028
Cryo-electron Microscopy Market in terms of revenue was estimated to be worth $1.1 billion in 2022 and is poised to reach $2.1 billion by 2028, growing at a CAGR of 11.6% from 2022 to 2028 according to a new report by MarketsandMarkets™. The major factors driving the growth of this market includes increasing use of high-end instruments in life science, nanotechnology, material science, healthcare, and lucrative opportunities in emerging markets.

Based on the product & service, the global cryo-electron microscopy market is segmented into instruments, software, and services. The services segment is anticipated to register the highest growth rate over the forecast period. Instruments segment accounted for the highest share of the cryo-electron microscopy market in 2021.

Single particle analysis segment accounted for the largest share of the cryo-electron microscopy market, by Technology in 2021.

Based on technology, the global cryo-electron microscopy market is segmented into electron crystallography, single particle analysis, cryo-electron tomography, and other technologies. Single particle analysis accounted for the largest share of the market in 2021, whereas cryo-electron tomography segment is expected to grow at the highest CAGR during the forecast period.
300 kV segment accounted for the largest share of the cryo-electron microscopy market, by voltage in 2021
Factors such as the growing use of cryo-electron microscopy in cell biology, virology, and infectious disease research along with launch of high-end instruments by major players are driving the growth of the market for cryo-electron microscopy.
The Asia Pacific market to register the highest growth in the market during the forecast period
Based on voltage, the global cryo-electron microscopy market is segmented into 300 kV, 200 kV, and 120 kV. 300 kV segment accounted for the largest share of the market in 2021. Factors such as rising healthcare expenditure and consistent increase in the installation of high-end instruments by different end users for 3-dimensional visualization of biological samples is driving the growth of this segment.
Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=217602093 Cryo-electron Microscopy Market Dynamics: Drivers:
The Asia Pacific cryo-electron microscopy market is anticipated to register the highest growth over the forecast period of 2022 to 2028. Major players in the market are focusing on expanding their manufacturing capabilities in the APAC region. This region is consistently witnessing a rise in the installation of cryo-electron microscopes, offering a significant growth opportunity for the key players.
Restraints: Opportunities:

1. Technological advancements in cryo-electron microscopes

2. Growing focus on nanotechnology

3. Increasing use of cryo-electron microscopy in drug discovery

4. Rising funding and grants for cryo-EM installations

Challenges:

Growing opportunities in emerging markets
Key Market Players:

1. Shortage of skilled professionals

2. Ambiguous regulatory network

Recent Developments
As of 2021, prominent players in the cryo-electron microscopy market are Thermo Fisher Scientific (US), Danaher (US), JEOL Ltd. (Japan), Intertek Group Plc (UK), and Charles River Laboratories (US).
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=217602093

In 2022, Thermo Fisher Scientific (US) launched the Glacios 2 Cryo-Transmission Electron Microscope (Cryo-TEM). The product features high-resolution capabilities and helps in drug discovery research.

In 2022, Leica Microsystems (US), a subsidiary of Danaher launched a new Coral Cryo-electron workflow solution to support researchers with high-precision confocal 3D targeting

In 2021, JEOL Ltd. (Japan) launched CRYO ARM 300 II. It is a cold emission cryo-electron microscope. It aims to enable the observation of biological specimens under high resolution

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/cryo-electron-microscopy-market-217602093.html

# data[].attributes.attachment_link.title
Cryo-electron Microscopy Market worth $2.1 billion by 2028

# data[].attributes.attachment_link.description
Published September 1, 2023 Browse 130 market data Tables and 33 Figures spread through 187 Pages and in-depth TOC on "Cryo-electron Microscopy Market by Product & Service (Instruments, Software, Services), Technology (Electron Crystallography, Cryo-ET), Voltage (300 kV), Application (Cancer, Omics, Gene Therapy, Nanotechnology, Vaccine) - Global Forecast to 2028 Download

# data[].attributes.headline
Leukapheresis Market worth $100 million by 2028

# data[].attributes.subject
Leukapheresis Market worth $100 million by 2028

# data[].attributes.body
The Global Leukapheresis Products Market was estimated to be worth USD 70 million in 2023 and is poised to reach USD 100 million by 2028, growing at a CAGR of 8.3%. The global leukopaks market was estimated to be worth USD 200 million in 2023 and is poised to reach USD 1020 million by 2028, growing at a CAGR of 38.1%.
One of the key trends in the leukopaks market is the increasing use of leukopaks in CAR T-cell therapy. CAR T-cell therapy is a type of immunotherapy that uses the patient's own immune cells to fight cancer. It is a promising new treatment for leukemia and other blood cancers. Leukopaks are used to collect the patient's immune cells, which are then modified to fight cancer. Other trends in the leukopaks market include the increasing demand for leukopaks in personalized medicine and the development of new leukopak collection and storage methods.

# data[].attributes.attachment_link.title
Leukapheresis Market Size, Share, Trends and Revenue Forecast [Latest]

# data[].attributes.attachment_link.description
The global leukapheresis market in terms of revenue was estimated to be worth $70 million in 2023 and is poised to reach $100 million by 2028, growing at a CAGR of 8.3% from 2023 to 2028.

# data[].attributes.headline
Unlocking Opportunities: Emerging Trends in the Cell Analysis Market

# data[].attributes.subject
Unlocking Opportunities: Emerging Trends in the Cell Analysis Market

# data[].attributes.body
The Global Cell Analysis Market in terms of revenue was estimated to be worth $20.2 billion in 2023 and is poised to reach $33.9 billion by 2028, growing at a CAGR of 10.9% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Increase in the preference for cell-bsaed assays along with strong funding for cell-based research is expected to drive the market growth. The conventional methods of toxicity and drug safety assessment (involving animal testing) are expensive, time-consuming, and offer low-throughput. In this regard, modern cell-based assays merge the advantages of cell cultures and animal models to allow researchers to identify problems with lead compounds in early screening, ensuring greater efficiency in the drug discovery and development process.

# data[].attributes.attachment_link.provider_name
MarketsandMarkets Blog - Market Research Insights

# data[].attributes.attachment_link.readable_text
The Global Cell Analysis Market in terms of revenue was estimated to be worth $20.2 billion in 2023 and is poised to reach $33.9 billion by 2028, growing at a CAGR of 10.9% from 2023 to 2028.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=157543946 Market Dynamics Drivers

Growing preference for cell-based assays in drug discovery

Increasing funding for cell-based research

Rising number of drug discovery activities

Restraints

High cost of instruments and restrictions on reagent use
Opportunities

High growth potential of single-cell sequencing

Application scope of novel cell-based assays in cancer research

Challenges

Standardization of protocols and data integration & quality control for developing cell therapies
North America was the largest regional market for cell analysis industry in 2022.
Geographically, the cell analysis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America region is expected to dominate the market through 2021-2028, followed by Europe. The US pharmaceutical industry has witnessed tremendous growth due to the increasing approval of first-in-class drugs by the Food and Drugs Administration (FDA), rising R&D expenditure by pharmaceutical companies, and the establishment of startups focusing on developing promising drugs for rare diseases and neurological conditions. This has propelled cell-based research activities, offering lucrative opportunities for the growth of the market in the US. Asia Pacific market is expected to grow at the fastest pace through 2023 to 2028.
Prominent Players:
Danaher (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), General Electric (US), Merck KGaA (US), Agilent Technologies (US), Olympus Corporation (Japan), Miltenyi Biotec (US), Bio-Rad Laboratories (US), BioStatus Limited (UK), Fluidigm Corporation (US), NanoCellect Biomedical (US), Cell Biolabs (US), Creative Bioarray (US), Meiji Techno (US), Promega Corporation (US), PerkinElmer (US), Tecan Trading AG (Switzerland), CELLINK (US), QIAGEN (Germany), Corning Incorporated (US), 10x Genomics (US), and Illumina (US).
Recent Developments of Cell Analysis Industry

In 2023, Becton, Dickinson and Company (US) launched a Spectral Cell Sorter that is coupled with high-speed cell imaging. this product combines real-time imaging technology with spectral flow cytometry.

In 2020, Miltenyi Biotec (Germany) launched MACS GMP Tyto Cartridge, a GMP-compliant cell sorter..

In 2020, Bio-Rad Laboratories, Inc. (US) acquired Celsee, Inc., a provider of instruments and consumables for the isolation, detection, and analysis of single cells. This acquisition expanded the company's product offerings in the flow cytometry market.

Request 10% Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=157543946

# data[].attributes.attachment_link.title
Unlocking Opportunities: Emerging Trends in the Cell Analysis Market - MarketsandMarkets Blog

# data[].attributes.attachment_link.description
The Global Cell Analysis Market in terms of revenue was estimated to be worth $20.2 billion in 2023 and is poised to reach $33.9 billion by 2028, growing at a CAGR of 10.9% from 2023 to 2028.

# data[].attributes.headline
Global Liquid Biopsy Market worth $10.0 billion by 2027 

# data[].attributes.subject
Global Liquid Biopsy Market worth $10.0 billion by 2027 

# data[].attributes.body
Liquid Biopsy Market is projected to reach USD 10.0 billion by 2027 from USD 4.3 billion in 2022, at a CAGR of 18.3% according to a new report by MarketsandMarkets™.  Rise in incidences and prevalence of various cancer types, improvements in liquid biopsy technology, rise in demand of non-invasive procedures, and promising government initiatives improve the market growth. However, lack of awareness about cancer and its risk factors, along with reduced access to advanced cancer diagnostics technologies in developing regions are expected to hinder the market growth. Furthermore, advantages of liquid biopsy over conventional invasive diagnostics methods are expected to present lucrative growth opportunities for the market

# data[].attributes.attachment_link.readable_text
In August 2022, Thermo Fisher Scientific Inc. (US) launched the first NGS-based tests to support both DNA and RNA input. The Ion Torrent Oncomine Myeloid MRD Assays (RUO) provide comprehensive and highly sensitive myeloid measurable residual (MDR) assessments from blood and bone marrow samples.

Liquid Biopsy Market is projected to reach USD 10.0 billion by 2027 from USD 4.3 billion in 2022, at a CAGR of 18.3% according to a new report by MarketsandMarkets™. Rise in incidences and prevalence of various cancer types, improvements in liquid biopsy technology, rise in demand of non-invasive procedures, and promising government initiatives improve the market growth. However, lack of awareness about cancer and its risk factors, along with reduced access to advanced cancer diagnostics technologies in developing regions are expected to hinder the market growth. Furthermore, advantages of liquid biopsy over conventional invasive diagnostics methods are expected to present lucrative growth opportunities for the market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 Browse in-depth TOC on "Liquid Biopsy Market" 208 - Tables 50 - Figures 271 - Pages
The increasing prevalence of cancer coupled with the rise in demand for fast, minimally invasive diagnostic tests drives the market growth. Rapid development in digital Polymerase Chain Reaction (PCR) and NGS-based technology has improved the accuracy of liquid biopsy. It can be performed repeatedly for disease monitoring and is anticipated to help overcome the limitations of tissue biopsies.
The assay kits segment accounted for the largest share of the liquid biopsy market, by product & service segment, in 2021
Based on product & service, the liquid biopsy market is segmented into assay kits, instruments, and services. The large share of the assay kits segment can be attributed to the recurrent requirement and large purchases of assay kits among end users.
Circulating tumor DNA (ctDNA) segment to register the highest growth rate during the forecast period
The liquid biopsy market is segmented into circulating tumor cells, circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVS), and other circulating biomarkers. Studies found that the screening of genetic mutations using ctDNA is highly sensitive and specific, suggesting that ctDNA analysis may significantly improve tumor diagnosis, even facilitating early-stage detection. The superiority of ctDNA to previous plasma biomarkers in sensitivity and clinical correlations is a major factor driving its growth.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350 The blood sample accounted for the largest share of the liquid biopsy, by sample type segment, in 2021
Based on sample type, the liquid biopsy market is segmented into blood and other sample types. In 2021, the blood samples accounted for the largest share of the liquid biopsy market. The large share of this segment can be attributed to factors such as the convenient, inexpensive, safe, and minimally invasive nature of this sample type.
North America is the largest regional market for liquid biopsy market
The global liquid biopsy market has been segmented into four major regions-North America, Europe, the Asia Pacific, and the Rest of the World. In 2021, North America accounted for the largest share of the liquid biopsy market. Easy accessibility and high adoption of advanced diagnostic technologies among healthcare professionals and the increasing prevalence of cancer in the US and Canada are the key factors driving the growth of the liquid biopsy market in North America.

The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics, Inc. (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (US), Guardant Health, Inc. (US), MDxHealth SA (Belgium), Exact Sciences Corporation (US), Illumina Inc. (US), Sysmex Inostics (US), Bio-Rad Laboratories, Inc. (US), Biocept, Inc. (US), NeoGenomics, Inc. (US), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy), Vortex Biosciences, Inc. (US), Exosome Diagnostics, Inc. (US), Agena Bioscience, Inc. (US), MedGenome Inc. (US), Epigenomics AG (Germany), and Personal Genome Diagnostics, Inc. (US).
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=13966350
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/liquid-biopsy-market-13966350.html

# data[].attributes.attachment_link.title
Liquid Biopsy Market worth $10.0 billion by 2027 - Exclusive Report by MarketsandMarkets™

# data[].attributes.attachment_link.description
In August 2022, Thermo Fisher Scientific Inc. (US) launched the first NGS-based tests to support both DNA and RNA input. The Ion Torrent Oncomine Myeloid MRD Assays (RUO) provide comprehensive and highly sensitive myeloid measurable residual (MDR) assessments from blood and bone marrow samples.

# data[].attributes.headline
Healthcare Data Monetization Market worth $0.9 billion by 2028

# data[].attributes.subject
Healthcare Data Monetization Market worth $0.9 billion by 2028

# data[].attributes.body
The Global Healthcare Data Monetization Market in terms of revenue was estimated to be worth $0.4 billion in 2023 and is poised to reach $0.9 billion by 2028, growing at a CAGR of 18.5% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of EHR adoption primarily drives the market growth, the increase in use of external data sources, the need to curtail escalating healthcare costs, increasing partnerships and collaborations among players, and growing investments in advanced analytics. Additionally, factors such rising adoption of AI in precision medicine, and the explosion in bioinformatics data and large healthcare datasets are also contributing to the market growth.

# data[].attributes.headline
The Rising Demand for Humanized Mouse and Rat Models in Biomedical Research

# data[].attributes.subject
The Rising Demand for Humanized Mouse and Rat Models in Biomedical Research

# data[].attributes.body
The global humanized mouse and rat model market in terms of revenue was estimated to be worth $259 million in 2023 and is poised to reach $349 million by 2028, growing at a CAGR of 6.2% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth in the humanized mouse and rat model market is majorly driven by the rising use of humanized models in drug discovery research, rising demand for personalized medicine, government-funded initiatives for cancer research, increasing R&D activities in pharmaceutical & biotechnology industry.

# data[].attributes.attachment_link.readable_text
Humanized Mouse and Rat Model Market

Humanized Mouse and Rat Model Market in terms of revenue was estimated to be worth $259 million in 2023 and is poised to reach $349 million by 2028, growing at a CAGR of 6.2% from 2023 to 2028 according to a new report by MarketsandMarkets™. Rising demand for personalized medicine is one of the prominent driving factor of the humanized mouse and rat model market. Existing mouse models have certain limitations in predictive research, unable to effectively gauge response in human cancer patients. Therefore, research institutes and academic institutes are focused on the development of advanced innovative models. Demand for personalized medicine is further driven by advancements in proteomics, genomics, and metabolomics. Additionally demand for targeted diagnostics and preventive medicine are propelling the demand for humanized mouse and rat research models.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral

The genetic models dominated the humanized mouse and rat model market in 2022.

Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. The humanized mouse models segment is further divided into genetic humanized mouse models and cell-based humanized mouse models. The genetic models generated highest revenue in 2022. In genetic humanized mouse models, the human protein/domain is expressed while the mouse protein/domain is suppressed in all cells and tissues. Genetic humanized mouse models have been successfully adopted in analyzing biological efficacy, safety testing, pharmaceutical compounds, and studying novel therapeutics. Humanized mouse models are gaining demand in studies around drug metabolism and immune system development & functioning.

The oncology segment represented a dominant share in the market in 2022.

Based on application, the humanized mouse and rat model market is segmented into toxicology, oncology, immunology and infectious diseases, hematopoiesis, neuroscience, and other applications. Humanized models mimic human cancers and act as essential platforms for cancer research. Cancer research involves studying cancer biology and understanding or predicting cancer, including tumor characterization, tumorigenesis, and metastasis. The growth of this segment can be attributed to the growing number of cancer research programs in academic & research institutes and favorable support by governments for cancer research.

The Asia Pacific region is the fastest-growing region of the humanized mouse and rat model market throughout the forecast period.

Based on the region, the humanized mouse and rat model market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is estimated to register the highest growth during the forecast period. Increase in demand for market products across China and India is the key contributive factor. Led by growing R&D activities, the outsourcing of preclinical, clinical, and laboratory testing services for small & large molecules is expected to increase in the country. The growing pharmaceutical industry, the rising number of CROs, and rising research activities will drive the growth of China's humanized mouse and rat model market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=131763955&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral

Humanized Mouse and Rat Model Market Dynamics:

Drivers:

Increasing research activities using humanized models
Rising demand for personalized medicine
Continuous support and initiatives from government and private sectors for cancer research
Growing R&D activities in pharmaceutical and biotechnology sectors

Restraints:

High cost of custom humanized models
Laws and regulations for ethical use of animal models in research

Opportunities:

Rising demand for humanized PDX models
Emergence of CRISPR as a powerful tool in biomedical research
Rising demand for humanized rat models

Challenges:

Alternatives for animal testing
Limitations of humanized mouse models

Key Market Players:

The prominent players in the global humanized mouse and rat model market include Charles River Laboratories (US), THE JACKSON LABORATORY (JAX) (US), Taconic Biosciences, Inc. (US), Crown Biosciences (US), Champions Oncology, Inc. (US), Hera BioLabs (US), genOway (France), Inotiv (US), Vitalstar Biotechnology (China), Ingenious Targeting Laboratory (US), TRANS GENIC (Japan), Harbour Antibodies BV (Netherlands), Oncodesign (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure services (France), Cyagen Biosciences (US), Aragen Life Sciences Ltd. (India), GemPharmatech (China), and Biocytogen (US).

Recent Developments:

In January 2022, Taconic Biosciences, Inc. (US) launched the huNOG-EXL EA (early access) humanized immune system (HIS) mouse.

In October 2021, The Jackson Laboratory (US) acquired RMS Business of Charles River Laboratories Japan, Inc. (Japan) which is Charles River Laboratories Japan's Research Models & Services (RMS) business as a wholly-owned subsidiary.

In September 2021, Biocytogen (US) collaborated with Envigo (US) in order to support the research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the US, Europe, and certain APAC regions.

In March 2021, Charles River Laboratories International, Inc. (US) acquired Cognate BioServices, Inc. (US) a cell and gene therapy contract development and manufacturing organization (CDMO) offering comprehensive manufacturing solutions for cell therapies. The acquisition expanded Charles River's broad capabilities across the major CDMO platforms for cell and gene therapies.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=131763955&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/humanized-mouse-model-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/humanized-mouse-model.asp

About MarketsandMarkets™:

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
This release was published on openPR.

# data[].attributes.attachment_link.title
Humanized Mouse and Rat Model Market worth $349 million by 2028 | Charles River Laboratories (US), THE JACKSON LABORATORY (JAX) (US), Taconic Biosciences, Inc. (US), Crown Biosciences (US)

# data[].attributes.attachment_link.description
Humanized Mouse and Rat Model Market in terms of revenue was estimated to be worth 259 million in 2023 and is poised to reach 349 million by 2028 growing at a CAGR of 6 2 from 2023 to 2028 according ...

# data[].attributes.headline
Global Animal Genetics Market worth $9.5 billion by 2028

# data[].attributes.subject
Global Animal Genetics Market worth $9.5 billion by 2028

# data[].attributes.body
The global animal genetics market in terms of revenue was estimated to be worth $6.6 billion in 2023 and is poised to reach $9.5 billion by 2028, growing at a CAGR of 7.4% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The new research study consists of industry trends, pricing analysis, patent analysis of key stakeholders and buying criteria in the market. Market growth is largely driven by factors such as the increasing consumption of animal-derived protein, growing global population & rapid urbanization, growing customer awareness, growing demand for companion animals, focus on superior breeds, and an emphasis on genetic services to prevent genetic diseases & business loss.

# data[].attributes.attachment_link.readable_text
, /PRNewswire/ -- In the near future, the animal genetics industry is poised to undergo a transformative revolution, driven by rapid advancements in genomics, biotechnology, and data analytics. This industry will witness the emergence of cutting-edge techniques such as precision breeding, gene editing, and synthetic biology, enabling the tailored enhancement of livestock traits for improved productivity, disease resistance, and environmental sustainability. Ethical considerations and regulatory frameworks will play a pivotal role in shaping the direction of this industry, ensuring that breakthroughs are balanced with responsible practices. As genetic insights continue to unravel, the animal genetics sector will likely foster collaborations between biotech companies, research institutions, and agricultural stakeholders to create a more resilient and efficient global food supply chain.

Animal Genetics Market in terms of revenue was estimated to be worth $6.6 billion in 2023 and is poised to reach $9.5 billion by 2028, growing at a CAGR of 7.4% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as better accessibility to technologies and well-established distribution channels drive growth in the developed markets across Europe and North America. Moreover, the growing demand for livestock food products has driven the need for genetic materials and live animals, as breeders and the animal food products industry seek higher productivity standards.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12462093 Browse in-depth TOC on "Animal Genetics Market" Animal Genetics Market Live animals segment accounted for the largest share of the animal genetics market. Scope: The poultry segment accounted for the largest share of the animal genetics market.
The animal genetic products segment is categorized into live animals and genetic materials. In 2022, the live animals segment commanded the largest share of the animal genetics market. This is attributed to the high demand for live animals to breed generations with high-productivity traits, high maternity ability, high growth rates, and feed efficiencies. Also, growing demand for animal proteins, the rising awareness of the benefits of genetic improvement in livestock, and the technological advancements in animal breeding are further boosting the market growth. The key players in the live animal genetics market are Genus plc, EW Group, , Cobb-Vantress, Topigs Norsvin, and Hendrix Genetics.
Europe accounted for the largest share of the animal genetics market.
The live animal segment is segmented into canine, poultry, porcine, bovine, and other live animals. The poultry segment accounted for largest share of the live animal market in 2022. The high demand for poultry meat and eggs in developed countries and the increasing demand for the same in developing countries due to the growing population and rapid urbanization drive the growth of the poultry segment.
Request Sample Pages: Animal Genetics Market Drivers: Dynamics: Restraints: https://www.marketsandmarkets.com/requestsampleNew.asp?id=12462093 Opportunities:
The global animal genetics market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, Europe accounted for the largest share of the animal genetics market, followed by North America and Asia Pacific. Market growth is driven by the need to improve livestock productivity, growing demand for animal food products, and the high intake of animal-derived proteins.
Challenges:

Growing global population and rapid urbanization
Key Market Players:

The emergence of alternative such as lab-based meat
Recent Developments:

Innovations in phenotyping services
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=12462093 Animal Genetics Market Advantages:

Economic sustainability in local breeds

Some of the major market players in the animal genetics market include Neogen Corporation (US), Genus (Uk), Urus (US), EW Group Gmbh (Germany), Groupe Grimaud (France).
Related Reports:

In March 2023, URUS Group collaborated with Genetics Australia. The JV will be 60 percent owned by URUS and 40 percent owned by Genetics Australia (GA). It will have access to the full suite of GENEX products and access to the PEAK program.

In January 2023, Zoetis collaborated with VAS to give farmers better compatibility crossover between Vas's PULSE platform, a broad farm management cloud-based software, and DairyComp, a herd health system with Zoetis's CLARIFIDE genetic and fertility testing.

Improved Productivity: Animal genetics advancements enable the breeding of livestock with enhanced traits such as faster growth rates, increased milk or egg production, and efficient feed conversion, leading to higher overall agricultural productivity.

Disease Resistance: Selective breeding and genetic engineering allow for the development of animals with increased resistance to diseases, reducing the need for antibiotics and minimizing disease-related economic losses.

Quality Enhancement: Genetic improvements can lead to better meat quality, improved taste, tenderness, and nutritional content, meeting consumer demands for high-quality and nutritious products.

Environmental Sustainability: By breeding animals that require fewer resources, produce less waste, and emit fewer greenhouse gases, the industry contributes to more sustainable and eco-friendly farming practices.

Resource Efficiency: Animal genetics helps optimize resource utilization by minimizing inputs such as feed, water, and land while maximizing outputs, thus reducing the overall environmental impact of agriculture.

Biodiversity Preservation: Focused breeding programs can help conserve and protect endangered or rare animal breeds, maintaining biodiversity within livestock populations.

Reduced Food Insecurity: Enhanced genetics lead to increased food production, helping to address global food security challenges and ensuring a stable supply of animal-derived products.

Economic Benefits: Farmers can benefit from increased profitability due to improved yields, reduced mortality rates, and access to premium markets willing to pay for genetically superior products.

Human Health Research: Studying animal genetics can provide insights into human genetics and diseases, contributing to advancements in medicine and biotechnology.

Innovation and Technological Progress: The animal genetics market drives technological innovation, fostering collaborations between biotech firms, researchers, and agricultural stakeholders to develop cutting-edge solutions.

Customization: Advances in gene editing and synthetic biology enable the customization of animal genetics to meet specific market demands and consumer preferences.

Ethical Considerations: Ethical practices within the industry, such as ensuring animal welfare and addressing potential concerns, help create a more responsible and transparent approach to genetic enhancements.

In summary, the animal genetics market offers a range of advantages that encompass improved agricultural productivity, environmental sustainability, economic growth, and ethical considerations, ultimately contributing to the development of a more resilient and responsible global food system.

Veterinary Equipment Market - Global Forecasts to 2027

Veterinary Diagnostics Market - Global Forecasts to 2027
About MarketsandMarkets™:
Veterinary Reference Laboratory Market - Global Forecasts to 2027

Companion Animal Pharmaceuticals Market - Global Forecasts to 2027

Next Generation Sequencing Market - Global Forecasts to 2027

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/animal-genetic-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/animal-genetic.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Animal Genetics Market worth $9.5 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
PRNewswire/ -- In the near future, the animal genetics industry is poised to undergo a transformative revolution, driven by rapid advancements in genomics,...

# data[].attributes.headline
Global Bone Cement & Glue Market worth $2,248 million by 2028

# data[].attributes.subject
Global Bone Cement & Glue Market worth $2,248 million by 2028

# data[].attributes.body
The Global Bone Cement & Glue Market is projected to reach USD 2,248 million by 2028 from USD 1,644 million in 2023, at a CAGR of 6.5% during the forecast period. The growth of this market is majorly driven by the Rising Demand for Minimally Invasive Surgeries with robotic assistance and Growing healthcare sector and Increasing Incidence of Orthopedic Conditions. However, Challenges associated with Variability of pathogen resistance may threat the growth of this market.

# data[].attributes.attachment_link.readable_text
, /PRNewswire/ -- In the near future, the bone cement and glue industry is poised for significant advancements and growth, driven by emerging technologies and a rising global demand for innovative medical solutions. Manufacturers in this sector are expected to develop more efficient and bio-compatible formulations, enhancing the efficacy of bone adhesives in orthopedic surgeries and dental applications. The adoption of 3D printing technology is likely to revolutionize the production process, enabling personalized and patient-specific implants and prosthetics. Additionally, research in bioactive additives and nanotechnology will pave the way for enhanced bone regeneration properties and reduced complications. With an aging population and increasing cases of musculoskeletal disorders, the bone cement and glue industry is anticipated to play a pivotal role in improving patient outcomes and quality of life through cutting-edge materials and techniques.

Bone Cement & Glue Market in terms of revenue was estimated to be worth $1,644 million in 2023 and is poised to reach $2,248 million by 2028, growing at a CAGR of 6.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. The growth of this market is majorly driven by Growing number of road traffic accidents and rising number of surgical procedures. However, High costs and Product-related complications may challenge the growth of this market.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131540876 Bone Cement & Glue Market France in European Bone cement & glue market to witness the highest shares during the forecast period. Scope: Hospitals, & Ambulatory Surgical Centers in End user' Bone cement & glue market to witness the highest growth rate during the forecast period.
The Europe Bone cement & glue market is segmented into Germany, France, the UK, and the Rest of Europe. France is projected to occupy the highest share during the forecast period. The major factors contributing to the growth of this market are the high prevalence of Orthopedic Conditions, the growing geriatric population, In addition, France has a well-developed healthcare system with access to advanced medical technologies and treatments. This infrastructure supports the adoption of bone cement and glue products in various orthopedic and dental procedures. Likewsie, France has a skilled workforce of healthcare professionals, including orthopedic surgeons, who are adept at using bone cement and glue products in surgical procedures.
China dominates the Asia Pacific Bone cement & glue market.
Based on the end user, the Bone cement & glue market is segmented into Hospitals, & Ambulatory Surgical Centers, and Clinics/Physician offices. The Hospitals, & Ambulatory Surgical Centers registered the highest CAGR, increasing orthopedic Surgical Procedures, Hospitals and ASCs are key providers of joint replacement surgeries, such as total hip arthroplasty (THA) and total knee arthroplasty (TKA), moreover Hospitals and ASCs cater to patients of all ages, but the aging population is more likely to require orthopedic surgeries that involve bone cement and glue. As the global population ages, the demand for joint replacement surgeries and other orthopedic procedures is increasing, benefiting the bone cement and glue market.
Request Sample Pages: Bone Cement & Glue Market Drivers:

Growing incidences of sports injuries

Restraints:

High costs and extensive clinical data requirements for launching new bone cements

Opportunities:

Rising awareness and demand for minimally invasive procedures

Challenges: Key Market Players: Dynamics: Recent Developments:

In 2021, The company Smith & Nephew (UK) acquired the Extremity Orthopedics business of Integra LifeSciences to expand its shoulder, upper, and lower extremities product portfolio.

In 2021, Zimmer Biomet (US) Completed the spinoff of spine and dental businesses into a new public company, ZimVie Inc. ("ZimVie"). The transaction was intended to benefit its stockholders by enhancing the focus of both Zimmer Biomet and ZimVie to meet the needs of patients and customers.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=131540876 Bone Cement & Glue Market Advantages:

Enhanced Surgical Outcomes: Bone cement and glue products provide strong and stable fixation in orthopedic surgeries, improving the chances of successful joint replacements and fracture repairs. These materials help in bonding implants to bone surfaces securely, reducing the risk of implant loosening or failure.

Minimally Invasive Procedures: The use of bone cement and glue allows for less invasive surgical techniques, as they eliminate the need for extensive hardware and screws. This leads to smaller incisions, reduced tissue damage, and faster patient recovery times.

Bone Support and Stability: These materials not only serve as adhesives but also provide structural support to weakened or damaged bones. They can help fill voids and gaps in bone structures, aiding in fracture stabilization and enhancing bone healing.

Bio-compatibility and Biodegradability: Advanced bone cements and glues are designed to be bio-compatible with the body's tissues, reducing the risk of adverse reactions or rejection. Additionally, some products are biodegradable, gradually breaking down over time as the natural bone regenerates and integrates with the material.

Versatility in Applications: Bone cement and glue products find applications in various medical specialties, including orthopedics, traumatology, neurosurgery, and dentistry. Their versatility allows healthcare professionals to address a wide range of bone-related issues effectively.

Customization and 3D Printing: Advancements in technology enable the customization of bone cement and glue products, providing tailored solutions for individual patients. 3D printing allows for patient-specific implants and prosthetics, enhancing surgical precision and patient satisfaction.

Cost-Effectiveness: Bone cement and glue can lead to cost savings in healthcare systems by reducing the need for more extensive and expensive surgical procedures, hospital stays, and long-term rehabilitation.

Faster Operating Room Procedures: The ease of use and quick setting times of bone cement and glue enable faster surgeries, leading to reduced operating room time and increased efficiency for healthcare providers.

Addressing Osteoporotic Fractures: With an aging population, osteoporosis-related fractures are becoming more prevalent. Bone cement and glue offer effective solutions for stabilizing and reinforcing weakened bones, improving the quality of life for elderly patients.

https://www.marketsandmarkets.com/requestsampleNew.asp?id=131540876 Related Reports:
The APAC amniotic products market is segmented into Japan, China, India, and Rest of Apac. In 2022, China accounted for the largest share of the Asian Bone cement & glue market. The large share of China can be attributed to the economic growth in the country, rising incidence of orthopedic cases, significantly high cases of road accidents, increasing disposable income of the middle-class population, growth in the geriatric population, and favourable government support.

The significant players in the Bone cement & glue market are Stryker (US), Zimmer Biomet (US), DePuy Synthes (a subsidiary of Johnson & Johnson - US), Enovis (US), Heraeus Holding (Germany), Medtronic (Ireland)

Overall, the advantages of bone cement and glue in the medical field highlight their essential role in promoting better patient outcomes, enabling advanced surgical techniques, and addressing various bone-related conditions with enhanced precision and effectiveness.

Cold Pain Therapy Market - Global Forecasts to 2027

Orthopedic Braces and Supports Market - Global Forecasts to 2027
About MarketsandMarkets™:
Physiotherapy Equipment Market - Global Forecasts to 2027

Foot and Ankle Devices Market - Global Forecasts to 2025

Biomaterials Market - Global Forecasts to 2025

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/bone-cement-glue-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/bone-cement-glue.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

View original content: https://www.prnewswire.com/news-releases/bone-cement--glue-market-worth-2-248-million--marketsandmarkets-301890102.html

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Bone Cement & Glue Market worth $2,248 million | MarketsandMarkets

# data[].attributes.attachment_link.description
In the near future, the bone cement and glue industry is poised for significant advancements and growth, driven by emerging technologies and a rising global demand for innovative medical solutions. Manufacturers in this sector are expected to develop more efficient and bio-compatible formulations, enhancing the efficacy of bone adhesives in orthopedic surgeries and dental applications.

# data[].attributes.headline
Animal Genetics Market worth $9.5 billion | MarketsandMarkets

# data[].attributes.subject
Animal Genetics Market worth $9.5 billion | MarketsandMarkets

# data[].attributes.body
Animal Genetics Market in terms of revenue was estimated to be worth $6.6 billion in 2023 and is poised to reach $9.5 billion by 2028, growing at a CAGR of 7.4% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as better accessibility to technologies and well-established distribution channels drive growth in the developed markets across Europe and North America. Moreover, the growing demand for livestock food products has driven the need for genetic materials and live animals, as breeders and the animal food products industry seek higher productivity standards.

# data[].attributes.attachment_link.readable_text
, /PRNewswire/ -- In the near future, the animal genetics industry is poised to undergo a transformative revolution, driven by rapid advancements in genomics, biotechnology, and data analytics. This industry will witness the emergence of cutting-edge techniques such as precision breeding, gene editing, and synthetic biology, enabling the tailored enhancement of livestock traits for improved productivity, disease resistance, and environmental sustainability. Ethical considerations and regulatory frameworks will play a pivotal role in shaping the direction of this industry, ensuring that breakthroughs are balanced with responsible practices. As genetic insights continue to unravel, the animal genetics sector will likely foster collaborations between biotech companies, research institutions, and agricultural stakeholders to create a more resilient and efficient global food supply chain.

Animal Genetics Market in terms of revenue was estimated to be worth $6.6 billion in 2023 and is poised to reach $9.5 billion by 2028, growing at a CAGR of 7.4% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as better accessibility to technologies and well-established distribution channels drive growth in the developed markets across Europe and North America. Moreover, the growing demand for livestock food products has driven the need for genetic materials and live animals, as breeders and the animal food products industry seek higher productivity standards.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12462093 Browse in-depth TOC on "Animal Genetics Market" Animal Genetics Market Live animals segment accounted for the largest share of the animal genetics market. Scope: The poultry segment accounted for the largest share of the animal genetics market.
The animal genetic products segment is categorized into live animals and genetic materials. In 2022, the live animals segment commanded the largest share of the animal genetics market. This is attributed to the high demand for live animals to breed generations with high-productivity traits, high maternity ability, high growth rates, and feed efficiencies. Also, growing demand for animal proteins, the rising awareness of the benefits of genetic improvement in livestock, and the technological advancements in animal breeding are further boosting the market growth. The key players in the live animal genetics market are Genus plc, EW Group, , Cobb-Vantress, Topigs Norsvin, and Hendrix Genetics.
Europe accounted for the largest share of the animal genetics market.
The live animal segment is segmented into canine, poultry, porcine, bovine, and other live animals. The poultry segment accounted for largest share of the live animal market in 2022. The high demand for poultry meat and eggs in developed countries and the increasing demand for the same in developing countries due to the growing population and rapid urbanization drive the growth of the poultry segment.
Request Sample Pages: Animal Genetics Market Drivers:

Growing global population and rapid urbanization

Restraints:

The emergence of alternative such as lab-based meat

Opportunities:

Innovations in phenotyping services

Challenges:

Economic sustainability in local breeds

Key Market Players: Dynamics: Recent Developments:

In March 2023, URUS Group collaborated with Genetics Australia. The JV will be 60 percent owned by URUS and 40 percent owned by Genetics Australia (GA). It will have access to the full suite of GENEX products and access to the PEAK program.

In January 2023, Zoetis collaborated with VAS to give farmers better compatibility crossover between Vas's PULSE platform, a broad farm management cloud-based software, and DairyComp, a herd health system with Zoetis's CLARIFIDE genetic and fertility testing.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=12462093 Animal Genetics Market Advantages:

Improved Productivity: Animal genetics advancements enable the breeding of livestock with enhanced traits such as faster growth rates, increased milk or egg production, and efficient feed conversion, leading to higher overall agricultural productivity.

Disease Resistance: Selective breeding and genetic engineering allow for the development of animals with increased resistance to diseases, reducing the need for antibiotics and minimizing disease-related economic losses.

Quality Enhancement: Genetic improvements can lead to better meat quality, improved taste, tenderness, and nutritional content, meeting consumer demands for high-quality and nutritious products.

Environmental Sustainability: By breeding animals that require fewer resources, produce less waste, and emit fewer greenhouse gases, the industry contributes to more sustainable and eco-friendly farming practices.

Resource Efficiency: Animal genetics helps optimize resource utilization by minimizing inputs such as feed, water, and land while maximizing outputs, thus reducing the overall environmental impact of agriculture.

Biodiversity Preservation: Focused breeding programs can help conserve and protect endangered or rare animal breeds, maintaining biodiversity within livestock populations.

Reduced Food Insecurity: Enhanced genetics lead to increased food production, helping to address global food security challenges and ensuring a stable supply of animal-derived products.

Economic Benefits: Farmers can benefit from increased profitability due to improved yields, reduced mortality rates, and access to premium markets willing to pay for genetically superior products.

Human Health Research: Studying animal genetics can provide insights into human genetics and diseases, contributing to advancements in medicine and biotechnology.

Innovation and Technological Progress: The animal genetics market drives technological innovation, fostering collaborations between biotech firms, researchers, and agricultural stakeholders to develop cutting-edge solutions.

Customization: Advances in gene editing and synthetic biology enable the customization of animal genetics to meet specific market demands and consumer preferences.

Ethical Considerations: Ethical practices within the industry, such as ensuring animal welfare and addressing potential concerns, help create a more responsible and transparent approach to genetic enhancements.

https://www.marketsandmarkets.com/requestsampleNew.asp?id=12462093 Related Reports:
The global animal genetics market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, Europe accounted for the largest share of the animal genetics market, followed by North America and Asia Pacific. Market growth is driven by the need to improve livestock productivity, growing demand for animal food products, and the high intake of animal-derived proteins.

Some of the major market players in the animal genetics market include Neogen Corporation (US), Genus (Uk), Urus (US), EW Group Gmbh (Germany), Groupe Grimaud (France).

In summary, the animal genetics market offers a range of advantages that encompass improved agricultural productivity, environmental sustainability, economic growth, and ethical considerations, ultimately contributing to the development of a more resilient and responsible global food system.

Veterinary Equipment Market - Global Forecasts to 2027

Veterinary Diagnostics Market - Global Forecasts to 2027
About MarketsandMarkets™:
Veterinary Reference Laboratory Market - Global Forecasts to 2027

Companion Animal Pharmaceuticals Market - Global Forecasts to 2027

Next Generation Sequencing Market - Global Forecasts to 2027

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/animal-genetic-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/animal-genetic.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

View original content to download multimedia: https://www.prnewswire.com/news-releases/animal-genetics-market-worth-9-5-billion--marketsandmarkets-301897610.html

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Animal Genetics Market worth $9.5 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
In the near future, the animal genetics industry is poised to undergo a transformative revolution, driven by rapid advancements in genomics, biotechnology, and data analytics. This industry will witness the emergence of cutting-edge techniques such as precision breeding, gene editing, and synthetic biology, enabling the tailored enhancement of livestock traits for improved productivity, disease resistance, and environmental sustainability.

# data[].attributes.headline
Laboratory Information Management System (LIMS) Market worth $3.3 billion by 2028 

# data[].attributes.subject
Laboratory Information Management System (LIMS) Market worth $3.3 billion by 2028 

# data[].attributes.body
The Global Laboratory Information Management Systems Market is projected to reach USD 3.3 billion by 2028 from USD 1.6 billion in 2023, at a CAGR of 14.6% during the forecast period. The significant growth potential in emerging markets such as China, India, Japan, Singapore, Brazil, and Middle Eastern countries, growing popularity of cloud-based LIMS pertaining to large volumes of data generated in laboratories & reduced total cost of ownership of laboratory informatics solutions are some of the critical factors offering opportunities to the market.

# data[].attributes.attachment_link.readable_text
Laboratory Information Management System (LIMS) Market

Laboratory Information Management System (LIMS) Market in terms of revenue was estimated to be worth $1.6 billion in 2023 and is poised to reach $3.3 billion by 2028, growing at a CAGR of 14.6% from 2023 to 2028 according to a new report by MarketsandMarkets™. The growing popularity of cloud-based LIMS, use of LIMS in industry, significant growth potential in emerging markets are some of the key factors that offer opportunities to the market during the forecast period. However, the dearth of trained professionals, and interfacing challenges with informatics software are some of the factors challenging the market growth to some extent.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=250610373&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral

The cloud-based segment is expected to register a substantial growth in the laboratory information management systems market, by deployment mode

The cloud-based segment is expected to register a substantial growth in the laboratory information management systems market, by deployment mode. This growth can be attributed to advantages of this deployment model, such as cost-effectiveness and ease of use. Factors such as on-demand self-serving analytics, their highly adaptable nature, ease of use, affordability, reliability, no upfront capital investment for hardware, extreme capacity flexibility, and a pay-as-you-go pricing model have also ensured the high growth of cloud-based LIMS.

Asia is to witness a considerable growth rate during the forecast period.

The Asian market is projected to grow at a considerable CAGR during the forecast period. Factors such as increasing medical tourism, growing investments expected to bring about the creation of new market participants, growing emergence of various technologies, and the rising foreign direct investments by North American and European pharmaceutical and biotechnology firms in Asia are anticipated to drive the development of laboratory information management systems applications in the Asia Pacific region.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=250610373&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral

Laboratory Information Management System (LIMS) Market Dynamics:

Drivers:

Increasing focus on improving the efficiency of laboratories

Restraints:

Limited adoption of LIMS in small and medium-sized companies

Opportunities:

Significant growth in emerging markets

Challenges:

A dearth of trained professionals

Key Market Players:

LabWare (US), LabVantage Solutions Inc. (US), Thermo Fisher Scientific (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies (US), LabLynx, Inc. (US), Dassault Systèmes (France), Labworks LLC (US), Autoscribe Informatics (a wholly owned subsidiary of Autoscribe Limited) (US), Accelerated Technology Laboratories (ATL) (US), CloudLIMS (US), Computing Solutions, Inc. (US), GenoLogics Inc. (an Illumina Company) (Canada), Siemens (Germany), Novatek International (Canada), Ovation (US), Clinsys (US) are the major players in this market. These companies are majorly focusing on the strategies such as agreements, collaborations, partnerships, and service launches in order to remain competitive and further increase their share in the market.

Recent Developments:

In October 2022, LabVantage Solutions, Inc. (US) and Biomax Informatics AG (Germany) announced the closure of their merger agreement. The merger aims to enhance scientific data contextualization, accelerate product development, and provide innovative capabilities for the life science and bio-manufacturing industries.

In March 2022, LabWare (US), acquired data analytics firm CompassRed (US). The merger aimed to create a LabWare Data Analytics Innovation Center and accelerate the transformation of data into actionable knowledge. The acquisition allowed LabWare to expand its services and establish a global presence.

In March 2022, Thermo Fisher Scientific, Inc. (US) and Symphogen (Denmark) announced the continuation of their collaboration to provide innovative tools and workflows for the efficient characterization of complex therapeutic proteins in biopharmaceutical discovery and development laboratories

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=250610373&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/laboratory-information-management-systems-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/laboratory-information-management-systems.asp

About MarketsandMarkets™:

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
This release was published on openPR.

# data[].attributes.attachment_link.title
Laboratory Information Management System (LIMS) Market worth $3.3 billion by 2028 | LabWare (US), LabVantage Solutions Inc. (US), Thermo Fisher Scientific (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies (US), LabLynx, Inc. (US)

# data[].attributes.attachment_link.description
Laboratory Information Management System LIMS Market in terms of revenue was estimated to be worth 1 6 billion in 2023 and is poised to reach 3 3 billion by 2028 growing at a CAGR of 14 6 from 2023 to ...

# data[].attributes.headline
Cell Analysis Market worth $33.9 billion | MarketsandMarkets

# data[].attributes.subject
Cell Analysis Market worth $33.9 billion | MarketsandMarkets

# data[].attributes.body
Cell Analysis Market in terms of revenue was estimated to be worth $20.2 billion in 2023 and is poised to reach $33.9 billion by 2028, growing at a CAGR of 10.9% from 2023 to 2028 according to a new report by MarketsandMarkets™. Rising preference for cell-based assays in drug discovery serves as one of the key driving factors of the cell analysis market. Pharmaceutical & biotechnology companies and CROs are replacing biochemical assays with cell-based assays for their lead identification and optimization processes in drug discovery. This is attributive to the several advantages over in vitro biochemical assays. They offer consistent tissue-specific responses in a biologically relevant microenvironment as opposed to biochemical assays.

# data[].attributes.attachment_link.readable_text
, July 10, 2023 /PRNewswire/ -- The cell analysis industry is poised to experience unprecedented growth and innovation in the near future. With advancements in technology and increasing demand for personalized medicine, the field of cell analysis is expected to revolutionize healthcare and scientific research. Cutting-edge techniques such as single-cell analysis, high-throughput screening, and multi-omics integration are set to provide unparalleled insights into cellular behaviour and disease mechanisms. The integration of artificial intelligence and machine learning algorithms will further enhance data analysis and interpretation, enabling rapid and accurate identification of biomarkers and drug targets. Moreover, the emergence of microfluidic devices and lab-on-a-chip technologies will streamline experimental workflows, making cell analysis more accessible and cost-effective. As a result, we anticipate significant progress in areas such as cancer research, immunology, regenerative medicine, and drug discovery, ultimately leading to improved diagnostics, targeted therapeutics, and personalized treatment strategies. The future of the cell analysis industry holds immense potential to revolutionize healthcare and advance our understanding of complex biological systems, paving the way for a healthier and more personalized future.

Cell Analysis Market in terms of revenue was estimated to be worth $20.2 billion in 2023 and is poised to reach $33.9 billion by 2028, growing at a CAGR of 10.9% from 2023 to 2028 according to a new report by MarketsandMarkets™. Rising preference for cell-based assays in drug discovery serves as one of the key driving factors of the cell analysis market. Pharmaceutical & biotechnology companies and CROs are replacing biochemical assays with cell-based assays for their lead identification and optimization processes in drug discovery. This is attributive to the several advantages over in vitro biochemical assays. They offer consistent tissue-specific responses in a biologically relevant microenvironment as opposed to biochemical assays.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=157543946 Cell Analysis Market The software segment is estimated to grow at the fastest pace through the forecast period Scope: The flow cytometry technique segment accounted for the largest share in the cell analysis market in 2022
Based on product & service, the global cell analysis market is segmented into reagents & consumables, instruments, accessories, software, and services. The software segment is a lucrative space owing to the advancements across single-cell analysis and flow cytometry techniques. This has elevated the influx of emerging companies entering cell analysis industry. Emerging companies building innovative software solutions has contributed to the robust growth rate registered by this segment.
The hospitals & clinical testing laboratories segment is estimated to grow with highest CAGR during the forecast period of cell analysis market
Based on technique, the global cell analysis market is segmented into flow cytometry, PCR, cell microarrays, microscopy, spectrophotometry, high-content screening, and other techniques. The flow cytometry segment accounted for the largest market share of in 2022. Significant demand for flow cytometry technique across single-cell analysis and other different analysis processes is set to propel the market growth. Through flow cytometry multiple characteristics of single-cell particles can be measured and analyzed making it a preferable cell analysis technique for fluid samples.
Asia Pacific has registered fastest growth rate during the forecast period in cell analysis market
On the basis of end users, the cell analysis market is segmented into pharmaceutical & biotechnology companies, hospitals & clinical testing laboratories, academic & research institutes, and other end users. The demand for cell analysis products is set to elevate across in-house diagnostic and research centers, in-house pathology centers, and reference laboratories; collectively contributing to the fastest growth rate of hospitals & clinical testing laboratories during the forecast period. The development of highly specialized and complex cell-based assays is expected to supplement this growth.
Request Sample Pages: Cell Analysis Market Drivers: Dynamics: Restraints: https://www.marketsandmarkets.com/requestsampleNew.asp?id=157543946 Opportunities:
The global cell analysis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. Rapid increase in the pharmaceutical & biopharmaceutical industries coupled with affordable with cell analysis services are the key contributing factors to the regional growth.
Key Market Players:

Growing number of drug discovery activities
Recent Developments:

High cost of instruments and restrictions on reagent use
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=157543946 Cell Analysis Market Advantages:

Application of novel cell-based assays in cancer research

The cell analysis market is fragmented in nature with prominent players operating in this market such as Danaher (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), General Electric (US), Merck KGaA (US), Agilent Technologies (US), Olympus Corporation (Japan), Miltenyi Biotec (US), Bio-Rad Laboratories (US), BioStatus Limited (UK), Fluidigm Corporation (US), NanoCellect Biomedical (US), Cell Biolabs (US), Creative Bioarray (US), Meiji Techno (US), Promega Corporation (US), PerkinElmer (US), Tecan Trading AG (Switzerland), CELLINK (US), QIAGEN (Germany), Corning Incorporated (US), 10x Genomics (US), and Illumina (US).
Cell Analysis Market - Report Highlights:

In 2023, Becton, Dickinson and Company (US) launched a Spectral Cell Sorter that is coupled with high-speed cell imaging. this product combines real-time imaging technology with spectral flow cytometry.

In 2020, Miltenyi Biotec (Germany) launched MACS GMP Tyto Cartridge, a GMP-compliant cell sorter.

In 2020, Bio-Rad Laboratories, Inc. (US) acquired Celsee, Inc., a provider of instruments and consumables for the isolation, detection, and analysis of single cells. This acquisition expanded the company's product offerings in the flow cytometry market.

Related Reports:

Comprehensive Understanding: Cell analysis techniques enable researchers to gain a comprehensive understanding of cellular behavior and function. By analyzing various cellular parameters, such as morphology, gene expression, protein levels, and metabolic activity, researchers can unravel complex biological processes and uncover underlying mechanisms of diseases.

Personalized Medicine: Cell analysis plays a crucial role in advancing personalized medicine. By studying individual cells, researchers can identify biomarkers that are specific to certain diseases or patient populations. This information enables the development of targeted therapies and personalized treatment strategies, optimizing patient outcomes.

Drug Discovery and Development: The cell analysis market contributes significantly to drug discovery and development. By using high-throughput screening and cell-based assays, researchers can evaluate the efficacy and toxicity of potential drug candidates. This helps in identifying promising drug candidates early in the development process, reducing costs and improving success rates.

Advancements in Technology: The cell analysis industry benefits from continuous advancements in technology. Innovations such as automated imaging systems, flow cytometry, single-cell sequencing, and high-resolution microscopy have enhanced the accuracy, efficiency, and throughput of cell analysis techniques. These technological advancements enable researchers to generate large-scale data sets and obtain more precise insights into cellular behavior.

Translational Research: Cell analysis facilitates translational research by bridging the gap between basic research and clinical applications. The findings from cellular studies can be translated into clinical diagnostics, prognostics, and therapeutics. This integration helps in improving patient care, developing novel treatment approaches, and accelerating the adoption of scientific discoveries into clinical practice.

Quality Control and Safety Testing: Cell analysis techniques play a vital role in quality control and safety testing in industries such as pharmaceuticals, biotechnology, and food and beverages. These methods ensure that products meet regulatory standards, evaluate potential toxicity, and verify the absence of contaminants, ensuring consumer safety.

Academic and Industrial Collaboration: The cell analysis market encourages collaboration between academic institutions, research organizations, and industries. This collaboration fosters knowledge exchange, accelerates innovation, and promotes interdisciplinary research, leading to advancements in both scientific understanding and practical applications

Overall, the cell analysis market offers numerous advantages, including a deeper understanding of cellular processes, personalized medicine approaches, advancements in drug discovery, technological progress, translational research impact, quality control, and collaborative opportunities. These advantages contribute to the growth and significance of the cell analysis industry.

The value chain analysis, ecosystem analysis, and regulatory scenario are added in the market overview chapter.

The new edition of the report provides updated market breakdown with detailed analysis on types of cell analysis techniques, products, and services. Compared to the previous report version, this report is inclusive of software, services, and techniques incorporated in cell analysis.

The new edition of the report provides updated financial information till 2022 (depending on availability) for each listed company in a graphical representation. This would help in the easy analysis of the present status of profiled companies in terms of their financial strength, profitability, key revenue-generating region/country, and business segment focus in terms of the highest revenue-generating segment.

Recent developments are helpful to understand market trends and growth strategies adopted by players in the market.

Tracking product portfolios of prominent market players helps to analyze the major products & services in the cell analysis market. The new edition of the report provides an updated product portfolio of the companies profiled in the report.

Market evaluation framework, market share analysis and competitive leadership mapping have been added in competitive landscape chapter of the report.

The competitive leadership mapping has been updated considering recent developments in the company evaluation matrix.

Single Cell Analysis Market - Global Forecasts to 2028

Cell-Based Assays Market - Global Forecasts to 2028
About MarketsandMarkets™:
Flow Cytometry Market - Global Forecasts to 2027

Microscopy Market - Global Forecasts to 2027

Cell Counting Market - Global Forecasts to 2025

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/cell-analysis-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/cell-analysis.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Cell Analysis Market worth $33.9 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
PRNewswire/ -- The cell analysis industry is poised to experience unprecedented growth and innovation in the near future. With advancements in technology and...

# data[].attributes.headline
Ultrasound Market worth $11.6 billion by 2028 

# data[].attributes.subject
Ultrasound Market worth $11.6 billion by 2028 

# data[].attributes.body
Ultrasound Market in terms of revenue was estimated to be worth $8.5 billion in 2023 and is poised to reach $11.6 billion by 2028, growing at a CAGR of 6.3% from 2023 to 2028 according to a new report by MarketsandMarkets™. The major factors driving the growth of this market include rising patient population, various chronic diseases, and technological advancements along with the increasing adoption of ultrasound for diagnostic imaging.

# data[].attributes.attachment_link.readable_text
, /PRNewswire/ -- In the near future, the ultrasound industry is poised for remarkable advancements, revolutionizing medical diagnostics and healthcare practices. Rapid technological innovations in ultrasound machines will enable higher resolution imaging, real-time 3D visualization, and enhanced portability, making them more accessible to remote and underserved areas. AI-driven algorithms will play a crucial role in automating image analysis, expediting diagnoses, and improving accuracy. Additionally, miniaturization and wearable ultrasound devices will empower patients to monitor their health in real-time, ushering in a new era of personalized medicine. As the cost of ultrasound technology decreases and its applications expand, we can expect a surge in adoption across various fields, from obstetrics and cardiology to musculoskeletal and point-of-care settings, ultimately enhancing patient outcomes and transforming the landscape of modern healthcare.

Ultrasound Market in terms of revenue was estimated to be worth $8.5 billion in 2023 and is poised to reach $11.6 billion by 2028, growing at a CAGR of 6.3% from 2023 to 2028 according to a new report by MarketsandMarkets™. The major factors driving the growth of this market include rising patient population, various chronic diseases, and technological advancements along with the increasing adoption of ultrasound for diagnostic imaging.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=467 Browse in-depth TOC on "Ultrasound Market" Ultrasound Market Technology segment to register significant growth rate over the forecast period of 2023-2028 Scope: Portability segment to register significant growth rate over the forecast period of 2023-2028
Based on technology, the global ultrasound imaging market is segmented into diagnostic and therapeutic ultrasound. The therapeutic ultrasound segment is anticipated to register the second highest growth rate over the forecast period. The diagnostic ultrasound segment accounted for the highest share of the ultrasound market in 2022.
Component segment accounted for the largest share of the ultrasound market, by application in 2022.
Based on the portability, the ultrasound market is segmented into trolly/cart-based ultrasound, compact/handheld ultrasound systems, and POC ultrasound systems. The trolly/cart-based ultrasound segment is anticipated to register the highest growth rate over the forecast period. The compact/handheld ultrasound systems segment accounted for the highest share of the ultrasound market in 2022.

Based on component, the global the ultrasound market is segmented into transducers/probes, workstations, other components. Transducer/probes segment accounted for the largest share of the market in 2022 and is expected to grow at the highest CAGR during the forecast period.
The hospital and clinics segment accounted for the largest share of the ultrasound market, by end user, in 2022
Factors such as the rising incidence of cancer cases, the growing geriatric population, and the launch of integrated modalities drive the growth of ultrasound products.
The Asia Pacific market to register a significant growth in the market during the forecast period
Based on end user, the ultrasound market is segmented into hospitals, surgical centres, diagnostic centres, maternity centres, ambulatory centres, research and academia and other end users. The hospitals, surgical centres, diagnostic centres segment accounts for the largest share of the market in 2022. Factors attributing to the share of this particular are increasing cancer incidences and increasing number of dermatological surgeries performed in hospitals and clinics are driving the growth of this segment.
Request Sample Pages: Ultrasound Market Drivers: Dynamics: Restraints: https://www.marketsandmarkets.com/requestsampleNew.asp?id=467 Opportunities:
The Asia Pacific ultrasound market is estimated to register a significant growth from 2023 to 2028. The increasing patient population, rising geriatric population, rapid economic growth and increasing disposable income are driving the market growth in APAC countries. This region is having a rise in healthcare investment and expenditure, offering significant growth opportunities for the key players.
Challenges:
1. Increasing prevalence of target diseases
Key Market Players:
1. Unfavorable healthcare reforms in the US
Recent Developments:
1. Expanding applications of therapeutic ultrasound
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=467 Ultrasound Market Advantages:
1. Growing end-user preference for refurbished equipment

As of 2022, prominent players in the ultrasound market are GE healthcare (US), Koninklijke Philips N.V. (Netherlands), Canon Medical Systems Corporation (Japan), Siemens AG (Germany), Fujifilm Corporation (Japan), and Hologic, Inc. (US)
Related Reports:

In February 2023, GE HealthCare has acquired Caption Health, thereby expanding the capabilities of ultrasound technology to assist new users through FDA-cleared, AI-powered image guidance. By leveraging Caption AI applications, ultrasound examinations can be streamlined, accelerating the process and empowering a wider range of healthcare professionals to perform fundamental echocardiogram exams.

In November 2022, Canon Inc. revealed its plans to form a new subsidiary called Canon Healthcare USA, Inc. With this strategic move, Canon intends to enhance its position within the influential American medical market and expedite the expansion of its medical business.

In April 2022, The enhanced partnership between GE HealthCare and Sinopharm focuses on the development and commercialization of medical equipment designed to meet the specific healthcare requirements of China.

Non-Invasive: Ultrasound is a non-invasive imaging technique, meaning it does not require any incisions or exposure to ionizing radiation, making it safer for patients and reducing the risk of complications.

Real-Time Imaging: Ultrasound provides real-time imaging, allowing medical professionals to observe and assess dynamic processes within the body, such as blood flow, organ movements, and fetal development.

Portability: Advancements in technology have led to the development of portable and handheld ultrasound devices, enabling point-of-care imaging in remote or resource-limited settings and increasing accessibility to medical care.

Cost-Effective: Compared to other imaging modalities like MRI or CT scans, ultrasound is generally more cost-effective, making it a cost-efficient choice for both healthcare providers and patients.

No Ionizing Radiation: Ultrasound uses sound waves instead of ionizing radiation, making it a safer option for imaging pregnant women, children, and individuals who require frequent imaging studies.

Wide Range of Applications: Ultrasound has a diverse range of applications across various medical specialties, including obstetrics, gynecology, cardiology, radiology, gastroenterology, and more, making it a versatile tool for healthcare professionals.

Real-Time Guidance: Ultrasound can be used in real-time to guide medical procedures, such as needle biopsies, drain placements, and catheter insertions, increasing accuracy and reducing the risk of complications.

High Patient Tolerance: Patients generally find ultrasound examinations comfortable and painless, contributing to improved patient compliance and satisfaction.

Safe for Repetitive Use: Ultrasound can be used repeatedly without any harm to the patient, making it suitable for monitoring and follow-up examinations.

Accessibility: Ultrasound machines are widely available in medical facilities, from large hospitals to smaller clinics, allowing for prompt and convenient access to imaging services.

Overall, the advantages of ultrasound make it an indispensable tool in modern medicine, facilitating early and accurate diagnoses, improving patient care, and contributing to better health outcomes.

Veterinary Ultrasound Market - Global Forecasts to 2027

Diagnostic Imaging Services Market - Global Forecasts to 2027
About MarketsandMarkets™:
Digital X-Ray Market - Global Forecasts to 2026

Minimally Invasive Surgical Instruments Market - Global Forecasts to 2026

Medical Equipment Maintenance Market - Global Forecasts to 2026

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Contact:
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/ultrasound-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/ultrasound-devices.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Ultrasound Market worth $11.6 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
PRNewswire/ -- In the near future, the ultrasound industry is poised for remarkable advancements, revolutionizing medical diagnostics and healthcare practices....

# data[].attributes.headline
Ultrasound Market worth $11.6 billion by 2028

# data[].attributes.subject
Ultrasound Market worth $11.6 billion by 2028

# data[].attributes.body
The report "Ultrasound Market by Technology (2D, 3D, Doppler, Contrast-Enhanced, HIFU, ESWL), Component (Workstation, Probe), Type (Cart, Handheld, PoC), Application (OB/GYN, CVD, Urology, Ortho), End-user (Hospitals, Clinics, ASCs) & Region - Global Forecast to 2028", is projected to reach USD 11.6 billion by 2028 from USD 8.5 billion in 2023, at a CAGR of 6.3% from 2023 to 2028. The major factors driving the growth of this market include rising patient population, various chronic diseases, and technological advancements along with the increasing adoption of ultrasound for diagnostic imaging.

# data[].attributes.attachment_link.readable_text
Market Size

The global ultrasound market is projected to reach USD 9.0 billion by 2026, at a CAGR of 6.3%.

Market Growth

Ongoing technological advancements in the field of diagnostic & therapeutic ultrasound imaging, availability of medical reimbursements for diagnostic ultrasound procedures in mature markets, and the growing applications of emerging ultrasound techniques (such as Doppler ultrasound in vascular imaging and 3D/4D ultrasound in oncology) are driving the growth of ultrasound market.

To know about the assumptions considered for the study, Request for Free Sample Report

Ultrasound Market Growth Dynamics

Driver: increasing prevalence of target diseases

The high and increasing incidence of target diseases and conditions will boost the adoption of effective diagnostic and therapeutic procedures. The burden of chronic and lifestyle diseases has increased in recent years. The burden of cancer, for example, was expected to increase from 14.1 million new cases in 2012 to 19.3 million new cases in 2020 (Source: GLOBOCAN, 2020).

As ultrasound technologies are cost-effective, safer, and offer earlier diagnosis & treatment of target diseases, their demand in disease management is expected to increase during the forecast period. Important statistics related to other major target diseases have been mentioned below:

According to the American Heart Association, by 2030, about 41.4% of US adults will have hypertension (an increase of 8.4% from 2012)

The burden of cancer, for example, is expected to increase from 14.1 million new cases to 18.1 million new cases during 2012– 2018 (Source: GLOBOCAN, 2018).

Globally, 415 million people had diabetes in 2015; by 2040, this figure will reach 642 million (Source: IDF Diabetes Atlas, 8th Edition). The number of diabetics in developing countries is expected to reach 228 million in 2025.

Restraint: Unfavorable healthcare reforms in the US

In August 2012, the US government planned to reduce Medicare spending by USD 716 billion over the next ten years (until 2022). Many industry participants expect that this health reform will negatively affect the cash flow for medical device companies operating in the US (including those involved in the manufacturing and marketing of ultrasound systems). This may limit the adoption of such devices in the US, as a number of healthcare facilities depend on government funds for purchasing high-end, highly expensive instruments.

Opportunity: Expanding applications of ultrasound

Minimally invasive therapies and image-guided procedures are increasingly being adopted by healthcare professionals and patients across the world. The ultrasound industry has witnessed a significant shift from being a conventional diagnostic modality for OB/GYN imaging to a therapeutic technique for renal stones, cancers, and other clinical conditions. It can be expected that such efforts will open up new avenues for revenue growth for manufacturers in this market.

Challenge: Growing end-user preference for refurbished equipment

Due to the high prices of novel ultrasound technologies (such as focused ultrasound) and budgetary constraints faced by small-sized healthcare providers, the preference for refurbished ultrasound equipment has grown. For instance, a typical 3D/4D ultrasound system costs USD 20,000–75,000 in North America, while a refurbished 3D/4D ultrasound system costs USD 5,000–40,000. The growing preference for refurbished systems is, therefore, expected to pose a significant challenge to market growth.

Ultrasound Market Ecosystem:

To know about the assumptions considered for the study, download the pdf brochure

By technology, the 2D ultrasound segment to account for the largest share of the ultrasound market in 2020

Based on technology, the ultrasound market is segmented into diagnostic ultrasound (2D, 3D & 4D, and Doppler ultrasound) and therapeutic ultrasound (focused ultrasound and shockwave lithotripsy). The diagnostic ultrasound segment is expected to account for the larger share of the ultrasound market in 2020. The large share of this segment can be attributed to the significant usage of 2D ultrasound in women's health, availability of medical reimbursements for diagnostic ultrasound procedures in mature markets, ongoing technological advancements in the field of diagnostic ultrasound imaging, and the growing applications of emerging ultrasound techniques.

Trolley/cart-based ultrasound systems segment to account for the largest share of the ultrasound market, by system portability, in 2020

On the basis of system portability, the ultrasound market is segmented into trolley/cart-based ultrasound systems, compact/handheld ultrasound systems, and point-of-care ultrasound systems. The trolley/cart-based ultrasound systems segment is expected to account for the largest share of the ultrasound market in 2020. The large share of this segment is attributed to the growing adoption of these systems across major markets due to their increased usage in acute care settings and emergency care in hospitals and healthcare institutions.

By application, radiology/general imaging to account for the largest share of the ultrasound market in 2020

On the basis of application, the ultrasound market is segmented into radiology/general imaging, obstetrics/gynecology, cardiologic applications, vascular applications, urological applications, orthopedic & musculoskeletal applications, pain management, and other applications. The radiology/general imaging applications segment is expected to command the largest share of the ultrasound market in 2020. Factors such as the rising incidence of various cancers across major countries, technological advancements in the field of ultrasound-based diagnosis and treatment, growing market availability and physician preference for HIFU in cancer treatment, increasing usage of ultrasound in cancer diagnosis and tissue biopsy, and the rising adoption of focused ultrasound in disease therapies are driving the growth of the radiology/general imaging segment.

Hospitals, surgical centers, and diagnostic centers to dominate the ultrasound market, by end user, in 2020; this trend to continue during the forecast period

Based on end user, the ultrasound market is segmented into hospitals, surgical centers, and diagnostic centers; maternity centers; ambulatory care centers; research and academia; and other end users. The hospitals, surgical centers, and diagnostic centers segment is expected to account for the largest share of the ultrasound market in 2020. The large share of this segment can be attributed to factors such as a significantnumber of ultrasound-based medical procedures performed in hospitals, coupled with the growing number of hospitals across major markets, and rising adoption of minimally invasive diagnostic & surgical procedures in these facilities.

Europe is expected to command the largest share of the ultrasound market in 2020

The report covers the ultrasound market across five major geographies, namely, Europe, North America, Asia Pacific, Latin America and MEA. Europe is expected to command the largest share of the ultrasound market in 2020. Factors such as a large number of ongoing clinical research projects in the field of ultrasound, expansions in the clinical applications of focused ultrasound and the early commercialization of these devices in the region, and the significant healthcare expenditure across mature European countries (such as Germany, France, the UK, Italy, and Spain) are driving the growth of the ultrasound market in Europe.

Key Market Players

The major players in the ultrasound market are GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Canon Medical Systems (Japan), Siemens AG (Germany), Hitachi (Japan), Samsung Electronics (South Korea), and FUJIFILM Holdings Corporation (Japan). The other prominent players operating in this market include Esaote S.p.A. (Italy), Mindray Medical International Ltd. (China), Analogic Corporation (US), Carestream (US), Hologic (US), Mobisnate (US), and Chison Medical Imaging (China).

GE Healthcare (a key business division of General Electric Company) is among the top players engaged in the development and manufacturing of diagnostic ultrasound systems. The company focuses on maintaining its leadership position in the ultrasound market through pipeline development and product commercialization. From 2018 to 2021, the ultrasound market witnessed the commercialization of key ultrasound products by GE Healthcare, including the Versana Premier ultrasound system, Invenia Automated Breast Ultrasound (ABUS) 2.0 system, and Versana Essential ultrasound.

Get online access to the report on the World's First Market Intelligence Cloud

Easy to Download Historical Data & Forecast Numbers

Company Analysis Dashboard for high growth potential opportunities

Research Analyst Access for customization & queries

Competitor Analysis with Interactive dashboard

Latest News, Updates & Trend analysis

Request Sample

Scope of the Report

Companies covered

GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Canon Medical Systems Corporation (Japan), Hitachi, Ltd. (Japan), Siemens Healthineers AG (Germany), Hologic, Inc. (US), FUJIFILM Holdings Corporation (Japan), Samsung Electronics Co., Ltd. (Korea), Mindray Medical International Limited (China), Analogic Corporation (US), Esaote S.p.A (Italy), Carestream Health (US), CURA Healthcare (India), Chison Medical Technologies Co., Ltd. (China), Mobisante, Inc. (US), Neusoft Corporation (China), Clarius Mobile Health (Canada), Medgyn Products, Inc. (US), and United Imaging Healthcare Co., Ltd. (China), among others

This report has segmented the global ultrasound market based on technology, device display, system portability, application, component, end user, and region.

Global Ultrasound Market, by Technology

Diagnostic Ultrasound

2D Ultrasound

3D & 4D Ultrasound

Doppler Ultrasound

Therapeutic Ultrasound

High-Intensity Focused Ultrasound (HIFU)

Extracorporeal Shockwave Lithotripsy (ESWL)

Global Ultrasound Market, by Device Display

Global Ultrasound Market, by Portability

Trolley/Cart-based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-care (PoC) Ultrasound Systems

Global Ultrasound Market, by Application

Radiology/General Imaging Applications

Obstetrics/Gynecology Applications

Cardiology Applications

Urology Applications

Vascular Applications

Orthopedic and Musculoskeletal Applications

Pain Management Applications

Other Applications (hepatology, neurology, bariatric surgery, breast imaging, and emergency care, among others)

Global Ultrasound Market, by Component

Transducers/ Probes

Curvilinear/ Convex Array Probes

Linear Array Probes

Phased Array Probes

Other Probes

Workstations

Other components

Global Ultrasound Market, by End User

Hospitals, Surgical Centers, and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Other End Users (physiotherapy clinics, independent associations, government organizations, and sports academies, among others)

Global Ultrasound Market, by Region

Recent Developments

In Sep 2021, GE Healthcare acquired BK Medical which extended GE Healthcare's ultrasound portfolio into surgical visualization and boosted its growth in precision health.

In Mar 2021, Koninklijke Philips N.V. partnered with DiA Imaging Analysis Ltd.; Philips will utilize/integrate DiA's automated solutions with ultrasound systems to deliver operational efficiency and access to care for POC customers in and out of hospitals.

In Dec 2020, Koninklijke Philips N.V. partnered with InSightec to expand access to MR-guided focused ultrasound for incision-less neurosurgery applications.

In Oct 2020, GE Healthcare partnered with St. Luke's University; GE has installed 76 ultrasound units to standardize the care in radiology, vascular, and echocardiography applications.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

# data[].attributes.attachment_link.title
Ultrasound Market Size, Growth, Drivers & Opportunities | MarketsandMarkets

# data[].attributes.attachment_link.description
The global ultrasound market is projected to reach USD 9.0 billion by 2026, at a CAGR of 6.3%. Ongoing technological advancements in the field of diagnostic & therapeutic ultrasound imaging, availability of medical reimbursements for diagnostic ultrasound procedures in mature markets, and the growing applications of emerging ultrasound techniques (such as Doppler ultrasound in vascular imaging and 3D/4D ultrasound in oncology) are driving the growth of ultrasound market.

# data[].attributes.headline
X-Ray Detectors Market worth $4.0 billion by 2027

# data[].attributes.subject
X-Ray Detectors Market worth $4.0 billion by 2027

# data[].attributes.body
The global X-ray detectors market in terms of revenue was estimated to be worth $3.1 billion in 2022 and is poised to reach $4.0 billion by 2027, growing at a CAGR of 5.2% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Due to increasing cardiac arrest in the US and all over the globe, the mortality rate has increased. The help of imaging systems and advancements in imaging products it is helping in cardiac imaging and the early detection of diseases. The developments are enhancing the diagnostic and prognostic skills of medical professionals, which are allowing them to better assist patients with tumors, orthopedic pains, veterinary doctors, and other healthcare providers.

# data[].attributes.attachment_link.readable_text
, /PRNewswire/ -- X-Ray Detectors Market size is projected to reach USD 4.0 billion by 2027 from USD 3.1 billion in 2022, at a CAGR of 5.2% according to a new report by MarketsandMarkets™. Increasing investments in advancing healthcare facilities & digital imaging technologies, growing demand for early diagnosis, and widening scope of clinical applications of X-ray detectors, rising chronic disorders which need quick examinations and increasing sedentary lifestyles are some of the key factors driving market growth.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=7004984 Browse in-depth TOC on "X-Ray Detectors Market" X-Ray Detectors Market Body Contouring segment to register significant growth rate over the forecast period of 2022-2027 Scope: Medical applications segment accounted for the largest share of the X-Ray detectors market by Applications in 2021
Based on the product type, the global X-Ray detector market is segmented into Flat Panel Detectors, Computed Radiography detectors, Line-Scan detectors, and Charged Coupled detectors. The flat-Panel detector segment is expected to register the highest growth rate over the forecast period. The computed Radiography segment accounts for the second share in the X-Ray detectors market.
The Asia Pacific market to register the highest growth in the market during the forecast period
The medical application segmented accounted for almost 70.1% of the total applications for X ray detectors. The vast share of this segment can be attributed to the factors like increasing disorders where screening is necessary before the diagnosis and increasing technological advancements in medical industry is also one of the reasons for the vast share.
Request Sample Pages: X-Ray Detectors Market Dynamics: Drivers: https://www.marketsandmarkets.com/requestsampleNew.asp?id=7004984
The Asia Pacific X-Ray detectors market is projected to register the highest growth during the forecast period of 2022 to 2027. Asia Pacific is registered to grow at the highest CAGR of 6.4%. Moreover, market players also focus on expanding their presence in the APAC healthcare imaging industry and are trying to establish new subsidiaries in the Asia Pacific region to attract huge market which will help them to increase their revenue.

1. Increasing demand for early diagnosis and widening scope of clinical applications of X-ray detectors

2. Investments to advance healthcare facilities and digital imaging technologies

3. Rising target patient population

4. Rising prevalence of animal diseases and growing number of veterinary practitioners

5. Growing demand for cosmetic dentistry
Restraints:
6. Increasing demand for X-ray-based security enhancement solutions at airports

7. Reimbursement cuts for analog X-rays
Opportunities:
1. High cost of X-ray detectors

2. Health hazards of full-body scanning
Challenges:
1. Rising healthcare expenditure across developing countries

2. Technological advancements

1. Lack of animal healthcare awareness in emerging countries
Key Market Players:
2. Increasing adoption of refurbished X-ray units
Recent Developments:
3. Hospital budget cuts
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=7004984 Related Reports:
The X-Ray detector market is moderately competitive, with both established companies and upcoming competitors for the same market share. As of 2021, the key player operating in the global X-Ray detector market are Varex Imaging Corporation (US), Canon Inc. (Japan), Agfa-Gevaert NV (Belgium), FUJIFILM Holdings Corporation (Japan)., Thales Group(France), Teledyne Technologies Incorporated (US), Carestream Health, Inc. (US), Konica Minolta, Inc. (Japan), Rayence (US), Vieworks Co., Ltd (South Korea), Hamamatsu Photonics KK (Japan), iRay Technology (China), CareRay Medical Systems Co. (China) and Analogic Corporation (US).

In November 2022, Varex Imaging Corporation launched the AZURE flat Panel detector in RSNA 2022. The product has faster integration with high speed and low noise for real-time image applications.

In March 2021, Thales Group launched Pixium 3040F, which has high image quality, optimized spatial resolution, higher contrast, and superior sensitivity at low doses when used in radiotherapy.

In March 2021, Canon Inc launched XCDI-RF wireless B1, wireless FPD in Japan for radiography and for fluoroscopy purposes.

Browse Adjacent Market: Medical Devices Market Research Reports & Consulting

Sterilization Services Market - Global Forecasts to 2027

Diagnostic Imaging Services Market - Global Forecasts to 2027
About MarketsandMarkets™:
Medical Power Supply Market - Global Forecasts to 2027

Teleradiology Market - Global Forecasts to 2026

Veterinary Imaging Market - Global Forecasts to 2026

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Contact:
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/x-ray-detectors-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/x-ray-detectors.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
X-Ray Detectors Market worth $4.0 billion by 2027 - Exclusive Report by MarketsandMarkets™

# data[].attributes.attachment_link.description
PRNewswire/ -- X-Ray Detectors Market size is projected to reach USD 4.0 billion by 2027 from USD 3.1 billion in 2022, at a CAGR of 5.2% according to a new...

# data[].attributes.headline
Global Viral Vector & Plasmid DNA Manufacturing Market worth $12.8 billion by 2028

# data[].attributes.subject
Global Viral Vector & Plasmid DNA Manufacturing Market worth $12.8 billion by 2028

# data[].attributes.body
The Global Viral Vector Manufacturing Market in terms of revenue was estimated to be worth $5.5 billion in 2023 and is poised to reach $12.8 billion by 2028, growing at a CAGR of 18.2% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of this market is majorly driven by g rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, and effectiveness of viral vectors in gene therapy delivery. On the other hand, high operational cost associated with cell & gene therapy manufacturing is restraining the growth of this market.

# data[].attributes.attachment_link.title
Viral Vector Manufacturing Market worth $12.8 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
/PRNewswire/ -- The viral vector manufacturing industry is poised for significant growth and innovation in the near future. As gene therapy and vaccine…

# data[].attributes.headline
Global Bone Cement & Glue Market worth $2,248 million by 2028

# data[].attributes.subject
Global Bone Cement & Glue Market worth $2,248 million by 2028

# data[].attributes.body
The Global Bone Cement & Glue Market is projected to reach USD 2,248 million by 2028 from USD 1,644 million in 2023, at a CAGR of 6.5% during the forecast period. The growth of this market is majorly driven by the Rising Demand for Minimally Invasive Surgeries with robotic assistance and Growing healthcare sector and Increasing Incidence of Orthopedic Conditions. However, Challenges associated with Variability of pathogen resistance may threat the growth of this market.

# data[].attributes.attachment_link.readable_text
1 Introduction (Page No. - 15)
1.1 Objectives of the Study
1.2 Definition
1.3 Market Scope
1.3.1 Markets Covered
1.4 Years Considered for the Study
1.5 Currency
1.6 Limitations
1.7 Stakeholders

2 Research Methodology (Page No. - 18)
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Breakdown of Primary Interviews
2.1.2.2 Key Data From Primary Sources
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Assumptions
3 Executive Summary (Page No. - 26)
4 Premium Insights (Page No. - 30)
4.1 Attractive Opportunities in Bone Cement Market
4.2 Asia Pacific: Market, By Application & Country
4.3 Global Market, By End User
4.4 Geographical Snapshot of the Global Market

5 Market Overview (Page No. - 34)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Incidence of Sports Injuries
5.2.1.2 Rapid Growth in Geriatric Population
5.2.1.3 Developments in the Field of Regenerative Medicine
5.2.1.4 Growing Number of Road Traffic Accidents
5.2.2 Restraints
5.2.2.1 Unfavorable Reimbursement Scenario
5.2.2.2 High Costs and Extensive Clinical Data Requirements for Launching New Bone Cements
5.2.3 Opportunities
5.2.3.1 Growth Opportunities in Emerging Economies
5.2.4 Challenges
5.2.4.1 Development of Novel Biomaterials With High Mechanical Properties and Adhesion Strength

6 Bone Cement Market, By Type (Page No. - 40)
6.1 Introduction
6.2 Bone Cement
6.2.1 Global Market, By Type
6.2.1.1 PMMA Cement
6.2.1.2 Calcium Phosphate Cement
6.2.1.3 Glass Polyalkenoate Cement
6.2.2 Global Market, By Loading
6.2.2.1 Non-Antibiotic-Loaded Bone Cement
6.2.2.2 Antibiotic-Loaded Bone Cement
6.3 Bone Glue
6.3.1 Bone Glue Market, By Type
6.3.1.1 Natural Bone Glue
6.3.1.2 Synthetic Bone Glue

7 Bone Cement Market, By Application (Page No. - 51)
7.1 Introduction
7.2 Arthroplasty
7.2.1 Total Knee Arthroplasty
7.2.2 Total Hip Arthroplasty
7.2.3 Total Shoulder Arthroplasty
7.3 Kyphoplasty
7.4 Vertebroplasty
7.5 Other Applications

8 Bone Glue Market, By End User (Page No. - 59)
8.1 Introduction
8.2 Hospitals
8.3 Ambulatory Surgery Centers
8.4 Clinics/Physician Offices

9 Global Bone Glue Market, By Region (Page No. - 64)
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.3 Europe
9.3.1 France
9.3.2 Germany
9.3.3 UK
9.3.4 Rest of Europe (RoE)
9.4 Asia Pacific
9.4.1 China
9.4.2 India
9.4.3 Japan
9.4.4 Rest of Asia Pacific (RoAPAC)
9.5 Rest of the World (RoW)

10 Global Bone Glue Market, Competitive Landscape (Page No. - 126)
10.1 Overview
10.2 Market Share Analysis, 2016
10.3 Competitive Scenario
10.3.1 Expansions
10.3.2 Acquisitions
10.3.3 Partnerships & Agreements
10.3.4 Product Launches

11 Global Bone Glue Market, Company Profiles (Page No. - 130)
(Business Overview, Products Offered, MnM View.)*
11.1 Stryker
11.2 Zimmer Biomet
11.3 Depuy Synthes (A Part of Johnson & Johnson)
11.4 Smith & Nephew
11.5 Arthrex
11.6 DJO Global
11.7 Exactech
11.8 Teknimed
11.9 Heraeus Medical
11.10 Cryolife
11.11 Cardinal Health
11.12 Trimph

*Business Overview, Products Offered, MnM View Might Not Be Captured in Case of Unlisted Companies.

12 Appendix (Page No. - 153)
12.1 Industry Insights
12.2 Discussion Guide
12.3 Knowledge Store: Marketsandmarkets' Subscription Portal
12.4 Introducing RT: Real-Time Market Intelligence
12.5 Available Customizations
12.6 Related Reports
12.7 Author Details

List of Tables (132 Tables)
List of Figures (37 Figures)
Table 1 Bone Cement Market Snapshot
Table 2 Geriatric Population, By Region, 2015 vs 2050 (Million)
Table 3 Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 4 Global Market, By Region, 2015–2022 (USD Million)
Table 5 Global Market, By Type, 2015–2022 (USD Million)
Table 6 PMMA Cement Market, By Region, 2015–2022 (USD Million)
Table 7 Calcium Phosphate Cement Market, By Region, 2015–2022 (USD Million)
Table 8 Glass Polyalkenoate Cement Market, By Region, 2015–2022 (USD Million)
Table 9 Global Market, By Loading, 2015–2022 (USD Million)
Table 10 Non-Antibiotic-Loaded Bone Cement Market, By Region, 2015–2022 (USD Million)
Table 11 Antibiotic-Loaded Bone Cement Market, By Region, 2015–2022 (USD Million)
Table 12 Bone Glue Market, By Region, 2015–2022 (USD Million)
Table 13 Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 14 Natural Bone Glue Market, By Region, 2015–2022 (USD Million)
Table 15 Synthetic Bone Glue Market, By Region, 2015–2022 (USD Million)
Table 16 Bone Glue Market, By Application, 2015–2022 (USD Million)
Table 17 Arthroplasty Bone Glue Market, By Region, 2015–2022 (USD Million)
Table 18 Arthroplasty Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 19 Total Knee Arthroplasty Bone Cement Market, By Region, 2015–2022 (USD Million)
Table 20 Total Hip Arthroplasty Bone Cement Market, By Region, 2015–2022 (USD Million)
Table 21 Total Shoulder Arthroplasty Bone Glue Market, By Region, 2015–2022 (USD Million)
Table 22 Kyphoplasty Bone Glue Market, By Region, 2015–2022 (USD Million)
Table 23 Vertebroplasty Bone Cement and Glue Market, By Region, 2015–2022 (USD Million)
Table 24 Other Applications Bone Cement and Glue Market, By Region, 2015–2022 (USD Million)
Table 25 Global Market, By End User, 2015–2022 (USD Million)
Table 26 Global Market for Hospitals, By Region, 2015–2022 (USD Million)
Table 27 Global Market for Ambulatory Surgery Centers, By Region, 2015–2022 (USD Million)
Table 28 Global Market for Clinics/Physician Offices, By Region, 2015–2022 (USD Million)
Table 29 Recent Expansion in APAC Countries By International Players
Table 30 Bone Cement & Glue Market, By Region, 2015–2022 (USD Million)
Table 31 North America: Bone Cement & Glue Market, By Country, 2015–2022 (USD Million)
Table 32 North America: Market, By Type, 2015–2022 (USD Million)
Table 33 North America: Market, By Type, 2015–2022 (USD Million)
Table 34 North America: Market, By Loading, 2015–2022 (USD Million)
Table 35 North America: Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 36 North America: Market, By Application, 2015–2022 (USD Million)
Table 37 North America: Arthroplasty Bone Cement & Glue Market, By Type, 2015–2022 (USD Million)
Table 38 North America: Bone Glue Market, By End User, 2015–2022 (USD Million)
Table 39 US: Bone Cement & Glue Market, By Type, 2015–2022 (USD Million)
Table 40 US: Market, By Type, 2015–2022 (USD Million)
Table 41 US: Market, By Loading, 2015–2022 (USD Million)
Table 42 US: Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 43 US: Bone Glue Market, By Application, 2015–2022 (USD Million)
Table 44 US: Arthroplasty Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 45 US: Bone Cement & Glue Market, By End User, 2015–2022 (USD Million)
Table 46 Canada: Bone Cement Market, By Type, 2015–2022 (USD Million)
Table 47 Canada: Market, By Type, 2015–2022 (USD Million)
Table 48 Canada: Market, By Loading, 2015–2022 (USD Million)
Table 49 Canada: Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 50 Canada: Bone Cement Market, By Application, 2015–2022 (USD Million)
Table 51 Canada: Arthroplasty Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 52 Canada: Market, By End User, 2015–2022 (USD Million)
Table 53 Europe: Bone Cement Market, By Country, 2015–2022 (USD Million)
Table 54 Europe: Market, By Type, 2015–2022 (USD Million)
Table 55 Europe: Market, By Type, 2015–2022 (USD Million)
Table 56 Europe: Market, By Loading, 2015–2022 (USD Million)
Table 57 Europe: Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 58 Europe: Market, By Application, 2015–2022 (USD Million)
Table 59 Europe: Arthroplasty Bone Cement Market, By Type, 2015–2022 (USD Million)
Table 60 Europe: Market, By End User, 2015–2022 (USD Million)
Table 61 France: Bone Cement Market, By Type, 2015–2022 (USD Million)
Table 62 France: Market, By Type, 2015–2022 (USD Million)
Table 63 France: Market, By Loading, 2015–2022 (USD Million)
Table 64 France: Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 65 France: Market, By Application, 2015–2022 (USD Million)
Table 66 France: Arthroplasty Bone Cement Market, By Type, 2015–2022 (USD Million)
Table 67 France: Market, By End User, 2015–2022 (USD Million)
Table 68 Germany: Bone Cement Market, By Type, 2015–2022 (USD Million)
Table 69 Germany: Market, By Type, 2015–2022 (USD Million)
Table 70 Germany: Market, By Loading, 2015–2022 (USD Million)
Table 71 Germany: Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 72 Germany: Market, By Application, 2015–2022 (USD Million)
Table 73 Germany: Arthroplasty Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 74 Germany: Market, By End User, 2015–2022 (USD Million)
Table 75 UK: Bone Cement Market, By Type, 2015–2022 (USD Million)
Table 76 UK: Market, By Type, 2015–2022 (USD Million)
Table 77 UK: Bone Cement Market, By Loading, 2015–2022 (USD Million)
Table 78 UK: Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 79 UK: Market, By Application, 2015–2022 (USD Million)
Table 80 UK: Arthroplasty Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 81 UK: Market, By End User, 2015–2022 (USD Million)
Table 82 RoE: Bone Cement Market, By Type, 2015–2022 (USD Million)
Table 83 RoE: Market, By Type, 2015–2022 (USD Million)
Table 84 RoE: Bone Cement Market, By Loading, 2015–2022 (USD Million)
Table 85 RoE: Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 86 RoE: Bone Glue Market, By Application, 2015–2022 (USD Million)
Table 87 RoE: Arthroplasty Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 88 RoE: Market, By End User, 2015–2022 (USD Million)
Table 89 Asia Pacific: Bone Cement Market, By Country/Region, 2015–2022 (USD Million)
Table 90 Asia Pacific: Market, By Type, 2015–2022 (USD Million)
Table 91 Asia Pacific: Market, By Type, 2015–2022 (USD Million)
Table 92 Asia Pacific: Bone Cement Market, By Loading, 2015–2022 (USD Million)
Table 93 Asia Pacific: Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 94 Asia Pacific: Bone Glue Market, By Application, 2015–2022 (USD Million)
Table 95 Asia Pacific: Arthroplasty Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 96 Asia Pacific: Market, By End User, 2015–2022 (USD Million)
Table 97 Incidence of Osteoporotic Fractures in China, 2015–2035
Table 98 China: Bone Cement Market, By Type, 2015–2022 (USD Million)
Table 99 China: Market, By Type, 2015–2022 (USD Million)
Table 100 China: Bone Cement Market, By Loading, 2015–2022 (USD Million)
Table 101 China: Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 102 China: Bone Cement Market, By Application, 2015–2022 (USD Million)
Table 103 China: Arthroplasty Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 104 China: Market, By End User, 2015–2022 (USD Million)
Table 105 India: Bone Cement Market, By Type, 2015–2022 (USD Million)
Table 106 India: Market, By Type, 2015–2022 (USD Million)
Table 107 India: Bone Cement Market, By Loading, 2015–2022 (USD Million)
Table 108 India: Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 109 India: Bone Glue Market, By Application, 2015–2022 (USD Million)
Table 110 India: Arthroplasty Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 111 India: Market, By End User, 2015–2022 (USD Million)
Table 112 Japan: Bone Cement Market, By Type, 2015–2022 (USD Million)
Table 113 Japan: Market, By Type, 2015–2022 (USD Million)
Table 114 Japan: Market, By Loading, 2015–2022 (USD Million)
Table 115 Japan: Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 116 Japan: Bone Cement & Glue Market, By Application, 2015–2022 (USD Million)
Table 117 Japan: Arthroplasty Bone Cement & Glue Market, By Type, 2015–2022 (USD Million)
Table 118 Japan: Market, By End User, 2015–2022 (USD Million)
Table 119 RoAPAC: Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 120 RoAPAC: Market, By Type, 2015–2022 (USD Million)
Table 121 RoAPAC: Market, By Loading, 2015–2022 (USD Million)
Table 122 RoAPAC: Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 123 RoAPAC: Bone Cement Market, By Application, 2015–2022 (USD Million)
Table 124 RoAPAC: Arthroplasty Bone Cement Market, By Type, 2015–2022 (USD Million)
Table 125 RoAPAC: Market, By End User, 2015–2022 (USD Million)
Table 126 RoW: Bone Cement Market, By Type, 2015–2022 (USD Million)
Table 127 RoW: Market, By Type, 2015–2022 (USD Million)
Table 128 RoW: Bone Cement Market, By Loading, 2015–2022 (USD Million)
Table 129 RoW: Bone Glue Market, By Type, 2015–2022 (USD Million)
Table 130 RoW: Market, By Application, 2015–2022 (USD Million)
Table 131 RoW: Arthroplasty Bone Cement & Glue Market, By Type, 2015–2022 (USD Million)
Table 132 RoW: Market, By End User, 2015–2022 (USD Million)

Figure 1 Research Design
Figure 2 Data Triangulation Methodology
Figure 3 Bone Cement and Glue Market, By Type, 2017 vs 2022 (USD Billion)
Figure 4 Bone Cement and Glue Market, By Application, 2017 vs 2022 (USD Billion)
Figure 5 Bone Cement and Glue Market, By End User, 2017 vs 2022 (USD Billion)
Figure 6 Bone Cement and Glue Market, By Region, 2017 vs 2022 (USD Billion)
Figure 7 Rapid Growth in Geriatric Population to Drive the Growth of the Bone Cement Market During the Forecast Period
Figure 8 Arthroplasty to Account for the Largest Market Share in 2017
Figure 9 Hospitals to Register the Highest CAGR During the Forecast Period
Figure 10 India to Register the Highest CAGR During the Forecast Period
Figure 11 Bone Cement and Glue Market: Drivers, Restraints, Opportunities, and Challenges
Figure 12 Bone Cement Segment to Dominate the Market During the Forecast Period
Figure 13 PMMA Cement Segment to Dominate the Market During the Forecast Period
Figure 14 Non-Antibiotic-Loaded Bone Cement Segment to Dominate the Market During the Forecast Period
Figure 15 Natural Bone Glue Segment to Dominate the Market During the Forecast Period
Figure 16 Arthroplasty Segment to Account for the Largest Share of the Market in 2017
Figure 17 Hospitals Segment to Dominate the Global Bone Cement and Glue Market in 2017
Figure 18 North America to Dominate the Global Market in 2017
Figure 19 North America: Market Snapshot
Figure 20 Bone Cement Segment to Dominate the North American Market in 2017
Figure 21 Europe: Market Snapshot
Figure 22 Arthroplasty Segment to Dominate the European Bone Cement Market in 2017
Figure 23 Asia Pacific: Market Snapshot
Figure 24 Hospitals Segment to Dominate the Asia Pacific Bone Glue Market in 2017
Figure 25 RoW: Market Snapshot
Figure 26 PMMA Cement Segment to Dominate the RoW Bone Cement Market in 2017
Figure 27 Key Development in Market, 2014 to 2017
Figure 28 Global Market Share Analysis - 2016
Figure 29 Stryker: Company Snapshot
Figure 30 Zimmer Biomet: Company Snapshot
Figure 31 Johnson & Johnson: Company Snapshot
Figure 32 Smith & Nephew: Company Snapshot
Figure 33 DJO Global: Company Snapshot
Figure 34 Exactech: Company Snapshot
Figure 35 Heraeus Holding: Company Snapshot
Figure 36 Cryolife: Company Snapshot
Figure 37 Cardinal Health: Company Snapshot

# data[].attributes.attachment_link.title
Bone Cement & Glue Market by Type, Application & End User - 2022 | MarketsandMarkets

# data[].attributes.attachment_link.description
1 Introduction (Page No. - 15) 1.1 Objectives of the Study 1.2 Definition 1.3 Market Scope 1.3.1 Markets Covered 1.4 Years Considered for the Study 1.5 Currency 1.6 Limitations 1.7 Stakeholders 2 Research Methodology (Page No.

# data[].attributes.headline
Global Healthcare Data Monetization Market Worth $0.9 Billion By 2028

# data[].attributes.subject
Global Healthcare Data Monetization Market Worth $0.9 Billion By 2028

# data[].attributes.body
The Global Healthcare Data Monetization Market in terms of revenue was estimated to be worth $0.4 billion in 2023 and is poised to reach $0.9 billion by 2028, growing at a CAGR of 18.5% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of EHR adoption primarily drives the market growth, the increase in use of external data sources, the need to curtail escalating healthcare costs, increasing partnerships and collaborations among players, and growing investments in advanced analytics. Additionally, factors such rising adoption of AI in precision medicine, and the explosion in bioinformatics data and large healthcare datasets are also contributing to the market growth.

# data[].attributes.attachment_link.readable_text
Healthcare Data Monetization Market in terms of revenue was estimated to be worth $0.4 billion in 2023 and is poised to reach $0.9 billion by 2028, growing at a CAGR of 18.5% from 2023 to 2028 according to a new report by MarketsandMarkets™

The healthcare data monetization industry is poised for significant growth in the near future. With the increasing digitalization of healthcare systems and the abundance of data being generated, healthcare organizations are recognizing the immense value of their data assets. In the coming years, we can expect to see a surge in initiatives focused on leveraging healthcare data for monetization purposes. This industry will witness the emergence of innovative data monetization platforms, advanced analytics tools, and secure data marketplaces.

Healthcare Data Monetization Market in terms of revenue was estimated to be worth $0.4 billion in 2023 and is poised to reach $0.9 billion by 2028, growing at a CAGR of 18.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as exponentially increasing data volume and generation of large and complex healthcare datasets, the need to curtail escalating healthcare costs, expanding partnerships and collaborations among players, and growing investments in the adoption of EHR systems primarily drive the growth of this market. Furthermore, the rising adoption of AI in precision medicine and the growing demand for real-world evidence (RWE) would provide lucrative opportunities to solution providers.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=56622234 Browse in-depth TOC on "Healthcare Data Monetization Market" 217 - Tables 60 - Figures 292 - Pages The cloud segment is expected to be the fastest-growing healthcare data monetization market, by deployment, during the forecast period.
Based on deployment, the market is segmented into on-premise and cloud. The cloud segment is expected to grow at a higher CAGR during the forecast period due to increased agility and scalability offered by cloud-based data monetization solutions. Cloud platforms provide secure and scalable storage solutions for vast amounts of healthcare data, including electronic health records, medical images, and patient-generated data. Furthermore, cloud-based analytics tools enable healthcare organizations to perform advanced data analysis, leveraging machine learning algorithms and artificial intelligence to gain valuable insights from complex datasets.
The pharmaceutical & biotechnology companies segment, by end-user, is expected to be the largest healthcare data monetization market in 2023
Based on the end user, the market is broadly segmented into pharmaceutical & biotechnology companies; healthcare payers; healthcare providers; medical technology companies; and other end users. Pharmaceutical & biotechnology companies would account for the largest share of the global end-user market in 2023. Market growth can be attributed to the rising demand for solutions to cut the time and costs of drug development. Pharmaceutical and biotechnology companies can benefit significantly from healthcare data monetization, as it can help them develop new drugs, identify potential markets, and improve patient outcomes.
Asia Pacific is expected to be the fastest-growing in healthcare data monetization market during the forecast period.
The global market has been segmented based on region: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Asia Pacific market is projected to register the highest CAGR during the forecast period. Emerging countries in the Asia Pacific, such as India and China, offer lucrative growth opportunities for market players, primarily due to the increasing adoption of digital healthcare technologies, increasing public and private funding, improving IT infrastructure, the demand for affordable healthcare, favorable government norms, growing awareness about precision medicine, and the high incidence of cancer and chronic diseases are expected to boost the adoption of healthcare data monetization solutions in Asia Pacific.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=56622234 Healthcare Data Monetization Market Dynamics: Drivers:

Increase in use of external data sources
Restraints:

Regulatory constraints to impact the growth of the market during the forecast period
Opportunities:

Rising Demand for Real-World Evidence
Challenges: Key Market Players:
Major players operating in the healthcare data monetization market are Oracle Corporation (US), Microsoft Corporation (US), Google (US), Salesforce, Inc. (US), SAS Institute Inc. (US), SAP SE (Germany), TIBCO Software Inc. (US), Sisense Inc. (US), Snowflake Inc. (US), QlikTech International AB (US), HealthVerity, Inc. (US), Accenture (Ireland), Availity, LLC (US), Domo, Inc. (US), Komodo Health, Inc. (US), ThoughtSpot Inc. (US), Datavant (US), Verato (US), Infor, Inc. (US), Virtusa (US), Infosys (India), Particle Health, Inc. (US), Innovaccer, Inc. (US), H1 (US), and Medoble Inc. (US).
Recent Developments:

In October 2022, Oracle Corporation introduced a planning solution for the healthcare industry as part of its Fusion Cloud Enterprise Performance Management (EPM) offering. The solution aims to help healthcare organizations improve financial performance and patient care by enabling them to model scenarios, optimize resources, and make better finance, workforce, and patient care decisions.

In April 2023, Microsoft Corporation and Epic Systems expanded their collaboration to integrate generative AI into healthcare by combining Azure OpenAI Service with Epic's electronic health record (EHR) software. The collaboration aimed to enhance patient care, increase productivity, and improve financial integrity in health systems globally.

In February 2023, Redox and Google Cloud partnered to simplify the exchange of healthcare data, enabling better and faster decision-making for healthcare organizations. Redox's platform would be replicated on Google Cloud, offering customers access to Redox's products and services.

In April 2023, Salesforce announced new Customer 360 for Health capabilities aimed at enhancing personalized patient experiences and reducing operational costs for healthcare providers. These innovations leverage real-time data, AI, and automation to address the challenges faced by healthcare organizations in meeting customer expectations.

In May 2023, HTEC Group joined the SAS IoT Partner Ecosystem to partner on delivering innovative solutions in industries such as healthcare, life sciences, logistics, and more. The partnership aimed to develop joint offerings that enable global enterprise companies to apply cutting-edge data-driven, IoT, edge, and cloud-enabled solutions to their business challenges.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=56622234
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/healthcare-data-monetization-market-56622234.html

# data[].attributes.attachment_link.title
Healthcare Data Monetization Market [2023-2028] Opportunities, Challenges, Trends with respect to Regions and Top Players

# data[].attributes.attachment_link.description
Healthcare Data Monetization Market in terms of revenue was estimated to be worth $0.4 billion in 2023 and is poised to reach $0.9 billion by 2028, growing at a CAGR of 18.5% from 2023 to 2028 according to a new report by MarketsandMarkets™ The healthcare data monetization industry is poised for significant growth in the near future.

# data[].attributes.headline
Global Lancets Market worth $3.6 billion by 2028

# data[].attributes.subject
Global Lancets Market worth $3.6 billion by 2028

# data[].attributes.body
Lancets Market in terms of revenue was estimated to be worth $2.3 billion in 2023 and is poised to reach $3.6 billion by 2028, growing at a CAGR of 9.7% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growth in the lancets market is mainly driven by the growing prevalence of diabetes, the high prevalence of chronic diseases, the rising geriatric population, and the increasing demand for painless lancets. In addition, emerging markets such as India and China are expected to offer growth opportunities for players operating in the Lancets market during the forecast period. However, the risk of lancet-related needlestick injuries, the reuse of lancets, and the poor reimbursement scenario in developing countries are restricting the growth of this market.

# data[].attributes.attachment_link.title
Lancets Market worth $3.6 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
The lancets industry is poised for significant growth and innovation in the near future. Lancets, which are small, pricking devices used for blood sampling, play a crucial role in various healthcare settings, including home-based testing, diagnostics, and monitoring of chronic conditions such as dia…

# data[].attributes.headline
Point of Care Diagnostics Market is Expected to Reach $75.5 billion | MarketsandMarkets.

# data[].attributes.subject
Point of Care Diagnostics Market is Expected to Reach $75.5 billion | MarketsandMarkets.

# data[].attributes.body
Point of Care Diagnostics market in terms of revenue was estimated to be worth $45.4 billion in 2022 and is poised to reach $75.5 billion by 2027, growing at a CAGR of 10.7% from 2022 to 2027 according to a latest report published by MarketsandMarkets™. Growth in this market is largely driven by factors such as the high prevalence of target conditions such as diabetes, cardiovascular diseases, and infectious diseases, and growing government policies, the shortage of skilled laboratory technicians, and the rising number of CLIA-waived POC tests.

# data[].attributes.attachment_link.title
Point of Care Diagnostics Market is Expected to Reach $75.5 billion | MarketsandMarkets.

# data[].attributes.attachment_link.description
The global point-of-care market is expected to reach $75.5 billion by 2027 from an estimated $45.4 billion in 2022, at a CAGR of 10.7% from 2022 to 2027.

# data[].attributes.headline
Cell Culture Media Market worth $13.0 billion by 2028

# data[].attributes.subject
Cell Culture Media Market worth $13.0 billion by 2028

# data[].attributes.body
The report "Cell Culture Media Market by Type(Serum-free (CHO, BHK, Vero Cell), Stem Cell, Chemically Defined, Classical, Specialty), Application(Biopharmaceutical (mAbs, Vaccine), Diagnostics, Tissue Engineering), End User(Pharma, Biotech) - Global Forecast to 2028", is projected to reach USD 13.0 billion by 2028 from USD 6.2 billion in 2023, at a CAGR of 16.0% during the forecast period. The growth of the market is majorly attributable to increased demand for biosimilars and mAbs globally, rising investment & funding for stem cell research, focus of key market players on launch of novel products in the market.

# data[].attributes.attachment_link.title
Cell Culture Media Market worth $10.3 billion by 2026 – Report by MarketsandMarkets™

# data[].attributes.attachment_link.description
The cell culture media industry is projected to grow from USD 4.9 billion in 2021 and to reach USD 10.3 billion by 2026, at a Compound Annual Growth Rate (CAGR) of 16.0% during the forecast period.

# data[].attributes.headline
Humanized Mouse and Rat Model Market worth $349 million | MarketsandMarkets

# data[].attributes.subject
Humanized Mouse and Rat Model Market worth $349 million | MarketsandMarkets

# data[].attributes.body
Humanized Mouse and Rat Model Market in terms of revenue was estimated to be worth $259 million in 2023 and is poised to reach $349 million by 2028, growing at a CAGR of 6.2% from 2023 to 2028 according to a new report by MarketsandMarkets™. Rising demand for personalized medicine is one of the prominent driving factor of the humanized mouse and rat model market. Existing mouse models have certain limitations in predictive research, unable to effectively gauge response in human cancer patients. Therefore, research institutes and academic institutes are focused on the development of advanced innovative models. Demand for personalized medicine is further driven by advancements in proteomics, genomics, and metabolomics. Additionally demand for targeted diagnostics and preventive medicine are propelling the demand for humanized mouse and rat research models.

# data[].attributes.attachment_link.readable_text
, July 21, 2023 /PRNewswire/ -- In the near future, the humanized mouse and rat model industry is set to undergo transformative advancements, revolutionizing biomedical research and drug development. These cutting-edge models, where mice and rats are genetically modified to possess human-like characteristics and immune systems, will play a pivotal role in bridging the gap between preclinical studies and clinical trials. Through refined genetic engineering techniques, these models will closely mimic human physiology, enabling more accurate and predictive assessments of drug safety, efficacy, and disease mechanisms. Moreover, the industry will witness the integration of advanced technologies, such as CRISPR/Cas9, to expedite the creation of customized humanized models, tailoring them to specific diseases or individual patient profiles. These advancements will spur collaboration between academia, pharmaceutical companies, and biotech firms, fostering a dynamic research ecosystem focused on targeted therapies and personalized medicine. Ultimately, the humanized mouse and rat model industry will emerge as a key driver in medical breakthroughs, enhancing our understanding of complex diseases and paving the way for transformative healthcare solutions.

Humanized Mouse and Rat Model Market in terms of revenue was estimated to be worth $259 million in 2023 and is poised to reach $349 million by 2028, growing at a CAGR of 6.2% from 2023 to 2028 according to a new report by MarketsandMarkets™. Rising demand for personalized medicine is one of the prominent driving factor of the humanized mouse and rat model market. Existing mouse models have certain limitations in predictive research, unable to effectively gauge response in human cancer patients. Therefore, research institutes and academic institutes are focused on the development of advanced innovative models. Demand for personalized medicine is further driven by advancements in proteomics, genomics, and metabolomics. Additionally demand for targeted diagnostics and preventive medicine are propelling the demand for humanized mouse and rat research models.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955 Browse in-depth TOC on "Humanized Mouse and Rat Model Market" Humanized Mouse and Rat Model Market The genetic models dominated the humanized mouse and rat model market in 2022. Scope: The oncology segment represented a dominant share in the market in 2022.
Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. The humanized mouse models segment is further divided into genetic humanized mouse models and cell-based humanized mouse models. The genetic models generated highest revenue in 2022. In genetic humanized mouse models, the human protein/domain is expressed while the mouse protein/domain is suppressed in all cells and tissues. Genetic humanized mouse models have been successfully adopted in analyzing biological efficacy, safety testing, pharmaceutical compounds, and studying novel therapeutics. Humanized mouse models are gaining demand in studies around drug metabolism and immune system development & functioning.
The Asia Pacific region is the fastest-growing region of the humanized mouse and rat model market throughout the forecast period.
Based on application, the humanized mouse and rat model market is segmented into toxicology, oncology, immunology and infectious diseases, hematopoiesis, neuroscience, and other applications. Humanized models mimic human cancers and act as essential platforms for cancer research. Cancer research involves studying cancer biology and understanding or predicting cancer, including tumor characterization, tumorigenesis, and metastasis. The growth of this segment can be attributed to the growing number of cancer research programs in academic & research institutes and favorable support by governments for cancer research.
Request Sample Pages: Humanized Mouse and Rat Model Market Drivers: Dynamics: Restraints: https://www.marketsandmarkets.com/requestsampleNew.asp?id=131763955 Opportunities:
Based on the region, the humanized mouse and rat model market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is estimated to register the highest growth during the forecast period. Increase in demand for market products across China and India is the key contributive factor. Led by growing R&D activities, the outsourcing of preclinical, clinical, and laboratory testing services for small & large molecules is expected to increase in the country. The growing pharmaceutical industry, the rising number of CROs, and rising research activities will drive the growth of China's humanized mouse and rat model market.
Challenges:

1. Increasing research activities using humanized models

2. Rising demand for personalized medicine

3. Continuous support and initiatives from government and private sectors for cancer research

4. Growing R&D activities in pharmaceutical and biotechnology sectors

Key Market Players:

1. High cost of custom humanized models

2. Laws and regulations for ethical use of animal models in research

Recent Developments:

1. Rising demand for humanized PDX models

2. Emergence of CRISPR as a powerful tool in biomedical research

3. Rising demand for humanized rat models

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=131763955

1. Alternatives for animal testing

2. Limitations of humanized mouse models

The prominent players in the global humanized mouse and rat model market include Charles River Laboratories (US), THE JACKSON LABORATORY (JAX) (US), Taconic Biosciences, Inc. (US), Crown Biosciences (US), Champions Oncology, Inc. (US), Hera BioLabs (US), genOway (France), Inotiv (US), Vitalstar Biotechnology (China), Ingenious Targeting Laboratory (US), TRANS GENIC (Japan), Harbour Antibodies BV (Netherlands), Oncodesign (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure services (France), Cyagen Biosciences (US), Aragen Life Sciences Ltd. (India), GemPharmatech (China), and Biocytogen (US).

In January 2022, Taconic Biosciences, Inc. (US) launched the huNOG-EXL EA (early access) humanized immune system (HIS) mouse.

In October 2021, The Jackson Laboratory (US) acquired RMS Business of Charles River Laboratories Japan, Inc. (Japan) which is Charles River Laboratories Japan's Research Models & Services (RMS) business as a wholly-owned subsidiary.

In September 2021, Biocytogen (US) collaborated with Envigo (US) in order to support the research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the US, Europe, and certain APAC regions.

In March 2021, Charles River Laboratories International, Inc. (US) acquired Cognate BioServices, Inc. (US) a cell and gene therapy contract development and manufacturing organization (CDMO) offering comprehensive manufacturing solutions for cell therapies. The acquisition expanded Charles River's broad capabilities across the major CDMO platforms for cell and gene therapies.

Related Reports:
Humanized Mouse and Rat Model Market Advantages:

Predictive Validity: Humanized models closely mimic human physiology, genetics, and immune responses, providing a more accurate representation of human disease progression and treatment outcomes. This predictive validity enhances the reliability of preclinical data and improves the likelihood of successful translation to clinical trials.

Reduced Ethical Concerns: Using humanized models reduces the need for animal testing on non-human species, addressing ethical concerns and promoting more humane research practices.

Personalized Medicine: These models can be customized to replicate specific patient profiles or disease conditions, enabling personalized medicine approaches for tailored treatment strategies.

Drug Efficacy and Safety Screening: Humanized models allow for rigorous assessment of drug efficacy and safety before progressing to human clinical trials, reducing the risk of adverse effects and optimizing the drug development process.

Understanding Disease Mechanisms: By closely resembling human biology, these models offer valuable insights into disease mechanisms and underlying molecular pathways, advancing our understanding of complex diseases.

Rapid and Cost-Effective Research: Humanized models can accelerate research timelines by providing faster results compared to traditional animal models. This efficiency reduces overall research costs and expedites the discovery of novel therapies.

Translatability to Humans: The ability of humanized models to recapitulate human responses enhances the likelihood of successful translation of research findings to human patients, fostering more effective treatments.

Targeted Therapies: Humanized models facilitate the evaluation of targeted therapies by replicating the specific molecular targets present in human diseases, aiding in the development of precision medicine approaches.

Infectious Disease Research: Humanized models are particularly valuable in studying infectious diseases, allowing researchers to study pathogen-host interactions and test potential vaccines and antiviral treatments.

Academic and Industry Collaboration: The widespread adoption of humanized models fosters collaboration between academic institutions, pharmaceutical companies, and biotech firms, encouraging a dynamic exchange of knowledge and resources to advance medical research collectively.

Overall, the humanized mouse and rat model market represents a pivotal advancement in the biomedical field, enabling researchers to overcome the limitations of traditional models and paving the way for more effective and personalized medical interventions in the future.

Mice Model Market - Global Forecasts to 2028

Life Science Instrumentation Market - Global Forecasts to 2028
About MarketsandMarkets™:
CRO Services Market - Global Forecasts to 2028

Clinical Trial Supplies Market - Global Forecasts to 2027

Patient Derived Xenograft/PDX Model Market - Global Forecasts to 2026

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/humanized-mouse-model-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/humanized-mouse-model.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Humanized Mouse and Rat Model Market worth $349 million | MarketsandMarkets

# data[].attributes.attachment_link.description
PRNewswire/ -- In the near future, the humanized mouse and rat model industry is set to undergo transformative advancements, revolutionizing biomedical...

# data[].attributes.headline
Global Intraoral/IOL Scanners Market worth $1.0 billion by 2028

# data[].attributes.subject
Global Intraoral/IOL Scanners Market worth $1.0 billion by 2028

# data[].attributes.body
The Global Intraoral Scanner Market in terms of revenue was estimated to be worth $0.6 billion in 2023 and is poised to reach $1.0 billion by 2028, growing at a CAGR of 11.0% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The incidence of dental problems such as dental caries, increase in awareness of oral health and hygiene, increase in the demand for clear aligners, increase in demand for same-day dentistry, technological advancements in intraoral scanners, and the growing market for dental tourism in developing countries are major key drivers for the market. However, the high cost of intraoral scanner systems and the high cost of dental procedures are the factors that impede market growth.

# data[].attributes.attachment_link.readable_text
, July 17, 2023 /PRNewswire/ -- The intraoral/intraoral scanners industry is poised for significant growth and advancements in the near future. With the increasing demand for digital dentistry and the growing adoption of intraoral scanning technology, this industry is set to revolutionize the way dental professionals capture and analyze oral structures. Intraoral scanners offer numerous advantages over traditional dental impressions, including faster and more accurate data acquisition, improved patient comfort, and enhanced workflow efficiency. With ongoing research and development, the near future holds the promise of even more compact, user-friendly, and technologically advanced intraoral scanners. These advancements are expected to expand the applications of intraoral scanning, ranging from restorative dentistry and orthodontics to implant planning and digital smile design. Furthermore, the integration of artificial intelligence and cloud-based platforms will enable seamless data management, analysis, and collaboration among dental teams. With its potential to enhance patient care, improve treatment outcomes, and streamline dental workflows, the intraoral/intraoral scanners industry is set to play a pivotal role in the future of digital dentistry.

Intraoral/IOL Scanners Market in terms of revenue was estimated to be worth $0.6 billion in 2023 and is poised to reach $1.0 billion by 2028, growing at a CAGR of 11.0% from 2023 to 2028 according to a new report by MarketsandMarkets™. Developing countries such as China, India, Mexico, Brazil, New Zealand, the Middle East, and other APAC and Latin American countries present a lucrative opportunity for players in the market. This is mostly due to their expanding middle-class population, increasing disposable incomes, and the rising demand for dental tourism.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=15959266 Browse in-depth TOC on "Intraoral/IOL Scanners Market"
Intraoral/IOL Scanners Market"During the forecast period, the wired scanner is expected to be the fastest growing segment of the intraoral scanner market." Scope: "In 2022, by end-user, dental hospitals clinics segment held the largest share of intraoral scanner market." 150 - Figures
"During the forecast period, Asia Pacific is expected to be the fastest growing region in the intraoral scanner market. " 300 - Pages Request Sample Pages: Intraoral/IOL Scanners Market Drivers: Dynamics: Restraints: https://www.marketsandmarkets.com/requestsampleNew.asp?id=15959266 Opportunities:
Under modality, the wired scanner is forecasted to grow at the highest CAGR from 2023 to 2028. The primary drivers of this market are the introduction of new technologies, which provide advantages for patients in terms of low operating costs and less time consumption. As the majority of wired scanners operate through plug-and-play technology, there is no depletion of the battery as the scanner uses the power from the computer or a laptop. These scanners provide detailed and accurate 3D impressions for better diagnosis and treatment plans.
Challenges:
By end user, the intraoral scanner market can be segmented into dental hospitals and clinics segment, dental research and academic institutes, and other end users. Due to the large adoption of the intraoral scanner market at dental hospitals and clinics, this segment occupied the largest share of the market in 2022. Additionally, there has been an increase in rise in demand for clear aligners and dental tourism, which has contributed to the growth of the market.
Key Market Players:
The intraoral scanner is segmented into five major regions, namely, North America, Europe, Asia Pacific (APAC), Latin America, and the Middle East and Africa. Asia Pacific is expected to be the fastest-growing region in the intraoral scanner market during the forecast period. Growth in the Asia Pacific intraoral scanner market is driven by the growing geriatric population, growing dental tourism in major Asian markets such as India, and factors such as the increasing number of dental professionals, the rising incidence of dental diseases, and the growing number of tooth repair procedures.
Recent Developments:

Technological advancements in intraoral scanners
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=15959266 Intraoral/IOL Scanners Market Advantages:

High cost of intraoral scanners and dental procedures
Related Reports:

Potential for growth in emerging countries

Dearth of trained dental practitioners

The key players in the intraoral scanner market include DENTSPLY SIRONA Inc (US), 3Shape (US), Envista Holdings Corporation (US), Medit Corp. (South Korea), and Align Technology Inc. (US).

In September 2022, DENTSPLY SIRONA Inc. launched a new laptop version of the prime scan intraoral scanner. It provides easy scanning of the intraoral cavity.

In September 2022, one of the market leaders, 3Shape, introduced TRIOS 5 Wireless, a completely new, state-of-the-art intraoral scanner designed to make it easier than ever for dentists to go digital with their dentistry.

In July 2021, DENTSPLY SIRONA Inc. (US) partnered with 3 Shape (Denmark) To provide better access for TRIOS users to SureSmile Clear aligners.

Accurate Digital Impressions: Intraoral/intraoral scanners provide precise and detailed digital impressions of oral structures, eliminating the need for messy and uncomfortable traditional dental impressions. This improves the accuracy of treatment planning and enables better-fitting restorations and prosthetics.

Enhanced Patient Comfort: Compared to traditional dental impressions, intraoral scanners offer a more comfortable experience for patients. They eliminate the need for uncomfortable trays and materials, reducing patient anxiety and improving overall satisfaction.

Time Efficiency: Intraoral scanners enable faster data acquisition and processing, resulting in streamlined workflows and reduced chairside time. Dentists can quickly capture digital impressions and immediately view and analyze them on a computer screen, expediting the treatment planning process.

Improved Treatment Outcomes: The high accuracy of intraoral scanners leads to improved treatment outcomes. Precise digital impressions allow for better-fitting restorations, crowns, bridges, and orthodontic appliances, reducing the need for adjustments or remakes and enhancing patient satisfaction.

Integration with CAD/CAM Systems: Intraoral scanners seamlessly integrate with computer-aided design and computer-aided manufacturing (CAD/CAM) systems. The digital impressions can be directly used to design and fabricate dental restorations, prosthetics, and appliances, resulting in efficient and precise manufacturing processes.

Technological Advancements: The intraoral/intraoral scanners market is driven by continuous technological advancements. Compact, user-friendly, and technologically advanced scanners are being developed, incorporating features such as artificial intelligence and machine learning algorithms to further improve accuracy, automate processes, and enhance diagnostic capabilities.

Enhanced Communication and Collaboration: Digital impressions captured by intraoral scanners can be easily shared with dental laboratories and other dental professionals, facilitating real-time communication and collaboration. This leads to improved coordination, faster turnaround times, and better overall treatment outcomes.

Cost-effectiveness: Intraoral scanners can contribute to cost savings in the long run. They reduce the need for traditional impression materials and shipping costs associated with physical impressions, while also minimizing the chances of remakes or adjustments.

About MarketsandMarkets™:
Dental 3D Printing Market - Global Forecasts to 2028

Dental Consumables Market - Global Forecasts to 2027

Dental Equipment Market - Global Forecasts to 2027

Orthodontic Supplies Market - Global Forecasts to 2027

Restorative Dentistry Market - Global Forecasts to 2027

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/intraoral-scanner-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/intraoral-scanner.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Intraoral/IOL Scanners Market worth $1.0 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
PRNewswire/ -- The intraoral/intraoral scanners industry is poised for significant growth and advancements in the near future. With the increasing demand for...

# data[].attributes.headline
Global Orthopedic Braces and Supports Market Size Worth USD 4.6 billion by 2027

# data[].attributes.subject
Global Orthopedic Braces and Supports Market Size Worth USD 4.6 billion by 2027

# data[].attributes.body
The Global Orthopedic Braces and Supports Market is estimated to reach USD 4.6 billion by 2027 from USD 3.4 billion in 2022, at a CAGR of 5.8% during the forecast period (2022-2027). Growth in the orthopedic braces and supports market is mainly driven by the increasing prevalence of orthopedic diseases & disorders, continuous product commercialization, greater product affordability and market availability, rising number of sports and accident-related injuries, and growing public awareness of preventive care.

# data[].attributes.attachment_link.title
Orthopedic Braces and Supports Market sales, global manufacturers, analysis and forecast 2027

# data[].attributes.attachment_link.description
The leading position of DJO LLC can be attributed to the extensive product portfolio of orthopedic braces and supports, and wide geographic presence.

# data[].attributes.headline
Laboratory Information Management System (LIMS) Market worth $3.3 billion by 2028

# data[].attributes.subject
Laboratory Information Management System (LIMS) Market worth $3.3 billion by 2028

# data[].attributes.body
The Global Laboratory Information Management Systems Market is projected to reach USD 3.3 billion by 2028 from USD 1.6 billion in 2023, at a CAGR of 14.6% during the forecast period. The significant growth potential in emerging markets such as China, India, Japan, Singapore, Brazil, and Middle Eastern countries, growing popularity of cloud-based LIMS pertaining to large volumes of data generated in laboratories & reduced total cost of ownership of laboratory informatics solutions are some of the critical factors offering opportunities to the market.

# data[].attributes.attachment_link.title
Laboratory Information Management System (LIMS) Market worth $3.3 billion by 2028 - MarketsandMarkets Blog

# data[].attributes.attachment_link.description
The Global Laboratory Information Management Systems Market is projected to reach USD 3.3 billion by 2028 from USD 1.6 billion in 2023, at a CAGR of 14.6% during the forecast period.

# data[].attributes.headline
The Booming Biobanking Market: Trends and Insights

# data[].attributes.subject
The Booming Biobanking Market: Trends and Insights

# data[].attributes.body
Based on sample type, the global biobanking market has been segmented into blood products, human tissues, nucleic acids, human waste products, cell lines, and biological fluids. The blood products segment held the largest share of the global biobanking market in 2022. This can be attributed to the rising incidence of blood disorders and the increasing demand for various types of blood products across the globe. With the ongoing expansion of biobanks and the increasing emphasis on precision medicine, the demand for blood products in biobanking is expected to remain strong, further propelling the growth of the global biobanking market

# data[].attributes.attachment_link.readable_text
Biobanking Market worth $5.0 billion | MarketsandMarkets

Biobanking Market in terms of revenue was estimated to be worth $2.9 billion in 2023 and is poised to reach $5.0 billion by 2028, growing at a CAGR of 11.4% from 2023 to 2028 according to a new report by MarketsandMarkets™. The global biobanking market is expected to grow at a CAGR of 11.4% during the forecast period. The growth of this market is driven by increasing number of private cord blood banks has led to a rise in competition among biobanks, which has driven innovation and improvements in the quality of biobanking services. This, in turn, has fueled growth in the biobanking market as more companies seek to enter this expanding field and meet the growing demand for cord blood stem cell preservation.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=594&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Browse in-depth TOC on "Biobanking Market"

380 - Tables
46 - Figures
324 - Pages

The blood products segment accounted for the largest share, by sample type in the biobanking market in 2022.

Based on sample type, the global biobanking market has been segmented into blood products, human tissues, nucleic acids, human waste products, cell lines, and biological fluids. The blood products segment held the largest share of the global biobanking market in 2022. This can be attributed to the rising incidence of blood disorders and the increasing demand for various types of blood products across the globe. With the ongoing expansion of biobanks and the increasing emphasis on precision medicine, the demand for blood products in biobanking is expected to remain strong, further propelling the growth of the global biobanking market

The manual storage segment accounted for the largest share of the storage type segment in the biobanking market in 2022.

Based on storage, the global biobanking market has been segmented into manual storage and automated storage. The manual storage segment held the larger market share in 2022. The large share of this segment can be attributed to the low cost and easy installation associated with this type of storage. Furthermore, many research centers and life science companies rely on manual processes for biological sample storage, this is further accelerating the market growth.

The North America region catered the largest share of the biobanking market in 2022.

The biobanking market in North America has experienced significant growth in recent years, showcasing a robust expansion trajectory. This can be attributed to the increasing number of biobanks and the growing investments in biobanking infrastructure. Major healthcare institutes and research organizations in North America have made substantial commitments to expanding their biobanking capabilities. Additionally, the rising prevalence of chronic diseases and the subsequent demand for personalized medicine has fueled the growth of the biobanking market in North America, with biobanks playing a pivotal role in storing and providing high-quality biological specimens for research and development purposes.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=594&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Biobanking Market Dynamics:

Drivers:

Growing investments and funding for biobanks
Focus on genetic testing and precision medicine
Increasing trend in preservation of cord blood stem cells from newborns
Favorable funding scenario for research related to regenerative medicine

Restraints:

High cost of automated equipment
Issues related to biospecimen sample management

Opportunities:

Emerging countries to provide lucrative opportunities

Challenges:

High operational cost of biobanks
Storage of samples

Key Market Players:

Key players in the biobanking market include Thermo Fisher Scientific, Inc. (US), PHC Holdings Corporation (Japan), Becton, Dickinson and Company (US), QIAGEN N.V. (Germany), Merck KGaA (Germany), Avantor, Inc. (US), Cryoport, Inc. (US), Tecan Trading AG (Switzerland), Azenta, Inc. (US), Greiner Holding AG (Austria), Hamilton Company (US), Micronic (Netherlands), AMSBIO (UK), Bay Biosciences LLC (US), BioKryo (Germany), SPT Labtech (UK), ASKION GmbH (Germany), Cell&Co BioServices (France), Ziath Ltd. (UK), CTIBiotech (France), Cureline (US), Firalis Group (France), Sopachem (Netherlands), ProteoGenex (US), and US Biolab Corporation, Inc. (US).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=594&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Recent Developments:

In February 2023, PHC Corporation of North America launched the PHCbi Brand VIP ECO SMART Ultra-low Temperature Freezer with industry-leading energy efficiency.

In September 2022, Cryoport entered into a strategic partnership with BioLife Plasma Services to offer supply chain solutions and service offerings, such as bioservices and cryo-processing, for BioLife Plasma Services.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/biobanking-devices-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/biobanking-devices.asp

About MarketsandMarkets™:

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
This release was published on openPR.

# data[].attributes.attachment_link.title
Biobanking Market worth $5.0 billion | Thermo Fisher Scientific, Inc. (US), PHC Holdings Corporation (Japan), Becton, Dickinson and Company (US), QIAGEN N.V. (Germany), Merck KGaA (Germany)

# data[].attributes.attachment_link.description
Biobanking Market in terms of revenue was estimated to be worth 2 9 billion in 2023 and is poised to reach 5 0 billion by 2028 growing at a CAGR of 11 4 from 2023 to 2028 according to a ...

# data[].attributes.headline
Innovations in Creatinine Measurement Technology: A Market Overview

# data[].attributes.subject
Innovations in Creatinine Measurement Technology: A Market Overview

# data[].attributes.body
The report "Creatinine Measurement Market by Product (Kits, Reagents), Test Type (Jaffe method, Enzymatic creatinine method), Sample (Serum Creatinine, Urine) and End User (Hospitals, Diagnostic Laboratories), Region (North America, Europe) - Global Forecast to 2023", is expected to reach USD 700.8 million by 2027 from USD 377.2 million in 2018, at a CAGR of 8.4%.

# data[].attributes.attachment_link.title
Creatinine Measurement Market Revenue Forecast | Latest Industry Updates | MarketsandMarkets

# data[].attributes.attachment_link.description
The global creatinine measurement market is projected to reach USD 564.5 Million by 2023, at a CAGR of 8.4%. Report provides crucial industry insights that will help your business grow.

# data[].attributes.headline
Understanding the Applications of Lateral Flow Assays in Healthcare

# data[].attributes.subject
Understanding the Applications of Lateral Flow Assays in Healthcare

# data[].attributes.body
The Global Lateral Flow Assays Market in terms of revenue was estimated to be worth $20.5 billion in 2022 and is poised to reach $22.6 billion by 2027, growing at a CAGR of 2.0% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Increasing adoption of kits & reagents and lateral flow assay readers for infectious diseases testing, veterinary diagnostics, and drug of abuse testing, cardiac marker testing. Whereas most of lateral flow assays are having limitation of qualitative detection, lot to lot variation like factors may hinder the growth of global market during the forecast period.

# data[].attributes.attachment_link.title
Lateral Flow Assays Market worth $22.6 billion | MarketsandMarkets | ABNewswire

# data[].attributes.headline
Laboratory Information Management System (LIMS) Market worth $3.3 billion by 2028

# data[].attributes.subject
Laboratory Information Management System (LIMS) Market worth $3.3 billion by 2028

# data[].attributes.body
The Global Laboratory Information Management Systems Market is projected to reach USD 3.3 billion by 2028 from USD 1.6 billion in 2023, at a CAGR of 14.6% during the forecast period. The significant growth potential in emerging markets such as China, India, Japan, Singapore, Brazil, and Middle Eastern countries, growing popularity of cloud-based LIMS pertaining to large volumes of data generated in laboratories & reduced total cost of ownership of laboratory informatics solutions are some of the critical factors offering opportunities to the market.

# data[].attributes.attachment_link.readable_text
, July 10, 2023 /PRNewswire/ -- The laboratory information system (LIS) industry is set to witness significant growth and transformation in the near future. With the increasing demand for integrated and streamlined healthcare solutions, LIS is expected to play a vital role in optimizing laboratory operations, enhancing data management, and improving patient care. Advancements in technology, such as cloud computing, interoperability, and data analytics, will revolutionize the LIS landscape, enabling seamless integration with electronic health records (EHRs), telemedicine platforms, and other healthcare systems. This integration will facilitate efficient data exchange, enhance communication between healthcare professionals, and support evidence-based decision-making. Furthermore, the emergence of artificial intelligence and machine learning algorithms will enable automated data interpretation, quality control, and predictive analytics, leading to improved diagnostic accuracy, faster turnaround times, and enhanced patient outcomes. The LIS industry will also witness increased emphasis on cybersecurity and data privacy to safeguard patient information. Overall, the future of the LIS industry holds tremendous potential to revolutionize laboratory workflows, enhance healthcare delivery, and drive innovation in diagnostic medicine.

Laboratory Information System (LIS) Market in terms of revenue was estimated to be worth $2.4 billion in 2023 and is poised to reach $4.0 billion by 2028, growing at a CAGR of 10.8% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as the need for laboratory automation, the development of integrated LIS, and growing investments in the adoption of EHR systems and subsequent integration with LIS primarily drive the growth of this market. Furthermore, the rising emergence of AI and advanced analytics, growing demand for LIS in biobanks and biorepositories, and rising demand for personalized medicine would provide lucrative opportunities to solution providers. AI-powered algorithms can automate routine tasks in the laboratory, such as sample handling, data entry, and result validation. AI can analyze images from laboratory tests, such as histopathology slides or radiology scans, to aid in the diagnosis and detection of abnormalities. Machine learning algorithms can learn from large datasets and provide accurate interpretations, assisting pathologists and radiologists in their evaluations. This reduces manual errors, improves turnaround times, and frees up laboratory staff for more complex tasks.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=232312738 Browse in-depth TOC on "Laboratory Information System (LIS) Market"
Laboratory Information System (LIS) Market The integrated LIS segment is expected to be the fastest-growing laboratory information systems market, by product, during the forecast period. Scope: The hospital laboratories segment, by end-user, is expected to be the largest laboratory information systems market in 2023 262 - Pages Asia Pacific is expected to be the fastest-growing laboratory information systems market during the forecast period.
Based on product, the laboratory information systems market is segmented into standalone LIS and integrated LIS. The integrated LIS segment is expected to grow at a higher CAGR during the forecast period. Integrated LISs allow seamless data sharing & interoperability across various healthcare settings and departments, enabling efficient communication among different stakeholders, such as laboratories, hospitals, clinics, and other healthcare providers. These systems facilitate the exchange of critical patient information, test results, and clinical data, leading to improved patient care coordination and continuity. The growth of the integrated LIS segment can be attributed to the advantages offered by these systems, such as enhanced data sharing & interoperability and robust analytics & reporting capabilities.
Request Sample Pages: Laboratory Information System (LIS) Market Drivers: Dynamics: Restraints: https://www.marketsandmarkets.com/requestsampleNew.asp?id=232312738 Opportunities:
Hospital laboratories would account for the largest share of the global end-user market in 2023. LIS solutions integrate various laboratory processes, including sample management, test ordering, result reporting, and data analysis. This integration reduces manual errors, enhances workflow efficiency, and promotes standardized practices. LIS solutions also provide a centralized platform for storing and managing patient and laboratory data. This enables healthcare professionals to access comprehensive patient information, track results, and analyze trends, leading to informed decision-making and improved patient care.
Challenges:
The global market has been divided into regions including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific market is anticipated to exhibit the highest CAGR throughout the forecast period. Emerging economies in the Asia Pacific region, such as India and China, present lucrative growth opportunities for market participants. Factors contributing to this growth include the increasing adoption of digital healthcare technologies, improving IT infrastructure, the demand for affordable healthcare, favorable government norms, rising number of chronic diseases, rising standards and quality of hospital care and clinical testing, and the high incidence of cancer and chronic diseases are expected to boost the adoption of laboratory information systems solutions in Asia Pacific.
Key Market Players:

Development of integrated LIS
Recent Developments:

Lack of integration standards for LIS
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=232312738 Laboratory Information System (LIS) Market Advantages:

Rising demand for personalized medicine

Requirement of specialized LIS solutions
High-Throughput Screening Market - Report Highlights:
Major players operating in the laboratory information systems market are Orchard Software Corporation (US), Clinisys (US), Oracle Corporation (US), Computer Programs and Systems, Inc. (US), CompuGroup Medical (Germany), Soft Computer Consultants, Inc. (US), American Soft. Solutions Corp. (US), Epic Systems Corporation (US), Altera Digital Health (US), Aspyra (US), Comp Pro Med Inc. (US), Computer Service & Support, Inc. (US), Clinical Software Solutions (US), GPI S.p.A. (Italy), LigoLab Information Systems (US), LabWare (US), LabVantage Solutions, Inc. (US), XiFin, Inc. (US), Seacoast Laboratory Data Systems (US), Veradigm LLC (US), WebPathLab (US), Apex Healthware (US), TECHNIDATA (France), Pathagility (US), HEX Laboratory Systems (US), Clinsis (Nicaragua), Alphasoft (Germany), and Dendi, Inc. (US).
Related Reports:

In May 2023, Clinisys acquired Promium, a provider of laboratory information management systems for environmental and analytical testing laboratories. This acquisition strengthens Clinisys' position in public health and toxicology diagnostics and supports its global expansion.

In January 2023, Orchard Software Corporation announced the release of its new Enterprise Toxicology solution, which aimed to enhance patient care in toxicology laboratories by providing information system tools. The solution offers features such as an integrated workflow engine, plate mapping tools for patient safety, medication consistency interpretation, and customizable report formats.

In November 2022, Oracle Cerner and LabCorp formed a new collaboration to streamline lab operations for a leading nonprofit Catholic health system. Labcorp would manage hospital-based laboratories in 10 states using Cerner's laboratory information system (LIS), aiming to enhance patient care and improve lab efficiency.

In November 2022, CompuGroup Medical (CGM) announced two add-on acquisitions in the areas of data solutions and US laboratory information systems. The acquisition of Medicus LIS strengthens CGM's position as a software leader in the independent US laboratory segment, while the acquisition of GHG business operations complements CGM's portfolio of data-based solutions for the healthcare sector.

In August 2022, Sparta Community Hospital, a critical access hospital in Sparta, Illinois, provided healthcare services to previously underserved areas through their Mobile Health Clinic. The hospital partnered with the Grand American World Trapshooting Championships to offer healthcare services. They leveraged the Evident EHR solution offered by Computer Programs and Systems, Inc. to provide primary care during the event. Sparta Community Hospital runs the full Evident EHR in its inpatient and clinic care settings.

Streamlined Workflow and Efficiency: LIS improves laboratory workflow by automating processes such as sample tracking, result entry, and report generation. It streamlines communication between laboratory departments, reducing manual errors and ensuring efficient operations. This leads to increased productivity, faster turnaround times, and enhanced overall efficiency.

Enhanced Data Management: LIS enables centralized and organized management of laboratory data. It provides a secure repository for storing and accessing patient information, test results, and other relevant data. This facilitates easy retrieval, data sharing, and analysis, leading to improved decision-making, research, and quality control.

Integration with Healthcare Systems: LIS integrates with other healthcare systems, such as electronic health records (EHRs), picture archiving and communication systems (PACS), and billing systems. This integration enables seamless data exchange and communication between different departments and healthcare professionals. It ensures a holistic view of patient information, promotes interdisciplinary collaboration, and improves continuity of care.

Quality Assurance and Regulatory Compliance: LIS incorporates quality control measures, ensuring adherence to regulatory standards and accreditation requirements. It facilitates standardization of laboratory procedures, tracks quality indicators, and provides comprehensive audit trails. These features enhance quality assurance, minimize errors, and support compliance with regulatory guidelines.

Data Analytics and Decision Support: LIS leverages data analytics capabilities to provide valuable insights for clinical decision-making and process optimization. It enables trend analysis, performance monitoring, and identification of potential bottlenecks. With the integration of artificial intelligence and machine learning algorithms, LIS can offer predictive analytics, aiding in early detection of diseases and treatment planning.

Cost Efficiency and Resource Optimization: LIS optimizes resource utilization by automating manual tasks, reducing paper-based processes, and minimizing duplication of efforts. It helps in inventory management, reducing wastage and unnecessary expenditures. Additionally, LIS aids in optimizing laboratory staffing, ensuring appropriate allocation of resources based on workload and priorities.

Improved Patient Care and Safety: LIS enhances patient care and safety by reducing errors, improving result accuracy, and facilitating timely access to critical information. It enables real-time alerts for abnormal results, enhances specimen traceability, and ensures proper patient identification. These features contribute to improved diagnostic accuracy, patient management, and patient outcomes.

Scalability and Adaptability: LIS systems are designed to accommodate the evolving needs of laboratories and healthcare organizations. They can scale up to handle increasing volumes of data and accommodate new tests and technologies. Additionally, LIS systems are adaptable to various laboratory settings, including clinical laboratories, research institutions, and reference laboratories.

In summary, the LIS market offers advantages such as streamlined workflow, enhanced data management, integration with healthcare systems, quality assurance, data analytics and decision support, cost efficiency, improved patient care and safety, and scalability. These advantages contribute to the growing importance of LIS in modern healthcare settings and highlight its potential to optimize laboratory operations, improve patient outcomes, and drive efficiency in healthcare delivery.

Market Overview: This edition includes updated market dynamics and market ecosystems specific to the laboratory information systems market.

Industry Trends: This new edition includes an updated market map, value chain analysis, revenue shift analysis, case studies, technology analysis, market ecosystem, regulatory landscape, Porter's Five Forces analysis, and trends/disruptions impacting customers' businesses that are specific to the laboratory information systems market.

Company Profiles: In this edition, 28 players have been profiled, and the product portfolios of the key players have been updated. It also includes updated financial information from 2020 to 2022/2021 (wherever available).

Recent Developments: Recent developments help understand the market trends and growth strategies adopted by the key players. For instance, in this market, product launches and enhancements increased during 2021-2023. Therefore, updated information for the mentioned period is provided.

Latest Product Portfolio: Tracking the products offered by the companies helps in improved analysis of the market segmentation. This edition provides updated product portfolios of the companies profiled.

Lab Automation Market - Global Forecasts to 2028
About MarketsandMarkets™:
Laboratory Information Management System Market - Global Forecasts to 2028

Laboratory Informatics Market - Global Forecasts to 2026

Laboratory Centrifuge Market - Global Forecasts to 2026

Medical Equipment Maintenance Market - Global Forecasts to 2026

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/laboratory-information-system-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/laboratory-information-system.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Laboratory Information System (LIS) Market worth $4.0 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
PRNewswire/ -- The laboratory information system (LIS) industry is set to witness significant growth and transformation in the near future. With the...

# data[].attributes.headline
Collagen and Gelatin Market worth $1.6 billion by 2028

# data[].attributes.subject
Collagen and Gelatin Market worth $1.6 billion by 2028

# data[].attributes.body
The Global Collagen and Gelatin Market size is projected to reach USD 1.6 billion by 2028 from USD 1.2 billion in 2023, at a CAGR of 6.5% during the forecast period. The rising incidence of chronic diseases, increasing demand for collagen and gelatin due to increased demand for wound care products, and strong emphasis on the launch of novel products by key market players are driving the market growth.

# data[].attributes.attachment_link.provider_name
MarketsandMarkets Blog - Market Research Insights

# data[].attributes.attachment_link.readable_text
The Global Collagen and Gelatin Market size is projected to reach USD 1.6 billion by 2028 from USD 1.2 billion in 2023, at a CAGR of 6.5% during the forecast period. The rising incidence of chronic diseases, increasing demand for collagen and gelatin due to increased demand for wound care products, and strong emphasis on the launch of novel products by key market players are driving the market growth.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=95663122 Global Collagen and Gelatin Market Dynamics DRIVER: Growing incidence of Chronic wounds, diabetes, and cancer
The prevalence of diabetes makes it a significant target indication due to its association with complex wound complications, including infections, ulcerations (such as leg or foot ulcers), and surgical wounds. Treating these complications incurs high medical expenses. In the US, approximately 25% of individuals with diabetes develop foot ulcers at some point in their lives, and around 15% of the diabetic population experiences diabetic foot ulcers (DFUs). As the prevalence of DFUs continues to rise, there is an increasing demand for regenerative medicine products such as grafts and matrices.
RESTRAINT: Availability of alternative biomaterials
The global market growth may be hindered due to the presence of substitute biomaterials that offer efficient and reliable healing, repair, and regeneration of damaged or diseased tissue and organs. Various biomaterials, including chitosan, alginate, cellulose, hyaluronic acid, polylactic acid (PLA), poly(lactic-co-glycolic acid) (PLGA), are being utilized as alternatives to collagen and gelatin in the field of regenerative medicine. The availability of these substitutes has the potential to impede the progress of the market on a global scale.
OPPORTUNITY: Implementation of the 21st Century Cures Act
In December 2016, The 21st Century Cures Act was signed into law in the US. The Act is intended to help accelerate medical product development and bring innovations and advances to patients who need them faster and more efficiently. Under this Act, a new Regenerative Medicine Advanced Therapy designation is been instituted, along with a fast-track approvals for novel regenerative medicine products. The implementation of the 21st Century Cures Act is likely to potentially result in the approval of new regenerative medicine products in the US and promote research and development in the field of regenerative medicine.
CHALLENGES: Insufficient processing technologies
The process of extracting and processing collagen and gelatin proteins is highly advanced and requires sophisticated technology. Once the edible collagen is extracted from porcine, bovine, or fish skins, it undergoes filtration and ion exchange. The filtration process utilizes microfiltration technology, allowing the fluid to pass through a porous membrane. Heat sterilization is then applied, requiring high-temperature heat treatment, followed by drying the product through spray drying technology. Unfortunately, these technologies are not widely developed in many regions, particularly in developing countries such as India, China, and the Rest of Asia Pacific. Consequently, collagen peptides and gelatin production are limited to certain countries, such as the US, the UK, and Germany. Developing countries with high demand for protein-based ingredients are at a disadvantage due to the lack of advanced technologies for manufacturing and marketing these products.
Request 10% Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=95663122 North America held a dominant share in the regional market for the collagen and gelatin market in 2022.
Geographically, the collagen and gelatin markets are segmented into North America, Europe, Asia Pacific, Rest of the World. In 2022, North America accounted for the largest share of the collagen and gelatin market, followed by Europe & Asia Pacific. The dominance of the region is attributable to various factors, such as the presence of top market players in the region, the presence of top medical facilities leading to the adoption of technologically advanced wound care products, and the increased number of surgeries in the region.
Key Market Players
Key players in the Collagen and Gelatin market include Integra LifeSciences (US), DSM (Netherlands), CollPlant Biotechnologies Ltd. (Israel), Nitta Gelatin Inc. (Japan), Collagen Solutions PLC (UK), and others.
Collagen and Gelatin Market, by Source Collagen Market, by Application Gelatin Market, by Application Collagen & Gelatin Market, by End User Recent Developments

In January 2023, TELA Bio, Inc. launched NIVIS Fibrillar Collagen Pack. NIVIS Fibrillar Collagen Pack is an absorbent matrix of Type I and Type III bovine collagen proposed to manage moderately to heavily exudating wounds and to control minor bleeding.

In October 2022, Collagen Matrix acquired Polyganics B.V. expanded its portfolio of bioresorbable solutions and technology platforms for bone and tissue repair.

In January 2021, Integra LifeSciences acquired ACell. This acquisition enabled the company to provide more comprehensive complex wound management solutions.

Report Link: ( Collagen and Gelatin Market )

# data[].attributes.attachment_link.title
Collagen and Gelatin Market worth $1.6 billion by 2028 - MarketsandMarkets Blog

# data[].attributes.attachment_link.description
The Global Collagen and Gelatin Market size is projected to reach USD 1.6 billion by 2028 from USD 1.2 billion in 2023, at a CAGR of 6.5% during the forecast period.

# data[].attributes.headline
How Single-cell Analysis is Revolutionizing Drug Discovery and Development

# data[].attributes.subject
How Single-cell Analysis is Revolutionizing Drug Discovery and Development

# data[].attributes.body
According to the new market research report "Asia Pacific Single-cell Analysis Market by Cell Type (Human, Animal, Microbial), Product (Reagent, Assays, Instruments), Technique (Flow Cytometry, NGS, PCR), Application (Cancer, Stemcell, IVF), End User (Academic, Research Labs) - Forecast to 2025", published by MarketsandMarkets™, the market is projected to reach USD 1,375 million by 2025 from USD 550 million in 2020, at a 20.1% CAGR.

Browse in-depth TOC on "Asia Pacific Single-cell Analysis Industry"

110 – Tables

43 – Figures

212 – Pages

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=257201069

The rising incidence of infectious diseases, increasing pandemics frequency, increasing R&D in the pharmaceutical and biotechnology industries for complex diseases, growth in stem cell research, and the rising prevalence of cancer are the major factors driving the growth of single-cell analysis market. However, the high cost of single-cell analysis products is a major factor hampering the growth of the Asia Pacific single-cell analysis market. Emerging economies such as Japan and China are providing lucrative opportunities for the players operating in the market.

The consumables segment accounted for the largest share of the market, by product segment, in 2019

Based on product, the APAC single-cell analysis market is segmented into consumables and instruments. The consumables segment accounted for the largest shareof the market in 2019. The frequent purchase of these products as compared to instruments, which are considered as a one-time investment, and their wide applications in research and genetic exploration, exosome analysis, and isolation of RNA and DNA are the major factors driving this segments growth.

Animal cells segment to register the highest growth rate during the forecast period

The APAC single-cell analysis market is segmented into human cells, animal cells, and microbial cells based on cell type. In 2019, the animal cells segment accounted for the highest growth rate. This can be attributed to the growth in the pharmaceutical industry and rising investments in animal cell research.

The academic & research laboratories segment accounted for the largest share of the Asia Pacific single-cell analysis market, by end-user segment, in 2019

Based on end-user, the APAC single-cell analysis market is segmented into academic & research laboratories, biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and cell banks & IVF centers. In 2019, the academic & research laboratories segment accounted for the largest share of the market. The increasing funding for life science research, increasing number of medical colleges and universities, and the increasing number of collaborations among research institutes and life science research companies are the major factors driving the growth of this end-user segment.

Request Free Sample Pages:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=257201069

Japan dominated the single-cell analysis market in Asia Pacific region

The Asia Pacific single-cell analysis market is segmented into Japan, China, India, South Korea, Singapore, Australia, Southeast Asia, and the Rest of Asia Pacific. In 2019, Japan accounted for the largest share of the Asia Pacific single-cell analysis market. This can be attributed to the rising geriatric population, increasing government initiatives to promote life science research, increasing investments in biotech R&D, and the growing focus on personalized medicine.

The major players operating in this APAC single-cell analysis market are Becton, Dickinson and Company (US), Danaher Corporation (US), Merck Millipore (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (US), General Electric Company (US), Promega Corporation (US), Illumina, Inc. (US), Bio-Rad Laboratories (US), Fluidigm Corporation (US), Agilent Technologies, Inc. (US), Tecan Group Ltd. (Switzerland), Sartorius AG (Germany), Luminex Corporation (US), Takara Bio (Japan), 10x Genomics (US), Fluxion Biosciences (US), Menarini Silicon Biosystems, Inc. (Italy), bioMérieux SA (France), Oxford Nanopore Technologies (UK), Cytek Biosciences (US), Corning Incorporated (US),  Apogee Flow Systems Ltd. (UK), NanoCellect Biomedical (US), and On-chip Biotechnologies Co., Ltd. (Japan).

Market Growth Drivers

·         Rising prevalence of cancer

·         Increasing R&D in the pharmaceutical and biotechnology industries for complex diseases

·         Growth in stem cell research

·         Growing focus on personalized medicine

Market Opportunities

·         High growth potential of single-cell sequencing

·         interaction and regulations of gene regulatory networks

Get 10% Free Customization on this Report:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=257201069

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: 1-888-600-6441

Email: sales@marketsandmarkets.com

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/asia-pacific-single-cell-analysis-market.asp

Visit Our Web Site: https://www.marketsandmarkets.com

Content Source:  https://www.marketsandmarkets.com/PressReleases/asia-pacific-single-cell-analysis.asp

https://www.prnewswire.com/news-releases/asia-pacific-single-cell-analysis-market-worth-1-375-million-by-2025--exclusive-report-by-marketsandmarkets-301209148.html

# data[].attributes.attachment_link.readable_text
[212 Pages Report] The Asia Pacific single-cell analysis market is projected to reach USD 1,375 million by 2025 from USD 550 million in 2020, at a CAGR of 20.1%. Asia Pacific single-cell analysis market growth is driven by the growing focus on personalized medicine, increasing R&D in the pharmaceutical and biotechnology industries for complex diseases, growth in stem cell research, and the increasing frequency of pandemics.

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on Asia Pacific Single-cell Analysis Market

The Asia Pacific region, the first area affected by the outbreak of COVID-19 (SARS-CoV-2), witnessed unprecedented disruptions that impacted the entire healthcare industry. COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a matter of a few weeks. With the World Health Organization (WHO) officially declaring the outbreak of COVID-19 a pandemic, a mix of established pharmaceutical and biopharmaceutical companies, as well as small startups, have stepped forward to develop treatments and vaccines that target the infection caused by the novel coronavirus.

According to the WHO, at present, there are currently more than 100 COVID-19 vaccine candidates under development, with a number of these in the human trial phase. The economic and social burden of the pandemic has prompted government bodies globally to increase support for vaccine development, which has led to an increase in the adoption of single-cell analysis products for COVID-19 research. There is an urgent need to better understand the host immune response during disease to better devise prognostic and diagnostic markers and to design appropriate therapeutic interventions for patients with severe disease presentation. Single-cell analysis can provide more information to understand immune cells on a single-cell basis and how the functional cells play a role in immune protection and pathogenesis, resulting in the development of better vaccines and immunotherapies.

Market Dynamics

Driver: Increasing R&D in the pharmaceutical and biotechnology industries for complex diseases

Pharmaceutical and biotechnology companies are major end users in the Asia Pacific single-cell analysis market. Single-cell analysis is carried out in the research and production of all biopharmaceutical products. Growth in the pharmaceutical and biotechnology sector across the Asia Pacific region serves as a direct driver for associated markets such as single-cell analysis.

Pharmaceutical and biotechnology companies utilize single-cell analysis products to achieve their clinical research goals. Biopharmaceutical companies focus on developing targeted therapies, especially for the treatment of cancer, complex diseases, and rare genetic disorders. As companies are focusing on developing targeted therapies, the need for single-cell analysis products has become imperative for determining the genetic profile of patients enrolled in clinical trials. Similarly, pharmaceutical companies are utilizing single-cell analysis instruments such as NGS technologies for biomarker research, which is a segment that has the potential to grow at a high CAGR in the coming years.

Opportunity: High growth potential of single-cell sequencing

Single-cell sequencing (SCS) helps understand the transcriptional stochasticity and cellular heterogeneity in more detail. It assists in the investigation of small groups of differentiating cells and circulating tumor cells. It also demonstrates the heterogeneity of gene expressions, interaction and regulations of gene regulatory networks, characteristics of putative cancer stem cells, gene expression profiles of intracellular compartments, mRNA locations, and allele-specific gene expression. Advancements in single-cell sequencing have improved the detection and analysis of infectious disease outbreaks, antibiotic drug-resistant strains, food-borne pathogens, and microbial diversities in the environment.

Trend: Integration of microfluidics in single-cell analysis

Currently, the isolation and analysis of circulating tumor cells (CTCs) and cells that are present in low quantities in the body is a major challenge faced by researchers and clinicians. Advances in microfluidics technology have provided robust solutions for the isolation and analysis of single cells. Moreover, microfluidic chips are easy to use and provide reliable and efficient isolation of single cells from a small sample volume.

Microfluidics has various advantages in single-cell analysis, including reduced reagent consumption, increased throughput, and ease of efficient automation. Citing the potential of this technology in single-cell analysis, various research studies are being performed for evaluating the performance of microfluidic chips in analyzing other types of cells.

The top players—Merck Millipore (US), Danaher Corporation (US), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (US), and Thermo Fisher Scientific, Inc. (US)—in the Asia Pacific single-cell analysis market accounted for a combined majority market share in 2019. There is a high degree of competition among the market players. Only major companies can afford high-capital investments as well as the high cost of R&D and manufacturing. Moreover, this will prevent new entrants from entering this market. Furthermore, the top players in this market are large and well-established and enjoy a high degree of brand loyalty.

In 2019, consumables segment accounted for the largest share of the Asia Pacific single-cell analysis market, by product"

Based on product, the Asia Pacific single-cell analysis market is segmented into consumables and instruments. The consumables segment includes beads, microplates, reagents, assay kits, and other consumables. The instruments segment includes flow cytometers, NGS systems, PCR instruments, spectrophotometers, microscopes, cell counters, HCS systems, microarrays, and other instruments. The consumables segment accounted for the largest market share in 2019. This segment is also expected to register the highest CAGR during the forecast period. The large share and high growth of this segment can primarily be attributed to the frequent purchase of these products as compared to instruments, which are considered as a one-time investment, and their wide applications in research and exosome analysis.

In 2019, human cells segment accounted for the largest share in the market, by cell type"

The Asia Pacific single-cell analysis market is segmented into human cells, animal cells, and microbial cells based on cell type. The human cells segment accounted for the largest market share in 2019, owing to the high adoption of human cells to develop novel cancer therapies.

Japan is the largest market for single-cell analysis"

The Asia Pacific single-cell analysis market is segmented into Japan, China, India, South Korea, Singapore, Australia, Southeast Asia, and the Rest of Asia Pacific. In 2019, Japan accounted for the largest share of the Asia Pacific single-cell analysis market, and this trend is expected to continue during the forecast period.

In terms of market share, China closely followed Japan in 2019. However, in the next five years, the share of Japan is expected to increase in the APAC single-cell analysis market as it is estimated to witness higher CAGR than China. This can be attributed to the large geriatric population, increasing life science research activities, and growing focus on personalized medicine in Japan.

Some key players in the Asia Pacific single-cell analysis market (2020- 2025)

Get online access to the report on the World's First Market Intelligence Cloud

Easy to Download Historical Data & Forecast Numbers

Company Analysis Dashboard for high growth potential opportunities

Research Analyst Access for customization & queries

Competitor Analysis with Interactive dashboard

Latest News, Updates & Trend analysis

Request Sample

Scope of the Report

This report categorizes the Asia Pacific single-cell analysis market into the following segments and subsegments:

By Product

Consumables

Beads

Microplates

Reagents

Assay Kits

Immunoassays

Cell-based Assays

Other Consumables

Instruments

Flow Cytometers

NGS Systems

PCR Instruments

Spectrophotometers

Microscopes

Cell Counters

HCS Systems

Microarrays

Other Instruments

By Cell Type

By Technique

By Application

Research Applications

Cancer

Immunology

Neurology

Stem Cell

Other Research Applications

Medical Applications

Noninvasive Prenatal Diagnosis

In Vitro Fertilization

Circulating Tumor Cell Detection

By End User

Academic & Research Laboratories

Biotechnology & Pharmaceutical Companies

Hospitals & Diagnostic Laboratories

Cell Banks & IVF Centers

By Country

Recent Developments

In September 2020, Lonza (Switzerland) launched Promega Corporation (US) launched the Spectrum Compact CE System.

In March 2020, Fluidigm Corporation (US) opened a new Center of Excellence (CoE) for Imaging Mass Cytometry (IMC) in Singapore, together with the Singapore Immunology Network (SIgN), part of the Agency for Science, Technology and Research.

In January 2020, Takara Bio (Japan) opened the Center for Gene and Cell Processing II for the research and manufacturing of regenerative medicine products in Kusatsu.

Frequently Asked Questions (FAQ):

What are the recent trends affecting the Asia Pacific single-cell analysis market?

Recent trends affecting the APAC single-cell analysis market are the COVID-19 outbreak, increasing focus on vaccine development, and rapid growth in the biotechnology and biopharmaceutical industries.

What are the different cell types used for single-cell analysis?

Based on cell type, the APAC single-cell analysis market is segmented into human cells, animal cells, and microbial cells. The human cells segment accounted for the largest share of the APAC single-cell analysis market in 2019. The large share of this segment can be attributed to the high utilization of human cells in research laboratories and academic institutes.

Who are the key players in the Asia Pacific single-cell analysis market?

The key players in this market are: Becton, Dickinson and Company (US), Danaher Corporation (US), Merck Millipore (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (US), General Electric Company (US), Promega Corporation (US), Illumina, Inc. (US), Bio-Rad Laboratories (US), Fluidigm Corporation (US), Agilent Technologies, Inc. (US), Tecan Group Ltd. (Switzerland), Sartorius AG (Germany), Luminex Corporation (US), Takara Bio (Japan), 10x Genomics (US), Fluxion Biosciences (US), Menarini Silicon Biosystems, Inc. (Italy), bioMérieux SA (France), Oxford Nanopore Technologies (UK), Cytek Biosciences (US), Corning Incorporated (US), Apogee Flow Systems Ltd. (UK), NanoCellect Biomedical (US), and On-chip Biotechnologies Co., Ltd. (Japan).

Who are the key end-users of the Asia Pacific single-cell analysis market?

Based on end user, the APAC single-cell analysis market is segmented into academic & research laboratories, biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and cell banks & IVF centers. The academic & research laboratories segment accounted for the largest share of the APAC single-cell analysis market in 2019. The large share of this segment is primarily attributed to the growing funding for life science research and the increasing number of medical colleges and universities.

Which country is lucrative for the Asia Pacific single-cell analysis market?

Japan, China, and India, the emerging economies in the Asia Pacific region will be the lucrative markets for single-cell analysis products. .

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

# data[].attributes.attachment_link.keywords[]
asia pacific single-cell analysis market

# data[].attributes.attachment_link.title
Asia Pacific Single-cell Analysis Market | By Cell Type, Technique, Application | Global Forecast to 2025 | MarketsandMarkets™

# data[].attributes.attachment_link.description
The asia pacific single-cell analysis market is projected to reach $1,375 million by 2025. APAC single-cell analysis market report provides crucial industry insights that will help your business grow.

# data[].attributes.headline
Understanding the Growing Collagen and Gelatin Market: Key Trends and Insights

# data[].attributes.subject
Understanding the Growing Collagen and Gelatin Market: Key Trends and Insights

# data[].attributes.body
The global collagen and gelatin market size is projected to reach USD 1.6 billion by 2028 from USD 1.2 billion in 2023, at a CAGR of 6.5% during the forecast period. The rising incidence of chronic diseases, increasing demand for collagen and gelatin due to increased demand for wound care products, and strong emphasis on the launch of novel products by key market players are driving the market growth.

# data[].attributes.attachment_link.readable_text
The global collagen and gelatin market size is projected to reach USD 1,083 million by 2026, at a CAGR of 7.0%. Major factors attributing to the growth of the market are rising burdern of cancer, diabetes and chronic wounds, especially among geriatric population along with rising number of surgical procedures.

To know about the assumptions considered for the study, Request for Free Sample Report

Collagen And Gelatin Market Dynamics

Drivers: Growing incidence of diabetes, cancer, and chronic wounds

In case of diabetes patients, there is high risk of infections, surgical wounds, leg or foot ulcers. This in trun is reponsble for the increase in medical expenses. According to the National Centre for Biological Information, in the US, around 15 to 25% of patients with diabetes mellitus are likely develop a diabetic foot ulcer (DFU) during their lifetime. The prevalence of DFU is expected to increase among these patient, which, in turn, is driving the demand for grafts and matrices. Hence, increase in number of diabetic population is expected to fuel the growth of the market during the forecasted period.

Restraints: Availability of alternative biomaterials

In recent years, a numer of alternatives to collagen & gelatin such as chitosan, alginate, cellulose, hyaluronic acid, polylactic acid (PLA), polyglycolic acid (PGA), and poly(lactic-co-glycolic acid) (PLGA) are being used in regenerative medicine. Use of these alternatives is expected to restraint the growth of collagen & gelatin market.

Opportunities: Implementation of the 21st Century Cures Act

In the US, the 21st Century Cures Act was signed into law in December 2016. A new Regenerative Medicine Advanced Therapy designation was established under this act. This also included introduction of pathways for fast-track approval of regenerative medicine. This led to an increase in R&D efforts by companies to develop new regenerative medicine products.

The orthopedic segment dominated the collagen and gelatin market in 2020

On the basis on application, the global collagen market is segmented into orthopedic, wound care, dental, surgical, cardiovascular, and other applications while the global gelatin market is segmented into orthopedic, wound care and others. In 2020, the orthopedic segment accounted for the largest share of the collagen market and the gelatin market in 2020. The largest share of the orthopedic segment is attributed to high demand for biomaterials and scaffolds for bone substitutes in orthopedics.

The hospitals segment accounted for the largest share in 2020

Based on end users, the collagen and gelatin market is segmented into hospitals and surgical centers. In 2020, the hospitals segment accounted for the largest share of the market and is projected to continue its dominance during the forecast period. Hospital are well equipped with highly advanced equipment and facilities, coupled with skilled healthcare professionals.

To know about the assumptions considered for the study, download the pdf brochure

North America was the largest regional market for collagen and gelatin in 2020.

Based on region, the collagen and gelatin markets is segmented into North America, Europe, Asia Pacific, and Rest of the World (ROW). In 2020, North America accounted for the largest share of the collagen and gelatin market, driven by increasing R&D expernditure in regenerative medicine, well-established healthcare infrastructure, and presence of prominent market players. Additionally, high incidence of periodontitis in the US is projected to offer growth opportunities in the collagen market as increasing use of collagen for tissue regeneration procedures in periodontal defects and oral surgical procedures. Asia Pacific is expected to grow at a highest CAGR during the forecast period owing to increase in diabetic population, especially in India and China.

Major players operating in this market are Integra LifeSciences (US), Royal DSM (Netherlands), CollPlant Biotechnologies (Israel), Nitta Gelatin Inc. (Japan), Collagen Solutions plc (UK), Collagen Matrix, Inc. (US), Symatese (France), GELITA AG (Germany), PB Leiner (Belgium), Smith & Nephew (UK), Zimmer Biomet (US).

Collagen and Gelatin Market Scope

Collagen and Gelatin Market Growth Drivers

Growing incidence of diabetes, cancer, and chronic wounds

Rising funding and investments for R&D

Growing number of surgical procedures

Collagen and Gelatin Market Growth Opportunities

Implementation of the 21st Century Cures Act

Updated financial information/ product portfolio of players

Updated market developments of profiled players

This report categorizes the global collagen and gelatin market into the following segments and subsegments:

By Source

By Application

By Application

By End Users

By Region

Recent Developments:

In January 2021, Integra LifeSciences completed the acquisition of ACell. This acquisition enabled the company to provide more comprehensive complex wound management solutions.

In September 2020, DSM partnered with PBC BioMed to develop regenerative bone adhesives for safer, more cost-effective surgical procedures.

Frequently Asked Questions (FAQ):

What is the size of Collagen and Gelatin Market ?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

# data[].attributes.attachment_link.title
Collagen and Gelatin Market Growth Drivers & Opportunities | MarketsandMarkets

# data[].attributes.attachment_link.description
The global collagen and gelatin market size is projected to reach USD 1,083 million by 2026, at a CAGR of 7.0%. Major factors attributing to the growth of the market are rising burdern of cancer, diabetes and chronic wounds, especially among geriatric population along with rising number of surgical procedures.

# data[].attributes.headline
Laboratory Information Management System (LIMS) Market worth $3.3 billion by 2028

# data[].attributes.subject
Laboratory Information Management System (LIMS) Market worth $3.3 billion by 2028

# data[].attributes.body
The Global Laboratory Information Management Systems Market is projected to reach USD 3.3 billion by 2028 from USD 1.6 billion in 2023, at a CAGR of 14.6% during the forecast period. The significant growth potential in emerging markets such as China, India, Japan, Singapore, Brazil, and Middle Eastern countries, growing popularity of cloud-based LIMS pertaining to large volumes of data generated in laboratories & reduced total cost of ownership of laboratory informatics solutions are some of the critical factors offering opportunities to the market.

# data[].attributes.attachment_link.readable_text
Updated on : July 06, 2023

The global laboratory information management system market in terms of revenue was estimated to be worth $1.6 billion in 2023 and is poised to reach $3.3 billion by 2028, growing at a CAGR of 14.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The significant growth potential in emerging markets such as China, India, Japan, Singapore, Brazil, and Middle Eastern countries, growing popularity of cloud-based LIMS pertaining to large volumes of data generated in laboratories & reduced total cost of ownership of laboratory informatics solutions are some of the critical factors offering opportunities to the market.

However, lack of technical expertise and interoperability issues are key factors challenging the growth of the laboratory information management systems market.

To know about the assumptions considered for the study, Request for Free Sample Report

Laboratory Information Management System Market Dynamics

Driver: Increasing focus on improving the efficiency of laboratories

With the increasing number of biobanking applications, organizations face immense pressure to manage the ever-increasing number of biosamples (blood, tissue, and DNA samples) and comply with regulatory requirements. The growing focus on translational research has greatly impacted biobanking as a source of samples for researchers. The value of these repositories lies in the samples and the metadata associated with each specimen. Biobanking modules help researchers efficiently use biorepositories to understand complex diseases and facilitate their integration with LIMS. As research activity and data generation grow, researchers have begun looking for systems that can help them reduce manual intervention. In this regard, the adoption of LIMS for various database applications can help researchers collect, organize, and track information, increase productivity, and reduce errors in accessing research information. Currently, LIMS is being adopted in biobanks, academic research institutes, and CROs to manage laboratory processes better.

Restraint: Limited adoption of LIMS in small and medium-sized companies

The shift to paperless informatics involves various stages of validation and complex documentation with high purchase and maintenance costs. Hence, it becomes challenging for small and medium-sized biopharma companies to implement such informatics solutions. Implementing informatics solutions requires information related to the proper software platform, integration with ERP, specific hardware configurations, and other necessary devices such as barcode scanners and label printers. Small and medium-sized companies lack such prerequisites for the implementation of informatics solutions. Also, most small and medium-sized companies do not have a dedicated budget allocated to purchasing these solutions. As a result, the adoption of LIMS solutions is low among small and medium-sized companies.

Opportunity: Significant growth in emerging markets

The significant growth of emerging countries presents a promising opportunity for the LIMS market. Emerging countries are experiencing rapid industrialization, advancements in healthcare infrastructure, and increased investment in research and development activities. These factors create a favorable environment for the adoption and growth of LIMS, opening up new avenues for market expansion. One of the key drivers for the LIMS market in emerging countries is the rising demand for improved quality control and regulatory compliance in various industries. As emerging economies witness growth in sectors such as pharmaceuticals, biotechnology, food and beverage, and environmental testing, there is a growing need for robust data management systems like LIMS to ensure accurate tracking, traceability, and compliance with regulatory standards. This demand creates a significant market opportunity for LIMS providers to offer their solutions in these regions.

Additionally, the expanding healthcare sector in emerging countries contributes to the growth of the LIMS market. As healthcare infrastructure develops and healthcare services become more accessible, there is a greater need for efficient laboratory operations and data management in hospitals, diagnostic laboratories, and research institutions. LIMS play a crucial role in managing patient data, tracking samples, and streamlining laboratory workflows, thereby improving efficiency and patient care. The increasing adoption of LIMS in the healthcare sector of emerging countries presents substantial growth potential for the market.

Challenge: A dearth of trained professionals

With the growing shift towards digitization, the adoption of IT solutions has increased significantly in the healthcare industry over the last decade. As a result, the demand for skilled IT professionals and personnel with advanced analytical skills to interpret data from HCIT solutions, including LIMS, is increasing; however, there is currently a huge demand-supply gap in the industry. This shortage of trained and skilled personnel may limit the adoption of LIMS, especially in pharmaceutical, biotechnology, and medical device companies, which account for over 50% of the LIMS market.

The US Department of Labor's (DOL) Bureau of Labor Statistics has reported that the employment of medical laboratory technologists and technicians is expected to increase by 13%, from 335,700 in 2016 to 378,400 in 2026. However, according to the University of Minnesota, there is a shortfall of ~4,500 laboratory professionals annually; by 2018, a shortfall of ~9,000 laboratory professionals per year was expected. This shortage of skilled manpower is restricting the adoption and utilization of complex software solutions in laboratories. Moreover, CROs and pharmaceutical companies are reluctant to invest time and money in training their research employees due to severe time constraints and increasing budget cuts. Such factors are expected to limit the adoption of LIMS to a certain extent in the coming years.

Laboratory Information Management System Market Ecosystem

The ecosystem of the LIMS market comprises data center providers, cloud professional service vendors, software developers, the life sciences industry (pharmaceutical & biotechnology companies, biobanks and biorepositories, contract service organizations, academic research institutes, clinical research laboratories, toxicology laboratories, and NGS labs), petrochemical refineries, oil & gas, chemicals, food & beverage, agriculture, environmental testing, forensic laboratories, and other industries.

Source: Secondary Literature, Interviews with Experts, and MarketsandMarkets Analysis

Software as a service (SAAS) segment of the laboratory information management system industry accounted to hold a significant share by the cloud-based deployment mode during the forecast period

Software as a service (SAAS) segment of the laboratory information management system market accounted to hold a significant share by the cloud-based deployment mode during the forecast period. The growth of SAAS segment is accounted to seamless integration of data from diverse cloud silos, unlimited users and provides access to users anytime and anywhere, low maintenance costs and increases the use of resources. The wide range of applications, including accounting, performance monitoring, and communicating via webmail and instant messengers served by SAAS model is also promoting the growth of this segment.

Biobanks & biorepositories segment accounted for a considerable share in the laboratory information management system industry, by the life sciences industry in 2022

In 2022, the biobanks & biorepositories segment accounted for a considerable share in the laboratory information management system market, by the life sciences industry. The large share of this segment can be attributed to the growing need for biobanks with the increasing focus of pharmaceutical companies on epidemiology research, biomedical research, personalized medicine, and cell-based research, which require more usable and well-maintained specimens, and the rising need for automated storage, preparation, and information management systems to obtain accurate, reliable, and standardized data.

North America dominated the laboratory information management system industry in 2022

North America accounted for the largest share of the laboratory information management system market. The large share of North America can be attributed to the developed infrastructure and growth in the demand for digitalized technologies across North America drive the implementation of different analytical solutions among industries, and a growing number of laboratory information management system companies catering to the healthcare industry in the region.

To know about the assumptions considered for the study, download the pdf brochure

Prominent companies in laboratory information management system market include LabWare (US), LabVantage Solutions Inc. (US), Thermo Fisher Scientific (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies (US), LabLynx, Inc. (US), Dassault Systèmes (France), Labworks LLC (US), Autoscribe Informatics (a wholly owned subsidiary of Autoscribe Limited) (US), Accelerated Technology Laboratories (ATL) (US), CloudLIMS (US), Computing Solutions, Inc. (US), GenoLogics Inc. (an Illumina Company) (Canada), Siemens (Germany), Novatek International (Canada), Ovation (US), Clinsys (US).

Scope of the Laboratory Information Management System Industry

The study categorizes the laboratory information management system market to forecast revenue and analyze trends in each of the following submarkets:

By Type

Broad-based LIMS

Industry-specific LIMS

By Component

By Deployment Model

On-premise LIMS

Cloud LIMS

Software-as-a-service

Infrastructure-as-a-service

Platform-as-a-service Others

Remotely Hosted LIMS

By Industry

Life Sciences

Pharmaceutical & Biotechnology Companies

Biobanks & Biorepositories

Contract Service Organizations

Academic Research Institutes

Clinical Research Laboratories

Toxicology Laboratories

NGS Laboratories

Food & Beverage And Agriculture

Petrochemicals And Oil & Gas

Chemicals

Environmental Testing

Forensics

Other Industries

By Region

Recent Developments of Laboratory Information Management System Industry

In October 2022, LabVantage Solutions, Inc. (US) and Biomax Informatics AG (Germany) announced the closure of their merger agreement. The merger aims to enhance scientific data contextualization, accelerate product development, and provide innovative capabilities for the life science and bio-manufacturing industries.

In March 2022, LabWare (US), acquired data analytics firm CompassRed (US). The merger aimed to create a LabWare Data Analytics Innovation Center and accelerate the transformation of data into actionable knowledge. The acquisition allowed LabWare to expand its services and establish a global presence.

In March 2022, Thermo Fisher Scientific, Inc. (US) and Symphogen (Denmark) announced the continuation of their collaboration to provide innovative tools and workflows for the efficient characterization of complex therapeutic proteins in biopharmaceutical discovery and development laboratories

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

# data[].attributes.attachment_link.keywords[]
laboratory information management system market

# data[].attributes.attachment_link.title
Laboratory Information Management System Market Revenue Forecast | Latest Industry Updates | MarketsandMarkets

# data[].attributes.attachment_link.description
The global laboratory information management system market in terms of revenue was estimated to be worth $1.6 billion in 2023 and is poised to reach $3.3 billion by 2028, growing at a CAGR of 14.6% from 2023 to 2028.

# data[].attributes.headline
How Animal Genetics Research is Revolutionizing Animal Health

# data[].attributes.subject
How Animal Genetics Research is Revolutionizing Animal Health

# data[].attributes.body
The Global Animal Genetics Market is projected to reach USD 7.7 billion by 2026 from USD 5.5 billion in 2021, at a CAGR of 7.1% during the forecast period. The growth in the animal genetics market is mainly driven by the rising consumption of animal-derived protein and increasing global population & rapid urbanization. Additionally, growing focus on identifying superior breeds, increased adoption of genetic services to prevent genetic diseases & business loss, and increased adoption of advanced genetic technologies also contribute to the growth of the market.

# data[].attributes.attachment_link.title
Animal Genetics Market Opportunities, Revenue, Future Scope and Forecast 2026 - MarketsandMarkets Blog

# data[].attributes.attachment_link.description
According to the new market research report "Animal Genetics Market by Products & Services (Live Animals (Poultry, Porcine, Bovine, Canine) Genetic Material (Semen (Bovine, Porcine), Embryo (Bovine, Equine)) Genetic Testing (DNA Testing, DNA Typing, Genetic Traits Testing)) (2022 - 2026)", is projected to reach USD 7.7 billion by 2026 from USD 5.5 billion in 2021,

# data[].attributes.headline
Humanized Mouse and Rat Model Market worth $338 million by 2027

# data[].attributes.subject
Humanized Mouse and Rat Model Market worth $338 million by 2027

# data[].attributes.body
The Global Humanized Mouse and Rat Model Market in terms of revenue was estimated to be worth $237 million in 2022 and is poised to reach $338 million by 2027, growing at a CAGR of 7.4% from 2022 to 2027.

# data[].attributes.attachment_link.readable_text
Medical and Health Markets

Humanized mouse and rat models are created by introducing human genes, cells, or tissues into the animal models, enabling the simulation of human physiological and pathological processes.

Humanized Mouse and Rat Model Market in terms of revenue was estimated to be worth $237 million in 2022 and is poised to reach $338 million by 2027, growing at a CAGR of 7.4% from 2022 to 2027
Download an Illustrative overview: www.marketsandmarkets.com/pdfdown...=131763955
Browse in-depth TOC on " Humanized Mouse and Rat Model Industry"

140 - Tables

27 - Figures

177 - Pages
Humanized Mouse and Rat Model Market Dynamics: Drivers:

Increasing research activities using humanized models

Rising demand for personalized medicine

Continuous support and initiatives from government and private sectors for cancer research

Growing R&D activities in pharmaceutical and biotechnology sectors

Restraints:

High cost of custom humanized models

Laws and regulations for ethical use of animal models in research

Opportunities:

Rising demand for humanized PDX models

Emergence of CRISPR as a powerful tool in biomedical research

Rising demand for humanized rat models

Challenges:

Alternatives for animal testing

Limitations of humanized mouse models

Key Market Players:
Key players in the humanized mouse and rat model Market include Charles River Laboratories International, Inc. (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), Crown Bioscience (US), and Envigo (US).
Recent Developments:

In January 2022, Taconic Biosciences, Inc. (US) launched the huNOG-EXL EA (early access) humanized immune system (HIS) mouse.

In October 2021, The Jackson Laboratory (US) acquired RMS Business of Charles River Laboratories Japan, Inc. (Japan) which is Charles River Laboratories Japan's Research Models & Services (RMS) business as a wholly-owned subsidiary.

In September 2021, Biocytogen (US) collaborated with Envigo (US) in order to support the research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the US, Europe, and certain APAC regions.

In March 2021, Charles River Laboratories International, Inc. (US) acquired Cognate BioServices, Inc. (US) a cell and gene therapy contract development and manufacturing organization (CDMO) offering comprehensive manufacturing solutions for cell therapies. The acquisition expanded Charles River's broad capabilities across the major CDMO platforms for cell and gene therapies.

News From

MarketsandMarkets™
Category: Market Research Publishers and Retailers Profile: MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on gro ...

# data[].attributes.attachment_link.title
Humanized Mouse and Rat Model Market worth $338 million by 2027 according to a new research report

# data[].attributes.attachment_link.description
The global humanized mouse and rat model market has an estimated compound annual growth rate (CAGR) of 7.4% and a revenue size in the region of $237 million in 2022.

# data[].attributes.headline
Cold Pain Therapy Market is Expected to Reach $2.4 billion by 2027

# data[].attributes.subject
Cold Pain Therapy Market is Expected to Reach $2.4 billion by 2027

# data[].attributes.body
The global cold pain therapy market in terms of revenue was estimated to be worth $1.8 billion in 2022 and is poised to reach $2.4 billion by 2027, growing at a CAGR of 5.1% from 2022 to 2027. A total of 25 companies have been profiled. The current edition of the report covers pricing analysis, case study analysis, value chain analysis, supply chain analysis, ecosystem analysis, market mapping, trade analysis, regulatory landscape analysis, technology analysis, trends and disruptions impacting the business of customers, key conferences and events in 2022–2023, key stakeholders in the buying process, and Porter’s five forces analysis in the market overview chapter. This edition also covers the product and geographical footprint of the key players in the competitive landscape chapter. Market growth is driven by the rising geriatric population, coupled with the increasing prevalence of musculoskeletal disorders and the easy availability of products for cold pain therapy.

# data[].attributes.attachment_link.readable_text
Chicago, March 13, 2023 (GLOBE NEWSWIRE) -- The global cold pain therapy market refers to the market for devices and products that provide relief from pain and inflammation through the application of cold temperatures. This market includes various products such as ice packs, cooling gels, sprays, and wraps, as well as more advanced technologies such as cryotherapy chambers and devices that use low-level laser therapy. The demand for cold pain therapy products is driven by various factors, including the increasing prevalence of musculoskeletal disorders, sports injuries, and arthritis, as well as a growing awareness of the benefits of non-invasive and drug-free pain management solutions. Additionally, the rise in the aging population, who are more susceptible to chronic pain, is also contributing to the growth of this market.

Cold Pain Therapy Market in terms of revenue was estimated to be worth $1.8 billion in 2022 and is poised to reach $2.4 billion by 2027, growing at a CAGR of 5.1% from 2022 to 2027 according to a latest report published by MarketsandMarkets™. Market growth is driven by the rising geriatric population coupled with increasing prevalence of musculoskeletal disorders, and easy availability of cold pain therapy products.
Download an Illustrative overview: Cold Pain Therapy Market Scope: Notable Cold Pain Therapy mergers and acquisitions for 2021 - 2022 include: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=55543905 Growth Drivers of Cold Pain Therapy Market from M Macro Level: acro to Micro: Micro Level:

Market Revenue in 2022

$1.8 billion

Estimated Value by 2027

$2.4 billion

Growth Rate

Poised to grow at a CAGR of 5.1%

Market Size Available for

2020-2027

Forecast Period

2022-2027

Forecast Units

Value (USD Billion)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

Product, Application, Distribution Channel and Region

Geographies Covered

North America, Europe, Asia Pacific, Latin America, and Middle East and Africa

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunity

Increasing adoption of analgesic patches

Key Market Drivers

Increasing number of hip and knee surgeries

Request for FREE Sample Pages: Hypothetic Challenges of Cold Pain Therapy Market in Near Future: https://www.marketsandmarkets.com/requestsampleNew.asp?id=55543905 Top 3 Use Cases of Cold Pain Therapy Market:

Medline Industries, Inc. acquired Strategent LLC in January 2021. Strategent is a healthcare solutions provider that specializes in product development and commercialization.

DJO Global, Inc. acquired Trilliant Surgical in February 2021. Trilliant Surgical is a manufacturer of orthopedic implants and instrumentation.

Sanofi acquired Kadmon Holdings, Inc. in September 2021. Kadmon is a biopharmaceutical company that develops therapies for immune and inflammatory diseases, including pain management.

Rohto Pharmaceutical Co., Ltd. acquired Mentholatum Company in October 2021. Mentholatum is a manufacturer of topical analgesic products, including pain relief creams and ointments.

Increasing prevalence of chronic pain: The growing incidence of musculoskeletal disorders, arthritis, and sports injuries is driving demand for non-invasive and drug-free pain management solutions such as cold pain therapy.

Growing awareness of the benefits of cold pain therapy: There is an increasing awareness among patients and healthcare professionals about the benefits of cold pain therapy in reducing inflammation and pain, without the risk of addiction or side effects associated with some pain medications.

Technological advancements in cold pain therapy devices: There have been significant advances in the development of cold pain therapy devices, such as cryotherapy chambers and low-level laser therapy devices, which offer more targeted and effective pain relief.

Increase in healthcare expenditure: As global healthcare expenditure continues to rise, the demand for pain management solutions is also increasing, driving growth in the cold pain therapy market.

Related Reports: Compression Therapy Market Neuromodulation Market Pain Management Devices Market Sports Medicine Market Patient Handling Equipment Market

Growing demand for over-the-counter (OTC) products: The growing trend towards self-medication and the availability of OTC cold pain therapy products is driving demand for these products among consumers.

Aging population: As the global population ages, there is an increasing incidence of chronic pain, which is driving demand for pain management solutions such as cold pain therapy.

Sports and fitness industry growth: The growing popularity of sports and fitness activities is driving demand for cold pain therapy products, particularly among athletes and fitness enthusiasts.

Online availability of cold pain therapy products: The increasing availability of cold pain therapy products through online channels is making these products more accessible to consumers, driving market growth.

Competition from alternative pain management solutions: While cold pain therapy has many benefits, there are many other pain management solutions available, such as heat therapy, acupuncture, and physical therapy. Increased competition from these alternatives could impact the demand for cold pain therapy products.

Stringent regulations: As cold pain therapy devices become more advanced, regulatory bodies may introduce more stringent regulations that could increase the time and cost of bringing new products to market.

Adverse effects of cold therapy: While cold pain therapy is generally considered safe, in rare cases, it can lead to adverse effects such as frostbite, nerve damage, or skin irritation. If there are reports of adverse effects, it could impact consumer confidence and demand for cold pain therapy products.

Availability of substitutes: As more alternative pain management solutions become available, some consumers may choose to use these substitutes rather than cold pain therapy products, leading to a decline in demand for these products.

Economic instability: In times of economic instability, consumers may cut back on discretionary spending, including spending on pain management products, which could impact market growth.

Sports medicine: Cold pain therapy is commonly used in sports medicine to treat acute injuries such as sprains, strains, and bruises. Athletes and sports professionals use cold therapy devices such as ice packs, cold compression therapy units, and cryotherapy chambers to reduce inflammation and pain, and to accelerate the healing process.

Arthritis and chronic pain management: Cold pain therapy is also widely used for chronic pain management, particularly for conditions such as osteoarthritis, rheumatoid arthritis, and fibromyalgia. Cold therapy devices such as cold therapy wraps, ice baths, and cold lasers are commonly used to alleviate pain and stiffness, and to improve joint mobility.

Post-operative recovery: Cold pain therapy is also used in post-operative recovery to reduce swelling, inflammation, and pain. Cold therapy devices such as cold therapy machines and ice packs are used to promote healing and improve patient comfort after surgeries such as joint replacements, orthopedic surgeries, and cosmetic surgeries.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=55543905

# data[].attributes.attachment_link.title
Cold Pain Therapy Market is Expected to Reach $2.4 billion | MarketsandMarkets.

# data[].attributes.attachment_link.description
Chicago, March 13, 2023 (GLOBE NEWSWIRE) -- The global cold pain therapy market refers to the market for devices and products that provide relief from...

# data[].attributes.headline
A Comprehensive Analysis of the Global Bronchoscopy Market: Trends and Insights

# data[].attributes.subject
A Comprehensive Analysis of the Global Bronchoscopy Market: Trends and Insights

# data[].attributes.body
The Global Bronchoscopy Market in terms of revenue was estimated to be worth $2.5 billion in 2022 and is poised to reach $3.7 billion by 2027, growing at a CAGR of 7.9% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is largely driven by the rising prevalence of respiratory diseases, growing hospital investments in bronchoscopy facilities, and technological improvement in bronchoscopes. On the other hand, risk associated with the bronchoscopy procedures is a major restrains to the growth of this market.

# data[].attributes.attachment_link.provider_name
MarketsandMarkets Blog - Market Research Insights

# data[].attributes.attachment_link.readable_text
Jun 28th, 2023 · Comments Off on A Comprehensive Analysis of the Global Bronchoscopy Market: Trends and Insights

The Global Bronchoscopy Market in terms of revenue was estimated to be worth $2.5 billion in 2022 and is poised to reach $3.7 billion by 2027, growing at a CAGR of 7.9% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is largely driven by the rising prevalence of respiratory diseases, growing hospital investments in bronchoscopy facilities, and technological improvement in bronchoscopes. On the other hand, risk associated with the bronchoscopy procedures is a major restrains to the growth of this market.
Browse in-depth TOC on " Flexible Bronchoscopy Industry"
301- Tables
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40057877
48- Figures
"The adult patients are accounted to hold the largest share of the Flexible bronchoscopy industry, by patients in 2021."
289- Pages
"The hospitals are accounted to hold the largest share of the Rigid bronchoscopy market, by end users in 2021."
The growth in this market growth is largely driven by the rising prevalence of respiratory diseases, the growing demand for minimally invasive surgeries, growing hospital investments in bronchoscopy facilities, and technological advancements in bronchoscopes. On the other hand, the dearth of trained physicians and pulmonologists is a major challenge to the growth of this market.
"North America accounted the largest share of the bronchoscopy industry in 2021."
On the basis of patients, the bronchoscopy equipment market is segmented into adult patients and pediatric patients. The adult patients segment accounted for the larger share of the bronchoscopy equipment market in 2021. The large share of this segment can be attributed to the high image quality achieved through reusable bronchoscopes and the availability of reusable accessories.

Based on end users, the bronchoscopy equipment market is segmented into hospitals and ambulatory surgery centers/clinics. The hospitals segment accounted for the largest share of the bronchoscopy equipment market in 2021. The large share of this segment can be attributed to the high patient preference for hospital treatment, availability of skilled healthcare professionals, and favorable reimbursement scenario.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=40057877
The large share of the North American market can be attributed to the increasing incidence and prevalence of chronic respiratory diseases, favorable reimbursement scenario in the US, the rising incidence of lung cancer in Canada, rapid increase in healthcare expenditure, easy accessibility to advanced technologies, and the strong presence of market players in the region

The major players operating in this market are Olympus Corporation (Japan), KARL STORZ (Germany), Ambu A/S (Denmark), Boston Scientific Corporation (US), Ethicon (US), FUJIFILM Holdings Corporation (Japan), Medtronic (Ireland), HOYA Corporation (Japan), Richard Wolf GmbH (Germany), Cook Medical (US), Broncus Medical Inc. (China), CONMED (US), Roper Technologies (US), Teleflex Incorporated (US), Laborie Medical Technologies Corp. (Canada), EFER Endoscopy (France), EMOS Technology GmbH (Germany), VBM Medizintechnik GmbH (Germany), Hunan Vathin Medical Instrument Co., Ltd. (China), and Machida Endoscope Co., Ltd. (China)

# data[].attributes.attachment_link.title
A Comprehensive Analysis of the Global Bronchoscopy Market: Trends and Insights - MarketsandMarkets Blog

# data[].attributes.attachment_link.description
The Global Bronchoscopy Market in terms of revenue was estimated to be worth $2.5 billion in 2022 and is poised to reach $3.7 billion by 2027, growing at a CAGR of 7.9% from 2022 to 2027. The new research study consists of an industry trend analysis of the market.

# data[].attributes.headline
Forecasting the Future of Healthcare Data Monetization

# data[].attributes.subject
Forecasting the Future of Healthcare Data Monetization

# data[].attributes.body
The global healthcare data monetization market in terms of revenue was estimated to be worth $0.4 billion in 2023 and is poised to reach $0.9 billion by 2028, growing at a CAGR of 18.5% from 2023 to 2028.

The rising demand for real-world evidence (RWE) presents a significant market opportunity for healthcare data monetization. Real-world evidence refers to data collected from real-world patient populations in everyday clinical practice, outside the controlled environment of clinical trials. This type of data provides valuable insights into treatment outcomes, safety profiles, comparative effectiveness, and patient experiences, which are essential for evidence-based decision-making in healthcare. Healthcare organizations that possess extensive and high-quality RWE datasets can monetize this data by collaborating with various stakeholders in the healthcare ecosystem.

# data[].attributes.attachment_link.readable_text
Healthcare Data Monetization Market in terms of revenue was estimated to be worth $0.4 billion in 2023 and is poised to reach $0.9 billion by 2028, growing at a CAGR of 18.5% from 2023 to 2028 according to a new report by MarketsandMarkets™

The healthcare data monetization industry is poised for significant growth in the near future. With the increasing digitalization of healthcare systems and the abundance of data being generated, healthcare organizations are recognizing the immense value of their data assets. In the coming years, we can expect to see a surge in initiatives focused on leveraging healthcare data for monetization purposes. This industry will witness the emergence of innovative data monetization platforms, advanced analytics tools, and secure data marketplaces.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=56622234 Browse in-depth TOC on "Healthcare Data Monetization Market" 217 - Tables 60 - Figures 292 - Pages The cloud segment is expected to be the fastest-growing healthcare data monetization market, by deployment, during the forecast period.
Healthcare Data Monetization Market in terms of revenue was estimated to be worth $0.4 billion in 2023 and is poised to reach $0.9 billion by 2028, growing at a CAGR of 18.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as exponentially increasing data volume and generation of large and complex healthcare datasets, the need to curtail escalating healthcare costs, expanding partnerships and collaborations among players, and growing investments in the adoption of EHR systems primarily drive the growth of this market. Furthermore, the rising adoption of AI in precision medicine and the growing demand for real-world evidence (RWE) would provide lucrative opportunities to solution providers.
The pharmaceutical & biotechnology companies segment, by end-user, is expected to be the largest healthcare data monetization market in 2023
Based on deployment, the market is segmented into on-premise and cloud. The cloud segment is expected to grow at a higher CAGR during the forecast period due to increased agility and scalability offered by cloud-based data monetization solutions. Cloud platforms provide secure and scalable storage solutions for vast amounts of healthcare data, including electronic health records, medical images, and patient-generated data. Furthermore, cloud-based analytics tools enable healthcare organizations to perform advanced data analysis, leveraging machine learning algorithms and artificial intelligence to gain valuable insights from complex datasets.
Asia Pacific is expected to be the fastest-growing in healthcare data monetization market during the forecast period.
Based on the end user, the market is broadly segmented into pharmaceutical & biotechnology companies; healthcare payers; healthcare providers; medical technology companies; and other end users. Pharmaceutical & biotechnology companies would account for the largest share of the global end-user market in 2023. Market growth can be attributed to the rising demand for solutions to cut the time and costs of drug development. Pharmaceutical and biotechnology companies can benefit significantly from healthcare data monetization, as it can help them develop new drugs, identify potential markets, and improve patient outcomes.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=56622234 Healthcare Data Monetization Market Dynamics: Drivers:
The global market has been segmented based on region: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Asia Pacific market is projected to register the highest CAGR during the forecast period. Emerging countries in the Asia Pacific, such as India and China, offer lucrative growth opportunities for market players, primarily due to the increasing adoption of digital healthcare technologies, increasing public and private funding, improving IT infrastructure, the demand for affordable healthcare, favorable government norms, growing awareness about precision medicine, and the high incidence of cancer and chronic diseases are expected to boost the adoption of healthcare data monetization solutions in Asia Pacific.
Restraints:

Increase in use of external data sources
Opportunities:

Regulatory constraints to impact the growth of the market during the forecast period
Challenges: Key Market Players:

Rising Demand for Real-World Evidence
Recent Developments:
Major players operating in the healthcare data monetization market are Oracle Corporation (US), Microsoft Corporation (US), Google (US), Salesforce, Inc. (US), SAS Institute Inc. (US), SAP SE (Germany), TIBCO Software Inc. (US), Sisense Inc. (US), Snowflake Inc. (US), QlikTech International AB (US), HealthVerity, Inc. (US), Accenture (Ireland), Availity, LLC (US), Domo, Inc. (US), Komodo Health, Inc. (US), ThoughtSpot Inc. (US), Datavant (US), Verato (US), Infor, Inc. (US), Virtusa (US), Infosys (India), Particle Health, Inc. (US), Innovaccer, Inc. (US), H1 (US), and Medoble Inc. (US).
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=56622234

In October 2022, Oracle Corporation introduced a planning solution for the healthcare industry as part of its Fusion Cloud Enterprise Performance Management (EPM) offering. The solution aims to help healthcare organizations improve financial performance and patient care by enabling them to model scenarios, optimize resources, and make better finance, workforce, and patient care decisions.

In April 2023, Microsoft Corporation and Epic Systems expanded their collaboration to integrate generative AI into healthcare by combining Azure OpenAI Service with Epic's electronic health record (EHR) software. The collaboration aimed to enhance patient care, increase productivity, and improve financial integrity in health systems globally.

In February 2023, Redox and Google Cloud partnered to simplify the exchange of healthcare data, enabling better and faster decision-making for healthcare organizations. Redox's platform would be replicated on Google Cloud, offering customers access to Redox's products and services.

In April 2023, Salesforce announced new Customer 360 for Health capabilities aimed at enhancing personalized patient experiences and reducing operational costs for healthcare providers. These innovations leverage real-time data, AI, and automation to address the challenges faced by healthcare organizations in meeting customer expectations.

In May 2023, HTEC Group joined the SAS IoT Partner Ecosystem to partner on delivering innovative solutions in industries such as healthcare, life sciences, logistics, and more. The partnership aimed to develop joint offerings that enable global enterprise companies to apply cutting-edge data-driven, IoT, edge, and cloud-enabled solutions to their business challenges.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/healthcare-data-monetization-market-56622234.html

# data[].attributes.attachment_link.title
Healthcare Data Monetization Market [2023-2028] Opportunities, Challenges, Trends with respect to Regions and Top Players

# data[].attributes.attachment_link.description
Healthcare Data Monetization Market in terms of revenue was estimated to be worth $0.4 billion in 2023 and is poised to reach $0.9 billion by 2028, growing at a CAGR of 18.5% from 2023 to 2028 according to a new report by MarketsandMarkets™ The healthcare data monetization industry is poised for significant growth in the near future.

# data[].attributes.headline
Rising Demand for Humanized Mouse and Rat Models in Drug Development: An Overview

# data[].attributes.subject
Rising Demand for Humanized Mouse and Rat Models in Drug Development: An Overview

# data[].attributes.body
The Global Humanized Mouse and Rat Model Market in terms of revenue was estimated to be worth $237 million in 2022 and is poised to reach $338 million by 2027, growing at a CAGR of 7.4% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The major factors driving the growth of this market include increasing number of research activities involving humanized models, growing demand for personalized medicine, continuous support in the form of investments and grants from the government and private sector, rising usage of mice models in virology and infectious disease testing, and growth in the number of R&D activities carried out by pharmaceutical and biotechnology companies. However, the high cost of humanized mouse and rat models and regulations & laws regarding the ethical use of animals in medical research are expected to restrain the growth of this market during the forecast period.

# data[].attributes.attachment_link.readable_text
Humanized Mouse and Rat Model Market

The report "Humanized Mouse and Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Oncology, Toxicology, Immunology & Infectious diseases, Hematopoiesis), End Users, and Region - Global Forecast to 2027", is projected to reach USD 338 million by 2027 from USD 237 million in 2022, at a CAGR of 7.4% during the forecast period of 2022 to 2027.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Factors such as advances in genomics, proteomics, and metabolomics; completion of the human genome map; the development of targeted diagnostics and therapeutics; and the growing emphasis on health, wellness, and preventive measures are driving the demand for personalized medicine and, subsequently the demand for relevant humanized mouse and rat research models. Also, grants from government and private organizations for cancer research have also supported the development of humanized models in oncology.

For instance, in 2020, the US NIH funded a large-scale project to find treatments for rare genetic diseases with a five-year grant of USD 10,625,000 to The Jackson Laboratory Center for Precision Genetics. In the same year, The Jackson Laboratory received a grant from the NIH for its Mouse Mutant Resource and Research Centers (MMRRC) program, established in 2009. The new grant provides a total of USD 6,119,082 over five years to the MMRRC. With such grants and funding from the government and private sectors, the demand for humanized mouse models is expected to increase.

The genetic humanized mouse model segment accounted for the largest share of the humanized mouse model segment in the humanized mouse and rat model market in 2021.

Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. The humanized mouse models segment is further divided into genetic humanized mouse models and cell-based humanized mouse models. In 2021, genetic humanized mouse segment accounted for the largest share of humanized mouse model market. Advances in genetic engineering technologies, such as gene targeting and gene editing, have led to the development of genetically engineered humanized mouse models that serve as an important tool for a variety of research applications. In addition to the widespread use of these mice in diverse research areas, the emerging CRISPR technology, increasing focus on personalized medicine with the continuous introduction of new models, and various licensing agreements are expected to drive market growth.

The immunology and infectious diseases segment accounted for the second largest share of the application segment in the humanized mouse and rat model market in 2021.

Based on application, the humanized mouse and rat model market is segmented into oncology, immunology and infectious diseases, neuroscience, Hematopoiesis, toxicology, and other applications. Immunology and Infectious diseases segment accounted for the second largest share of the humanized mouse and rat model market in 2021. Mouse models are used in immunology and inflammation studies as they help assess the physiological relevance of an experimental finding. The use of mouse models allows suitable alterations in the mouse genome at random or in specific regions, enabling a detailed study of immunological processes. They also assist in identifying the function of newly identified surface receptors in host defense as well as the developmental consequences of a disturbed signaling pathway or removing a transcription factor. Such mouse models are developed on a large scale in laboratories or institutes and are used for application in Immunology and Infectious diseases segment. Thus, making it the second largest segment in the market.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=131763955&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

The Asia Pacific region is the fastest-growing region of the humanized mouse and rat model market in 2021.

Based on the region, the humanized mouse and rat model market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is estimated to register the highest growth during the forecast period. Global pharmaceutical firms are increasingly moving to APAC to tap into its thriving market and lower their production costs by shifting manufacturing and laboratory testing to the region. The rapidly increasing demand for the outsourcing of quality control safety testing (including efficacy testing) in countries such as China, India, Japan, and Singapore is expected to drive market growth in the Asia Pacific during the forecast period.

Key players in the humanized mouse and rat model Market include Charles River Laboratories International, Inc. (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), Crown Bioscience (US), and Envigo (US).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=131763955&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Recent Developments:

In January 2022, Taconic Biosciences, Inc. (US) launched the huNOG-EXL EA (early access) humanized immune system (HIS) mouse.
In October 2021, The Jackson Laboratory (US) acquired RMS Business of Charles River Laboratories Japan, Inc. (Japan) which is Charles River Laboratories Japan's Research Models & Services (RMS) business as a wholly-owned subsidiary.

In September 2021, Biocytogen (US) collaborated with Envigo (US) in order to support the research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the US, Europe, and certain APAC regions.

In March 2021, Charles River Laboratories International, Inc. (US) acquired Cognate BioServices, Inc. (US) a cell and gene therapy contract development and manufacturing organization (CDMO) offering comprehensive manufacturing solutions for cell therapies. The acquisition expanded Charles River's broad capabilities across the major CDMO platforms for cell and gene therapies.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/humanized-mouse-model-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/humanized-mouse-model.asp

About MarketsandMarkets™:

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
This release was published on openPR.

# data[].attributes.attachment_link.title
Humanized Mouse and Rat Model Market worth $338 million | Charles River Laboratories International, Inc. (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US)

# data[].attributes.attachment_link.description
The report Humanized Mouse and Rat Model Market by Type Genetic Cell Based CD34 PBMC BLT Application Neuroscience Oncology Toxicology Immunology Infectious diseases Hematopoiesis End Users and Region Global Forecast to 2027 is projected to reach USD 338 million by ...

# data[].attributes.headline
Global Breast Reconstruction Market Size Worth USD 647 million by 2026 

# data[].attributes.subject
Global Breast Reconstruction Market Size Worth USD 647 million by 2026 

# data[].attributes.body
The Global Breast Reconstruction Market in terms of revenue was estimated to be worth $567 million in 2021 and is poised to reach $647 million by 2026, growing at a CAGR of 2.7% from 2021 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. This industry is experiencing significant growth due to rising incidences of breast cancer, increasing awareness, and the availability of reimbursements.

# data[].attributes.attachment_link.title
Breast Reconstruction Market is Expected to Reach $647 million | MarketsandMarkets.

# data[].attributes.attachment_link.description
Chicago, May 10, 2023 (GLOBE NEWSWIRE) -- The breast reconstruction industry is expected to witness significant advancements and growth in the near…

# data[].attributes.headline
The Future of Cell Dissociation Technology: Innovations and Advancements

# data[].attributes.subject
The Future of Cell Dissociation Technology: Innovations and Advancements

# data[].attributes.body
Cell Dissociation Market in terms of revenue was estimated to be worth $0.6 billion in 2023 and is poised to reach $1.4 billion by 2028, growing at a CAGR of 17.8% from 2023 to 2028 according to a new report by MarketsandMarkets™. Key drivers of the cell dissociation market include, growing use of tissue dissociation products in mammalian cell culture and expanding cell therapy production facilities. The mammalian-based capacity for recombinant proteins grew yearly at 10.8%, whereas recombinant microbial-based capacity grew at 3.0% yearly. As cell culture is an integral part of developing mammalian-based recombinant therapeutics, the uptake of cell dissociation products is expected to increase with it.

# data[].attributes.attachment_link.title
Cell Dissociation Market Size Detailed Report with Driving Factors and Company Analysis | Research by MarketsandMarkets | ABNewswire

# data[].attributes.headline
Lancets Market Size, Trends, Future Scope, Opportunity and Forecast to 2028

# data[].attributes.subject
Lancets Market Size, Trends, Future Scope, Opportunity and Forecast to 2028

# data[].attributes.body
The global lancets market in terms of revenue was estimated to be worth $2.3 billion in 2023 and is poised to reach $3.6 billion by 2028, growing at a CAGR of 9.7% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The increasing demand of the lancets market is mainly driven by the Growing prevalence of diabetes and increasing adoption of self-monitoring devices, the rising geriatric population, the high prevalence of chronic diseases and the increasing demand for painless lancets.

# data[].attributes.attachment_link.readable_text
CHICAGO, May 29, 2023 /PRNewswire/ -- The lancets industry is poised for significant growth and innovation in the near future. Lancets, which are small, pricking devices used for blood sampling, play a crucial role in various healthcare settings, including home-based testing, diagnostics, and monitoring of chronic conditions such as diabetes. In the coming years, we can expect several advancements in lancet technology and design to improve patient experience, safety, and accuracy. This may include the development of lancets with smaller and more precise needles, painless sampling techniques, and integrated safety features to minimize the risk of needlestick injuries. Furthermore, the integration of lancet devices with digital health platforms and mobile applications may enable better data management, real-time monitoring, and seamless integration of blood glucose or other health measurements into patient health records. The Lancets industry is likely to witness increased adoption and demand, driven by the rising prevalence of chronic diseases, the growing need for point-of-care testing, and the emphasis on patient-centric healthcare solutions.

Lancets Market in terms of revenue was estimated to be worth $2.3 billion in 2023 and is poised to reach $3.6 billion by 2028, growing at a CAGR of 9.7% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growth in the lancets market is mainly driven by the growing prevalence of diabetes, the high prevalence of chronic diseases, the rising geriatric population, and the increasing demand for painless lancets. In addition, emerging markets such as India and China are expected to offer growth opportunities for players operating in the Lancets market during the forecast period. However, the risk of lancet-related needlestick injuries, the reuse of lancets, and the poor reimbursement scenario in developing countries are restricting the growth of this market.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=86063487 Safety Lancets segment is expected to account for the largest share in 2022.
The lancets market, by type has been segmented into safety and standard lancets. Increasing demand for painless lancets is expected to drive the safety lancets market. The increasing demand for painless lancets can be attributed to improved patient comfort, increased prevalence of diabetes, improved technology, and convenience. As healthcare technology continues to advance, there will be more innovations in painless lancet technology to meet the growing demand.
The Glucose Testing segment held the largest market share in the application market.
By application, the global lancets market is broadly segmented into Glucose Testing, Hemoglobin Testing, Coagulation Testing, Cholesterol Testing, Allergy Testing and Neonatal Screening. Growing prevalence of diabetes and increasing adoption of self-monitoring devices have revolutionized the application of lancets in research. According to the Centers for Disease Control and Prevention (CDC), in 2020, more than 34 million Americans had diabetes, which is nearly 11% of the US population. There are 1.5 million new cases of diabetes in the United States each year.
North America dominates the global lancets market
Based on the region, the lancets market is segmented into North America, Europe, Asia Pacific and Rest of the world. North America market is driven by growing focus on rising prevalence of various chronic diseases and growing geriatric population. Thus, the rising geriatric population and the corresponding increase in the incidence of chronic diseases have increased the demand for lancets for early disease diagnostics. According to the WHO, globally, by 2030, 1 in every 6 individuals will be aged 60 years or over in the world. By 2050, the world's geriatric population (aged 60 years and older) will witness a two-fold increase (2.1 billion). The number of individuals aged 80 years or older is expected to grow three times between 2020 and 2050 to reach 426 million. There are over 46 million older adults living in the US as of 2021, and by 2050, the geriatric population is expected to grow to over 90 million.
Request Sample Pages: Lancets Market Drivers: Dynamics: Restraints: https://www.marketsandmarkets.com/requestsampleNew.asp?id=86063487 Opportunities:

1. Growing prevalence of diabetes and increasing adoption of self-monitoring devices

2. Rising prevalence of various chronic diseases

3. Increasing demand for painless lancets

4. Growing geriatric population

5. Rising number of hospitals and surgical centers

Challenges: Key Market Players:

1. Increasing incidence of lancet-related needlestick injuries and infections

2. Pricing pressure owing to reimbursement cuts and budget constraints

Get 10% Free Customization on this Report: Recent Developments: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=86063487 Lancets Market Advantages:

1. High growth prospects in emerging countries

2. Increasing awareness of novel technologies

Major players in lancets market include Becton, Dickinson and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), B. Braun SE (Germany), and Abbott Laboratories (US).
Lancets market - Report Highlights:

In 2023, Astellas Pharma announced that it has entered into an agreement with Roche Diabetes Care Japan Co., Ltd. for the development and commercialization of Roche Diabetes Care's world-renowned Accu-Chek Guide Me blood glucose monitoring system with advanced accuracy as a combined medical product with BlueStar.

In 2022, BD announced the completion of the spinoff of Embecta Corp., which holds BD's former Diabetes Care business and is one of the largest diabetes management companies in the world.

In 2021, Greiner Bio-One introduced MiniCollect PIXIE Heel Incision Safety Lancet to expand its portfolio. The new safety lancet is specially designed for heel incisions.

Related Reports:

Convenience and Ease of Use: Lancets provide a convenient and easy-to-use method for blood sampling. They are compact, portable, and require minimal training to operate, making them suitable for use in various healthcare settings, including home-based testing. Patients can perform blood sampling themselves, reducing the need for frequent visits to healthcare facilities.

Minimized Pain and Discomfort: The advancement of lancet technology has led to the development of devices with smaller and finer needles, resulting in reduced pain and discomfort during blood sampling. This is particularly important for individuals who require regular blood glucose monitoring, such as those with diabetes. Minimizing pain and discomfort improves patient compliance and encourages regular testing.

Safety Features: Many lancets now come with integrated safety features to minimize the risk of needlestick injuries. These features may include mechanisms that retract the lancet after use, preventing accidental pricks and reducing the risk of cross-contamination and the spread of infectious diseases. Safety-enhanced lancets contribute to healthcare worker safety and infection control measures.

Precision and Accuracy: Lancets are designed to provide precise and accurate blood samples for diagnostic purposes. They are often used in conjunction with glucose meters, hemoglobin meters, or other testing devices to measure specific parameters. Accurate and reliable results obtained from lancet-based blood sampling aid in the diagnosis, monitoring, and management of various medical conditions.

Cost-effectiveness: Lancets are generally cost-effective compared to other blood sampling methods, such as venipuncture. They are single-use devices, reducing the risk of cross-contamination and eliminating the need for expensive sterilization procedures. The affordability and accessibility of lancets make them a viable option for routine blood sampling and point-of-care testing, particularly in resource-limited healthcare settings.

Integration with Digital Health: The lancets market is increasingly integrating with digital health platforms and mobile applications. This integration allows for the seamless transfer and analysis of blood sampling data, enabling real-time monitoring, trend analysis, and improved management of chronic conditions. Integrated lancets and digital health solutions contribute to personalized and patient-centric care.

Overall, the advantages of the lancets market make it a valuable tool in healthcare, providing convenient and reliable blood sampling methods for various diagnostic and monitoring purposes. The continuous advancements in lancet technology aim to further enhance patient comfort, safety, and accuracy, reinforcing its importance in modern healthcare practices.

Recession Impact Analysis: The existing report includes an analysis of the impact of recession on the lancets the market overview section.

Newer and improved representation of financial information: The new edition of the report provides updated financial information till 2022-2023 (depending on the availability) for each listed company in a graphical representation in a single diagram (instead of multiple tables). This will allow for the easy analysis of the present status of profiled companies in terms of their financial strength, profitability, key revenue-generating country/region, and business segment focus in terms of the highest revenue-generating segment.

Recent Market Developments: Recent developments are helpful to know the market trend and growth strategies adopted by players in the market. The report provides the updated developments in terms of acquisitions, agreements, expansions, and agreements/collaboration etc.

Latest Product portfolio: The new edition of the report provides an updated product portfolio of the companies profiled in the report.

Competitive leadership mapping: The competitive landscape chapter has been updated with the market evaluation matrix. The competitive landscape also includes the market share analysis for 2023, updated competitive leadership mapping, and competitive situation & trends. This report version has added the vendor dive matrix, covering a comprehensive study of the key vendors. Competitive leadership mapping has also been done for start-ups/SMEs.

Additional analysis by segment: The new edition of the report provides an analysis of additional segments in the ME chapters for all regions. The current edition of the report includes the pricing analysis, value chain analysis, supply chain analysis, ecosystem analysis, trade analysis, technology analysis, regulatory landscape analysis, patent analysis, Porter's five forces analysis, trends & disruptions impacting customers' business, key conferences and events in 2023-2024, and key stakeholders and buying criteria in the market overview chapter. This edition of the report also covers the product and geographical footprint of key players in the competitive landscape chapter.

Blood Collection Devices Market - Global Forecasts to 2027

Point of Care Diagnostics Market - Global Forecasts to 2027
About MarketsandMarkets™:
Patient Monitoring Devices Market - Global Forecasts to 2027

Pen Needles Market - Global Forecasts to 2026

Diabetes Care Devices Market - Global Forecasts to 2025

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/lancets-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/lancets.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Lancets Market worth $3.6 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
PRNewswire/ -- The lancets industry is poised for significant growth and innovation in the near future. Lancets, which are small, pricking devices used for...

# data[].attributes.headline
Cryo-electron Microscopy Market: Analysis of Revenue Growth and Demand Forecast

# data[].attributes.subject
Cryo-electron Microscopy Market: Analysis of Revenue Growth and Demand Forecast

# data[].attributes.body
The Global Cryo-Electron Microscopy Market in terms of revenue was estimated to be worth $1.1 billion in 2022 and is poised to reach $2.1 billion by 2028, growing at a CAGR of 11.6% from 2022 to 2028. The increasing focus on nanotechnology has risen the use of cryo-electron microscopes globally. Different academic and research institutes has increased the adoption of technologically advanced cryo-electron microscopes.

# data[].attributes.attachment_link.readable_text
The cryo-electron microscopy market is moderately competitive, with both established companies and upcoming competitors for the same market share. As of 2021, the key player operating in the global cryo-electron microscopy market are Thermo Fisher Scientific (US), Danaher (US), JEOL Ltd. (Japan), Intertek Group Plc (UK)

The global cryo-electron microscopy market in terms of revenue was estimated to be worth $1.1 billion in 2022 and is poised to reach $2.1 billion by 2028, growing at a CAGR of 11.6% from 2022 to 2028

The cryo-electron microscopy (cryo-EM) industry is expected to grow significantly in the coming years. This growth is due to the increasing use of cryo-EM in various fields, such as drug discovery, structural biology, and material science. Additionally, the development of new technologies, such as automated sample preparation, improved electron detectors, and better electron microscopes, are expected to further promote the growth of the cryo-EM industry. Furthermore, government funding and the increasing use of cryo-EM in the academic and industrial sectors are also likely to fuel the industry's growth in the near future.

Cryo-electron Microscopy Market in terms of revenue was estimated to be worth $1.1 billion in 2022 and is poised to reach $2.1 billion by 2028, growing at a CAGR of 11.6% from 2022 to 2028 according to a new report by MarketsandMarkets™. The major factors driving the growth of this market includes increasing use of high-end instruments in life science, nanotechnology, material science, healthcare, and lucrative opportunities in emerging markets.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=217602093 Browse in-depth TOC on "Cryo-electron Microscopy Market" 130 - Tables 33 - Figures 187 - Pages Services segment to register significant growth rate over the forecast period of 2022-2028
Based on the product & service, the global cryo-electron microscopy market is segmented into instruments, software, and services. The services segment is anticipated to register the highest growth rate over the forecast period. Instruments segment accounted for the highest share of the cryo-electron microscopy market in 2021.

Single particle analysis segment accounted for the largest share of the cryo-electron microscopy market, by Technology in 2021.

Based on technology, the global cryo-electron microscopy market is segmented into electron crystallography, single particle analysis, cryo-electron tomography, and other technologies. Single particle analysis accounted for the largest share of the market in 2021, whereas cryo-electron tomography segment is expected to grow at the highest CAGR during the forecast period.

Factors such as the growing use of cryo-electron microscopy in cell biology, virology, and infectious disease research along with launch of high-end instruments by major players are driving the growth of the market for cryo-electron microscopy.
300 kV segment accounted for the largest share of the cryo-electron microscopy market, by voltage in 2021
Based on voltage, the global cryo-electron microscopy market is segmented into 300 kV, 200 kV, and 120 kV. 300 kV segment accounted for the largest share of the market in 2021. Factors such as rising healthcare expenditure and consistent increase in the installation of high-end instruments by different end users for 3-dimensional visualization of biological samples is driving the growth of this segment.
The Asia Pacific market to register the highest growth in the market during the forecast period
The Asia Pacific cryo-electron microscopy market is anticipated to register the highest growth over the forecast period of 2022 to 2028. Major players in the market are focusing on expanding their manufacturing capabilities in the APAC region. This region is consistently witnessing a rise in the installation of cryo-electron microscopes, offering a significant growth opportunity for the key players.
Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=217602093 Cryo-electron Microscopy Market Dynamics: Drivers:

1. Technological advancements in cryo-electron microscopes

2. Growing focus on nanotechnology

3. Increasing use of cryo-electron microscopy in drug discovery

4. Rising funding and grants for cryo-EM installations

Restraints: Opportunities:

Growing opportunities in emerging markets
Challenges:

1. Shortage of skilled professionals

2. Ambiguous regulatory network

Key Market Players:
As of 2021, prominent players in the cryo-electron microscopy market are Thermo Fisher Scientific (US), Danaher (US), JEOL Ltd. (Japan), Intertek Group Plc (UK), and Charles River Laboratories (US).
Recent Developments

In 2022, Thermo Fisher Scientific (US) launched the Glacios 2 Cryo-Transmission Electron Microscope (Cryo-TEM). The product features high-resolution capabilities and helps in drug discovery research.

In 2022, Leica Microsystems (US), a subsidiary of Danaher launched a new Coral Cryo-electron workflow solution to support researchers with high-precision confocal 3D targeting

In 2021, JEOL Ltd. (Japan) launched CRYO ARM 300 II. It is a cold emission cryo-electron microscope. It aims to enable the observation of biological specimens under high resolution

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=217602093 Objectives of the Study:

To define, describe, and forecast cryo-electron microscopy market on the basis of product & service, technology, application, and region

To provide detailed information regarding the major factors influencing the growth potential of the global cryo-electron microscopy market (drivers, restraints, opportunities, challenges, and trends)

To analyze the micro markets with respect to individual growth trends, future prospects, and contributions to the global cryo-electron microscopy market.

To analyze key growth opportunities in the global cryo-electron microscopy market for key stakeholders and provide details of the competitive landscape for market leaders

To forecast the size of market segments and/or subsegments with respect to five major regions, namely, North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the RoE), Asia Pacific (Japan, China, India, Australia, South Korea and the RoAPAC), Latin America, and the Middle East & Africa

To profile the key players in the cryo-electron microscopy market and comprehensively analyze their market shares and core competencies

To track and analyze the competitive developments undertaken in the global cryo-electron microscopy market, such as product launches; agreements; expansions; and mergers & acquisitions

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/cryo-electron-microscopy-market-217602093.html

# data[].attributes.attachment_link.title
Cryo-electron Microscopy Market worth $2.1 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
The cryo-electron microscopy market is moderately competitive, with both established companies and upcoming competitors for the same market share. As of 2021, the key player operating in the global cryo-electron microscopy market are Thermo Fisher Scientific (US), Danaher (US), JEOL Ltd.

# data[].attributes.headline
Humanized Mouse and Rat Models: A Cost-Effective Solution for Preclinical Research

# data[].attributes.subject
Humanized Mouse and Rat Models: A Cost-Effective Solution for Preclinical Research

# data[].attributes.body
The Global Humanized Mouse and Rat Model Market in terms of revenue was estimated to be worth $237 million in 2022 and is poised to reach $338 million by 2027, growing at a CAGR of 7.4% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The major factors driving the growth of this market include increasing number of research activities involving humanized models, growing demand for personalized medicine, continuous support in the form of investments and grants from the government and private sector, rising usage of mice models in virology and infectious disease testing, and growth in the number of R&D activities carried out by pharmaceutical and biotechnology companies. However, the high cost of humanized mouse and rat models and regulations & laws regarding the ethical use of animals in medical research are expected to restrain the growth of this market during the forecast period.

# data[].attributes.attachment_link.readable_text
Northbrook, IL 60062 -- ( SBWIRE) -- 05/19/2023 -- The humanized mouse and rat model industry is expected to witness significant growth in the near future. These models are essential tools in biomedical research and drug development, allowing scientists to better understand human diseases and evaluate the efficacy and safety of potential treatments. Humanized mouse and rat models are created by introducing human genes, cells, or tissues into the animal models, enabling the simulation of human physiological and pathological processes. With advancements in gene-editing technologies like CRISPR-Cas9, the creation of more precise and sophisticated humanized models is becoming possible. This opens up new avenues for studying complex diseases, such as cancer, autoimmune disorders, and infectious diseases, and facilitates the development of targeted therapies. The use of humanized models in preclinical studies can help accelerate the drug discovery process, reduce costs, and improve the success rates of clinical trials. As a result, the humanized mouse and rat model industry is poised to play a pivotal role in advancing biomedical research and personalized medicine in the near future.

Humanized Mouse and Rat Model Market in terms of revenue was estimated to be worth $237 million in 2022 and is poised to reach $338 million by 2027, growing at a CAGR of 7.4% from 2022 to 2027 according to a new report by MarketsandMarkets™. Factors such as advances in genomics, proteomics, and metabolomics; completion of the human genome map; the development of targeted diagnostics and therapeutics; and the growing emphasis on health, wellness, and preventive measures are driving the demand for personalized medicine and, subsequently the demand for relevant humanized mouse and rat research models. Also, grants from government and private organizations for cancer research have also supported the development of humanized models in oncology. For instance, in 2020, the US NIH funded a large-scale project to find treatments for rare genetic diseases with a five-year grant of USD 10,625,000 to The Jackson Laboratory Center for Precision Genetics. In the same year, The Jackson
Laboratory received a grant from the NIH for its Mouse Mutant Resource and Research Centers (MMRRC) program, established in 2009. The new grant provides a total of USD 6,119,082 over five years to the MMRRC. With such grants and funding from the government and private sectors, the demand for humanized mouse models is expected to increase.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955

Browse in-depth TOC on "Humanized Mouse and Rat Model Market"
140 - Tables
27 - Figures
177 - Pages

The genetic humanized mouse model segment accounted for the largest share of the humanized mouse model segment in the humanized mouse and rat model market in 2021.
Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. The humanized mouse models' segment is further divided into genetic humanized mouse models and cell-based humanized mouse models. In 2021, genetic humanized mouse segment accounted for the largest share of humanized mouse model market. Advances in genetic engineering technologies, such as gene targeting and gene editing, have led to the development of genetically engineered humanized mouse models that serve as an important tool for a variety of research applications. In addition to the widespread use of these mice in diverse research areas, the emerging CRISPR technology, increasing focus on personalized medicine with the continuous introduction of new models, and various licensing agreements are expected to drive market growth.

The immunology and infectious diseases segment accounted for the second largest share of the application segment in the humanized mouse and rat model market in 2021.
Based on application, the humanized mouse and rat model market is segmented into oncology, immunology and infectious diseases, neuroscience, Hematopoiesis, toxicology, and other applications. Immunology and Infectious diseases segment accounted for the second largest share of the humanized mouse and rat model market in 2021. Mouse models are used in immunology and inflammation studies as they help assess the physiological relevance of an experimental finding. The use of mouse models allows suitable alterations in the mouse genome at random or in specific regions, enabling a detailed study of immunological processes. They also assist in identifying the function of newly identified surface receptors in host defense as well as the developmental consequences of a disturbed signaling pathway or removing a transcription factor. Such mouse models are developed on a large scale in laboratories or institutes and are used for application in Immunology and Infectious diseases segment. Thus, making it the second largest segment in the market.

The Asia Pacific region is the fastest-growing region of the humanized mouse and rat model market in 2021.
Based on the region, the humanized mouse and rat model market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is estimated to register the highest growth during the forecast period. Global pharmaceutical firms are increasingly moving to APAC to tap into its thriving market and lower their production costs by shifting manufacturing and laboratory testing to the region. The rapidly increasing demand for the outsourcing of quality control safety testing (including efficacy testing) in countries such as China, India, Japan, and Singapore is expected to drive market growth in the Asia Pacific during the forecast period.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=131763955

Humanized Mouse and Rat Model Market Dynamics:

Drivers:
1. Increasing research activities using humanized models
2. Rising demand for personalized medicine
3. Continuous support and initiatives from government and private sectors for cancer research
4. Growing R&D activities in pharmaceutical and biotechnology sectors

Restraints:
1. High cost of custom humanized models
2. Laws and regulations for ethical use of animal models in research

Opportunities:
1. Rising demand for humanized PDX models
2. Emergence of CRISPR as a powerful tool in biomedical research
3. Rising demand for humanized rat models

Challenges:
1. Alternatives for animal testing
2. Limitations of humanized mouse models

Key Market Players:

Key players in the humanized mouse and rat model Market include Charles River Laboratories International, Inc. (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), Crown Bioscience (US), and Envigo (US).

View detailed Table of Content here@
https://www.marketsandmarkets.com/Market-Reports/humanized-mouse-model-market-131763955.html

Recent Developments:
- In January 2022, Taconic Biosciences, Inc. (US) launched the huNOG-EXL EA (early access) humanized immune system (HIS) mouse.

- In October 2021, The Jackson Laboratory (US) acquired RMS Business of Charles River Laboratories Japan, Inc. (Japan) which is Charles River Laboratories Japan's Research Models & Services (RMS) business as a wholly-owned subsidiary.

- In September 2021, Biocytogen (US) collaborated with Envigo (US) in order to support the research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the US, Europe, and certain APAC regions.

- In March 2021, Charles River Laboratories International, Inc. (US) acquired Cognate BioServices, Inc. (US) a cell and gene therapy contract development and manufacturing organization (CDMO) offering comprehensive manufacturing solutions for cell therapies. The acquisition expanded Charles River's broad capabilities across the major CDMO platforms for cell and gene therapies.

Humanized Mouse and Rat Model Market Advantages:

- Enhanced translatability: Humanized mouse and rat models closely mimic human physiology and disease conditions, allowing for more accurate translation of research findings to human patients. This increases the likelihood of successful translation from preclinical studies to clinical trials.

- Study of human-specific diseases: Humanized models enable the study of human-specific diseases that cannot be effectively studied in traditional animal models. These models provide insights into the mechanisms of diseases such as cancer, autoimmune disorders, and infectious diseases, leading to the development of targeted therapies.

- Evaluation of drug efficacy and safety: Humanized models allow researchers to evaluate the efficacy and safety of potential drug candidates in a more relevant and predictive manner. This leads to more informed decision-making in drug development, reducing the likelihood of failures in later stages of clinical trials.

- Personalized medicine advancements: Humanized models enable the exploration of personalized medicine approaches by allowing researchers to assess the response of specific patient populations to different therapies. This can aid in the development of tailored treatments and improve patient outcomes.

- Reduction in animal usage: By using humanized models, researchers can minimize the reliance on traditional animal models, reducing the number of animals used in research studies while obtaining more clinically relevant data.

# data[].attributes.attachment_link.keywords[]
humanized mouse model market by applicati

# data[].attributes.attachment_link.title
Humanized Mouse and Rat Model Market Size, Growth, Drivers & Opportunities | MarketsandMarkets

# data[].attributes.attachment_link.description
The global humanized mouse and rat model market in terms of revenue was estimated to be worth $237 million in 2022 and is poised to reach $338 million by 2027, growing at a CAGR of 7.4% from 2022 to 2027.

# data[].attributes.headline
Lancets Market Size, Trends, Future Scope, Opportunity and Forecast to 2028

# data[].attributes.subject
Lancets Market Size, Trends, Future Scope, Opportunity and Forecast to 2028

# data[].attributes.body
The lancets industry is poised for significant growth and innovation in the near future. Lancets, which are small, pricking devices used for blood sampling, play a crucial role in various healthcare settings, including home-based testing, diagnostics, and monitoring of chronic conditions such as diabetes. In the coming years, we can expect several advancements in lancet technology and design to improve patient experience, safety, and accuracy.

# data[].attributes.attachment_link.title
Lancets Market worth $3.6 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
The lancets industry is poised for significant growth and innovation in the near future. Lancets, which are small, pricking devices used for blood sampling, play a crucial role in various healthcare settings, including home-based testing, diagnostics, and monitoring of chronic conditions such as dia…

# data[].attributes.headline
The Booming Biobanking Market: Trends and Insights

# data[].attributes.subject
The Booming Biobanking Market: Trends and Insights

# data[].attributes.body
Based on sample type, the global biobanking market has been segmented into blood products, human tissues, nucleic acids, human waste products, cell lines, and biological fluids. The blood products segment held the largest share of the global biobanking market in 2022. This can be attributed to the rising incidence of blood disorders and the increasing demand for various types of blood products across the globe. With the ongoing expansion of biobanks and the increasing emphasis on precision medicine, the demand for blood products in biobanking is expected to remain strong, further propelling the growth of the global biobanking market

# data[].attributes.attachment_link.readable_text
Biobanking Market worth $5.0 billion | MarketsandMarkets

Biobanking Market in terms of revenue was estimated to be worth $2.9 billion in 2023 and is poised to reach $5.0 billion by 2028, growing at a CAGR of 11.4% from 2023 to 2028 according to a new report by MarketsandMarkets™. The global biobanking market is expected to grow at a CAGR of 11.4% during the forecast period. The growth of this market is driven by increasing number of private cord blood banks has led to a rise in competition among biobanks, which has driven innovation and improvements in the quality of biobanking services. This, in turn, has fueled growth in the biobanking market as more companies seek to enter this expanding field and meet the growing demand for cord blood stem cell preservation.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=594&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Browse in-depth TOC on "Biobanking Market"

380 - Tables
46 - Figures
324 - Pages

The blood products segment accounted for the largest share, by sample type in the biobanking market in 2022.

Based on sample type, the global biobanking market has been segmented into blood products, human tissues, nucleic acids, human waste products, cell lines, and biological fluids. The blood products segment held the largest share of the global biobanking market in 2022. This can be attributed to the rising incidence of blood disorders and the increasing demand for various types of blood products across the globe. With the ongoing expansion of biobanks and the increasing emphasis on precision medicine, the demand for blood products in biobanking is expected to remain strong, further propelling the growth of the global biobanking market

The manual storage segment accounted for the largest share of the storage type segment in the biobanking market in 2022.

Based on storage, the global biobanking market has been segmented into manual storage and automated storage. The manual storage segment held the larger market share in 2022. The large share of this segment can be attributed to the low cost and easy installation associated with this type of storage. Furthermore, many research centers and life science companies rely on manual processes for biological sample storage, this is further accelerating the market growth.

The North America region catered the largest share of the biobanking market in 2022.

The biobanking market in North America has experienced significant growth in recent years, showcasing a robust expansion trajectory. This can be attributed to the increasing number of biobanks and the growing investments in biobanking infrastructure. Major healthcare institutes and research organizations in North America have made substantial commitments to expanding their biobanking capabilities. Additionally, the rising prevalence of chronic diseases and the subsequent demand for personalized medicine has fueled the growth of the biobanking market in North America, with biobanks playing a pivotal role in storing and providing high-quality biological specimens for research and development purposes.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=594&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Biobanking Market Dynamics:

Drivers:

Growing investments and funding for biobanks
Focus on genetic testing and precision medicine
Increasing trend in preservation of cord blood stem cells from newborns
Favorable funding scenario for research related to regenerative medicine

Restraints:

High cost of automated equipment
Issues related to biospecimen sample management

Opportunities:

Emerging countries to provide lucrative opportunities

Challenges:

High operational cost of biobanks
Storage of samples

Key Market Players:

Key players in the biobanking market include Thermo Fisher Scientific, Inc. (US), PHC Holdings Corporation (Japan), Becton, Dickinson and Company (US), QIAGEN N.V. (Germany), Merck KGaA (Germany), Avantor, Inc. (US), Cryoport, Inc. (US), Tecan Trading AG (Switzerland), Azenta, Inc. (US), Greiner Holding AG (Austria), Hamilton Company (US), Micronic (Netherlands), AMSBIO (UK), Bay Biosciences LLC (US), BioKryo (Germany), SPT Labtech (UK), ASKION GmbH (Germany), Cell&Co BioServices (France), Ziath Ltd. (UK), CTIBiotech (France), Cureline (US), Firalis Group (France), Sopachem (Netherlands), ProteoGenex (US), and US Biolab Corporation, Inc. (US).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=594&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Recent Developments:

In February 2023, PHC Corporation of North America launched the PHCbi Brand VIP ECO SMART Ultra-low Temperature Freezer with industry-leading energy efficiency.

In September 2022, Cryoport entered into a strategic partnership with BioLife Plasma Services to offer supply chain solutions and service offerings, such as bioservices and cryo-processing, for BioLife Plasma Services.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/biobanking-devices-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/biobanking-devices.asp

About MarketsandMarkets™:

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
This release was published on openPR.

# data[].attributes.attachment_link.title
Biobanking Market worth $5.0 billion | Thermo Fisher Scientific, Inc. (US), PHC Holdings Corporation (Japan), Becton, Dickinson and Company (US), QIAGEN N.V. (Germany), Merck KGaA (Germany)

# data[].attributes.attachment_link.description
Biobanking Market in terms of revenue was estimated to be worth 2 9 billion in 2023 and is poised to reach 5 0 billion by 2028 growing at a CAGR of 11 4 from 2023 to 2028 according to a ...

# data[].attributes.headline
Metaverse in Healthcare Market Current Scenario and Future Prospects

# data[].attributes.subject
Metaverse in Healthcare Market Current Scenario and Future Prospects

# data[].attributes.body
Based on technology, the metaverse in healthcare market is segmented into augmented and virtual reality, mixed reality, artificial intelligence, blockchain, digital twin, Internet of Things, and medical wearables. The augmented and virtual reality segment accounted for the largest share of 28.2% of the metaverse in healthcare market in 2022. The large share of the augmented and virtual reality segment can be attributed to the growing adoption of VR and AR in the healthcare industry, improved patient outcomes, and the growing focus on enhancing medical training, reducing costs, increasing accessibility, improving patient engagement, and driving innovation.

# data[].attributes.attachment_link.readable_text
Metaverse in Healthcare Market

Metaverse in Healthcare Market in terms of revenue was estimated to be worth $9.5 billion in 2023 and is poised to reach $79.6 billion by 2028, growing at a CAGR of 52.9% from 2023 to 2028 according to a new report by MarketsandMarkets™. The increasing adoption of mixed reality for performing minimally invasive surgeries, growing focus on telemedicine, increasing use of digital twins, and the growing importance of blockchain technology in healthcare are the key factors driving the growth of this market. However, increasing concerns over data privacy and security and the high implementation cost of technologies are expected to restrain the growth of this market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=225839181&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Browse in-depth TOC on "Metaverse in Healthcare Market"

121 - Tables
39 - Figures
237 - Pages

The Software segment accounted for the largest share in the metaverse in healthcare market, by component.

The metaverse in healthcare market, by component, is segmented into hardware, software, and services. The software segment includes platforms and applications that enable the creation, customization, and deployment of virtual experiences. The hardware segment includes devices such as head-mounted displays and haptic feedback gloves that enable users to interact with the virtual environment, while the services segment includes consulting, development, and support services that enable healthcare providers to integrate the metaverse into their workflows.

In 2022, the software segment accounted for the largest market share in metaverse in healthcare market. The large share of this segment is attributed to the increased adaptation of AR/VR software in the healthcare industry and the significant rise in investments made in software development.

By Technology, the Augmented/Virtual reality segment registered the highest growth in the metaverse in healthcare market during the forecast period

Based on technology, the metaverse in healthcare market is segmented into augmented and virtual reality, mixed reality, artificial intelligence, blockchain, digital twin, Internet of Things, and medical wearables. The augmented and virtual reality segment accounted for the largest share of 28.2% of the metaverse in healthcare market in 2022. The large share of the augmented and virtual reality segment can be attributed to the growing adoption of VR and AR in the healthcare industry, improved patient outcomes, and the growing focus on enhancing medical training, reducing costs, increasing accessibility, improving patient engagement, and driving innovation.

By Application, the medical education and surgical training segment accounted for the largest share in the metaverse in healthcare market.

In 2022, Based on application, the medical education and surgical training segment accounted for the largest share of 26.6% of the metaverse in healthcare market. The large share of this segment can be attributed to factors such as the increasing budget of hospitals to improve the quality of care provided and reduce the cost of care.

By End User, the healthcare providers segment accounted for the largest share in the metaverse in healthcare market.

In 2022, The healthcare providers segment accounted for the largest share of the metaverse in healthcare market. The large share of this segment can be attributed to the rising need for an efficient healthcare system, growing patient volume, increasing number of hospitals and ambulatory care centers, growth in telehealth, and the rising adoption of metaverse technology in healthcare.

Asia Pacific is expected to exhibit the highest growth during the forecast period

The Asia Pacific market is estimated to register the highest CAGR during the forecast period. Favorable government initiatives for implementing metaverse technologies in the healthcare industry, the growing adoption of AR/VR in healthcare, the rising need for advanced healthcare technologies to track and monitor the large volume of patients, and the rising demand for quality healthcare at low costs are driving the growth of this regional market.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=225839181&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Metaverse in Healthcare Market Dynamics:

Drivers:

Increasing adoption of mixed reality for performing minimally invasive surgeries
Applications of metaverse in telemedicine
Increasing use of digital twins
Increasing importance of blockchain technology in healthcare

Restraints:

Data privacy and security concerns
High implementation cost
Health and mental issues from excessive use

Opportunities:

Increasing use of metaverse in medical education and training
Use of metaverse in surgical applications

Challenges:

HIPAA regulations for healthcare metaverse
Interoperability issues
Local government restrictions coupled with environmental impact

Key Market Players:

Microsoft (US), NVIDIA Corporation (US), XRHealth (US), CAE Inc. (Canada), Koninklijke Philips N.V. (Netherlands), ImmersiveTouch, Inc. (US), Wipro (India), Siemens Healthineers AG (Germany), Medtronic plc (Ireland), GE HealthCare (US), Intuitive Surgical (US), 8Chili, Inc. (US), MindMaze (Switzerland), AccuVein, Inc. (US), EON Reality (US), Brainlab AG (Germany), Novarad Corporation (US), Oodles Technologies (India), CMR Surgical (UK), Merative (US), BioflightVR (US), WorldViz, Inc. (US), Google (US), Oculus (Meta Platforms, Inc.) (US), and Augmedics (US) are the major players in this market. These companies are majorly focusing on the strategies such as acquisitions, product launches, agreements, collaborations, partnerships, and expansions in order to remain competitive and further increase their share in the market.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=225839181&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/metaverse-in-healthcare-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/metaverse-in-healthcare.asp

About MarketsandMarkets™:

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
This release was published on openPR.

# data[].attributes.attachment_link.title
Metaverse in Healthcare Market Current Scenario and Future Prospects

# data[].attributes.attachment_link.description
Metaverse in Healthcare Market in terms of revenue was estimated to be worth 9 5 billion in 2023 and is poised to reach 79 6 billion by 2028 growing at a CAGR of 52 9 from 2023 to 2028 according ...

# data[].attributes.headline
Particle Counters Market worth $825 million by 2027

# data[].attributes.subject
Particle Counters Market worth $825 million by 2027

# data[].attributes.body
The Global Particle Counters Market in terms of revenue was estimated to be worth $511 million in 2022 and is poised to reach $826 million by 2027, growing at a CAGR of 10.0% from 2022 to 2027. Favorable conditions and the high adoption of advanced technologies in various medical and industrial sectors have aided the growth of end-use industries for particle counters, such as automotive, aerospace, energy, and oil & gas. Moreover, favorable regulatory scenario, and growing focus on the quality of food products are the key factors driving the growth of this market. In addition, emerging economies (such as Brazil, India, South Korea, and China).

# data[].attributes.attachment_link.readable_text
, July 13, 2022 /PRNewswire/ -- According to the new market research report ' Particle Counters Market by Type (Airborne, Liquid Particle Counters), Application (Cleanroom Monitoring, Contamination Monitoring of Liquid, Aerosol Monitoring), End User (Life Sciences & Medical Devices, Semiconductor), Region - Global Forecasts to 2027,' published by MarketsandMarkets™, the Particle Counters Market is estimated to reach USD 825 million by 2027 from USD 511 million in 2022, at a CAGR of 10.0% from 2022 to 2027.
Browse in-depth TOC on Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=221564539 The airborne particle counters segment accounted for the largest share of the particle counters market, by type, in 2021 'Particle Counters Market'
151 - Tables
29 - Figures
197 - Pages
Cleanroom monitoring segment accounted for the largest share of the particle counters applications market in 2021

The factors such as robust growth in applied markets, the favorable regulatory scenario, and growing focus on the quality of food products are driving the growth of the particle counters market during the forecast period.
Life sciences & medical device industries are the largest end users of the particle counters market

The airborne particle counters segment accounted for the largest share of the particle counter market in 2021. This can be attributed to the increasing use of these counters for cleanroom monitoring and the rising stringency of air pollution monitoring, which has supported their adoption.
Request Sample Pages: North America to dominate the particle counters market during the forecast period
https://www.marketsandmarkets.com/requestsampleNew.asp?id=221564539
The cleanroom monitoring segment accounted for the largest share of the particle counters market, by application, in 2021. Cleanrooms are used extensively in semiconductors, manufacturing, pharmaceuticals, medical devices, life sciences, and critical process manufacturing common in the aerospace, optics, military, and energy industries. Growth of these industries in developed as well as developing regions will boost the demand for particle counters in near future.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=221564539 Browse Related Reports:

In 2021, the life sciences & medical device industry segment accounted for the largest share of the particle counter market. Major share of the end user segment are attributed to the technological advancements coupled with increasing demand for quality assurance and stringent regulation of manufacturing environments to ensure product quality. Moreover, significant investments in infrastructure expansion of pharmaceutical and medical devices companies in emerging markets, such as India, China are the other factors boosting the demand for particles counter.

In 2021, North America accounted for the largest share of the particle counter market. This can be attributed to the public-private funding and investments to support air pollution monitoring-based research, faster adoption of technologically advanced particle counters, and strong pharmaceutical and biotechnology research trends. According to PhRMA, US companies conduct most of the world's pharmaceutical and medical device R&D. These industries are highly regulated with an extensive focus on quality and safety, which resulted in increased demand for paricle counters for cleanroom monitoring as well as liquid contamination monitoring applications. Moreover, the US and Canada governments implemented several strategies and awareness programs to enhance the demand for pollution monitoring products across the country.

As of 2021, prominent players in the particle counters market are Particle Measuring Systems, Inc. (US), Beckman Coulter (US), RION Co., Ltd. (Japan), Lighthouse Worldwide Solutions, Inc. (US), TSI Incorporated (US), Climet Instruments Company (US), Met One Instruments, Inc. (US), Particle Plus, Inc. (US), Setra Systems (US), PAMAS (Germany), Chemtrac, Inc. (US), HAL Technology (US), Kanomax USA, Inc. (US), Veltek Associates, Inc. (US), PCE Instruments UK Ltd. (UK), GrayWolf Sensing Solutions (US), Extech Instruments (US), Palas GmbH (Germany), HYDAC International (Australia), and Fluke Corporation (US), among others.

Browse Adjacent Markets: Analytical and Scientific Instrumentation Market Research Reports & Consulting

Particle Size Analysis Market by Technology (Laser Diffraction, DLS, Imaging, Coulter Principle, Sieving, Nanoparticle Tracking), Dispersion (Wet, Dry, Spray), Enduser (Pharma-biotech, Cosmeceutical, Chemicals, Food, Academia) - Global Forecasts to 2026
https://www.marketsandmarkets.com/Market-Reports/particle-size-analysis-market-74084833.html

Environmental Monitoring Market by Product Type (Sensors, Indoor Monitors, Outdoor Monitors), Sampling Method, Component, Application, End-User, and Region (North America, Europe, APAC, Latin America, MEA) (2022 - 2026)
https://www.marketsandmarkets.com/Market-Reports/environmental-monitoring-market-216846315.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/particle-counter-market.asp
Visit Our Web Site: https://www.marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/particle-counter.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Particle Counters Market worth $825 million by 2027 - Exclusive Report by MarketsandMarkets™

# data[].attributes.attachment_link.description
July 13, 2022 /PRNewswire/ -- According to the new market research report ' Particle Counters Market by Type (Airborne, Liquid Particle Counters), Application (Cleanroom Monitoring, Contamination Monitoring of Liquid, Aerosol Monitoring), End User (Life Sciences & Medical Devices, Semiconductor), Region - Global Forecasts to 2027,' published by MarketsandMarkets™, the Particle Counters Market is estimated to reach USD 825 million by 2027 from USD 511 million in 2022, at a CAGR of 10.0% from 2022 to 2027.

# data[].attributes.headline
Unlocking the Value: Exploring the Global Healthcare Data Monetization Market

# data[].attributes.subject
Unlocking the Value: Exploring the Global Healthcare Data Monetization Market

# data[].attributes.body
The Global Healthcare Data Monetization Market in terms of revenue was estimated to be worth $0.4 billion in 2023 and is poised to reach $0.9 billion by 2028, growing at a CAGR of 18.5% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of EHR adoption primarily drives the market growth, the increase in use of external data sources, the need to curtail escalating healthcare costs, increasing partnerships and collaborations among players, and growing investments in advanced analytics. Additionally, factors such rising adoption of AI in precision medicine, and the explosion in bioinformatics data and large healthcare datasets are also contributing to the market growth.

# data[].attributes.attachment_link.readable_text
, June 13, 2023 /PRNewswire/ -- The healthcare data monetization industry is poised for significant growth in the near future. With the increasing digitalization of healthcare systems and the abundance of data being generated, healthcare organizations are recognizing the immense value of their data assets. In the coming years, we can expect to see a surge in initiatives focused on leveraging healthcare data for monetization purposes. This industry will witness the emergence of innovative data monetization platforms, advanced analytics tools, and secure data marketplaces. Healthcare organizations will actively explore opportunities to collaborate with research institutions, pharmaceutical companies, and technology firms to unlock the potential of their data for research, development, and commercial purposes. The healthcare data monetization industry will not only drive additional revenue streams for healthcare organizations but also foster data-driven decision-making, accelerate medical research, and ultimately contribute to improved patient outcomes. However, it will be crucial to address concerns related to data privacy, security, and regulatory compliance to build trust and ensure ethical data practices in this evolving landscape.

Healthcare Data Monetization Market in terms of revenue was estimated to be worth $0.4 billion in 2023 and is poised to reach $0.9 billion by 2028, growing at a CAGR of 18.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as exponentially increasing data volume and generation of large and complex healthcare datasets, the need to curtail escalating healthcare costs, expanding partnerships and collaborations among players, and growing investments in the adoption of EHR systems primarily drive the growth of this market. Furthermore, the rising adoption of AI in precision medicine and the growing demand for real-world evidence (RWE) would provide lucrative opportunities to solution providers.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=56622234 Browse in-depth TOC on "Healthcare Data Monetization Market"
Healthcare Data Monetization Market The cloud segment is expected to be the fastest-growing healthcare data monetization market, by deployment, during the forecast period. Scope: The pharmaceutical & biotechnology companies segment, by end-user, is expected to be the largest healthcare data monetization market in 2023 292 - Pages Asia Pacific is expected to be the fastest-growing in healthcare data monetization market during the forecast period.
Based on deployment, the market is segmented into on-premise and cloud. The cloud segment is expected to grow at a higher CAGR during the forecast period due to increased agility and scalability offered by cloud-based data monetization solutions. Cloud platforms provide secure and scalable storage solutions for vast amounts of healthcare data, including electronic health records, medical images, and patient-generated data. Furthermore, cloud-based analytics tools enable healthcare organizations to perform advanced data analysis, leveraging machine learning algorithms and artificial intelligence to gain valuable insights from complex datasets.
Request Sample Pages: Healthcare Data Monetization Market Drivers: Dynamics: Restraints: https://www.marketsandmarkets.com/requestsampleNew.asp?id=56622234 Opportunities:
Based on the end user, the market is broadly segmented into pharmaceutical & biotechnology companies; healthcare payers; healthcare providers; medical technology companies; and other end users. Pharmaceutical & biotechnology companies would account for the largest share of the global end-user market in 2023. Market growth can be attributed to the rising demand for solutions to cut the time and costs of drug development. Pharmaceutical and biotechnology companies can benefit significantly from healthcare data monetization, as it can help them develop new drugs, identify potential markets, and improve patient outcomes.
Challenges: Key Market Players:
The global market has been segmented based on region: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Asia Pacific market is projected to register the highest CAGR during the forecast period. Emerging countries in the Asia Pacific, such as India and China, offer lucrative growth opportunities for market players, primarily due to the increasing adoption of digital healthcare technologies, increasing public and private funding, improving IT infrastructure, the demand for affordable healthcare, favorable government norms, growing awareness about precision medicine, and the high incidence of cancer and chronic diseases are expected to boost the adoption of healthcare data monetization solutions in Asia Pacific.
Get 10% Free Customization on this Report: Recent Developments: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=56622234 Healthcare Data Monetization Market Advantages:

Increase in use of external data sources
Healthcare Data Monetization Market - Key Stakeholders:

Regulatory constraints to impact the growth of the market during the forecast period
Related Reports:

Rising Demand for Real-World Evidence

Major players operating in the healthcare data monetization market are Oracle Corporation (US), Microsoft Corporation (US), Google (US), Salesforce, Inc. (US), SAS Institute Inc. (US), SAP SE (Germany), TIBCO Software Inc. (US), Sisense Inc. (US), Snowflake Inc. (US), QlikTech International AB (US), HealthVerity, Inc. (US), Accenture (Ireland), Availity, LLC (US), Domo, Inc. (US), Komodo Health, Inc. (US), ThoughtSpot Inc. (US), Datavant (US), Verato (US), Infor, Inc. (US), Virtusa (US), Infosys (India), Particle Health, Inc. (US), Innovaccer, Inc. (US), H1 (US), and Medoble Inc. (US).

In October 2022, Oracle Corporation introduced a planning solution for the healthcare industry as part of its Fusion Cloud Enterprise Performance Management (EPM) offering. The solution aims to help healthcare organizations improve financial performance and patient care by enabling them to model scenarios, optimize resources, and make better finance, workforce, and patient care decisions.

In April 2023, Microsoft Corporation and Epic Systems expanded their collaboration to integrate generative AI into healthcare by combining Azure OpenAI Service with Epic's electronic health record (EHR) software. The collaboration aimed to enhance patient care, increase productivity, and improve financial integrity in health systems globally.

In February 2023, Redox and Google Cloud partnered to simplify the exchange of healthcare data, enabling better and faster decision-making for healthcare organizations. Redox's platform would be replicated on Google Cloud, offering customers access to Redox's products and services.

In April 2023, Salesforce announced new Customer 360 for Health capabilities aimed at enhancing personalized patient experiences and reducing operational costs for healthcare providers. These innovations leverage real-time data, AI, and automation to address the challenges faced by healthcare organizations in meeting customer expectations.

In May 2023, HTEC Group joined the SAS IoT Partner Ecosystem to partner on delivering innovative solutions in industries such as healthcare, life sciences, logistics, and more. The partnership aimed to develop joint offerings that enable global enterprise companies to apply cutting-edge data-driven, IoT, edge, and cloud-enabled solutions to their business challenges.

Revenue Generation: Healthcare organizations possess vast amounts of valuable data, including patient records, clinical data, claims data, and real-world evidence. By monetizing this data, healthcare organizations can generate additional revenue streams. They can sell anonymized and aggregated data to researchers, pharmaceutical companies, insurance providers, and other interested parties, creating a new source of income.

Data-Driven Decision Making: Monetizing healthcare data encourages organizations to invest in robust data analytics capabilities. By analyzing and deriving insights from the data, healthcare providers and stakeholders can make informed decisions to improve patient outcomes, optimize operations, and identify opportunities for innovation. Data monetization drives a data-driven culture within the healthcare industry.

Research and Development: Monetizing healthcare data can accelerate research and development activities. Pharmaceutical companies and medical researchers can access comprehensive datasets for drug discovery, clinical trials, epidemiological studies, and population health research. This fosters collaboration and innovation, ultimately leading to the development of new treatments, therapies, and medical advancements.

Improving Healthcare Delivery: By monetizing healthcare data, organizations can gain insights into patient populations, disease patterns, and treatment outcomes. This information can be leveraged to enhance care delivery, optimize care pathways, and implement personalized medicine approaches. Data monetization drives continuous improvement in healthcare delivery by facilitating evidence-based decision making and enhancing patient outcomes.

Cost Optimization: Healthcare data monetization can help organizations optimize costs and resource allocation. By analyzing data on healthcare utilization, supply chain management, and operational efficiencies, organizations can identify areas for cost reduction, waste elimination, and process improvement. This leads to more efficient healthcare operations and better financial sustainability.

Collaborative Opportunities: Monetizing healthcare data opens up opportunities for collaboration and partnerships. By sharing data with external stakeholders, such as research institutions or technology companies, healthcare organizations can foster innovation, develop new solutions, and drive advancements in healthcare. Collaborative data initiatives promote knowledge exchange, interdisciplinary research, and the overall growth of the healthcare ecosystem.

Improved Patient Outcomes: Leveraging healthcare data for monetization purposes contributes to the advancement of personalized medicine and precision healthcare. By analyzing patient data, providers can tailor treatment plans, predict disease risks, and implement preventive measures. This leads to improved patient outcomes, reduced healthcare costs, and enhanced patient satisfaction.

Enhanced Data Governance: Monetizing healthcare data necessitates robust data governance frameworks, ensuring compliance with privacy regulations, data security standards, and ethical considerations. Organizations that engage in data monetization are compelled to prioritize data governance practices, leading to better data management, improved data quality, and increased patient privacy protection.

Overall, healthcare data monetization offers numerous advantages, including revenue generation, data-driven decision making, research acceleration, improved healthcare delivery, cost optimization, collaborative opportunities, improved patient outcomes, and enhanced data governance. These benefits collectively contribute to the growth and advancement of the healthcare industry.

Healthcare Data Monetization Solution Providers

Platform Providers

Technology Providers

AI System Providers

Raw Data Providers

Data Buyers

Data Sellers

Healthcare Providers

Healthcare Payers

Pharmaceutical & Biotechnology Companies

Medical Technology Companies

Physician Groups and Organizations

Universities and Research Organizations

Forums, Alliances, and Associations

Academic Research Institutes

Healthcare Institutions

Distributors

Venture Capitalists

Government Organizations

Institutional Investors and Investment Banks

Investors/Shareholders

Consulting Companies in the Data Monetization Sector

Raw Materials and Component Manufacturers

About MarketsandMarkets™:
Population Health Management Market - Global Forecasts to 2027

Healthcare Payer Services Market - Global Forecasts to 2027

Healthcare IT Market - Global Forecasts to 2027

Medical Terminology Software Market - Global Forecasts to 2027

5G in Healthcare Market - Global Forecasts to 2026

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/healthcare-data-monetization-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/healthcare-data-monetization.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Healthcare Data Monetization Market worth $0.9 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
PRNewswire/ -- The healthcare data monetization industry is poised for significant growth in the near future. With the increasing digitalization of healthcare...

# data[].attributes.headline
Lancets Market Worth $3.6 billion by 2028| MarketsandMarkets

# data[].attributes.subject
Lancets Market Worth $3.6 billion by 2028| MarketsandMarkets

# data[].attributes.body
The Global Lancets Market in terms of revenue was estimated to be worth $2.3 billion in 2023 and is poised to reach $3.6 billion by 2028, growing at a CAGR of 9.7% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The increasing demand of the lancets market is mainly driven by the Growing prevalence of diabetes and increasing adoption of self-monitoring devices, the rising geriatric population, the high prevalence of chronic diseases and the increasing demand for painless lancets.

# data[].attributes.attachment_link.readable_text
Lancets Market in terms of revenue was estimated to be worth $2.3 billion in 2023 and is poised to reach $3.6 billion by 2028, growing at a CAGR of 9.7% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growth in the lancets ...

# data[].attributes.attachment_link.title
Lancets Industry Archives - MarketsandMarkets Blog

# data[].attributes.attachment_link.description
Lancets Market in terms of revenue was estimated to be worth $2.3 billion in 2023 and is poised to reach $3.6 billion by 2028, growing at a CAGR of 9.7% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growth in the lancets ...

# data[].attributes.headline
Revolutionizing Healthcare Education: Exploring the Growing Healthcare Simulation Market

# data[].attributes.subject
Revolutionizing Healthcare Education: Exploring the Growing Healthcare Simulation Market

# data[].attributes.body
The Global Healthcare Simulation Market in terms of revenue was estimated to be worth $1.9 billion in 2022 and is poised to reach $4.2 billion by 2027, growing at a CAGR of 16.1% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The major factors driving the growth of this market includes the need to maintain regulatory compliance, rising need to curtail healthcare costs, and growing demand for patient-centric healthcare. However, dearth of skilled IT professionals, and security concerns is challenging the growth of the global medical simulation market to a certain extent.

# data[].attributes.attachment_link.title
Revolutionizing Healthcare Education: Exploring the Growing Healthcare Simulation Market - MarketsandMarkets Blog

# data[].attributes.attachment_link.description
The Global Healthcare Simulation Market in terms of revenue was estimated to be worth $1.9 billion in 2022 and is poised to reach $4.2 billion by 2027, growing at a CAGR of 16.1% from 2022 to 2027.

# data[].attributes.headline
Lancets Market worth $3.6 billion | MarketsandMarkets

# data[].attributes.subject
Lancets Market worth $3.6 billion | MarketsandMarkets

# data[].attributes.body
Lancets Market in terms of revenue was estimated to be worth $2.3 billion in 2023 and is poised to reach $3.6 billion by 2028, growing at a CAGR of 9.7% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growth in the lancets market is mainly driven by the growing prevalence of diabetes, the high prevalence of chronic diseases, the rising geriatric population, and the increasing demand for painless lancets. In addition, emerging markets such as India and China are expected to offer growth opportunities for players operating in the Lancets market during the forecast period. However, the risk of lancet-related needlestick injuries, the reuse of lancets, and the poor reimbursement scenario in developing countries are restricting the growth of this market.

# data[].attributes.attachment_link.readable_text
CHICAGO, May 29, 2023 /PRNewswire/ -- The lancets industry is poised for significant growth and innovation in the near future. Lancets, which are small, pricking devices used for blood sampling, play a crucial role in various healthcare settings, including home-based testing, diagnostics, and monitoring of chronic conditions such as diabetes. In the coming years, we can expect several advancements in lancet technology and design to improve patient experience, safety, and accuracy. This may include the development of lancets with smaller and more precise needles, painless sampling techniques, and integrated safety features to minimize the risk of needlestick injuries. Furthermore, the integration of lancet devices with digital health platforms and mobile applications may enable better data management, real-time monitoring, and seamless integration of blood glucose or other health measurements into patient health records. The Lancets industry is likely to witness increased adoption and demand, driven by the rising prevalence of chronic diseases, the growing need for point-of-care testing, and the emphasis on patient-centric healthcare solutions.

Lancets Market in terms of revenue was estimated to be worth $2.3 billion in 2023 and is poised to reach $3.6 billion by 2028, growing at a CAGR of 9.7% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growth in the lancets market is mainly driven by the growing prevalence of diabetes, the high prevalence of chronic diseases, the rising geriatric population, and the increasing demand for painless lancets. In addition, emerging markets such as India and China are expected to offer growth opportunities for players operating in the Lancets market during the forecast period. However, the risk of lancet-related needlestick injuries, the reuse of lancets, and the poor reimbursement scenario in developing countries are restricting the growth of this market.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=86063487 Safety Lancets segment is expected to account for the largest share in 2022.
The lancets market, by type has been segmented into safety and standard lancets. Increasing demand for painless lancets is expected to drive the safety lancets market. The increasing demand for painless lancets can be attributed to improved patient comfort, increased prevalence of diabetes, improved technology, and convenience. As healthcare technology continues to advance, there will be more innovations in painless lancet technology to meet the growing demand.
The Glucose Testing segment held the largest market share in the application market.
By application, the global lancets market is broadly segmented into Glucose Testing, Hemoglobin Testing, Coagulation Testing, Cholesterol Testing, Allergy Testing and Neonatal Screening. Growing prevalence of diabetes and increasing adoption of self-monitoring devices have revolutionized the application of lancets in research. According to the Centers for Disease Control and Prevention (CDC), in 2020, more than 34 million Americans had diabetes, which is nearly 11% of the US population. There are 1.5 million new cases of diabetes in the United States each year.
North America dominates the global lancets market
Based on the region, the lancets market is segmented into North America, Europe, Asia Pacific and Rest of the world. North America market is driven by growing focus on rising prevalence of various chronic diseases and growing geriatric population. Thus, the rising geriatric population and the corresponding increase in the incidence of chronic diseases have increased the demand for lancets for early disease diagnostics. According to the WHO, globally, by 2030, 1 in every 6 individuals will be aged 60 years or over in the world. By 2050, the world's geriatric population (aged 60 years and older) will witness a two-fold increase (2.1 billion). The number of individuals aged 80 years or older is expected to grow three times between 2020 and 2050 to reach 426 million. There are over 46 million older adults living in the US as of 2021, and by 2050, the geriatric population is expected to grow to over 90 million.
Request Sample Pages: Lancets Market Drivers: Dynamics: Restraints: https://www.marketsandmarkets.com/requestsampleNew.asp?id=86063487 Opportunities:

1. Growing prevalence of diabetes and increasing adoption of self-monitoring devices

2. Rising prevalence of various chronic diseases

3. Increasing demand for painless lancets

4. Growing geriatric population

5. Rising number of hospitals and surgical centers

Challenges: Key Market Players:

1. Increasing incidence of lancet-related needlestick injuries and infections

2. Pricing pressure owing to reimbursement cuts and budget constraints

Get 10% Free Customization on this Report: Recent Developments: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=86063487 Lancets Market Advantages:

1. High growth prospects in emerging countries

2. Increasing awareness of novel technologies

Major players in lancets market include Becton, Dickinson and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), B. Braun SE (Germany), and Abbott Laboratories (US).
Lancets market - Report Highlights:

In 2023, Astellas Pharma announced that it has entered into an agreement with Roche Diabetes Care Japan Co., Ltd. for the development and commercialization of Roche Diabetes Care's world-renowned Accu-Chek Guide Me blood glucose monitoring system with advanced accuracy as a combined medical product with BlueStar.

In 2022, BD announced the completion of the spinoff of Embecta Corp., which holds BD's former Diabetes Care business and is one of the largest diabetes management companies in the world.

In 2021, Greiner Bio-One introduced MiniCollect PIXIE Heel Incision Safety Lancet to expand its portfolio. The new safety lancet is specially designed for heel incisions.

Related Reports:

Convenience and Ease of Use: Lancets provide a convenient and easy-to-use method for blood sampling. They are compact, portable, and require minimal training to operate, making them suitable for use in various healthcare settings, including home-based testing. Patients can perform blood sampling themselves, reducing the need for frequent visits to healthcare facilities.

Minimized Pain and Discomfort: The advancement of lancet technology has led to the development of devices with smaller and finer needles, resulting in reduced pain and discomfort during blood sampling. This is particularly important for individuals who require regular blood glucose monitoring, such as those with diabetes. Minimizing pain and discomfort improves patient compliance and encourages regular testing.

Safety Features: Many lancets now come with integrated safety features to minimize the risk of needlestick injuries. These features may include mechanisms that retract the lancet after use, preventing accidental pricks and reducing the risk of cross-contamination and the spread of infectious diseases. Safety-enhanced lancets contribute to healthcare worker safety and infection control measures.

Precision and Accuracy: Lancets are designed to provide precise and accurate blood samples for diagnostic purposes. They are often used in conjunction with glucose meters, hemoglobin meters, or other testing devices to measure specific parameters. Accurate and reliable results obtained from lancet-based blood sampling aid in the diagnosis, monitoring, and management of various medical conditions.

Cost-effectiveness: Lancets are generally cost-effective compared to other blood sampling methods, such as venipuncture. They are single-use devices, reducing the risk of cross-contamination and eliminating the need for expensive sterilization procedures. The affordability and accessibility of lancets make them a viable option for routine blood sampling and point-of-care testing, particularly in resource-limited healthcare settings.

Integration with Digital Health: The lancets market is increasingly integrating with digital health platforms and mobile applications. This integration allows for the seamless transfer and analysis of blood sampling data, enabling real-time monitoring, trend analysis, and improved management of chronic conditions. Integrated lancets and digital health solutions contribute to personalized and patient-centric care.

Overall, the advantages of the lancets market make it a valuable tool in healthcare, providing convenient and reliable blood sampling methods for various diagnostic and monitoring purposes. The continuous advancements in lancet technology aim to further enhance patient comfort, safety, and accuracy, reinforcing its importance in modern healthcare practices.

Recession Impact Analysis: The existing report includes an analysis of the impact of recession on the lancets the market overview section.

Newer and improved representation of financial information: The new edition of the report provides updated financial information till 2022-2023 (depending on the availability) for each listed company in a graphical representation in a single diagram (instead of multiple tables). This will allow for the easy analysis of the present status of profiled companies in terms of their financial strength, profitability, key revenue-generating country/region, and business segment focus in terms of the highest revenue-generating segment.

Recent Market Developments: Recent developments are helpful to know the market trend and growth strategies adopted by players in the market. The report provides the updated developments in terms of acquisitions, agreements, expansions, and agreements/collaboration etc.

Latest Product portfolio: The new edition of the report provides an updated product portfolio of the companies profiled in the report.

Competitive leadership mapping: The competitive landscape chapter has been updated with the market evaluation matrix. The competitive landscape also includes the market share analysis for 2023, updated competitive leadership mapping, and competitive situation & trends. This report version has added the vendor dive matrix, covering a comprehensive study of the key vendors. Competitive leadership mapping has also been done for start-ups/SMEs.

Additional analysis by segment: The new edition of the report provides an analysis of additional segments in the ME chapters for all regions. The current edition of the report includes the pricing analysis, value chain analysis, supply chain analysis, ecosystem analysis, trade analysis, technology analysis, regulatory landscape analysis, patent analysis, Porter's five forces analysis, trends & disruptions impacting customers' business, key conferences and events in 2023-2024, and key stakeholders and buying criteria in the market overview chapter. This edition of the report also covers the product and geographical footprint of key players in the competitive landscape chapter.

Blood Collection Devices Market - Global Forecasts to 2027

Point of Care Diagnostics Market - Global Forecasts to 2027
About MarketsandMarkets™:
Patient Monitoring Devices Market - Global Forecasts to 2027

Pen Needles Market - Global Forecasts to 2026

Diabetes Care Devices Market - Global Forecasts to 2025

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/lancets-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/lancets.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

# data[].attributes.attachment_link.title
Lancets Market worth $3.6 billion | MarketsandMarkets

# data[].attributes.attachment_link.description
PRNewswire/ -- The lancets industry is poised for significant growth and innovation in the near future. Lancets, which are small, pricking devices used for...

# data[].attributes.headline
Regenerative Medicine Market Analysis, Size, Demand, Growth, and Comprehensive Research Study 2027

# data[].attributes.subject
Regenerative Medicine Market Analysis, Size, Demand, Growth, and Comprehensive Research Study 2027

# data[].attributes.body
The Global Regenerative Medicine Market in terms of revenue was estimated to be worth $12.2 Billion in 2022 and is poised to grow at a CAGR of 27.2% from 2022 to 2027. Market growth is driven by the availability of funding and rising investments in R&D, increasing clinical trials for stem cell and CAR-T cell therapies, and rising advancements in tissue-engineered products. However, the high treatment cost of RM therapies and issues associated with commercialization and regulatory compliance factors are expected to restrain the market growth during the forecast period.

# data[].attributes.attachment_link.readable_text
Regenerative Medicine Market

Regenerative Medicine market in terms of revenue was estimated to be worth $12.2 Billion in 2022 and is poised to reach $40.6 Billion by 2027, growing at a CAGR of 27.2% from 2022 to 2027 according to a latest report published by MarketsandMarkets™. Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products. However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Notable Regenerative Medicine mergers and acquisitions for 2021 - 2022 include:

Johnson & Johnson and Lineage Cell Therapeutics: Johnson & Johnson completed the acquisition of Lineage Cell Therapeutics in early 2021, which will help the company expand its presence in the regenerative medicine field.

Baxter International and Xygen Medical: In February 2021, Baxter International announced its acquisition of Xygen Medical, a leading developer of regenerative medicine technologies.

Vertex Pharmaceuticals and Mast Therapeutics: In March 2021, Vertex Pharmaceuticals announced its acquisition of Mast Therapeutics, a biopharmaceutical company focused on regenerative medicine.

Takeda Pharmaceuticals and TiGenix: In April 2021, Takeda Pharmaceuticals announced its acquisition of TiGenix, a regenerative medicine company focused on stem cell therapies.

Novartis and Endocyte: In May 2021, Novartis announced its acquisition of Endocyte, a biopharmaceutical company focused on developing regenerative medicine treatments for cancer.

Astellas Pharma and CellSight: In June 2021, Astellas Pharma announced its acquisition of CellSight, a regenerative medicine company focused on developing cell therapies.

Cellectis and Tmunity: In July 2021, Cellectis announced its acquisition of Tmunity, a regenerative medicine company focused on developing cell therapies for cancer.

Roche and Cell Design Labs: In August 2021, Roche announced its acquisition of Cell Design Labs, a regenerative medicine company focused on developing cell therapies for cancer.

Medtronic and CartiHeal: In September 2021, Medtronic announced its acquisition of CartiHeal, a regenerative medicine company focused on developing cell therapies for orthopedic applications.

Novo Nordisk and TiGenix: In October 2021, Novo Nordisk announced its acquisition of TiGenix, a regenerative medicine company focused on developing stem cell therapies.

Growth Drivers of Regenerative Medicine Market from macro to micro:

Increasing Prevalence of Chronic Diseases: Chronic diseases, such as heart diseases, cancer, diabetes, and neurological disorders, are on the rise globally.

This is driving the adoption of regenerative medicines as a potential treatment for such diseases.

Government Initiatives: Governments around the world are increasingly investing in regenerative medicine research and development to support the development of innovative therapies.

Growing Investment: As the potential of regenerative medicine becomes more apparent, the number of venture capital and private equity investments in the field is increasing.

Technological Advancements: Recent advances in stem cell research and 3D printing technology have enabled the development of novel regenerative medicine therapies.

Increasing Adoption of Advanced Therapy Medicinal Products (ATMPs): ATMPs are becoming more widely accepted and adopted, which is fueling the growth of the regenerative medicine market.

Growing Focus on Precision Medicine: Precision medicine is gaining traction in healthcare, as it allows for more personalized treatments. This is driving the development of regenerative medicine therapies.

Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=65442579&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Hypothetic challenges of Regenerative Medicine market in near future:

Regulation: Regulation of regenerative medicine products varies from country to country. In some countries, there are no regulations in place for the approval or access to regenerative medicine products. This could become a major challenge for companies operating in the regenerative medicine market by limiting their ability to bring their products to market.

Cost: Cost of regenerative medicine products is currently high due to the high cost of production and research involved. This could limit the accessibility of the products and result in a slower growth of the market.

Accessibility: Accessibility is a major challenge for companies operating in the regenerative medicine market. There is limited access to the products for patients in certain parts of the world due to the lack of availability of the products. This could result in slower growth of the market.

Clinical Trials: Clinical trials are required in order to assess the safety and efficacy of regenerative medicine products. This could prove to be a challenge due to the long time frames required for the trials and the associated costs.

Reimbursement: Reimbursement for regenerative medicine products is currently limited in many countries. This could limit the access to the products for patients, as well as the growth of the market.

Top 3 use cases of Regenerative Medicine market:

Cell Therapy: Cell therapy involves the use of adult stem cells to repair or replace damaged or diseased cells, tissues, and organs. This can be used to treat a wide range of medical conditions, including diabetes, Parkinson's disease, stroke, heart disease, and more.

Gene Therapy: Gene therapy is a form of regenerative medicine that involves using genetic material to modify existing cells or create new ones to replace damaged or dysfunctional ones. This can be used to treat genetic disorders, cancer, and other conditions.

Tissue Engineering: Tissue engineering is a process of regenerating or replacing damaged tissues and organs using cells, scaffolds, and bioactive molecules. This can be used to treat musculoskeletal injuries, skin injuries, and other conditions.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=65442579&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
This release was published on openPR.

# data[].attributes.attachment_link.title
Regenerative Medicine Market is Expected to Reach $40.6 Billion | MarketsandMarkets

# data[].attributes.attachment_link.description
Regenerative Medicine market in terms of revenue was estimated to be worth 12 2 Billion in 2022 and is poised to reach 40 6 Billion by 2027 growing at a CAGR of 27 2 from 2022 to 2027 according to ...

# data[].attributes.headline
The Latest Developments in the Metaverse in Healthcare Market 

# data[].attributes.subject
The Latest Developments in the Metaverse in Healthcare Market 

# data[].attributes.body
Metaverse in Healthcare Market in terms of revenue was estimated to be worth $9.5 billion in 2023 and is poised to reach $79.6 billion by 2028, growing at a CAGR of 52.9% from 2023 to 2028 according to a new report by MarketsandMarkets™. The increasing adoption of mixed reality for performing minimally invasive surgeries, growing focus on telemedicine, increasing use of digital twins, and the growing importance of blockchain technology in healthcare are the key factors driving the growth of this market. However, increasing concerns over data privacy and security and the high implementation cost of technologies are expected to restrain the growth of this market.

# data[].attributes.attachment_link.readable_text
The report "Metaverse in Healthcare Market by Component (Hardware, Services, Software), Technology (AR/VR, MR, AI, Blockchain, IoT), Application(Telehealth, Diagnostics, Medical Training & Education), End User (Provider, Patients, Payers, Pharma) - Global Forecast to 2028", is projected to reach USD 79.6 billion by 2028 from USD 9.5 billion in 2023, at a CAGR of 52.9% during the forecast period.

Browse 121 market data Tables and 39 Figures spread through 237 Pages and in-depth TOC on "Metaverse in Healthcare Market by Component (Hardware, Services, Software), Technology (AR/VR, MR, AI, Blockchain, IoT), Application(Telehealth, Diagnostics, Medical Training & Education), End User (Provider, Patients, Payers, Pharma) - Global Forecast to 2028"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/metaverse-in-healthcare-market-225839181.html

The increasing adoption of mixed reality for performing minimally invasive surgeries, growing focus on telemedicine, increasing use of digital twins, and the growing importance of blockchain technology in healthcare are the key factors driving the growth of this market. However, increasing concerns over data privacy and security and the high implementation cost of technologies are expected to restrain the growth of this market.

The Software segment accounted for the largest share in the metaverse in healthcare market, by component.

The metaverse in healthcare market, by component, is segmented into hardware, software, and services. The software segment includes platforms and applications that enable the creation, customization, and deployment of virtual experiences. The hardware segment includes devices such as head-mounted displays and haptic feedback gloves that enable users to interact with the virtual environment, while the services segment includes consulting, development, and support services that enable healthcare providers to integrate the metaverse into their workflows.

In 2022, the software segment accounted for the largest market share in metaverse in healthcare market. The large share of this segment is attributed to the increased adaptation of AR/VR software in the healthcare industry and the significant rise in investments made in software development.

By Technology, the Augmented/Virtual reality segment registered the highest growth in the metaverse in healthcare market during the forecast period

Based on technology, the metaverse in healthcare market is segmented into augmented and virtual reality, mixed reality, artificial intelligence, blockchain, digital twin, Internet of Things, and medical wearables. The augmented and virtual reality segment accounted for the largest share of 28.2% of the metaverse in healthcare market in 2022. The large share of the augmented and virtual reality segment can be attributed to the growing adoption of VR and AR in the healthcare industry, improved patient outcomes, and the growing focus on enhancing medical training, reducing costs, increasing accessibility, improving patient engagement, and driving innovation.

By Application, the medical education and surgical training segment accounted for the largest share in the metaverse in healthcare market.

In 2022, Based on application, the medical education and surgical training segment accounted for the largest share of 26.6% of the metaverse in healthcare market. The large share of this segment can be attributed to factors such as the increasing budget of hospitals to improve the quality of care provided and reduce the cost of care.

By End User, the healthcare providers segment accounted for the largest share in the metaverse in healthcare market.

In 2022, The healthcare providers segment accounted for the largest share of the metaverse in healthcare market. The large share of this segment can be attributed to the rising need for an efficient healthcare system, growing patient volume, increasing number of hospitals and ambulatory care centers, growth in telehealth, and the rising adoption of metaverse technology in healthcare.

Asia Pacific is expected to exhibit the highest growth during the forecast period

The Asia Pacific market is estimated to register the highest CAGR during the forecast period. Favorable government initiatives for implementing metaverse technologies in the healthcare industry, the growing adoption of AR/VR in healthcare, the rising need for advanced healthcare technologies to track and monitor the large volume of patients, and the rising demand for quality healthcare at low costs are driving the growth of this regional market.

Microsoft (US), NVIDIA Corporation (US), XRHealth (US), CAE Inc. (Canada), Koninklijke Philips N.V. (Netherlands), ImmersiveTouch, Inc. (US), Wipro (India), Siemens Healthineers AG (Germany), Medtronic plc (Ireland), GE HealthCare (US), Intuitive Surgical (US), 8Chili, Inc. (US), MindMaze (Switzerland), AccuVein, Inc. (US), EON Reality (US), Brainlab AG (Germany), Novarad Corporation (US), Oodles Technologies (India), CMR Surgical (UK), Merative (US), BioflightVR (US), WorldViz, Inc. (US), Google (US), Oculus (Meta Platforms, Inc.) (US), and Augmedics (US) are the major players in this market. These companies are majorly focusing on the strategies such as acquisitions, product launches, agreements, collaborations, partnerships, and expansions in order to remain competitive and further increase their share in the market.

Don't miss out on business opportunities in Metaverse in Healthcare Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

# data[].attributes.attachment_link.keywords[]
metaverse in healthcare industry analysis

# data[].attributes.attachment_link.description
The report "Metaverse in Healthcare Market by Component (Hardware, Services, Software), Technology (AR/VR, MR, AI, Blockchain, IoT), Application(Telehealth, Diagnostics, Medical Training & Education), End User (Provider, Patients, Payers, Pharma) - Global Forecast to 2028", is projected to reach USD 79.6 billion by 2028 from USD 9.5 billion in 2023, at a CAGR of 52.9% during the forecast period.

# data[].attributes.headline
Healthcare Data Monetization Market worth $0.9 billion by 2028

# data[].attributes.subject
Healthcare Data Monetization Market worth $0.9 billion by 2028

# data[].attributes.body
The Global Healthcare Data Monetization Market in terms of revenue was estimated to be worth $0.4 billion in 2023 and is poised to reach $0.9 billion by 2028, growing at a CAGR of 18.5% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of EHR adoption primarily drives the market growth, the increase in use of external data sources, the need to curtail escalating healthcare costs, increasing partnerships and collaborations among players, and growing investments in advanced analytics. Additionally, factors such rising adoption of AI in precision medicine, and the explosion in bioinformatics data and large healthcare datasets are also contributing to the market growth.

# data[].attributes.attachment_link.readable_text
Updated on : June 07, 2023

The global healthcare data monetization market in terms of revenue was estimated to be worth $0.4 billion in 2023 and is poised to reach $0.9 billion by 2028, growing at a CAGR of 18.5% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of EHR adoption primarily drives the market growth, the increase in use of external data sources, the need to curtail escalating healthcare costs, increasing partnerships and collaborations among players, and growing investments in advanced analytics. Additionally, factors such rising adoption of AI in precision medicine, and the explosion in bioinformatics data and large healthcare datasets are also contributing to the market growth.

To know about the assumptions considered for the study, Request for Free Sample Report

Healthcare Data Monetization Market Dynamics

Driver: Increase in use of external data sources

External data sources refer to data collected from sources outside of a healthcare organization, such as social media, wearables, consumer data brokers, and other sources. By incorporating external data sources into their analytics and insights, healthcare organizations can gain a more comprehensive view of patient health and behavior, which can lead to improved outcomes and new revenue streams.

One example of the increasing use of external data sources is the integration of data from wearables and other digital devices into healthcare analytics platforms. Wearables such as fitness trackers and smartwatches can collect a wide range of patient health and behavior data, including activity levels, heart rate, and sleep patterns. By integrating this data into healthcare analytics platforms, healthcare organizations can gain a more comprehensive view of patient health and behavior, which can lead to improved outcomes and new revenue streams. The global IoT medical devices market is expected to grow at a CAGR of 28.9% from 2021 to 2026. While according to a research study, the number of active IoT devices is expected to grow to ~31 billion by 2025. As healthcare organizations look to gain a more comprehensive view of patient health and behavior and create new revenue streams through data-driven insights, the rapidly increasing demand for wearables and medical IoT devices is expected to offer several opportunities to market players.

Restraint: Regulatory constraints to impact the growth of the market during the forecast period

Regulatory constraints are a significant challenge impacting healthcare data monetization growth. Healthcare data is subject to various laws and regulations governing data privacy, security, and use, making it challenging for organizations to collect, store, and use data for commercial purposes.

One of the primary regulations impacting healthcare data monetization is the Health Insurance Portability and Accountability Act (HIPAA). HIPAA is a federal law that sets national standards for protecting the privacy and security of protected health information (PHI). PHI includes any information that can be used to identify an individual's health status or healthcare services. Covered entities, such as healthcare providers and health plans, are required to comply with HIPAA regulations to protect the privacy and security of PHI. This can include obtaining patient consent before using or disclosing their data, implementing technical and administrative safeguards to protect data, and reporting data breaches.

HIPAA regulations can be a barrier to healthcare data monetization as organizations must comply with strict requirements to use and disclose PHI. For example, a healthcare provider looking to sell patient data to a pharmaceutical company for research must ensure that they have obtained patient consent and implemented appropriate safeguards to protect the data. Failure to comply with HIPAA regulations can result in significant fines and penalties.

Opportunity: Rising Demand for Real-World Evidence

The rising demand for real-world evidence (RWE) presents a significant market opportunity for healthcare data monetization. Real-world evidence refers to data collected from real-world patient populations in everyday clinical practice, outside the controlled environment of clinical trials. This type of data provides valuable insights into treatment outcomes, safety profiles, comparative effectiveness, and patient experiences, which are essential for evidence-based decision-making in healthcare. Healthcare organizations that possess extensive and high-quality RWE datasets can monetize this data by collaborating with various stakeholders in the healthcare ecosystem.

Challenge: Security concerns

Increased use of automated technologies such as EHRs, medical claims processing, and the move towards healthcare integration and health information exchanges (HIEs) have helped expand healthcare privacy and security landscape. Electronic exchange of patient data offers greater reach and efficiency in healthcare delivery but has high-security risks due to the broader access offered.

Approximately one-third of data breaches result in medical identity theft in the healthcare industry, mainly due to the lack of internal control over patient information, outdated policies, and procedures or non-adherence to existing ones, and inadequate personnel training. The HIPAA Journal recorded 712 healthcare data breaches in its 2021 breach list in the US, an increase of 10.9% over the total number of breaches tracked in 2020. Between 2009 and 2021, 4,419 healthcare data breaches of 500 or more records have been reported to the HHS Office for Civil Rights. Those breaches have resulted in the loss, theft, exposure, or impermissible disclosure of 314,063,186 healthcare records. That equates to more than 94.63% of the 2021 population of the US. In 2018, healthcare data breaches of 500 or more records were reported at around 1 per day. The rate has only doubled in the four years since. In 2021, an average of 1.95 healthcare data breaches of 500 or more records were reported daily. Thus, creating a secure communication platform is a significant challenge faced by IT vendors catering to the healthcare industry. Potential security concerns related to HCIT systems may lead to a rise in the sense of insecurity among users and, hence, restrain their adoption until secure healthcare data monetization solutions are available in the market.

Healthcare Data Monetization Market Ecosystem

Well-known, financially secure producers of data monetization systems and platforms are prominent players in this market. These companies have been in operation for a while and have a broad range of products, cutting-edge technologies, and robust international sales and marketing networks. Key companies in this market include Oracle Corporation (US), Microsoft Corporation (US), Google (US), Salesforce, Inc. (US), SAS Institute Inc. (US), SAP SE (Germany), and others.

Direct data monetization is expected to acquire the largest size of healthcare data monetization market, by type

Based on type, the market is segmented into direct data monetization and indirect data monetization. The direct data monetization segment is expected to dominate the market in 2023. Direct data monetization is becoming popular in healthcare due to the need for efficient data management, interoperability, cost reduction, and improved patient outcomes. It allows healthcare providers to access data from multiple sources in real-time, standardize data formats, reduce infrastructure costs, and make informed decisions about patient care by identifying trends and patterns in patient data.

Based on deployment, on-premise segment is anticipated to dominate the healthcare data monetization market in 2023

Based on deployment, the market is segmented into on-premise and cloud. On-premise segment is expected to dominate the market in 2023. On-premise models offer multivendor architecture, which lowers the risk of data breaches and external attacks. Buyers mainly opt for these delivery models due to the security benefits associated with them. These factors are driving the growth of the on-premise deployment model segment.

Based on the end user, pharmaceutical & biotechnology companies segment of the healthcare data monetization market is expected to register the highest CAGR during the forecast period

Based on the end user, the market is broadly segmented into pharmaceutical & biotechnology companies, healthcare payers, healthcare providers, medical technology companies, and other end users. The pharmaceutical & biotechnology companies segment is expected to register the highest CAGR during the forecast period. The pharma and biotech companies segment includes pharma and biotech companies, and contract research and manufacturing organizations. Pharmaceutical companies are one of the key stakeholders in the healthcare ecosystem and are likely to benefit the most from comprehensive health data. The data serves to inform decision making, influence the direction of research efforts, as well as provide information on the potential expansion of certain medications. For instance. Data that is linked in any way to health behavior, such as medication usage patterns, is also a hot commodity for many pharmaceuticals. Hence, this segment represents a key source to fund the collection/procurement of health data that they will then utilize for their operations. Pharma companies often able to use that data or resell it for large profits to other interested entities.

To know about the assumptions considered for the study, download the pdf brochure

North America is expected to account for the largest share in healthcare data monetization market in 2023

The global market has been segmented based on region: North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. In 2023, North America is expected to account for the largest market share followed by Europe. The large share of North America in the global healthcare analytics market can be attributed to the implementation of federal health mandates that encourage the adoption of HCIT solutions, an increasing focus on population health management, a significant amount of VC investments, growing pressure to reduce healthcare costs, technological advancements, and high product & service availability in this region. Moreover, most of the leading players in the healthcare analytics market have their headquarters in North America.

The healthcare data monetization market is dominated by a few globally established players such as Oracle Corporation (US), Microsoft Corporation (US), Google (US), Salesforce, Inc. (US), SAS Institute Inc. (US), SAP SE (Germany), TIBCO Software Inc. (US), Sisense Inc. (US), among others.

Healthcare Data Monetization Market Report Scope

This report categorizes the global healthcare data monetization market to forecast revenue and analyze trends in each of the following submarkets:

By Type

Direct Data Monetization

Indirect Data Monetization

By Deployment

By End User

Pharmaceutical & Biotechnology Companies

Healthcare Providers

Healthcare Payers

Medical Technology Companies

Other End Users

By Region

Recent Developments

In October 2022, Oracle Corporation introduced a planning solution for the healthcare industry as part of its Fusion Cloud Enterprise Performance Management (EPM) offering. The solution aims to help healthcare organizations improve financial performance and patient care by enabling them to model scenarios, optimize resources, and make better finance, workforce, and patient care decisions.

In April 2023, Microsoft Corporation and Epic Systems expanded their collaboration to integrate generative AI into healthcare by combining Azure OpenAI Service with Epic's electronic health record (EHR) software. The collaboration aimed to enhance patient care, increase productivity, and improve financial integrity in health systems globally.

In February 2023, Redox and Google Cloud partnered to simplify the exchange of healthcare data, enabling better and faster decision-making for healthcare organizations. Redox's platform would be replicated on Google Cloud, offering customers access to Redox's products and services.

In April 2023, Salesforce announced new Customer 360 for Health capabilities aimed at enhancing personalized patient experiences and reducing operational costs for healthcare providers. These innovations leverage real-time data, AI, and automation to address the challenges faced by healthcare organizations in meeting customer expectations.

In May 2023, HTEC Group joined the SAS IoT Partner Ecosystem to partner on delivering innovative solutions in industries such as healthcare, life sciences, logistics, and more. The partnership aimed to develop joint offerings that enable global enterprise companies to apply cutting-edge data-driven, IoT, edge, and cloud-enabled solutions to their business challenges.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

# data[].attributes.attachment_link.title
Healthcare Data Monetization Market Revenue Trends and Growth Drivers | MarketsandMarkets

# data[].attributes.attachment_link.description
Updated on : June 07, 2023 The global healthcare data monetization market in terms of revenue was estimated to be worth $0.4 billion in 2023 and is poised to reach $0.9 billion by 2028, growing at a CAGR of 18.5% from 2023 to 2028.

# data[].attributes.headline
Central Fill Pharmacy Automation Market Size, Trends, Industry Analysis and Forecast 2024

# data[].attributes.subject
Central Fill Pharmacy Automation Market Size, Trends, Industry Analysis and Forecast 2024

# data[].attributes.body
[129 Pages Report] The central fill pharmacy automation market is projected to reach USD 656 million by 2024 from USD 381 million in 2019, at a CAGR of 11.5%. The increasing demand for specialty drugs being dispensed by central fill pharmacies is one of the primary drivers propelling the growth of this market.

# data[].attributes.attachment_link.readable_text
1 Introduction (Page No. - 13)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Stakeholders
1.6 Limitations

2 Research Methodology (Page No. - 16)
2.1 Research Approach
2.1.1 Secondary Research
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Research
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Break Down of Primaries
2.1.2.3 Key Industry Insights
2.2 Market Size Estimation
2.3 Data Triangulation Approach
2.4 Market Share Estimation
2.5 Assumptions for the Study
3 Executive Summary (Page No. - 24)
4 Premium Insights (Page No. - 28)
4.1 Central Fill Pharmacy Automation: Market Overview
4.2 Central Fill Pharmacy Automation Market: Geographic Growth Opportunities
4.3 Regional Mix: Central Fill Pharmacy Automation Market (2019–2024)

5 Market Overview (Page No. - 31)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Market Drivers
5.2.1.1 Increasing Specialty Drug Dispensing
5.2.1.2 Growing Need to Minimize Medication Errors
5.2.1.3 Rising Patient Pool
5.2.1.4 Growing Focus on Automation to Reduce Labor Costs
5.2.2 Market Restraints
5.2.2.1 High Initial Capital Investments
5.2.3 Market Opportunities
5.2.3.1 Untapped Emerging Markets
5.2.4 Market Challenges
5.2.4.1 Logistical Challenges
5.3 Market Trend
5.3.1 Multichannel Communication
5.4 Regulatory Landscape

6 Central Fill Pharmacy Automation Market, By Product & Service (Page No. - 37)
6.1 Introduction
6.2 Equipment
6.2.1 Automated Medication Dispensing Systems
6.2.1.1 Automated Medication Dispensing Systems Dispense Thousands of Prescriptions Per Hour, Utilizing Point-Of-Dispense Barcode Scanning
6.2.2 Integrated Workflow Automation Systems
6.2.2.1 Integrated Workflow Automation Systems are Used in the Designing, Automation, and Execution of Specific Tasks Which Require A Set Pattern That is Automated By Software
6.2.3 Automated Packaging and Labeling Systems
6.2.3.1 Automated Packaging and Labeling Systems are Used to Improve the Dispensing Process
6.2.4 Automated Tabletop Counters
6.2.4.1 Automated Tabletop Counters Have Pre-Programmed Protocols That Reduce the Chances of Error
6.2.5 Automated Medication Compounding Systems
6.2.5.1 Automated Medication Compounding Systems Reduce the Cost-Per-Dose of Medication and the Need for Medication Outsourcing
6.2.6 Automated Storage and Retrieval Systems
6.2.6.1 Rising Focus on Reducing the Time and Cost Involved in Functions Related to the Storage and Retrieval of Medications in Pharmacies to Drive Market Growth
6.2.7 Other Automated Systems
6.3 Software
6.3.1 Software Solutions Automate the Inventory Ordering, Receiving, Stocking, Picking, and Verification Processes By Integrating All the Systems in A Particular Central Fill Facility
6.4 Services
6.4.1 Consulting
6.4.1.1 Consulting Services Segment Accounted for the Largest Share of the Central Fill Pharmacy Automation Services Market in 2018
6.4.2 Workflow & Process Optimization
6.4.2.1 Companies Provide This Service on the Fee for Service Model and Also Offer Multi-Level Training to the Pharmacy Staff in Order to Ensure Maximum Efficiency of the Workflow
6.4.3 Facility Designing
6.4.3.1 A Good Facility Design Helps Optimize the Workflow By Eliminating Unnecessary Steps
6.4.4 Custom Software Development
6.4.4.1 High Cost of Developing and Integrating These Software Solutions May Hinder Market Growth to A Certain Extent
6.4.5 Other Services (Licensing, Inventory Management, Turnkey System Manufacturing, Staffing)

7 Central Fill Pharmacy Automation Market, By Vendor (Page No. - 58)
7.1 Introduction
7.2 Equipment Vendors
7.2.1 Equipment Vendors Dominated the Market in 2018
7.3 Consulting Vendors
7.3.1 Need for Dedicated Consulting to Start A Central Fill Facility to Aid Market Growth

8 Central Fill Pharmacy Automation Market, By Region (Page No. - 62)
8.1 Introduction
8.2 North America
8.2.1 US
8.2.1.1 Increasing Specialty Drug Dispensing is A Major Growth Factor for the Market
8.2.2 Canada
8.2.2.1 The Country is Adopting Centralized Medication Dispensing to Minimize Medication Errors
8.3 Europe
8.3.1 European Market to Grow at the Highest Rate During the Forecast Period
8.4 Asia Pacific
8.4.1 Currently Under-Penetrated, the APAC Market to Provide Potential Growth Opportunities in the Coming Years
8.5 Rest of the World
8.5.1 Government Efforts Towards Increasing the Accessibility and Affordability of Healthcare Services to Aid Market Growth

9 Competitive Landscape (Page No. - 82)
9.1 Overview
9.2 Market Share Analysis
9.3 Competitive Situation and Trends
9.3.1 Product & Services Launches
9.3.2 Expansions
9.3.3 Acquisitions
9.3.4 Agreements and Partnerships

10 Company Profiles (Page No. - 90)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
10.1 Mckesson Corporation
10.2 Omnicell, Inc.
10.3 Arxium, Inc.
10.4 Innovation
10.5 Scriptpro LLC
10.6 Tcgrx Pharmacy Workflow Solutions
10.7 Rxsafe, LLC.
10.8 Kuka AG
10.9 Tension Packaging & Automation
10.10 R/X Automation Solutions
10.11 Cornerstone Automation Systems, LLC. (CASI)
10.12 Quality Manufacturing Systems, Inc. (QMSI)

*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured in Case of Unlisted Companies.

11 Appendix (Page No. - 121)
11.1 Insights of Industry Experts
11.2 Discussion Guide
11.3 Knowledge Store: Marketsandmarkets' Subscription Portal
11.4 Available Customizations
11.5 Related Reports
11.6 Author Details

List of Tables (60 Tables)
List of Figures (24 Figures)
Table 1 Market Dynamics: Impact Analysis
Table 2 Central Fill Pharmacy Automation Market, By Product & Service, 2017–2024 (USD Million)
Table 3 Central Fill Pharmacy Automation Market, By Region, 2017–2024 (USD Million)
Table 4 Central Fill Pharmacy Automation Equipment Market, By Type, 2017–2024 (USD Million)
Table 5 Central Fill Pharmacy Automation Equipment Market, By Region, 2017–2024 (USD Million)
Table 6 Popular Automated Medication Dispensing Systems Available in the Market
Table 7 Automated Medication Dispensing Systems Market, By Region, 2017–2024 (USD Million)
Table 8 Popular Integrated Workflow Automated Systems Available in the Market
Table 9 Integrated Workflow Automation Systems Market, By Region, 2017–2024 (USD Million)
Table 10 Popular Automated Packaging & Labeling Systems Available in the Market
Table 11 Automated Packaging & Labeling Systems Market, By Region, 2017–2024 (USD Million)
Table 12 Popular Automated Tabletop Counters Available in the Market
Table 13 Automated Tabletop Counters Market, By Region, 2017–2024 (USD Million)
Table 14 Popular Automated Medication Compounding Systems Available in the Market
Table 15 Automated Medication Compounding Systems Market, By Region, 2017–2024 (USD Million)
Table 16 Popular Automated Storage & Retrieval Systems Available in the Market
Table 17 Automated Storage & Retrieval Systems Market, By Region, 2017–2024 (USD Million)
Table 18 Other Automated Systems Market, By Region, 2017–2024 (USD Million)
Table 19 Central Fill Pharmacy Automation Software Market, By Region, 2017–2024 (USD Million)
Table 20 Central Fill Pharmacy Automation Services Market, By Type, 2017–2024 (USD Million)
Table 21 Central Fill Pharmacy Automation Services Market, By Region, 2017–2024 (USD Million)
Table 22 Consulting Services Market, By Region, 2017–2024 (USD Million)
Table 23 Workflow & Process Optimization Services Market, By Region, 2017–2024 (USD Million)
Table 24 Facility Designing Services Market, By Region, 2017–2024 (USD Million)
Table 25 Custom Software Development Services Market, By Region, 2017–2024 (USD Million)
Table 26 Other Central Fill Pharmacy Automation Services Market, By Region, 2017–2024 (USD Million)
Table 27 Central Fill Pharmacy Automation Market, By Vendor, 2017–2024 (USD Million)
Table 28 Central Fill Pharmacy Automation Market for Equipment Vendors, By Region, 2017–2024 (USD Million)
Table 29 Central Fill Pharmacy Automation Market for Consulting Vendors, By Region, 2017–2024 (USD Million)
Table 30 Central Fill Pharmacy Automation Market, By Region, 2017–2024 (USD Million)
Table 31 North America: Central Fill Pharmacy Automation Market, By Country, 2017–2024 (USD Million)
Table 32 North America: Central Fill Pharmacy Automation Market, By Product & Service, 2017–2024 (USD Million)
Table 33 North America: Central Fill Pharmacy Automation Equipment Market, By Type, 2017–2024 (USD Million)
Table 34 North America: Central Fill Pharmacy Automation Services Market, By Type, 2017–2024 (USD Million)
Table 35 North America: Central Fill Pharmacy Automation Market, By Vendor, 2017–2024 (USD Million)
Table 36 US: Central Fill Pharmacy Automation Market, By Product & Service, 2017–2024 (USD Million)
Table 37 US: Central Fill Pharmacy Automation Equipment Market, By Type, 2017–2024 (USD Million)
Table 38 US: Central Fill Pharmacy Automation Services Market, By Type, 2017–2024 (USD Million)
Table 39 US: Central Fill Pharmacy Automation Market, By Vendor, 2017–2024 (USD Million)
Table 40 Canada: Central Fill Pharmacy Automation Market, By Product & Service, 2017–2024 (USD Million)
Table 41 Canada: Central Fill Pharmacy Automation Equipment Market, By Type, 2017–2024 (USD Million)
Table 42 Canada: Central Fill Pharmacy Automation Services Market, By Type, 2017–2024 (USD Million)
Table 43 Canada: Central Fill Pharmacy Automation Market, By Vendor, 2017–2024 (USD Million)
Table 44 Europe: Central Fill Pharmacy Automation Market, By Product & Service, 2017–2024 (USD Million)
Table 45 Europe: Central Fill Pharmacy Automation Equipment Market, By Type, 2017–2024 (USD Million)
Table 46 Europe: Central Fill Pharmacy Automation Services Market, By Type, 2017–2024 (USD Million)
Table 47 Europe: Central Fill Pharmacy Automation Market, By Vendor, 2017–2024 (USD Million)
Table 48 Asia Pacific: Central Fill Pharmacy Automation Market, By Product & Service, 2017–2024 (USD Million)
Table 49 Asia Pacific: Central Fill Pharmacy Automation Equipment Market, By Type, 2017–2024 (USD Million)
Table 50 Asia Pacific: Central Fill Pharmacy Automation Services Market, By Type, 2017–2024 (USD Million)
Table 51 Asia Pacific: Central Fill Pharmacy Automation Market, By Vendor, 2017–2024 (USD Million)
Table 52 RoW: Central Fill Pharmacy Automation Market, By Product & Service, 2017–2024 (USD Million)
Table 53 RoW: Central Fill Pharmacy Automation Equipment Market, By Type, 2017–2024 (USD Million)
Table 54 RoW: Central Fill Pharmacy Automation Services Market, By Type, 2017–2024 (USD Million)
Table 55 RoW: Central Fill Pharmacy Automation Market, By Vendor, 2017–2024 (USD Million)
Table 56 Central Fill Pharmacy Automation Market Share, By Key Player, 2018
Table 57 Product and Service Launches, 2016–2018
Table 58 Expansions, 2016–2018
Table 59 Acquisitions, 2016–2018
Table 60 Agreements and Partnerships, 2016–2018

Figure 1 Central Fill Pharmacy Automation Market
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designations, and Region
Figure 4 Bottom-Up Approach
Figure 5 Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Central Fill Pharmacy Automation Market, By Product & Service, 2019 vs 2024 (USD Million)
Figure 8 Central Fill Pharmacy Automation Equipment Market, By Type, 2019 vs 2024 (USD Million)
Figure 9 Central Fill Pharmacy Automation Services Market, By Type, 2019 vs 2024 (USD Million)
Figure 10 Central Fill Pharmacy Automation Market, By Vendor, 2019 vs 2024 (USD Million)
Figure 11 Geographical Snapshot of the Central Fill Pharmacy Automation Market
Figure 12 Increasing Specialty Drug Dispensing Through Centralized Facilities to Drive Market Growth
Figure 13 US Dominated the Central Fill Pharmacy Automation Market in 2018
Figure 14 Europe to Register the Highest Growth Rate During the Forecast Period (2019–2024)
Figure 15 Projected Growth in the Geriatric Population, 2010 vs 2015 vs 2030
Figure 16 Equipment Segment to Dominate the Central Fill Pharmacy Automation Products & Services Market During the Forecast Period
Figure 17 Integrated Workflow Automation Systems Segment to Witness the Highest Growth During the Forecast Period
Figure 18 Equipment Vendors Segment Will Continue to Dominate the Central Fill Pharmacy Automation Market During the Forecast Period
Figure 19 North America: Central Fill Pharmacy Automation Market Snapshot
Figure 20 Declining Pharmacy Funding in England (2006–2015)
Figure 21 Product Launches—Key Growth Strategy Adopted By Market Players From 2016 to March 2019
Figure 22 Mckesson Corporation: Company Snapshot (2018)
Figure 23 Omnicell, Inc.: Company Snapshot (2018)
Figure 24 Kuka AG: Company Snapshot (2018)

# data[].attributes.attachment_link.title
Central Fill Pharmacy Automation Market - 2024 | MarketsandMarkets

# data[].attributes.attachment_link.description
1 Introduction (Page No. - 13) 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Markets Covered 1.3.2 Years Considered for the Study 1.4 Currency 1.5 Stakeholders 1.6 Limitations 2 Research Methodology (Page No.

# data[].attributes.headline
Exploring the Growing Demand for Prefilled Syringes in the Healthcare Industry

# data[].attributes.subject
Exploring the Growing Demand for Prefilled Syringes in the Healthcare Industry

# data[].attributes.body
The global prefilled syringes market in terms of revenue was estimated to be worth $5.6 billion in 2020 and is poised to reach $8.6 billion by 2025, growing at a CAGR of 9.0% from 2020 to 2025. Growth in the global market is majorly driven by the rising demand for prefilled syringes is attributed to the growing prevalence of chronic diseases, technological advancements, rising adoption of self-injecting parenteral devices, and supportive government regulations (especially needlestick legislations). In addition, growing awareness on the benefits of prefilled syringes among patients and healthcare professionals, along with the growing number of biologics and biosimilars in the pharmaceuticals market, is supporting the growth of the global market.

# data[].attributes.attachment_link.title
Prefilled Syringes Market - Growth Drivers & Opportunities | MarketsandMarkets

# data[].attributes.attachment_link.description
The global prefilled syringes market size is projected to reach $8.6 billion by 2025. Report provides crucial industry insights that will help your business grow.

# data[].attributes.headline
The Growing Demand for Medical Cameras: A Comprehensive Market Analysis

# data[].attributes.subject
The Growing Demand for Medical Cameras: A Comprehensive Market Analysis

# data[].attributes.body
The global medical cameras market in terms of revenue was estimated to be worth $2.9 billion in 2021 and is poised to reach $4.1 billion by 2026, growing at a CAGR of 7.3% from 2021 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The market's growth is largely driven by the increasing number of surgical procedures, growing demand for endoscopic procedures, technological advancements, and increasing investments in endoscopy and laparoscopy facilities. However, the high cost of medical cameras is a major restraint on market growth. Product discontinuations, a shortage of trained medical professionals, and the availability of refurbished products are also major challenges limiting market growth to a certain extent.

# data[].attributes.attachment_link.readable_text
The report "Medical Cameras Market by Camera Type (Endoscopy Cameras, Ophthalmology Cameras, Dermatology Cameras), Resolution (HD Cameras, SD Cameras), Sensor (CMOS, CCD), End-Users (Hospitals & Ambulatory Surgery Centers, Specialty Clinics) - Global Forecast to 2026" The medical cameras market is projected to reach USD 4.1 billion by 2026 from USD 2.9 billion in 2021, at a CAGR of 7.3% during the forecast period. Market growth is largely driven by the increasing number of surgical procedures, growing demand for endoscopic procedures, technological advancements, and increasing investments in endoscopy and laparoscopy facilities.

Browse 166 market data Tables and 38 Figures spread through 185 Pages and in-depth TOC on "Medical Cameras Market by Camera Type (Endoscopy Cameras, Ophthalmology Cameras, Dermatology Cameras), Resolution (HD Cameras, SD Cameras), Sensor (CMOS, CCD), End-Users (Hospitals & Ambulatory Surgery Centers, Specialty Clinics) - Global Forecast to 2026"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/medical-camera-market-201071746.html
Endoscopy Cameras accounted for the larger share of the share of global medical cameras market in 2020.
Based on type, the medical cameras market is segmented into surgical microscopy cameras, endoscopy cameras, dermatology cameras, ophthalmology cameras, dental cameras, and other medical cameras. The Endoscopy cameras segment accounted for the largest share of global medical cameras market. This can be attributed to the increasing number of endoscopy procedures across the globe.
By sensor, the CMOS Sensor segment accounted for the largest market share in 2020.
Based on sensor, the medical cameras market is segmented into CMOS Sensor and CCD Sensor. CMOS Sensors accounted for the largest share of the global medical cameras market in 2020. This can be attributed various advantages of CMOS sensors over CCD sensors, such as low power consumption, ease of integration, and faster frame rate. Moreover, the cost of manufacturing these sensors is lower than that of CCD sensors.
By Resolution, High-definition cameras accounted for largest market share in 2020
Based on resolution, the medical cameras market is segmented into standard-definition (SD) cameras and high-definition (HD) cameras. High-definition cameras accounted for the largest share of the global medical cameras market in 2020. The large share of this segment can primarily be attributed to the greater demand for HD cameras among end users due to the significant requirement of high-quality images in medical specialties.
Hospitals & ambulatory surgery centers are the largest end-users of the medical cameras market
Based on end users, the global medical cameras market is segmented into hospitals & ambulatory surgery centers and specialty clinics. Hospitals & ambulatory surgery centers accounted for the largest share of the global medical cameras market in 2020. This can be attributed to the increasing number of hospitals, especially in India, China, and Africa, and growing government & private investments to upgrade healthcare infrastructures.
North America dominates the global medical cameras market
The medical cameras market is divided into five regions, namely, North America, Europe, Asia Pacific, and Rest of the World. North America dominated the global medical cameras market. The large share of the North American region is mainly attributed to the technological advancements in medical cameras, implementation of favorable government initiatives, and rise in the number of surgical procedures.

The major players in the medical cameras market are Olympus Corporation (Japan), Richard WOLF GmbH (Germany), TOPCON CORPORATION (Japan), Sony Corporation (Japan), Stryker Corporation (US), Danaher Corporation (US), Canon Inc. (Japan), Carl Zeiss AG (Germany), Smith & Nephew (UK), Carestream Dental LLC (US), and Basler AG (Germany)
Don't miss out on business opportunities in Medical Cameras Market. Speak to our analyst and gain crucial industry insighs that will help your businessgrow. About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

# data[].attributes.attachment_link.description
The report "Medical Cameras Market by Camera Type (Endoscopy Cameras, Ophthalmology Cameras, Dermatology Cameras), Resolution (HD Cameras, SD Cameras), Sensor (CMOS, CCD), End-Users (Hospitals & Ambulatory Surgery Centers, Specialty Clinics) - Global Forecast to 2026" The medical cameras market is projected to reach USD 4.1 billion by 2026 from USD 2.9 billion in 2021, at a CAGR of 7.3% during the forecast period.

# data[].attributes.headline
The Latest Advancements in Bone Growth Stimulator Technology

# data[].attributes.subject
The Latest Advancements in Bone Growth Stimulator Technology

# data[].attributes.body
The global bone growth stimulator market in terms of revenue was estimated to be worth $1.4 billion in 2022 and is poised to reach $1.8 billion by 2027, growing at a CAGR of 5.9% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growing demand for bone growth stimulators in spinal fusion surgeries, delayed union and nonunion bone fracture applications, and the increasing demand for bone growth stimulator devices are the major driving factors of this market.

# data[].attributes.attachment_link.readable_text
The bone growth stimulators market size is projected to reach USD 1.8 billion by 2027, at a CAGR of 5.9% from 2022 to 2027. The growing demand for bone growth stimulators in spinal fusion surgeries, delayed union and nonunion bone fractures applications and the increasing demand for bone growth stimulator devices are the major driving factors of this market.

Growth Opportunities in Bone Growth Stimulators Market

e-estimated, p-projected

To know about the assumptions considered for the study, Request for Free Sample Report

Bone Growth Stimulators Market Size, Share, Trends and Dynamics

Drivers: Growing patient preference for non-invasive and minimally invasive surgical treatments

The rising incidence of age-related disorders (such as rheumatoid arthritis, osteoarthritis, osteoporosis and fractures) and sports injuries drive the demand of non-invasive and minimally invasive surgical treatments worldwide.

Minimally invasive therapeutic procedures are increasingly being preferred owing to their benefits, such as painless treatment, reduced postoperative hospital stay, reduced surgical trauma, limited tissue scarring, reduced surgical risks, improved patient care, shorter postoperative recovery periods, and greater affordability. These procedures are used for a broad range of spinal disorders, such as spondylosis/spondylolisthesis, stenosis, pseudarthrosis, fractures, trauma, and bone healing.

Restraint: Limited medical reimbursement for bone stimulation products

The healthcare system is facing a number of challenges owing to the rising healthcare costs and rising geriatric population (coupled with the growth in the prevalence of age-related disorders). Medical reimbursement is among the major factors that affect the adoption and demand of specific diagnostic or therapeutic products among patients and healthcare providers at the country level. many private insurance providers do not include insurance or reimbursement for bone growth stimulation surgeries. For instance, most healthcare insurance providers worldwide (except in the US) do not cover the cost of plasma therapy owing to a lack of sufficient clinical data related to its therapeutic efficacy. This factor may act as a restraint in the bone growth stimulators market.

Opportunity: Increasing use of PRP in other applications

Platelet-rich plasma (PRP) is increasingly being used in various therapeutic areas as the first-line therapy for various orthopedic conditions, such as musculoskeletal injuries, arthritis, and chronic tendinitis. This can primarily be attributed to the effective tissue growth capabilities and the advantages offered by PRP (such as no or fewer immunogenic reactions or disease transfer as it is prepared from autologous blood). PRP-based therapy is noninvasive, clinically safer, and helps in faster patient recovery as compared to conventional surgical therapies. For instance, PRP therapy is widely preferred during hair transplantation and plastic surgeries. PRP is also effective in the treatment of cardiac muscle injuries and nerve injuries, and its use is increasing in periodontal surgeries and wound healing. The clinical applications of PRP are expected to increase across major healthcare markets in the coming years, mainly due to the minimal clinical risks associated with its use. This, in turn, is expected to offer significant growth opportunities to players offering PRP products in the market.

Challenge: Side effects associated with BMP-based orthopedic treatment

Although BMPs are increasingly being used in spinal fusion and bone healing, they are associated with certain side effects. Tissue swelling, male infertility, and implant dislodgement are the major side effects associated with BMPs during spinal fusion surgery. During bone healing, BMPs are reported to cause antigenic reactions and stimulation of oncogenes. Medtronic reported several clinical complications associated with its BMP product during its use in spinal fusion surgeries for bone healing. Patients treated with high doses of rhBMP are at a higher risk of cancer as compared to patients treated with other alternatives. rhBMP-based spinal surgeries are associated with 10–50% higher risks of adverse effects as compared to conventional spinal surgeries. Adverse reactions and clinical risks associated with BMP-based therapies during orthopedic treatment are expected to restrict their demand, thereby hindering market growth.

Bone Growth Stimulators Market Ecosystem

By Product

In 2021, spinal fusion surgeries segment accounted for the largest share of the bone growth stimulator market, by product

By product type, the global bone growth stimulators market is segmented into bone growth stimulation devices, bone morphogenetic proteins (BMPs), and platelet-rich plasma (PRP). In 2021, the bone growth stimulation devices segment accounted for the largest share of the global bone growth stimulators market. The growing prevalence of nonunion fractures and increasing preference for non-surgical treatment procedures, will boost the market growth.

By Application

In 2021, Spinal fusion surgeries dominated bone growth stimulators market

On the basis of application, the global bone growth stimulators market is broadly segmented into spinal fusion surgeries, delayed union and nonunion bone fractures, oral and maxillofacial surgeries, and other applications. The spinal fusion surgeries segment accounted for the largest share of the global bone growth stimulators market in 2021. The market growth can be attributed to growing demand of spinal fusion surgeries.

By Region

In 2021, North America accounted for the largest share of the bone growth stimulators market

The global bone growth stimulators market is segmented into four major regions namely, North America, Europe, the Asia Pacific, Latin America and Middle East & Africa. North America accounted for the largest share of the bone growth stimulators market in 2021. Factors such as the growing demand for minimally invasive orthopedic therapies is contributing to the large share of this regional segment.

To know about the assumptions considered for the study, download the pdf brochure

Bone Growth Stimulators Market - Key Players

The bone growth stimulators market is dominated by players such as Orthofix Medical Inc. (US), Enovis Corporation (Formerly Colfax (US), ZimVie (US), Bioventus LLC (US) and Medtronic plc (Ireland).

Scope of the Bone Growth Stimulator Market Report

Region Covered:

North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA)

Segments Covered:

By Product, Application, and Region

Companies Covered:

Orthofix Medical Inc. (US), Enovis (US), ZimVie (US), Bioventus LLC (US), Medtronic plc (Ireland), Stryker (US), DePuy Synthes (US), Arthrex, Inc. (US), Isto Biologics (US Terumo Corporation (Japan), Ember Therapeutics, Inc. (US), Ossatec Benelux Ltd. (Netherlands), Altis Biologics (Pty) Ltd. (South Africa), Regen Lab SA (Switzerland), ITO Co., Ltd. (Japan), Elizur Corporation (US), BTT Health GmbH (Germany), Stimulate Health (Canada), VQ OrthoCare (US), and Kinex Medical Company, LLC (US), Dr. PRP USA LLC (US), Fintek Bio-Electric Inc., Exactech, Inc., and IGEA S.p.A. (Italy). Major 25 players covered.

This research report categorizes the bone growth stimulators market based on product, application, end user and region.

Bone Growth Stimulators Market, by Material Type

Bone Growth Stimulation Devices
External Bone Growth Stimulators

Ultrasonic Bone Growth Stimulators

Implanted Bone Growth Stimulators

Bone Morphogenetic Proteins

Platelet-Rich Plasma

Bone Growth Stimulators Market, by Application

Spinal Fusion Surgeries

Delayed Union & Nonunion Bone Fractures

Oral & Maxillofacial Surgeries

Other Applications

Bone Growth Stimulators Market, by End User

Hospitals and Ambulatory Surgical Centers

Home Care Settings

Academic and Research Institutes

Bone Growth Stimulators Market, by Region

Recent Developments

In 2022, Orthofix Medical Inc. (US) received FDA premarket approval for the AccelStim Bone Growth Stimulation Device.

In 2021, The company announced the competition of its spinoff of ZimVie. The spinoff marks a major milestone in the active portfolio management of Zimmer Biomet.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

# data[].attributes.attachment_link.title
Bone Growth Stimulator Market - Global Growth Drivers & Opportunities | MarketsandMarkets

# data[].attributes.attachment_link.description
The bone growth stimulators market size is projected to reach USD 1.8 billion by 2027, at a CAGR of 5.9% from 2022 to 2027. The growing demand for bone growth stimulators in spinal fusion surgeries, delayed union and nonunion bone fractures applications and the increasing demand for bone growth stimulator devices are the major driving factors of this market.

# data[].attributes.headline
Veterinary Equipment and Supplies Market worth $2.9 Billion by 2027

# data[].attributes.subject
Veterinary Equipment and Supplies Market worth $2.9 Billion by 2027

# data[].attributes.body
The Global Veterinary Equipment Market in terms of revenue was estimated to be worth $2.0 billion in 2022 and is poised to reach $2.9 billion by 2027, growing at a CAGR of 8.1% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Veterinary equipment and supplies are used in surgeries and the monitoring & treatment of diseases in animals. Growth in the companion animal population, growing demand for pet insurance and rising animal health expenditure, and the increasing prevalence of diseases in animals are the primary growth drivers for the global market during the forecast period.

However, high costs of veterinary equipment and rising pet care costs are expected to restrain the growth of this market to a certain extent. This problem will be further exacerbated by the low animal health awareness and shortage of skilled veterinarians in emerging markets.

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=14169630

Key Players:

B. Braun Vet Care GmbH (Germany), Covetrus Inc. (US), BD Animal Health (US), Cardinal Health (US), ICU Medical, Inc. (US), Neogen Corporation (US), Integra LifeSciences (US), Midmark Corporation (US), Jorgensen Laboratories (US), Shenzhen Mindray Animal Medical Technology Co., Ltd. (China), Nonin Medical (US), Digicare Animal Health (US), Hallowell Engineering And Manufacturing Corporation (US), Grady Medical (US), Mila International Inc. (US), Burtons Medical Equipment Ltd (UK), Bionet America, Inc (South Korea), Masimo Corporation (US), Vetronic Services Ltd (UK), Advancis Veterinary (UK), New Gen Medical Systems (India), Dispomed (Canada), Eickemeyer (Germany), J & J Instruments (US), and Avante Animal Health (US).

# data[].attributes.attachment_link.title
Veterinary Equipment & Supplies Market Size, Share | 2022 - 2027 | MarketsandMarkets

# data[].attributes.attachment_link.description
The global veterinary equipment & supplies market is projected to reach $2.9 Billion by 2027, Provides crucial industry insights that will help your business grow.

# data[].attributes.headline
The Latest Techniques in Single-Cell Analysis: A Comprehensive Overview

# data[].attributes.subject
The Latest Techniques in Single-Cell Analysis: A Comprehensive Overview

# data[].attributes.body
The Asia Pacific single-cell analysis market is projected to reach USD 1,375 million by 2025 from USD 550 million in 2020, at a CAGR of 20.1%. Asia Pacific single-cell analysis market growth is driven by the growing focus on personalized medicine, increasing R&D in the pharmaceutical and biotechnology industries for complex diseases, growth in stem cell research, and the increasing frequency of pandemics.

# data[].attributes.attachment_link.readable_text
The report "Asia Pacific Single-cell Analysis Market by Cell Type (Human, Animal, Microbial), Product (Reagent, Assays, Instruments), Technique (Flow Cytometry, NGS, PCR), Application (Cancer, Stemcell, IVF), End User (Academic, Research Labs) - Forecast to 2025", is projected to reach USD 1,375 million by 2025 from USD 550 million in 2020, at a 20.1% CAGR. The rising incidence of infectious diseases, increasing pandemics frequency, increasing R&D in the pharmaceutical and biotechnology industries for complex diseases, growth in stem cell research, and the rising prevalence of cancer are the major factors driving the growth of Asia Pacific single-cell analysis market. However, the high cost of single-cell analysis products is a major factor hampering the growth of the Asia Pacific single-cell analysis market. Emerging economies such as Japan and China are providing lucrative opportunities for the players operating in the APAC single-cell analysis market.

Browse 110 market data Tables and 43 Figures spread through 212 Pages and in-depth TOC on "Asia Pacific Single-cell Analysis Market by Cell Type (Human, Animal, Microbial), Product (Reagent, Assays, Instruments), Technique (Flow Cytometry, NGS, PCR), Application (Cancer, Stemcell, IVF), End User (Academic, Research Labs) - Forecast to 2025"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/asia-pacific-single-cell-analysis-market-257201069.html
The consumables segment accounted for the largest share of the Asia Pacific single-cell analysis market, by product segment, in 2019
Based on product, the Asia Pacific single-cell analysis market is segmented into consumables and instruments. The consumables segment accounted for the largest shareof the APAC single-cell analysis market in 2019. The frequent purchase of these products as compared to instruments, which are considered as a one-time investment, and their wide applications in research and genetic exploration, exosome analysis, and isolation of RNA and DNA are the major factors driving this segments growth.
Animal cells segment to register the highest growth rate during the forecast period
The Asia Pacific single-cell analysis market is segmented into human cells, animal cells, and microbial cells based on cell type. In 2019, the animal cells segment accounted for the highest growth rate. This can be attributed to the growth in the pharmaceutical industry and rising investments in animal cell research.
The academic & research laboratories segment accounted for the largest share of the Asia Pacific single-cell analysis market, by end-user segment, in 2019 Japan dominated the single-cell analysis market in Asia Pacific region
Based on end-user, the APAC single-cell analysis market is segmented into academic & research laboratories, biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and cell banks & IVF centers. In 2019, the academic & research laboratories segment accounted for the largest share of the APAC single-cell analysis market. The increasing funding for life science research, increasing number of medical colleges and universities, and the increasing number of collaborations among research institutes and life science research companies are the major factors driving the growth of this end-user segment.

The Asia Pacific single-cell analysis market is segmented into Japan, China, India, South Korea, Singapore, Australia, Southeast Asia, and the Rest of Asia Pacific. In 2019, Japan accounted for the largest share of the Asia Pacific single-cell analysis market. This can be attributed to the rising geriatric population, increasing government initiatives to promote life science research, increasing investments in biotech R&D, and the growing focus on personalized medicine.
Don't miss out on business opportunities in Asia Pacific Single-cell Analysis Market. Speak to our analyst and gain crucial industry insights that will help your business grow.
The major players operating in this market are Becton, Dickinson and Company (US), Danaher Corporation (US), Merck Millipore (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (US), General Electric Company (US), Promega Corporation (US), Illumina, Inc. (US), Bio-Rad Laboratories (US), Fluidigm Corporation (US), Agilent Technologies, Inc. (US), Tecan Group Ltd. (Switzerland), Sartorius AG (Germany), Luminex Corporation (US), Takara Bio (Japan), 10x Genomics (US), Fluxion Biosciences (US), Menarini Silicon Biosystems, Inc. (Italy), bioMérieux SA (France), Oxford Nanopore Technologies (UK), Cytek Biosciences (US), Corning Incorporated (US), Apogee Flow Systems Ltd. (UK), NanoCellect Biomedical (US), and On-chip Biotechnologies Co., Ltd. (Japan).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

# data[].attributes.attachment_link.keywords[]
asia pacific single-cell analysis market

# data[].attributes.attachment_link.title
Asia Pacific Single-cell Analysis Market

# data[].attributes.attachment_link.description
The report "Asia Pacific Single-cell Analysis Market by Cell Type (Human, Animal, Microbial), Product (Reagent, Assays, Instruments), Technique (Flow Cytometry, NGS, PCR), Application (Cancer, Stemcell, IVF), End User (Academic, Research Labs) - Forecast to 2025", is projected to reach USD 1,375 million by 2025 from USD 550 million in 2020, at a 20.1% CAGR.

# data[].attributes.headline
Exploring the Benefits of Single-Use Assemblies in Cell Culture and Fermentation

# data[].attributes.subject
Exploring the Benefits of Single-Use Assemblies in Cell Culture and Fermentation

# data[].attributes.body
The Single-use Assemblies Market size is projected to reach USD 6.5 Billion by 2027, growing at a CAGR of 18.8%.

The growth of the single-use assemblies market is largely driven by the increased pharmaceutical research & development and rising adoption of single use assemblies over traditional methods. Furthermore, single-use assemblies has been prominently adopted biologics manufacturing industry for multiple stages, i.e., in the upstream process, media & buffer preparation, downstream process, and process-intermediate storage.

# data[].attributes.attachment_link.title
Thermo Fisher Scientific, Inc. (US) and Sartorius Stedim Biotech (France) are Leading Players in the Single-Use Assemblies Market

# data[].attributes.attachment_link.description
The research insight on single-use assemblies market highlights the growth strategies of the companies. Know the future scenario, forecast, and current trends in single-use assemblies.